<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3-976-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        QUET 200 mg Film-coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        QUETIAPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        43.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DEVA HOLDING A.S." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DEVA HOLDING A.S.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1613]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            PharmaZone (Netaq Al Dawa) Pharmaceuticals
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DEVA HOLDING A.S.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AH04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>QUET is white, round film coated tablet. QUET 200 mg is presented in packs of 30 and 60<br />tablets.<br />Quet belongs to a group of medicines called anti-psychotics. Quetiapine can be used to treat<br />several illnesses such as:<br />&bull; Bipolar depression: where you may feel sad all the time or you may find that you feel<br />depressed, feel guilty, lack energy, lose your appetite or can&rsquo;t sleep.<br />&bull; Mania: where you may feel very excited, elated, agitated, enthusiastic or hyperactive or have<br />poor judgment including being aggressive or disruptive.<br />&bull; Schizophrenia: where you may hear or feel things that are not there, believe things that are not<br />true or feel unusually suspicious, anxious, confused, guilty, tense or depressed.<br />It is recommended that medication therapy for pediatric schizophrenia and bipolar disorder be<br />initiated only after a thorough diagnostic evaluation has been performed and careful<br />consideration given to the risks associated with medication treatment. Medication treatment for<br />both pediatric schizophrenia and bipolar disorder is indicated as part of a total treatment program<br />that often includes psychological, educational and social interventions.Your doctor may continue to give you QUET even when you are feeling better to prevent your<br />symptoms from returning.<br />You may find it helpful to tell a friend or relative that you are suffering from these symptoms,<br />and ask them to read this leaflet. You might ask them to tell you if they think your symptoms are<br />getting worse, or if they are worried about any other changes in your behaviour.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>QUET should not be used by elderly patients with loss of brain function (dementia). This is<br />because the group of medicines that QUET belongs to may increase the risk of stroke and in<br />some cases the risk of death in elderly patients with dementia.</p><p>In clinical studies with QUET and other drugs of this group, increased risk of death was reported<br />in elderly patients with dementia and behavioral disorder. QUET is not approved for this type of<br />administration.<br />Do not take QUET if:<br />You are hypersensitive (allergic) to quetiapine or any of the other ingredients of QUET (see list<br />of the other ingredients),<br />Take special care with QUET<br />If you are depressed and/or if you have another psychiatric disease, you may sometimes have<br />thoughts of harming or killing yourself.<br />Data obtained from clinical studies with children, adolescents and young adults demonstrated that<br />risk of suicidal thoughts and/or behavior in children, adolescents and young adults less than 25<br />years taking antidepressants was increased.<br />QUET is not approved for children and adolescents less than 18 years of age with bipolar<br />depression.<br />If you have thoughts of harming or killing yourself at any time, contact your doctor straight<br />away.<br />If</p><p>You have heart disease,<br />You have low blood pressure,<br />You have had stroke or especially if you are elderly,<br />You have had a convulsion,<br />You have discomfort in your arms and legs,<br />You experience uncontrollable movements, mainly of your face and tongue,<br />You experience fever, mental confusion and muscle stiffness,<br />You know that you have had low levels of white blood cells in the past (which may or may not<br />have been caused by other medicines).<br />You have diabetes or have a risk of getting diabetes. Increases in blood sugar and hyperglycaemia<br />(high blood sugar) have been observed in clinical trials with QUET. Also, occasional cases of<br />diabetes have been reported. If you have a risk of getting diabetes (a family history of diabetes,<br />high blood sugar during pregnancy) you should tell your doctor about this situation. If you<br />already have diabetes, you should be monitored for worsening of your diabetes.<br />You have high levels of triglyceride and cholesterol,</p><p>You or someone else in your family has a history of blood clots, as medicines like these have<br />been associated with formation of blood clots,<br />You have problems with your liver,<br />You have swallowing difficulty,<br />You have cataracts,<br />Please consult your doctor, even if these warnings were applicable to you at any time in the past.<br />Thoughts of suicide and worsening of your depression<br />If you are depressed you may sometimes have thoughts of harming or killing yourself. These<br />may be increased when first starting treatment, since these medicines all take time to work,<br />usually about two weeks but sometimes longer. Such thoughts may be increased when you<br />suddenly stop taking the drug. You may be more likely to think like this if you are a young adult.<br />Information from clinical trials has shown an increased risk of suicidal thoughts and/or suicidal<br />behavior in young adults aged less than 25 years with depression.<br />If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a<br />hospital straight away. You may find it helpful to tell a relative or close friend that you are<br />depressed, and ask them to read this leaflet. You might ask them to tell you if they think your<br />depression is getting worse, or if they are worried about changes in your behavior.<br />Taking QUET with food and drink:<br />QUET can be taken with or without food.<br />Be careful how much alcohol you drink. This is because the combined effect of QUET and<br />alcohol can make you feel sleepy.<br />Do not drink grapefruit juice while you are taking QUET. It can affect the way the medicine<br />works</p><p>&nbsp;Pregnancy<br />Consult your doctor or pharmacist before taking this medicine.<br />QUET should only be used during pregnancy if the expected benefits justify the potential risks to<br />the infant and when it is absolutely necessary.<br />If you realize you are pregnant during your treatment, immediately consult your doctor or<br />pharmacist.<br />Breast-feeding<br />Consult your doctor or pharmacist before taking this medicine.<br />Do not breast-feed your infant during the period when you take the drug.<br />Driving and using machines<br />Your tablets may make you feel sleepy. Do not drive or use any tools or machines until you know<br />how the tablets affect you.<br />Important information about some of the ingredients of QUET<br />QUET contains lactose which is a type of sugar. If you have been told by your doctor that you<br />cannot tolerate some sugars, talk to your doctor before taking this medicine.<br />Taking other medicines<br />Please tell your doctor if you are taking any of the following medicines:<br /> Medicines used to treat anxiety or depression (like imipramine, fluoxetine)</p><p> Epilepsy medicines (like phenytoin or carbamazepine)<br /> High blood pressure medicines<br /> Barbiturates (for difficulty sleeping).<br /> Some medicines used to treat HIV (like HIV-protease inhibitors)<br /> Thioridazine (another anti-psychotic medicine).<br /> Medicines that affect the heart rate<br /> Diuretics (water pills)<br />Tell your doctor if you are taking or about to stop taking the medicines used to treat infection,<br />such as the following.<br /> Rifampicin for tuberculosis<br /> Ketoconazole for fungal infection<br /> Erythromycin or clarithromycin as antibiotics<br />If you are currently taking or you have recently taken any prescribed or non-prescribed<br />medicine, please inform your doctor or pharmacist about such medicine.<br />Urine drug screen<br />If you have a urine drug screen, taking QUET could cause positive results for methadone or<br />drugs for depression called tricyclic antidepressants (TCAs), even though you may not be taking<br />methadone or TCAs. The result will need to be confirmed by a more specific test.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take QUET exactly as your doctor has told you.<br />You should check with your doctor or pharmacist if you are not sure.<br />Your doctor will decide on your starting dose and tell you how many QUET tablets you will need<br />to take each day.<br />Route and method of administration:<br /> QUET tablet is only for oral administration.<br /> You will generally take your tablets twice a day.<br /> Swallow your tablets whole with a drink of water.<br /> Do not stop taking your tablets even if you feel better, unless your doctor tells you.<br /> If you suddenly stop taking QUET, you may feel nauseous or vomit and or be unable to<br />sleep.<br /> Do not drink grapefruit juice while you are taking QUET. It can affect the way the<br />medicine works.<br />Different age groups<br />Use in children and adolescents:<br />When using QUET in children and adolescents, always comply with instructions of your doctor.<br />You should check with your doctor or pharmacist if you are not sure.<br />Your doctor will decide on your starting dose and tell you how many QUET tablets you will need<br />to take each day.<br />Use in the elderly:<br />It should be used with care especially during the initial period of treatment. In elderly patients,<br />treatment should be started at the low dose of 25 mg and gradually increased.</p><p>Special conditions:<br />Use in renal/hepatic insufficiency:<br />Dose adjustment is not required for patients with renal insufficiency.<br />In patients with known hepatic impairment, QUET should be used with care especially during<br />the initial period of treatment. Treatment should be started at the low dose of 25 mg and<br />gradually increased.<br />If you have the impression that the effect of QUET is too strong or too weak, talk to your doctor<br />or pharmacist.<br />If you take more QUET than you should:<br />If you take more QUET than prescribed by your doctor, contact your doctor or pharmacist<br />straight away.<br />In such case, you may feel sleepy, feel faint or dizzy and have palpitations.<br />If you forget to take QUET:<br />Do not take a double dose to make up for a forgotten dose.<br />If you forget to take a dose, take it as soon as you remember unless it is almost time to take the<br />next dose.<br />If you stop taking QUET:<br />If you suddenly stop taking QUET, you may feel nauseous or vomit or be unable to sleep.<br />Your doctor may suggest you reduce the dose gradually before stopping treatment.<br />Do not stop taking this medication without consulting your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The<br />following side effects may happen with this medicine.<br />If any of the following happen, stop taking QUET and contact a doctor or go to the nearest<br />hospital straight away, as you may need urgent medical attention:<br />Uncommon (affects less than 1 in 100 people):<br />&bull; Fits or seizures.<br />&bull; Allergic reactions that may include raised lumps (weals), swelling of the skin and swelling<br />around the mouth.<br />&bull; Uncontrollable movements, mainly of your face or tongue (Tardive dyskinesia).<br />Rare (affects less than 1 in 1,000 people):<br />&bull; A combination of high temperature (fever), sweating, stiff muscles, feeling very drowsy or<br />faint, large increase in blood pressure or heartbeat (a disorder called &ldquo;neuroleptic malignant<br />syndrome&rdquo;).<br />&bull; Jaundice (yellowing of the skin and eyes).<br />&bull; Hepatitis (inflammation of the liver).<br />&bull; Priapism (a long-lasting and painful erection).<br />&bull; Blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in<br />the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in<br />breathing.<br />Very rare (affects less than 1 in 10,000 people):<br />&bull; Severe allergic reaction (called anaphylaxis) which may cause difficulty in breathing or shock.<br />&bull; Rapid swelling of the skin, usually around the eyes, lips and throat (angioedema).</p><p>Other possible side effects:<br />Very common (affects more than 1 in 10 people):<br />&bull; Dizziness (may lead to falls), headache, dry mouth.<br />&bull; Feeling sleepy (this may go away with time, as you keep taking quetiapine) (may lead to falls).<br />&bull; Discontinuation symptoms (symptoms which occur when you stop taking quetiapine) include<br />not being able to sleep (insomnia), feeling sick (nausea), headache, diarrhoea, being sick<br />(vomiting), dizziness and irritability. Gradual withdrawal over a period of at least 1 to 2 weeks is<br />advisable.<br />&bull; Putting on weight.<br />Common (affects less than 1 in 10 people):<br />&bull; Rapid heartbeat or fainting.<br />&bull; Feeling like your heart is pounding, racing or has skipped beats.<br />&bull; Stuffy nose.<br />&bull; Indigestion or constipation.<br />&bull; Feeling weak (may lead to falls).<br />&bull; Swelling of arms or legs.<br />&bull; Increased levels of sugar in the blood.<br />&bull; Low blood pressure when standing. This may make you feel dizzy or faint (may lead to falls).<br />&bull; Blurred vision.<br />&bull; Abnormal muscle movements. These include difficulty starting muscle movements, shaking,<br />feeling restless or muscle stiffness without pain.<br />&bull; Abnormal dreams and nightmares.<br />&bull; Feeling more hungry.<br />&bull; Feeling irritated.<br />&bull; Disturbance in speech or language.<br />&bull; Thoughts of suicide and worsening of your depression.<br />&bull; Shortness of breath.<br />&bull; Vomiting (mainly in the elderly).<br />&bull; Fever</p><p>Uncommon (affects less than 1 in 100 people):<br />&bull; Unpleasant sensations in the legs (also called restless legs syndrome).<br />&bull; Difficulty swallowing.<br />&bull; Sexual dysfunction.<br />&bull; Worsening of pre-existing diabetes.<br />&bull; Change in electrical activity of the heart seen on ECG (QT prolongation)<br />Rare (affects less than 1 in 1,000 people):<br />&bull; Swelling of breasts and unexpected production of breast milk (galactorrhoea).<br />&bull; Menstrual disorder.<br />&bull; Walking, talking, eating or other activities while you are asleep.<br />&bull; Body temperature decreased (hypothermia).<br />&bull; Inflammation of the pancreas<br />Very rare (affects less than 1 in 10,000 people):<br />&bull; A severe rash, blisters or red patches on the skin.<br />&bull; Inappropriate secretion of a hormone that controls urine volume.<br />&bull; Breakdown of muscle fibres and pain in muscles (rhabdomyolysis).</p><p>Not known (cannot be estimated from the available data)<br />&bull; Skin rash with irregular red spots (erythema multiforme)<br />&bull; Serious, sudden allergic reaction with symptoms such as fever and blisters on the skin and<br />peeling of the skin (toxic epidermal necrolysis)<br />The class of medicines to which quetiapine belongs can cause heart rhythm problems, which can<br />be serious and in severe cases may be fatal.<br />Some side effects are only seen when a blood test is taken. These include changes in the amount<br />of certain fats (triglycerides and total cholesterol) or sugar in the blood, changes in the amount of<br />thyroid hormones in your blood, increased liver enzymes, decreases in the number of certain<br />types of blood cells, decrease in the amount of red blood cells, increased blood creatine<br />phosphokinase (a substance in the muscles), decrease in the amount of sodium in the blood and<br />increases in the amount of the hormone prolactin in the blood.<br />Increases in the hormone prolactin could in rare cases lead to the following.<br />&bull; Men and women to have swelling of the breasts and unexpectedly produce breast milk.<br />&bull; Women to have no monthly period or irregular periods.<br />Your doctor may ask you to have blood tests from time to time.<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side<br />effects not listed in this leaflet.<br />Children and adolescents<br />The same side effects that may occur in adults may also occur in children and adolescents.<br />The following side effect has been seen only in children and adolescents:<br />Very common (affects more than 1 in 10 people):<br />&bull; Increase in blood pressure.<br />The following side effects have been seen more often in children and adolescents:<br />Very common (affects more than 1 in 10 people):<br />&bull; Increase in the amount of a hormone called prolactin, in the blood.<br />&bull; Increases in the hormone prolactin could in rare cases lead to the following:<br />- boys and girls to have swelling of breasts and unexpectedly produce breast milk</p><p>- girls to have no monthly period or irregular periods.<br />&bull; Increased appetite.<br />&bull; Abnormal muscle movements. These include difficulty starting muscle movements, shaking,<br />feeling restless or muscle stiffness without pain.<br />Common (affects less than 1 in 10 people):<br />&bull; Feeling irritated.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>5. How to store QUET<br />Keep QUET out of reach and sight of children and in its original container.<br />Store below 30C.<br />Take note of the expiration date of your medication.<br />Do not take QUET after the expiry date which is stated on the container.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Drug substance:<br />200 mg quetiapine (as quetiapine fumarate)<br />&bull; The other ingredients:<br />Dibasic calcium phosphate dihydrate, Lactose monohydrate, Povidone, Sodium starch glycolate,<br />Magnesium stearate, Colloidal silicon dioxide, Microcrystalline cellulose, Sodium stearyl<br />fumarate, Hydroxypropylmethylcellulose, Titanium dioxide (E 171), Polyethylene glycol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                QUET is white, round film coated tablet. QUET 200 mg is presented in packs of 30 and 60
tablets
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Deva Holding A.Ş.<br />Halkalı Merkez Mah. Basın Ekspres Cad.<br />No:1 34303 K&uuml;&ccedil;&uuml;k&ccedil;ekmece-/ İSTANBUL / TURKEY<br />Tel: +90 212 692 92 92<br />Fax: +90212 697 00 24<br />Manufacturing site:<br />Deva Holding A.Ş.<br />Organize Sanayi B&ouml;lgesi Atat&uuml;rk Mah. Atat&uuml;rk Cad. No:32<br />Karaağa&ccedil;-&Ccedil;erkezk&ouml;y/ TEKİRDAĞ/TURKEY</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                version number 02
 17.03.2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>كويت هو قرص أبيض، دائري مغلف. يتوفر كويت 022 ملجم في عبوة سعة 32 و 02 قرص.<br />ينتمي كويت، إلى مجموعة من الأدوية تسمى مضادات الذهان. يمكن أن يستخدم كيوتابين لعلاج العديد من<br />الأمراض مثل:<br />الإكتئاب مزدوج القطبية: والذي عند الإصابة به قد تشعر بالحزن في جميع الأوقات، أو قد تشعر <br />بالاكتئاب، أو قد ينتابك الشعور بالذنب، نقص الطاقة، وفقد شهيتك وعدم القدرة على النوم.<br />الهوس: عندما تشعر بالنشاط الزائد، الإعجاب، الهيجان، فرط الحماس، أو فرط النشاط أو أن يكون <br />الحكم لديك غير جيد ويشمل ذلك الأفكار العدوانية أو التخريبية.<br />انفصام الشخصية: حيث قد تسمع أو تشعر بأشياء ليست هناك، وتعتقد بأمور ليست صحيحة أو تشعر <br />بالشك بطريقة غير طبيعية، والقلق، والخلط، والشعور بالذنب، أو التوتر والاكتئاب.<br />من المستحسن أن يبدأ علاج مرض انفصام الشخصية والاضطراب الثنائي القطب لدى الأطفال بعد أن يتم إجراء<br />تقييم شامل وتشخيص دقيق مع اعتبار المخاطر المرتبطة مع العلاج الدوائي. العلاج الدوائي للأطفال الذين<br />يعانون الفصام والاضطراب الثنائي القطب هو جزء من برنامج العلاج الكلي الذي غالبا ما يتضمن التدخلات<br />النفسية والتربوية والاجتماعية.</p><p>طبيبك قد يستمر بإعطائك كويت حتى عندما تشعر بالتحسن لمنع انتكاسة الأعراض مرة أخرى.<br />قد تجد أنه من المفيد أن تقول لصديق أو قريب أنك تعاني من هذه الأعراض، وتطلب منهم قراءة هذه النشرة.<br />بإمكانك أن تطلب منهم إخبارك إذا كانوا يعتقدون أن الأعراض الخاصة بك تزداد سوءا، أو إذا كانوا يشعرون<br />بالقلق بشأن أي تغييرات أخرى في سلوكك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا ينبغي أن يستخدم كويت من قبل المرضى المسنين الذين يعانون من فقدان وظائف الدماغ )الخرف(. لأن هذه<br />المجموعة من الأدوية الذي ينتمي إليها كويت قد تزيد من خطر الاصابة بالسكتة الدماغية و بعض الحالات من<br />خطر الموت في المرضى المسنين المصابين بالخرف</p><p>في الدراسات السريرية لكويت مع أدوية الأخرى من نفس المجموعة، تم تسجيل زيادة مخاطر الوفاة في المرضى<br />المسنين الذين يعانون من الخرف واضطرابات سلوكية. استخدام كويت غير معترف به في هذه الحالة.<br />لا تتناول كويت إذا:<br />كنت شديد الحساسية )متحسس( لكيوتيابين أو أي من المكونات الأخرى من كويت )انظر قائمة المكونات<br />الأخرى(.<br />اتبع عناية خاصة مع كويت<br />إذا كنت مكتئبا و / أو إذا كان لديك أمراض ا نفسية أخرى، إو إذا راودتك في بعض الأحيان أفكار ا لإيذاء أو قتل<br />نفسك.<br />أظهرت البيانات التي تم الحصول عليها من الدراسات السريرية التي أجريت على الأطفال والمراهقين والبالغين<br />من الشباب أن خطر الأفكار و/أو السلوك الانتحاري لدى الأطفال والمراهقين والبالغين من الشباب الذين تقل<br />أعمارهم عن 05 سنة ممن يتناولون مضادات الاكتئاب قد زادت.<br />لم تتم الموافقة على استخدام كويت للأطفال والمراهقين أقل من 11 سنة الذين يعانون من اكتئاب ذي القطبين .<br />إذا راودتك أفكار إيذاء أو قتل نفسك في أي وقت، فاتصل بطبيبك مباشرة.</p><p>إذا<br />كان لديك مرض القلب،<br />كان لديك انخفاض في ضغط الدم،<br />اذا عانيت من سكتة الدماغية أوخصوصا إذا كنت من كبار السن،<br />أصبت بنوبة تشنج،<br />كنت تعاني من عدم راحة في الذراعين والساقين،<br />واجهت تحركات لا يمكن السيطرة عليها، وخصوصا في الوجه واللسان،<br />عانيت من الحمى، والتشوش الذهني وتصلب العضلات،<br />كنت تعرف أنه كان لديك مستويات منخفضة من خلايا الدم البيضاء في الماضي )والتي قد تكون بسبب أوبدون<br />استخدام أدوية الأخرى(.<br />كنت مصابا بداء السكري أو لديك خطر الإصابة بمرض السكري. لوحظ في التجارب السريرية مع كويت زيادة<br />في نسبة السكر في الدم وفرط سكر الدم )ارتفاع نسبة السكر في الدم( . أيضا، سجلت بعض الحالات العرضية<br />من مرض السكري. إذا كنت عرضة لخطر الإصابة بمرض السكري )تاريخ عائلي للإصابة بمرض السكري،<br />ارتفاع نسبة السكر في الدم أثناء الحمل( يجب أن تخبر طبيبك عن هذا الوضع. إذا كان لديك بالفعل مرض<br />السكري، يجب أن تراقب تفاقم مرض السكري لديك.<br />كان لديك مستويات عالية من الدهون الثلاثية والكوليسترول في الدم،</p><p>كنت أنت أو أي شخص آخر في عائلتك لديكم تاريخ من جلطات الدم، لأن الأدوية هذه يمكن أن تكون مرتبطة<br />بتشكيل جلطات الدم،<br />كان لديك مشاكل في الكبد،<br />كان لديك صعوبة في البلع،<br />كتن لديك إعتام عدسة العين،<br />يرجى استشارة الطبيب، حتى لو كانت هذه التحذيرات انطبقت عليك في أي وقت في الماضي.</p><p>الأفكار الانتحارية وتفاقم الاكتئاب الخاص بك<br />إذا كنت مكتئبا قد تراودك بعض الأحيان أفكار إيذاء أو قتل نفسك. هذه الأفكار يمكن أن تزيد عند بدء أول العلاج،<br />لأن هذه الأدوية قد تستغرق وقتا طويلا في العمل، عادة حوالي أسبوعين ولكن في بعض الأحيان فترة أطول. هذه<br />الأفكار يمكن أن تزيد أيضا عند التوقف المفاجئ لاستخدام الدواء. قد تكون أكثر عرضة للتفكير في مثل هذا إذا<br />كنت من الشباب البالغين.<br />وقد أظهرت النتائج من التجارب السريرية زيادة خطر الأفكار الانتحارية و / أو السلوك الانتحاري في الشباب<br />الذين تقل أعمارهم عن 05 سنة والذين يعانون من الاكتئاب.<br />إذا تبادرت لديك أفكار بإيذاء أو قتل نفسك في أي وقت، اتصل بطبيبك أو اذهب إلى المستشفى على الفور. قد تجد<br />أنه من المفيد أن تقول لصديق أو قريب أنك تعاني من الاكتئاب، وتطلب منهم أن يقرؤوا هذه النشرة. اطلب منهم<br />ان يخبروك إذا كانوا يعتقدون أن الاكتئاب يزداد سوءا لديك، أو إذا كانوا قلقين بشأن التغيرات في سلوكك.<br />تناول كويت مع الطعام والشراب:<br />يمكن تناول كويت مع أو بدون الطعام.<br />كن حريصا بالنسبة لكمية الكحول التي تتناولها. التأثير المشترك لكويت مع الكحول يمكن أن يجعلك تشعر<br />بالنعاس.<br />لا تشرب عصير الجريب فروت وأنت تتناول كويت. يمكن أن يؤثر على طريقة عمل الدواء.</p><p>فترة الحمل<br />استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.<br />يجب استخدام كويت فقط خلال فترة الحمل إذا كانت الفوائد المتوقعة تبرر المخاطر المحتملة للجنين وعندما يكون<br />ذلك ضروريا تماما.<br />إذا علم ت أن ك حامل أثناء تناول ك للعلاج، استشيري الطبيب على الفور أو الصيدلي.</p><p>الرضاعة الطبيعية<br />استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.<br />لاتقومي بإرضاع طفلك خلال فترة تناولك للدواء.<br />القيادة واستخدام الآليات<br />هذه الأقراص قد تجعلك تشعر بالنعاس. لا تقد أو تستخدم أي أدوات أو آلات حتى تعرف كيف تؤثر هذه<br />الأقراص عليك.<br />معلومات هامة حول بعض مكونات كويت<br />كويت يحتوي على اللاكتوز وهو نوع من السكر. إذا كان قد أخبرك الطبيب من قبل أنه لا يمكنك استخدام بعض<br />أنواع السكريات، تحدث مع طبيبك قبل تناول هذا الدواء.<br />تناول أدوية أخرى<br />يرجى إخبار الطبيب إذا كنت تتناول أي من الأدوية التالية:<br />الأدوية المستخدمة لعلاج القلق أو الاكتئاب )مثل إيميبرامين، فلوكستين(</p><p>أدوية الصرع )مثل الفينيتوين أو كاربامازيبين( <br />أدوية ارتفاع ضغط الدم <br />الباربيتورات )لصعوبة النوم(. <br />بعض الأدوية المستخدمة لعلاج فيروس نقص المناعة البشرية )مثل مثبطات الأنزيم البروتيني لفيروس نقص <br />المناعة البشرية(<br />الثيوريدازين )دواء آخر مضاد للذهان(. <br />الأدوية التي تؤثر على معدل ضربات القلب</p><p>مدرات البول )أقراص الماء( <br />أخبر طبيبك إذا كنت تتناول أو على وشك التوقف عن تناول الأدوية المستخدمة لعلاج العدوى، مثل ما يلي.<br />ريفامبيسين لمرض السل <br />الكيتوكونازول للعدوى فطرية <br />الاريثروميسين أوالكلاريثروميسين كمضادات حيوية <br />إذا كنت تتناول حاليا أو كنت قد تناولت مؤخرا أي نوع من الأدوية بوصفة أو بدون وصفة الرجاء إبلاغ الطبيب<br />أو الصيدلي عن هذه الادوية.<br />فحص الدواء في البول<br />إذا كان لديك فحص للدواء في البول، يمكن أن يسبب كويت نتائج إيجابية للميثادون أو أدوية الاكتئاب التي تسمى<br />مضادات الاكتئاب ثلاثية الحلقات )مضادات الاكتئاب ثلاثية الحلقات(، على الرغم من أنك قد لا تكون تناولت<br />الميثادون أو مضادات الاكتئاب ثلاثية الحلقات. سوف تحتاج إلى تأكيد النتيجة من خلال اختبار أكثر تحديدا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول كويت تماما كما أخبرك طبيبك.<br />يجب عليك التحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد.<br />طبيبك سيقرر جرعة البداية ويخبرك كم حبة كويت ستحتاج لأخذها كل يوم.</p><p>قرص كويت هو فقط للتناول عن طريق الفم. <br />عادة تؤخذ الأقراص مرتين في اليوم. <br />ابلع الأقراص كاملة مع شرب الماء. <br />لا تتوقف عن تناول الأقراص الخاصة بك حتى لو كنت تشعر بالتحسن، ما لم يخبرك طبيبك. <br />إذا توقفت فجأه عن تناول كويت، قد تشعر بالغثيان أو القيء و/أو تكون غير قادر على النوم. <br />لا تشرب عصير الجريب فروت وأنت تتناول كويت. يمكن أن يؤثر على طريقة عمل الدواء. <br />مختلف الفئات العمرية<br />الاستخدام في الأطفال والمراهقين:<br />عند استخدام كويت في الأطفال والمراهقين، دائما امتثل لتعليمات الطبيب.<br />يجب عليك التحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد.<br />طبيبك سيقرر جرعة البداية ويقول لك كم حبة كويت ستحتاج لأخذه يوميا.</p><p>الاستخدام في كبار السن:<br />يجب استخدامه بحذر وخاصة خلال الفترة الأولى من العلاج. في المرضى المسنين، يجب أن يبدأ العلاج بجرعة<br />منخفضة وهي 05 ملجم وتزيد تدريجيا.<br />حالات خاصة:<br />استخدامه في القصور الكلوي / الكبدي:<br />لا يلزم تعديل الجرعة في مرضى القصور الكلوي.<br />في المرضى الذين يعانون من قصور كبدي معروف، ينبغي أن يستخدم كويت بحذر خصوصا خلال الفترة<br />الأولى من العلاج. يجب أن يبدأ العلاج بجرعة منخفضة من 05 ملجم و تزيد تدريجيا.<br />إذا كنت تعتقد أن تأثير كويت قوي جدا أو ضعيف جدا، تحدث مع طبيبك أو الصيدلي.</p><p>اذا تناولت أكثر من الجرعة التي يجب عليك تناولها من كويت:<br />إذا تناولت جرعة زائدة من كويت أكثر مما حددها لك الطبيب، اتصل بطبيبك أو الصيدلي على الفور.<br />في مثل هذه الحالة، قد تشعر بالنعاس، وقد تشعر بالدوار والاغماء أو الشعور بضربات القلب.<br />إذا كنت قد نسيت أن تتناول كويت:<br />لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.<br />إذا كنت قد نسيت أن تتناول الجرعة، تناولها حالما تتذكر إلا اذا كان قد اقترب موعد الجرعة التالية.<br />إذا توقفت عن تناول كويت:<br />إذا كنت قد توقفت فجأة عن تناول كويت، قد تشعر بالغثيان أو القيء أو قد تكون غير قادر على النوم.<br />قد يقترح عليك الطبيب تقليل الجرعة تدريجيا قبل وقف العلاج.<br />لا تتوقف عن تناول هذا الدواء دون استشارة الطبيب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يتسبب هذا الدواء بحصول آثارا جانبية، بالرغم من أنه ليس من الضروري أن يصاب بها<br />الجميع. فإن الآثار الجانبية التالية قد تحدث مع هذا الدواء.<br />إذا حدث أي من التالي، توقف عن استخدام كويت واتصل بالطبيب أو اذهب مباشرة إلى أقرب مستشفى على<br />الفور، لأنك قد تحتاج عناية طبية سريعة:<br />غير شائعة )تظهر في 1 من بين 100 شخص(:<br />نوبات أو تشنجات. <br />تفاعلات تحسسية والتي قد تشمل تكون بقع بارزة على الجلد )على هيئة اطار(، تورم الجلد، وتورم حول <br />الفم.<br />حركات غير متوازنة، غالبا تظهر على الوجه واللسان )عسر الحركة الآجل(. <br />نادرة )تظهر في أقل من شخص من بين 1000 شخص(:<br />مزيج من ارتفاع في درجة الحرارة )حمى(، تعرق، وتصلب العضلات، وشعور بالدوخة الشديدة <br />أوالاغماء ، زيادة ملحوظة في ضغط الدم أو ضربات القلب )اضطراب يسمى متلازمة الذهان الخبيثة(.<br />يرقان )اصفرار الجلد والعينين( <br />التهاب الكبد )التهاب في الكبد( <br />القساح ) انتصاب طويل الأمد ومؤلم ( <br />جلطات الدم في الأوردة وخصوصا في الساقين ) تشمل الأعراض تورم وألم و احمرار في الساق (، <br />والتي قد تنتقل عبر الأوعية الدموية إلى الرئتين مما يسبب ألم في الصدر وصعوبة في التنفس.<br />نادرة جدا )تظهر في أقل من شخص من بين 10000 شخص(:<br />حساسية شديدة )الحساسية المفرطة( والتي تؤدي في بعض الأحيان إلى صعوبة في التنفس وصدمة. <br />تورم سريع في الجلد، وخصوصا حول العين والشفاه و الحلق ) وذمة وعائية (</p><p>آثار جانبية أخرى محتملة:<br />شائعة جدا )تظهر في أكثر من شخص من بين 10 أشخاص(:<br />دوخة )قد يؤدي إلى السقوط(، صداع، جفاف الفم. <br />الشعور بالنعاس )و يمكن أن يزول مع مرور الوقت، عند استمرارك بتناول كويتابين( )قد يؤدي إلى <br />السقوط(.<br />أعراض التوقف )الأعراض التي تحدث عند التوقف عن تناول كويتابين( تشمل عدم القدرة على النوم <br />)أرق(، الشعور بالإعياء )غثيان(، الصداع، الإسهال، الإصابة بالإعياء )التقيوء(، الدوخة والهيجان. من<br />0 أسابيع . - المستحسن سحب الدواء تدريجيا على مدى فترة من 1<br />زيادة الوزن. </p><p>شائعة )تظهر في أقل من شخص من بين 10 أشخاص(:<br />سرعة ضربات القلب أو إغماء. <br />الشعور بأن هناك قصف في قلبك، أو تسارع، أن هناك بعض الخفقات قد تم تخطيها. <br />انسداد الأنف <br />عسر الهضم أو الإمساك <br />الشعور بالضعف )قد يؤدي إلى السقوط(. <br />تورم الذراعين أو الساقين <br />إرتفاع نسبة السكر في الدم <br />انخفاض ضغط الدم عند الوقوف. وهذا قد يجعلك تشعر بالدوار أو شعور بالاغماء )قد يؤدي إلى <br />السقوط(.<br />عدم وضوح الرؤية <br />حركات العضلات غير طبيعية. وتشمل صعوبة في بداية تحريك العضلات، رجفة، الشعور بالتململ أو <br />تصلب العضلات من دون ألم.<br />أحلام غير طبيعية وكوابيس. <br />الشعور بالجوع أكثر <br />الشعور بالهيجان </p><p>اضطراب في الكلام أو اللغة <br />افكار انتحارية أو تدهور حالة الكآبة لديك. <br />صعوبة التنفس. <br />التقيؤ )غالبا في كبار السن(. <br />حمى.</p><p>غير شائعة )تظهر في أقل من شخص من بين 100 شخص(:<br />شعور غير لطيف في الساقين )تسمى متلازمة تململ الساق(. <br />صعوبة في البلع. <br />الضعف الجنسي. <br />تفاقم حالة داء السكري الموجود من قبل. <br />تغير في النشاط الكهربي للقلب ويلاحظ ذلك على مخطط كهربية القلب )استطالة موجة كيو تي(. <br />نادرة )تظهر في أقل من شخص من بين 1000 شخص(:<br />تورم الثديين وإفرازغير متوقع من حليب الثدي )ثر اللبن(. <br />اضطراب الطمث. <br />المشي، التحدث، والأكل ونشاطات أخرى أثناء النوم . <br />التهاب البنكرياس. <br />نادرة جدا )تظهر في أقل من شخص من بين 10000 شخص(:<br />طفح جلدي شديد، وظهور بثور أو بقع حمراء على الجلد. <br />إفراز غير متوقع من الهرمون الذي يتحكم في حجم البول. <br />تكسر ألياف العضلات وآلام في العضلات ) انحلال الربيدات(. </p><p>غير معروفة )لا يمكن تقييمها من البيانات المتاحة(:<br />طفح جلدي مع ظهور بقع حمراء غير منتظمة )الحمامي متعدد الأشكال(.</p><p>وتقشر الجلد )انحلال البشرة التسممي(.<br />قد تسبب مجموعة هذه الأدوية التي ينتمي إليها كويتابين إلى حدوث خلل في انتظام ضربات القلب، والتي قد تكون<br />خطيرة وفي الحالات الشديدة تعتبر قاتلة.<br />بعض الآثار الجانبية تحدث فقط عند اجراء فحص الدم. وتشمل هذه التغييرات في كمية بعض الدهون <br />)الدهون الثلاثية والكوليسترول الكلي( أو السكر في الدم، أو تغير في كمية هرمون الغدة الدرقية في الدم<br />لديك، أو إرتفاع في إنزيمات الكبد، أو نقص في عدد أنواع معينة من خلايا الدم، كالنقص في خلايا الدم<br />الحمراء، وزيادة كرياتين فوسفوكاينيز الدم )وهي مادة في العضلات(، نقص كمية الصوديوم في الدم<br />وزيادة في كمية هرمون البرولاكتين في الدم.<br />زيادة هرمون البرولاكتين في حالات نادرة يمكن أن يؤدي إلى :<br />تورم الثديين عند الرجال والنساء وإفراز غير متوقع لحليب الثدي. <br />غياب الدورة الشهرية أو عدم انتظام الدورة الشهرية عند النساء. <br />قد يطلب منك طبيبك عمل فحوصات للدم من حين لآخر.<br />إذا أصبت بأي من الآثار الجانبية، تحدث مع طبيبك أو الصيدلي. هذا يشمل أي أثر جانبي محتمل ولم يتم</p><p>ذكره في هذه النشرة.<br />الأطفال والمراهقين:<br />نفس الآثار الجانبية التي قد تحدث في البالغين قد تحدث أيضا في الأطفال والمراهقين.<br />الأعراض الجانبية التالية شوهدت فقط في الأطفال والمراهقين:</p><p>شائعة جدا )تظهر في أكثر من شخص من بين 10 أشخاص(:<br />زيادة ضغط الدم. <br />الآثار الجانبية التالية قد تحدث غالبا فقط في الأطفال والمراهقين.<br />شائعة جدا )تظهر في أكثر من شخص من بين 10 أشخاص(:<br />زيادة في كمية هرمون بالدم يسمى البرولاكتين، في الدم. <br />زيادات في هرمون البرولاكتين يمكن في حالات نادرة أن تؤدي إلى ما يلي: <br />- تورم الثديين عند الفتيان والفتيات وإفراز غير متوقع لحليب الثدي<br />- غياب الدورة الشهرية أو اضطرابات الدورة الشهرية لدى الفتيات<br />&bull; زيادة الشهية<br />&bull; حركات عضلات غير طبيعية. وتشمل صعوبة في بداية حركة العضلات، الرجفة ،الشعور بالتململ أو<br />تصلب العضلات من دون ألم.<br />شائعة )تظهر في أقل من شخص من بين 10 أشخاص(:<br />الشعور بالهيجان</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدا عن متناول ونظر الأطفال وفي عبوته الأصلية.<br />يحفظ في درجة حرارة أقل من 32 درجة مئوية.<br />انتبه لتاريخ انتهاء الدواء الخاص بك.<br />لا تتناول كويت بعد تاريخ انتهاء الصلاحية المدون على العبوة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الدوائية:<br />022 ملجم كويتيابين )كويتيابين فيوماريت(<br />المكونات الأخرى:<br />فوسفات الكالسيوم ثنائي القاعدة ثنائي الهيدرات، اللاكتوز أحادي الهيدرات، بوفيدون، غليكولات صوديوم النشا،<br />ستيرات المغنيسيوم، وثاني أكسيد السيليكون الغروي، سيلولوز دقيق البلورات، فومارات ستياريل الصوديوم،<br />هيدروكسي بروبايل ميثايل سيليلوز، وثاني أكسيد التيتانيوم )إي 171 (، بولي ايثيلين جلايكول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كويت هو قرص أبيض، دائري مغلف. يتوفر كويت 022 ملجم في عبوة سعة 32 و 02 قرص</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>Deva Holding A.Ş.<br />Halkalı Merkez Mah. Basın Ekspres Cad.<br />No:1 34303 K&uuml;&ccedil;&uuml;k&ccedil;ekmece-/ İSTANBUL / TURKEY<br />Tel: +90 212 692 92 92<br />Fax: +90212 697 00 24<br />مكان التسويق:<br />Deva Holding A.Ş.<br />Organize Sanayi B&ouml;lgesi Atat&uuml;rk Mah. Atat&uuml;rk Cad. No:32<br />Karaağa&ccedil;-&Ccedil;erkezk&ouml;y/ TEKİRDAĞ/TURKEY</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
تمت الموافقة على هذه النشرة في؛ العدد رقم 02
17-03-2014

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                QUET 200 mg film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Quetiapine 200 mg (as 230.26 quetiapine fumarate)
Lactose monohydrate 108.74 mg
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
White, round, film-coated tablets with homogenous appearance
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>QUET is indicated for the treatment of schizophrenia (adults and adolescents aged 13 to 17<br />years),<br />Treatment of moderate to severe manic episodes in bipolar disorder (adults, children and<br />adolescents aged 10 to 17 years),<br />Treatment of major depressive episodes in bipolar disorder,<br />For preventing recurrence in bipolar disorder in patients whose manic or depressive episode has<br />responded to quetiapine treatment.<br />It is recommended that medication therapy for pediatric schizophrenia and bipolar disorder be<br />initiated only after a thorough diagnostic evaluation has been performed and careful<br />consideration given to the risks associated with medication treatment. Medication treatment for&nbsp;both pediatric schizophrenia and bipolar disorder is indicated as part of a total treatment program<br />that often includes psychological, educational and social interventions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>QUET can be administered with or without food.<br />Frequency and duration of administration:<br />In adults:<br />For the treatment of schizophrenia: QUET should be administered twice a daily.<br />The total daily dose for the first 4 days of therapy is 50mg (Day 1), 100mg (Day 2), 200mg<br />(Day 3) and 300mg (Day 4).<br />From Day 4 onwards, the dose should be titrated to the usual effective dose range of 300 to<br />450mg quetiapine per day. Depending on the clinical response and tolerability of the individual<br />patient, the dose may be adjusted within the range 150 to 750mg per day.<br />Adolescents (13-17 years)<br />QUET should be administered twice daily. However, based on clinical response and tolerability<br />of the individual patient QUET may be administered three times daily where needed.<br />The total daily dose for the initial five days of therapy is 50 mg (Day 1), 100 mg (Day 2), 200 mg<br />(Day 3), 300 mg (Day 4) and 400 mg (Day 5).<br />After Day 5, the dose should be adjusted within the recommended dose range of 400 mg/day to<br />800 mg/day based on response and tolerability. Dosage adjustments should be in increments of<br />no greater than 100 mg/day. Efficacy was demonstrated with quetiapine at both 400 mg and 800<br />mg; however, no additional benefit was seen in the 800 mg group.<br />For the treatment of moderate to severe manic episodes in bipolar disorder:<br />QUET should be administered twice a daily. The total daily dose for the first four days of therapy<br />is 100mg (Day 1), 200mg (Day 2), 300mg (Day 3) and 400mg (Day 4). Further dosage<br />adjustments up to 800 mg per day by Day 6 should be in increments of no greater than 200mg<br />per day.<br />The dose may be adjusted depending on clinical response and tolerability of the individual<br />patient, within the range of 200 to 800mg quetiapine per day. The usual effective dose is in the<br />range of 400 to 800mg per day.<br />Children and Adolescents (10 to 17 years) (monotherapy)&nbsp;QUET should be administered twice daily. However, based on clinical response and tolerability<br />of the individual patient QUET may be administered three times daily where needed.<br />The total daily dose for the initial five days of therapy is 50 mg (Day 1), 100 mg (Day 2), 200 mg<br />(Day 3), 300 mg (Day 4) and 400 mg (Day 5).<br />After Day 5, the dose should be adjusted within the recommended dose range of 400 to 600<br />mg/day based on response and tolerability. Dosage adjustments should be in increments of no<br />greater than 100 mg/day. Efficacy was demonstrated with quetiapine at both 400 mg and 600 mg;<br />however, no additional benefit was seen in the 600 mg group.<br />For the treatment of depressive episodes in bipolar disorder<br />QUET should be administered once daily at bedtime. The recommended daily dose is 300 mg. The<br />total daily dose for the first four days of therapy is 50mg (Day 1), 100mg (Day 2), 200mg (Day 3)&nbsp;and 300mg (Day 4). No additional benefit was seen with the 600mg dose.<br />In clinical trials, no additional benefit was seen in the 600mg group compared to the 300mg group.<br />Individual patients may benefit from a 600mg dose. Doses greater than 300 mg should be initiated<br />by physicians experienced in treating bipolar disorder. In individual patients, in the event of<br />tolerance concerns, clinical trials have indicated that dose reduction to a minimum of 200mg could<br />be considered.<br />For preventing recurrence in bipolar disorder:<br />For prevention of recurrence of bipolar disorder, patients who have responded to QUET for acute<br />treatment of bipolar disorder should continue therapy with QUET at the same dose. QUET dose<br />may then be adjusted depending on clinical response and tolerability of the individual patient,<br />within the range of 300 to 800mg/day administered twice daily. It is important that the lowest<br />effective dose is used for maintenance therapy.<br />Method of administration:<br />Tablets orally administered are swallowed with a small amount of water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                QUET is contraindicated in patients with hypersensitivity to any component of this product
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a meta-analysis of atypical antipsychotic drugs, it has been reported that elderly patients with<br />dementia-related psychosis are at an increased risk of death compared to placebo. However in two<br />10-week placebo-controlled QUET studies in the same patient population (n=710; mean age: 83<br />years; range: 56-99 years) the incidence of mortality in QUET -treated patients was 5.5% versus<br />3.2% in the placebo group. The patients in these trials died from a variety of causes that were<br />consistent with expectations for this population. These data do not establish a causal relationship<br />between QUET treatment and death in elderly patients with dementia.<br />Suicide/suicidal thoughts or clinical worsening:<br />Depression in bipolar disorder is associated with an increased risk of suicidal thoughts, self-harm and<br />suicide (suicide-related events). This risk persists until significant remission occurs. As improvement<br />may not occur during the first few weeks or more of treatment, patients should be closely monitored<br />until such improvement occurs. It is general clinical experience that the risk of suicide may increase in<br />the early stages of recovery.<br />Other psychiatric conditions for which quetiapine is prescribed can also be associated with an<br />increased risk of suicide-related events. In addition, these conditions may be co-morbid with<br />major depressive disorder. The same precautions observed when treating patients with major<br />depressive disorder should therefore be observed when treating patients with other psychiatric<br />disorders.<br />Patients with a history of suicide-related events, or those exhibiting a significant degree of<br />suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal<br />thoughts or suicide attempts, and should receive careful monitoring during treatment.<br />An FDA meta-analysis of placebo-controlled clinical trials of antidepressant drugs in<br />approximately 4,400 children and adolescents and 77,000 adult patients with psychiatric<br />disorders showed an increased risk of suicidal behavior with antidepressants compared to<br />placebo in children, adolescents, and young adult patients less than 25 years old. This metaanalysis&nbsp;did not include trials involving quetiapine. (See Section 5.1 Pharmacodynamic<br />Properties).<br />In addition, physicians should consider the potential risk of suicide-related events after abrupt cessation<br />of quetiapine treatment, due to the known risk factors for the disease being treated.<br />Cardiovascular disease:<br />QUET should be used with caution in patients with known cardiovascular disease, cerebrovascular<br />disease, or other conditions predisposing to hypotension.<br />QUET may induce orthostatic hypotension, especially during the initial dose-titration period; this is<br />more common in elderly patients than in young patients.&nbsp;Seizures:<br />In controlled clinical trials there was no difference in the incidence of seizures in patients treated with<br />QUET or placebo. As with other antipsychotics, caution is recommended when treating patients with a<br />history of seizure.<br />Extrapyramidal symptoms:<br />In placebo-controlled clinical trials with patients treated for schizophrenia and bipolar mania, the<br />incidence of extrapyramidal symptoms was no different from that of placebo across the<br />recommended therapeutic dose range. In short-term, placebo-controlled clinical trials in adult<br />patients for bipolar depression, the incidence of extrapyramidal symptoms was higher in<br />quetiapine treated patients than in placebo treated patients (See Section 4.8 Undesirable Effects).<br />Tardive dyskinesia:<br />As with other antipsychotics, there is potential for QUET to cause tardive dyskinesia after longterm<br />treatment. If signs and symptoms of tardive dyskinesia appear, dose reduction or<br />discontinuation of QUET should be considered.<br />Severe Neutropenia:<br />Severe neutropenia (&lt;0.5 X 109/L) has been uncommonly reported in QUET clinical trials. Most<br />cases of severe neutropenia have occurred within the first two of months of starting therapy with<br />QUET. There was no apparent dose relationship. Possible risk factors for neutropenia include<br />pre-existing low white cell count (WBC) and history of drug induced neutropenia. Quetiapine<br />should be discontinued in patients with a neutrophil count &lt;1.0 X 109/L. These patients should be<br />observed for signs and symptoms of infection and neutrophil counts followed (until they exceed<br />1.5 X 109/L) (See Section 4.8 Undesirable Effects).<br />Lactose:<br />QUET contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp<br />lactase deficiency or glucose-galactose malabsorption should not take this medicine&nbsp;</p><p>Venous thromboembolism:<br />Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since<br />patients treated with antipsychotics often present with acquired risk factors for VTE, all possible<br />risk factors for VTE should be identified before and during treatment with quetiapine and<br />preventive measures undertaken.<br />Hyperglycaemia:<br />Hyperglycemia or exacerbation of pre-existing diabetes have been reported during treatment with<br />quetiapine. Appropriate clinical monitoring is advisable in diabetic patients and in patients with<br />risk factors for the development of diabetes mellitus (See Section 4.8 Undesirable Effects).<br />Lipids:<br />Increases in triglycerides and cholesterol have been observed in clinical trials with quetiapine (See<br />Section 4.8 Undesirable Effects). Lipid increases should be managed as clinically appropriate.<br />Metabolic risk:<br />Given the observed changes in weight, blood glucose (see hyperglycaemia) and lipids seen in<br />clinical studies, there may be possible worsening of the metabolic risk profile in individual<br />patients, which should be managed as clinically appropriate (See Section 4.8).</p><p>Neuroleptic malignant syndrome:<br />Neuroleptic malignant syndrome has been associated with antipsychotic treatment, including<br />QUET (see section 4.8 Undesirable Effects). Clinical manifestations include hyperthermia, altered<br />mental status, muscular rigidity, autonomic instability, and increased creatine phosphokinase. In<br />such an event, QUET should be discontinued and appropriate medical treatment given.<br />QT prolongation:<br />In clinical studies and when used in accordance with the Summary of Product Characteristics,<br />quetiapine was not associated with a persisting extension of the absolute QT interval. QT<br />prolongation was reported with quetiapine in overdose (see section 4.9 Overdose). Quetiapine<br />should not be used especially in the elderly, in patients with congenital prolonged QT syndrome,<br />congestive heart failure, cardiac hypertrophy, hypokalaemia and hypomagnesaemia and with other<br />drugs known to prolong the QTc interval (see section 4.5).<br />Acute withdrawal symptoms<br />Acute withdrawal symptoms including nausea, vomiting, and insomnia have been rarely described<br />after abrupt cessation of high doses of antipsychotic medicinal products. When therapy is<br />discontinued in such a way, symptoms of psychosis may recur; moreover, involuntary movement<br />disorders such as akathisia, dystonia and dyskinesia were also reported. Therefore, a gradual and<br />slow withdrawal is advisable.<br />Children and adolescents (10 to 17 years of age):<br />Although not all adverse reactions that have been identified in adult patients have been observed<br />in clinical trials of children and adolescent patients, the same warnings and precautions for use<br />that appear for adults should be considered for paediatrics. Changes in blood pressure and<br />thyroid function tests and increases in weight and prolactin levels have been observed and should<br />be managed as clinically appropriate (see section 4.8 Undesirable Effects).<br />Long-term safety data including growth, maturation, and behavioural development, beyond 26<br />weeks of treatment with QUET, is not available for children and adolescents 10 to 17 years for age&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Given the primary central nervous system effects of QUET it should be used with caution in<br />combination with other centrally acting medicinal products and alcohol.<br />The pharmacokinetics of lithium were not altered when co-administered with QUET.<br />Coadministration of valproate semisodium also known as Divalproex Sodium did not cause<br />clinically significant changes in pharmacokinetics of valproic acid and quetiapine. Valproate<br />semisodium is a stable compound comprised of 1:1 molar sodium valproate and valproic acid.<br />The pharmacokinetics of quetiapine were not significantly altered following co-administration<br />with the antipsychotics risperidone or haloperidol. However co-administration of QUET and<br />thioridazine caused increases in the clearance of quetiapine.<br />Quetiapine did not cause induction of hepatic enzyme systems which play role on antipyrine<br />metabolism. However, in a multiple dose trial in patients to assess the pharmacokinetics of<br />quetiapine given before and during treatment with carbamazepine (a known hepatic enzyme<br />inducer), co-administration of carbamazepine significantly increased the clearance of quetiapine.<br />This increase in clearance reduced systemic quetiapine exposure (measured by AUC) to an average&nbsp;</p><p>of 13% of the exposure during administration of quetiapine alone; although a greater effect was<br />seen in some patients. As a consequence of this interaction, lower plasma concentrations can<br />occur, and hence, in each patient, consideration for a higher dose of QUET, depending on<br />clinical response, should be considered. Continued treatment at higher doses should only be<br />considered as a result of careful consideration of the benefit risk assessment for an individual<br />patient. It should be noted that the recommended maximum daily dose of QUET is 600-800<br />mg/day depending on the indication (see section 4.2).<br />Co-administration of QUET and phenytoin (microsomal enzyme inducer) led to a greatly increased<br />clearance of quetiapine (approximately 450%). In patients co-administered QUET and phenytoin<br />or other hepatic enzyme inducers (e.g. barbiturates, rifampicin etc.), QUET therapy should only be<br />initiated if the physician considers that the benefits of such therapy outweigh the risks of<br />discontinuing the hepatic enzyme inducer treatment. It is important that any change in the inducer<br />treatment is gradual, and if required, inducer may be replaced with a non-inducing agent (eg<br />sodium valproate) (see also section 4.4).<br />CYP3A4 is the primary enzyme responsible for cytochrome P450 mediated metabolism of<br />quetiapine. In an interaction study in healthy subjects a co-administration of quetiapine (25mg)<br />and ketoconazole (CYP3A4 inhibitor) resulted in a factor 5 to 8 increase in the AUC of<br />quetiapine. On the basis of this, concomitant use of quetiapine with azole antifungals,<br />macrolide antibiotics and strong CYP3A4 inhibitors like protease inhibitors is contraindicated.<br />It is also not recommended to take quetiapine together with grapefruit juice. The<br />pharmacokinetics of quetiapine were not altered following co-administration with cimetidine, a<br />known P450 enzyme inhibitor. The pharmacokinetics of quetiapine were not significantly<br />altered following co-administration with the antidepressants imipramine (a known CYP 2D6<br />inhibitor) or fluoxetine (a known CYP 3A4 and CYP 2D6 inhibitor).There have been reports of false positive results in enzyme immunoassays for methadone and<br />tricyclic antidepressants in patients who have taken quetiapine. Confirmation of questionable<br />immunoassay screening results by an appropriate chromatographic technique is recommended. 1<br />Concomitant use of QUET with hepatic enzyme inducers such as carbamazepine may<br />substantially decrease systemic exposure to quetiapine. Depending on clinical response, higher<br />doses of QUET may need to be considered if QUET is used concomitantly with a hepatic<br />enzyme inducer.<br />During concomitant administration of medicines that are potent CYP3A4 inhibitors (such as<br />azole antifungals and macrolide antibiotics), plasma concentrations of quetiapine can be<br />significantly higher than observed in patients in clinical trials (See Section 5.2 Pharmacokinetic<br />propts.). As a consequence of this, lower doses of QUET should be used. Special consideration<br />should be given in elderly and debilitated patients. The risk-benefit ratio needs to be considered<br />on an individual basis in all patients</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy category is C<br />Women with childbearing potential/Contraception<br />The safety and efficacy of quetiapine during human pregnancy have not been established.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy,<br />embryonal/foetal development, parturition or postnatal development (See Section 5.3). It should<br />not be used unless necessary.<br />Pregnancy<br />There is no sufficient data on use of quetiapine to pregnant women.<br />Animal studies have shown reproductive toxicity (see Section 5.3)<br />Potential risk for humans is unknown.<br />Therefore, QUET should only be used during pregnancy if the benefits justify the potential risks.<br />Following pregnancies in which quetiapine was used, neonatal withdrawal symptoms were<br />observed.<br />Lactation<br />The degree to which quetiapine is excreted into human milk is unknown. Women who are breastfeeding<br />should therefore be advised to avoid breast-feeding while taking QUET.<br />Fertility<br />Effects related to elevated prolactin levels (marginal reduction in male fertility and<br />pseudopregnancy, protracted periods of diestrus, increased precoital interval and reduced<br />pregnancy rate) were seen in rats, although these are not directly relevant to humans because of<br />species differences in hormonal control of reproduction.<br />Quetiapine had no teratogenic effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Given its primary central nervous system effects, quetiapine may interfere with activities requiring<br />mental alertness. Therefore, patients should be advised not to drive or operate machinery, until<br />individual susceptibility to this is known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported Adverse Drug Reactions (ADR) with quetiapine are somnolence,<br />dizziness, dry mouth, mild asthenia, constipation, tachycardia, orthostatic hypotension and<br />dyspepsia.<br />As with other antipsychotics, weight gain, syncope, neuroleptic malignant syndrome, leucopenia,<br />neutropenia and peripheral oedema have been associated with quetiapine. The incidences of<br />ADRs associated with quetiapine therapy, are tabulated below according to the format<br />recommended by the Council for International Organizations of Medical Sciences (CIOMS III<br />Working Group; 1995).<br />The frequencies of adverse events are ranked according to the following: Very common (&gt;1/10),<br />common (&gt;1/100, &lt;1/10), uncommon (&gt;1/1000, &lt;1/100), rare (&gt;1/10,000, &lt;1/1000) and very<br />rare (&lt;1/10,000).<br />Blood and lymphatic system disorders<br />Very common Decreased haemoglobin23<br />Common: Leucopenia27, decreased neutrophil count, eosinophils increased28<br />Uncommon: Thrombocytopenia, anaemia, platelet count decreased14<br />Unknown: Neutropenia&nbsp;Immune system disorders<br />Uncommon: Hypersensitivity (including allergic skin reactions)<br />Very rare: Anaphylactic reaction6<br />Endocrine disorders<br />Common: Hyperprolactinaemia16, decreases in total T4<br />25, decreases in free T4<br />25, decreases in total T3<br />25, increases in TSH 25<br />Uncommon Decreases in free T3 25, hypothyroidism22<br />Very rare: Inappropriate antidiuretic hormone secretion<br />Metabolism and nutritional disorders<br />Very common Elevations in serum triglyceride levels11,31, elevations in total<br />cholesterol (predominantly LDL cholesterol)12,31,<br />decreases in HDL cholesterol18,31, weight gain9,31<br />Common: Increased appetite, blood glucose increased to hyperglycaemic<br />levels 7,31<br />Uncommon: Hyponatraemia20, diabetes mellitus 1,5,6<br />Rare: Metabolic syndrome30<br />Psychiatric disorders&nbsp;Common: Abnormal dreams and nightmares, suicidal ideation and suicidal<br />behaviour21<br />Rare: Somnambulism and r related reactions such as sleep talking and<br />sleep related eating disorder<br />Nervous system disorders<br />Very common: Dizziness4, 17, somnolence2, 17, headache<br />Common: Syncope4, 17, extrapyramidal symptoms1, 22, dysarthria<br />Uncommon: Seizure1, restless legs syndrome, tardive dyskinesia1, 6<br />Cardiac disorders<br />Common: Tachycardia4, palpitations24<br />Uncommon QT prolongation 1,13, 19<br />Eye disorders<br />Common: Vision blurred&nbsp;Vascular disorders<br />Common: Orthostatic hypotension4, 17<br />Rare: Venous thromboembolism1<br />Respiratory, thoracic and mediastinal disorders<br />Common: Rhinitis, dyspnea24<br />Gastrointestinal disorders<br />Very common: Dry mouth<br />Common: Constipation, dyspepsia, vomiting26<br />Uncommon: Dysphagia1, 8<br />Rare Pancreatitis<br />Hepato-biliary disorders<br />Common Elevations in serum transaminases (ALT, AST)3, elevations in<br />gamma-GT levels3<br />Rare: Jaundice6, hepatitis<br />Skin and subcutaneous tissue disorders<br />Very rare: Angioedema6, Stevens-Johnson syndrome6<br />Pregnancy, puerperium and perinatal conditions&nbsp;Not known: Drug withdrawal syndrome neonatal (see section 4.6)<br />Musculoskeletal and connective tissue disorders<br />Very rare: Rhabdomyolysis<br />Reproductive system and breast disorders<br />Uncommon: Sexual dysfunction<br />Rare: Priapism, galactorrhoea, breast swelling, menstrual disorder<br />General disorders and administration site conditions<br />Very common: Withdrawal (discontinuation) symptoms1, 10<br />Common: Mild asthenia, peripheral oedema, irritability, pyrexia<br />Rare: Neuroleptic malignant syndrome1, hypothermia<br />Investigations</p><p>&nbsp;Rare: Elevations in blood creatine phosphokinase 15</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical trials, survival has been reported following acute overdoses of up to 30 grams of<br />quetiapine. Most patients who overdosed reported no adverse events or recovered fully from the&nbsp;reported events. Death has been reported in a clinical trial following an overdose of 13.6 grams<br />of quetiapine alone.<br />In postmarketing experience, there have been very rare reports of overdose of quetiapine alone<br />resulting in death or coma.<br />In general, reported signs and symptoms were those resulting from an exaggeration of the known<br />pharmacological effects of the active substance, i.e., drowsiness and sedation, tachycardia and<br />hypotension.<br />Treatment of overdose<br />There is no specific antidote to quetiapine. In cases of severe intoxication, the possibility of<br />multiple drug involvement should be considered, and intensive care procedures are<br />recommended, including establishing and maintaining a patent airway, ensuring adequate<br />oxygenation and ventilation, and monitoring and support of the cardiovascular system.<br />In cases of quetiapine overdose, refractory hypotension should be treated with appropriate<br />measures such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine<br />should be avoided, since beta stimulation may worsen hypotension in the setting of quetiapineinduced<br />alpha blockade).9<br />Close medical supervision and monitoring should be continued until the patient recovers.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antipsychotics<br />ATC code: NO5A H04<br />Mechanism of action:<br />Quetiapine is an atypical antipsychotic agent interacting with a broad range of neurotransmitter<br />receptors. It has a greater affinity for serotonin (5HT2) receptors in brain than for dopamine D1<br />and D2 receptors. Quetiapine and norquetiapine also have high affinity at histaminergic and<br />adrenergic &alpha;1 receptors, with a lower affinity at adrenergic &alpha;2 receptors and serotonin 5HT1A<br />receptors; however, Quetiapine has no appreciable affinity at cholinergic muscarinic or<br />benzodiazepine receptors. Quetiapine is active in tests for antipsychotic activity, such as<br />conditioned avoidance.<br />Pharmacodynamic effects:<br />As a result of pre-clinical tests which examine the tendency for EPS by antipsychotics, it has<br />been shown that Quetiapine does not produce dopamine D2 receptor supersensitivity after<br />chronic administration. Quetiapine produces only weak catalepsy at effective dopamine D2<br />receptor blocking doses. Quetiapine demonstrates selectivity for the limbic system by producing<br />depolarisation blockade of the A10 mesolimbic but not the A9 nigrostriatal dopamine-containing<br />neurones following chronic administration. Quetiapine exhibits minimal dystonic liability in<br />haloperidol-sensitised or drug-naive monkeys after acute and chronic administration.<br />Clinical efficacy:<br />Clinical trials have demonstrated that QUET is effective when given twice a day, although<br />quetiapine has a pharmacokinetic half-life of approximately 7 hours. This is further supported by&nbsp;the data from a positron emission tomography (PET) study which identified that for quetiapine,<br />5HT2 and D2 receptor occupancy is maintained for up to 12 hours. The safety and efficacy of<br />doses greater than 800mg/day have not been evaluated.<br />Schizophrenia:<br />In clinical studies, QUET has been demonstrated to be effective on both positive and negative<br />symptoms of schizophrenia. In comparative clinical studies, it has been demonstrated that QUET<br />is as effective as standard antipsychotic drugs such as chlorpromazine and haloperidol.<br />Bipolar Mania:<br />In clinical trials, QUET has been shown to be effective as monotherapy or as adjunct therapy in<br />reducing manic symptoms in patients with bipolar mania. The mean last week median dose of<br />quetiapine in responders, was approximately 600 mg and approximately 85% of the responders<br />were in the dose range of 400 to 800 mg/day.<br />Bipolar Depression:<br />In four clinical trials, which included patients who are bipolar I, bipolar II and patients with and<br />without rapid cycling courses, quetiapine has been shown to be effective in patients with bipolar<br />depression at doses of 300 and 600 mg/day, however, no additional benefit was seen with the 600<br />mg dose during short-term treatment.<br />In all studies, quetiapine XR was superior to placebo in reduction of Montgomery-Asberg<br />Depression Scale (MADRS) total score. The antidepressant effect of quetiapine was significant<br />at Day 8 (Week 1) and was maintained through the end of the studies (Week 8).<br />Treatment with either quetiapine 300 or 600 mg at bedtime reduced depressive symptoms and<br />anxiety symptoms in patients with bipolar depression. There were fewer episodes of treatment<br />emergent mania with either dose of quetiapine than with placebo.<br />In 3 out of 4 studies, for the 300 mg and 600 mg dose group, statistically significant<br />improvements over placebo were seen in reductions in suicidal thinking as measured by MADRS&nbsp;item 10 and in 2 out of 3 studies, for the 300 mg dose group, overall quality of life and<br />satisfaction related to various areas of functioning, as measured using the Quality of Life<br />Enjoyment and Satisfaction Questionnaire (Q-LES-Q).<br />In two bipolar depression clinical trials, maintenance of antidepressant efficacy was established.<br />These trials included an 8-week placebo-controlled acute phase, followed by a placebocontrolled<br />continuation phase of at least 26 weeks but up to 52-weeks in duration. Patients were<br />required to be stable at the end of the acute phase in order to be in the randomized into the<br />continuation phase. In both trials, quetiapine was superior to placebo in increasing the time to<br />recurrence of any mood event (depressed, mixed or manic). The risk reduction from the pooled<br />trials was 49%. The risk of a mood event for quetiapine versus placebo was reduced by 41% for<br />the 300 mg dose and by 55% for the 600 mg dose.<br />Preventing recurrence in maintenance treatment of bipolar disorder:<br />The efficacy of quetiapine in the monotherapy treatment for recurrence prevention was<br />established in 1 placebo-controlled trial in 1226 patients who met DSM-IV criteria for Bipolar I<br />Disorder. The trial included patients whose most recent mood episode was manic, mixed, or<br />depressive, with or without psychotic features. In the open-label phase, patients were required to<br />be stabilised on quetiapine for a minimum of 4 weeks in order to be randomized. In the<br />randomization phase, patients either continued treatment with quetiapine (300 to 800 mg per day:<br />average dose 546 mg per day) or were to receive lithium or placebo for up to 104 weeks.<br />quetiapine was superior to placebo in increasing the time to recurrence of any mood event&nbsp;(manic, mixed, or depressive), the primary endpoint. The risk reductions were 74%, 73%, and<br />75% for mood, manic and depressive events, respectively.<br />The efficacy of quetiapine in the combination treatment for recurrence prevention was<br />established in 2 placebo-controlled trials in 1326 patients who met DSM-IV criteria for Bipolar I<br />Disorder. The trials included patients whose most recent mood episode was manic, mixed, or<br />depressive, with or without psychotic features. In the open-label phase, patients were required to<br />be stabilised on quetiapine in combination with mood stabilizer (lithium or valproate) for a<br />minimum of 12 weeks in order to be randomized. In the randomization phase, patients either<br />continued treatment with quetiapine (400 to 800 mg per day average dose 507 mg per day) in<br />combination with mood stabiliser or received placebo in combination with mood stabiliser for up<br />to 104 weeks. quetiapine was superior to placebo in increasing the time to recurrence of any<br />mood event (manic, mixed or depressive), the primary endpoint. The risk reductions were 70%,<br />67%, and 74% for mood, manic and depressive events, respectively.<br />Suicide/Suicidal thoughts or Clinical worsening:<br />In short-term placebo-controlled clinical trials across all indications and age groups, the incidence<br />of suicide related events was 0.8% (75/9238) for quetiapine and 0.8% (37/4745) for placebo.<br />In the trials of patients with schizophrenia, the incidence of suicide related events was 1.4%<br />(3/212) for quetiapine and 1.6% (1/62) for placebo in patients 18 to 24 years of age; 0.8%<br />(13/1663) for quetiapine and 1.1% (5/463) for placebo in patients  25 years of age; and 1.4%<br />(2/147) for quetiapine and 1.3% (1/75) for placebo in patients &lt; 18 years of age.<br />In the trials of patients with bipolar mania, the incidence of suicide related events in was 0% for<br />both quetiapine (0/60) and placebo (0/58) in patients aged between 18 and 24; 1.2% or both<br />quetiapine (6/496) and placebo (6/503) in patients  25 years of age; 1.0% for quetiapine (2/193)<br />and 0% for placebo (0/90) in patients &lt; 18 years of age.<br />In the trials of patients with bipolar depression the incidence of suicide related events was 3.0%<br />(7/233) for quetiapine and 0% (0/120) for placebo in patients aged between 18-24 and 1.8% for<br />both quetiapine (19/1616) and placebo (11/622) in patients &ge; 25 years of age. There have been no<br />trials conducted in patients &lt;18 years of age with bipolar depression (See Section 4.4 Special<br />warnings and precautions for use).<br />Cataracts/lens opacities:<br />In a clinical trial to evaluate the cataractogenic potential of quetiapine (200-800 mg/day) versus<br />risperidone (2-8 mg) in patients with schizophrenia or schizoaffective disorder, the percentage of<br />patients with increased lens opacity grade (LOCS II Lens opacity grading system; nuclear<br />opacity, cortical and posterior subcapsular standards for LOCS II) was similar in respect of 2-<br />year event incidence, for patients with at least 21 months of exposure (See Section 5.3 Preclinical<br />safety data) 4.<br />Children and adolescents (10 to 17 years of age):<br />Bipolar Mania:<br />The efficacy of quetiapine in the acute treatment of manic episodes associated with bipolar I<br />disorder in children and adolescents (10 to 17 years of age) was demonstrated in a 3-week,<br />double-blind, placebo-controlled, multicenter trial. Patients who met DSM-IV diagnostic criteria<br />for a manic episode were randomized into one of three treatment groups: Quetiapine 400 mg/day<br />(n = 95), Quetiapine 600 mg/day (n = 98), or placebo (n = 91). Study medication was initiated at&nbsp;50 mg/day and on day 2 increased to 100 mg/day (divided doses given two or three times daily).<br />Subsequently, the dose was titrated to a target dose of 400 mg/day or 600 mg/day using<br />increments of 100 mg/day, given in divided doses two or three times daily. The primary efficacy<br />variable was the mean change from baseline in total YMRS score.<br />Results of trial demonstrate that Quetiapine 400 mg/day and 600 mg/day were superior to<br />placebo. No additional benefit was seen with the 600 mg dose compared to 400 mg dose.<br />Schizophrenia:<br />The efficacy of quetiapine in the treatment of schizophrenia in adolescents (13&ndash;17 years of age)<br />was demonstrated in a 6-week, double-blind, placebo-controlled trial. Patients who met DSM-IV<br />diagnostic criteria for schizophrenia were randomized into one of three treatment groups:<br />quetiapine 400 mg/day (n = 73), quetiapine 800 mg/day (n = 74), or placebo (n = 75). Study<br />medication was initiated at 50 mg/day and on day 2 increased to 100 mg/per day (divided and<br />given two or three times per day). Subsequently, the dose was titrated to the target dose of 400<br />mg/day or 800 mg/day using increments of 100 mg/day, divided and given two or three times<br />daily. The primary efficacy variable was the mean change from baseline in total Positive and<br />Negative Syndrome Scale (PANSS).<br />Results of trial demonstrate that quetiapine at 400 mg/day and 800 mg/day was superior to<br />placebo. No additional benefit was seen with the 800 mg dose compared to 400 mg dose.<br />Weight gain in children and adolescents:<br />In one 6-week, placebo-controlled trial in adolescent patients (13-17 years of age) with<br />schizophrenia, the mean increase in body weight, was 2.0 kg in the quetiapine group and 0.4 kg<br />in the placebo group. Twenty one percent of quetiapine-treated patients and 7% of placebotreated<br />patients gained &ge; 7% of their body weight.<br />In one 3-week, placebo-controlled trial in children and adolescent patients (10-17 years of age)<br />with bipolar mania, the mean increase in body weight was 1.7 kg in the quetiapine group and 0.4<br />kg in the placebo group. Twelve percent of quetiapine-treated patients and 0% of placebo-treated<br />patients gained &ge; 7% of their body weight.<br />In the open-label study that enrolled patients from the above two trials, 63% of patients<br />(241/380) completed 26 weeks of therapy with quetiapine. After 26 weeks of treatment, the mean<br />increase in body weight was 4.4 kg. Forty five percent of patients gained &ge; 7% of their body<br />weight, not adjusted for normal growth. In order to adjust for normal growth over 26 weeks an<br />increase of at least 0.5 standard deviation from baseline in BMI was used as a measure of a<br />clinically significant change; 18.3% of patients on quetiapine met this criterion after 26 weeks of<br />treatment.<br />Extrapryamidal symptoms&nbsp;in children and adolescent population:<br />In a short-term placebo-controlled monotherapy trial with quetiapine in adolescent patients (13-<br />17 years of age) with schizophrenia, the aggregated incidence of extrapyramidal symptoms was<br />12.9% for quetiapine and 5.3% for placebo, though the incidence of the individual adverse events<br />(e.g. akathisia, tremor, extrapyramidal disorder, hypokinesia, restlessness, psychomotor<br />hyperactivity, muscle rigidity, dyskinesia) did not exceed 4.1% in any treatment group. In a<br />short-term placebo-controlled monotherapy trial with quetiapine in children and adolescent<br />patients (10-17 years of age) with bipolar mania, the aggregated incidence of extrapyramidal<br />symptoms was 3.6% for quetiapine and 1.1% for placebo.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption:<br />The bioavailability of quetiapine is not significantly affected by administration with food.<br />Quetiapine is well absorbed and extensively metabolised following oral administration.<br />Distribution:<br />Quetiapine is approximately 83% bound to plasma proteins. Steady-state peak molar<br />concentrations of the active metabolite norquetiapine are 35% of that observed for quetiapine.<br />The elimination half-life of quetiapine and norquetiapine are approximately 7 hours and 12<br />hours, respectively.<br />Clinical trials have demonstrated that quetiapine is effective in schizophrenia and mania when<br />given twice a day. This is further supported by the data from a positron emission tomography<br />(PET) study which identified that for quetiapine, 5HT2 and D2 receptor occupancy is maintained<br />for up to 12 hours.<br />Biotransformation:<br />In vitro investigations established that CYP3A4 is the primary enzyme responsible for cytochrome<br />P450 mediated metabolism of quetiapine.<br />Elimination:<br />The elimination half-life of quetiapine is approximately 7 hours.<br />Quetiapine is extensively metabolised by the liver, with parent compound accounting for less than<br />5% of unchanged drug-related material in the urine or faeces, following the administration of radio<br />labelled quetiapine. Approximately 73% of the radioactivity is excreted in the urine and 21% in the<br />faeces.<br />Linearity/Nonlinearity<br />The pharmacokinetics of quetiapine and norquetiapine are linear within the approved dosage<br />range. The pharmacokinetics of quetiapine is linear and there is no difference between men and<br />women as to the kinetics of quetiapine. The mean clearance of quetiapine in the elderly is<br />approximately 30 to 50% lower than that seen in adults aged 18 to 65 years.<br />Characteristics of patients<br />Age:<br />The&nbsp;mean clearance of quetiapine in the elderly was reduced approximately by 30 to 50%<br />compared to adults aged between 18 and 65 years.<br />Children and adolescents (10 to 17 years of age):<br />At steady-state the pharmacokinetics of the parent compound, in children and adolescents (10-17<br />years of age), were similar to adults. However, when adjusted for dose and weight, AUC and<br />Cmax of the parent compound were 41% and 39% lower, respectively, in children and<br />adolescents than in adults. For the active metabolite, norquetiapine, AUC and Cmax were 45%<br />and 31% higher, respectively, in children and adolescents than in adults. When adjusted for dose<br />and weight, the pharmacokinetics of the metabolite, norquetiapine, was similar between children<br />and adolescents and adults (See 4.2. Posology and method of administration).&nbsp;Renal impairment:<br />The mean plasma clearance of quetiapine was reduced by approximately 25% in subjects with<br />severe renal impairment (creatinine clearance less than 30 mL/min/1.73m2), but the individual<br />clearance values are within the range for normal subjects. The average molar dose fraction of<br />free quetiapine and the active human plasma metabolite norquetiapine is &lt;5% excreted in the<br />urine.<br />Quetiapine is extensively metabolised by the liver with parent compound accounting for less than<br />5% of unchanged drug-related material in the urine or faeces, following the administration of<br />radiolabelled quetiapine. Approximately 73% of the radioactivity is excreted in the urine and<br />21% in the faeces.<br />Hepatic impairment:<br />The mean plasma clearance of quetiapine is reduced by approximately 25% in subjects with<br />hepatic impairment (stable alcoholic cirrhosis). Since quetiapine is extensively metabolised by<br />the liver, higher plasma levels are expected in the hepatically impaired population, and dosage<br />adjustment may be needed in these patients (see section 4.2). It should not be used in patients<br />with severe hepatic impairment.<br />Drug-drug interaction:<br />In a multiple-dose trial in healthy volunteers to assess the pharmacokinetics of quetiapine given<br />before and during treatment with ketoconazole, co-administration of ketoconazole resulted in an<br />increase in mean Cmax and AUC of quetiapine of 235% and 522%, respectively, with a<br />corresponding decrease in mean oral clearance of 84%. The mean half-life of quetiapine<br />increased from 2.6 to 6.8 hours, but the mean tmax was unchanged.<br />Quetiapine and several of its metabolites (including norquetiapine) were found to be weak<br />inhibitors of human cytochrome P450 1A2, 2C9, 2C19, 2D6 and 3A4 activities in vitro. In vitro<br />CYP inhibition is observed only at concentrations approximately 10 to 50 fold higher than those<br />observed at a dose range of 300 to 450 mg/day in humans. Based on these in vitro results, it is<br />unlikely that coadministration of quetiapine with other medicines will result in clinically<br />significant medicine inhibition of cytochrome P450 mediated metabolism of the other medicine.<br />In vitro investigations established that CYP3A4 is the primary enzyme responsible for<br />cytochrome P450 mediated metabolism of quetiapine. Norquetiapine is primarily formed and<br />eliminated via CYP3A4.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute toxicity studies:<br />Quetiapine has low acute toxicity. Findings in mice and rats after oral (500 mg/kg) or<br />intraperitoneal (100 mg/kg) dosing were typical of an effective neuroleptic agent and included<br />decreased motor activity, ptosis, loss of righting reflex, fluid around the mouth and convulsions.<br />Repeat-dose toxicity studies:<br />In multiple-dose studies in rats, dogs and monkeys, anticipated central nervous system effects of<br />an antipsychotic drug were observed with quetiapine (e.g. sedation at lower doses and tremor,<br />convulsions or prostration at higher exposures).<br />Hyperprolactinaemia, induced through the dopamine D2 receptor antagonist activity of<br />quetiapine or its metabolites, varied between species but was most marked in the rat, and a range<br />of effects consequent to this were seen in the 12-month study, including mammary hyperplasia,<br />increased pituitary weight, decreased uterine weight and enhanced growth of females.Reversible morphological and functional effects on the liver, consistent with hepatic enzyme<br />induction, were seen in mouse, rat and monkey.<br />Thyroid follicular cell hypertrophy and concomitant changes in plasma thyroid hormone levels<br />occurred in rat and monkey. Pigmentation of a number of tissues, particularly the thyroid, was<br />not associated with any morphological or functional effects.<br />Transient increases in heart rate, unaccompanied by an effect on blood pressure, occurred in<br />dogs.<br />Posterior triangular cataracts seen after 6 months in dogs at 100 mg/kg/day were consistent with<br />inhibition of cholesterol biosynthesis in the lens. No cataracts were observed in Cynomolgus<br />monkeys dosed up to 225 mg/kg/day, nor in rodents. Monitoring in clinical studies did not reveal<br />drug-related corneal opacities in man. (See Section 5.1 Pharmacodynamic properties) 4.<br />No evidence of neutrophil reduction or agranulocytosis was seen in any of the toxicity studies.<br />Carcinogenicity studies<br />In the rat study (doses 0, 20, 75 and 250 mg/kg/day) the incidence of mammary adenocarcinomas<br />was increased at all doses in female rats, consequential to prolonged hyperprolactinaemia.<br />In male rat (250 mg/kg/day) and mouse (250 and 750 mg/kg/day), there was an increased<br />incidence of thyroid follicular cell benign adenomas, consistent with known rodent-specific<br />mechanisms resulting from enhanced hepatic thyroxine clearance.<br />Reproduction Studies<br />Effects related to elevated prolactin levels (marginal reduction in male fertility and<br />pseudopregnancy, protracted periods of diestrus, increased precoital interval and reduced<br />pregnancy rate) were seen in rats, although these are not directly relevant to humans because of<br />species differences in hormonal control of reproduction.<br />Quetiapine had no teratogenic effects.Mutagenicity studies<br />Genetic toxicity studies with quetiapine show that it is not a mutagen or clastogen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>List of excipients<br />Dibasic calcium phosphate dihydrate<br />Lactose monohydrate<br />Povidone<br />Sodium starch glycolate<br />Magnesium stearate<br />Colloidal silicon dioxide<br />Microcrystalline cellulose<br />Sodium stearyl fumarate<br />Hydroxypropylmethylcellulose<br />Titanium dioxide (E 171)<br />Polyethylene glycol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unknown</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Opaque PVC/printed aluminum foil blister containing 10 film-coated tablets.<br />Each cardboard box contains 30 or 60 film coated tablets.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If applicable, unused products or waste materials must be disposed per &ldquo;Legislation for Control<br />of Medical Wastes&rdquo; and &ldquo;Legislation for Control of Packages and Package Wastes</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Deva Holding A.Ş.
Halkalı Merkez Mah. Basın Ekspres Cad.
No:1 34303 Küçükçekmece-İSTANBUL
Tel: + 90 212 692 92 92
Fax: + 90 212 697 00 24
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                26.11.2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="data:image/jpg; base64,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&#x2B;jp6vHy8/T19vf4&#x2B;fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4&#x2B;Tl5ufo6ery8/T19vf4&#x2B;fr/2gAMAwEAAhEDEQA/AP38ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorzj47/te/DH9mSz87x5448O&#x2B;GXZDJHbXd2PtcyjukC5lf8A4Cpr4n/aG/4OSvhd4Ht5rb4d&#x2B;HNe8d6gMhLm6H9lWHswLhpm9dpiXPqO30GU8K5vmdvqOHlJPra0f/AnaP4n0mT8IZzmrX1DDSmn9q1o/wDgTtH8T9H81z/xF&#x2B;K/hf4Q6C2qeK/EWh&#x2B;GtNXObrVL6K0h45I3SMAT7V&#x2B;EPx//AOC&#x2B;P7QPxqhuLTS9Y0vwDps2V8vQLTZcFfe4lLyK3&#x2B;1GU/Cvj7xl471z4ja7JqniHWdV17U5v9Zd6jdyXU8n1dyWP4mv1HKPBHHVbTzGvGmu0VzP79EvlzH6xk3gNj6tp5nXjTXaK5n83ol8uY/c79oL/g4Z&#x2B;BfwnW5tvC5134ianDlUGnWxtbIuOzTzbTt/2o45Ae2RXPfsmf8ABxX8M/jBqS6X8R9IuvhrqM85S3u/ON/pjqT8vmSqivE3YlkKcZLKOB&#x2B;HtFfoMfBzh5YZ0GpuT&#x2B;3ze8vRW5f/ACU/SI&#x2B;CfDawroWm5v7fN7y9FZR&#x2B;&#x2B;J/WH4V8XaV460C11bRdSsNY0u&#x2B;QSW95ZXCXFvOp/iR0JVh7g1o1/Lr&#x2B;zf8AtffEj9knxSurfD/xZqmgS7t01sknmWd3xjEsD5jk47spI6gg4Nfp1&#x2B;x7/wAHJOj6&#x2B;8Gk/Grw7/YVwQqDXtCiee0Y9C01sSZIx3zGZMn&#x2B;ACvyjiLwfzbA3q4F&#x2B;3h5aTX/AG71/wC3W2&#x2B;yPx/ibwXzjL71cvf1in5K01/27rf/ALdbb7I/VCiuR&#x2B;DPx68GftD&#x2B;EI9e8D&#x2B;JtH8UaS52mewuFl8puuyRfvRv/suAw9K66vyitRqUpunVi4yW6as16pn4/Wo1KM3SqxcZLRpqzT809gooorMzCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiignAoAKKje6Re&#x2B;fpUL3rH7oxQBapjzqnVqqNKz9WNNoAsPff3V/OopJ2lUgng9qZRQB43&#x2B;1V&#x2B;wL8K/2ytC&#x2B;y&#x2B;OPC9ndXsaFbbVrUfZtStOONkyjJA67H3J6qa/Ln9sP/g3e8efC959W&#x2B;E&#x2B;pDx9oqhnOm3ZjtdWtwOy5Iin47qUYngIa/aqivsOHeO84yZqOFq3h/JLWPyW6/7daPtuGfEDOsjajhKvNT/kl70fkt4/9utH8p/jLwVrHw68TXmi&#x2B;INK1HRNY09/LubK&#x2B;t3t7i3b0ZHAZT35FZdf08ftG/sd/DT9rPQP7P8AH3hHSde2oUhu3j8u9tev&#x2B;qnTEidc4DYPcGvy5/bF/wCDc/xV4JafVvg3rP8Awl2m5LHRNVljttShHXEc3ywzf8C8sjgDca/fuG/F7KswtRx37ip5u8G/KXT/ALeSXmz&#x2B;iOF/GbKMxtRx/wDs9T&#x2B;87wb8pdP&#x2B;3kl5s/M2itz4i/DPxF8IvFt1oPinQ9U8Pa1ZnE1lqFs9vNHnodrAHB6g9CORkVh1&#x2B;sU6kZxU4O6ezWqZ&#x2B;v06kakVODTT1TWqa8goooqizqvg/wDHHxh8APGEOveC/Emr&#x2B;GdWgYEXFhcNEZADna6j5ZE9VcFT3Br9Jv2Qv&#x2B;DkzWNHuLXSfjR4bj1azxsOvaDEsN2p/vS2zERv7mMx4A4RjX5X0V85n3CeVZxDlx9FSfSS0kvSS1&#x2B;TuvI&#x2B;Z4g4PyjOocuYUVJ9JLSS9JLX5O68j&#x2B;ob9m39sn4Z/tc&#x2B;H21D4feLtK8QCFA9xaxuY720B4/e27hZUGeMsuD2Jr06v5PvB/jXWPh74ht9X0HVtS0TVbNt0F5YXL29xCfVXQhh&#x2B;Br9AP2O/wDg4j&#x2B;JHwfNrpPxPsI/iNoSEIb9StrrFunAzvA8ubA7Oqsx6yV&#x2B;FcR&#x2B;C2MoXq5RP2sf5ZWUvk9Iy/8AJfRn8/8AE3gbjcPetk1T2sf5JWU/k9Iy/wDJfRn7g0V4X&#x2B;yj/wAFIfg/&#x2B;2ZFHD4K8XWcmtMhd9Evx9k1KPAy2IX5kC92jLqPWvdM1&#x2B;M4zA4nB1XQxUHCa6STT&#x2B;5n4jjsvxOCrPD4unKnNbqSaf3MKKKK5TjCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooprSqnVhQA6ioXvVH3RmoXu3f/AGfpQBbZwvU4qJ7xV6fNVUnJooAme8ZumFqJmL9TmkooAKKKzfGXiCHwp4T1LUp7hbSGwtpJ3ne3e4SAKpO9o0&#x2B;ZlXqQpBwDyOtOMW3ZEykormZpUV4B&#x2B;x94E&#x2B;Llj4q8ReKPHvxI8N&#x2B;LvDniMi40TT9DBnsLWJjvV4ZXQSBcEgAvKGVhyCoLP/a6/bC039mq6trpvHnwt077Op&#x2B;26F4gvJob64HUNC1sJZV9CDbSA8HK9D3f2fOWI&#x2B;r0Wpvyvv22&#x2B;Xa/U8z&#x2B;1qcML9bxEXTj/ecU7X33tZ773t0L/wDwUC8beOvCf7NWuQ/DC60uH4gagixaXHc3kMFw6b185rdZSFeZUJ2qe5yMnCnzz9lT9vi4s/hVoukfF3TfiRZePLO2A1a6n&#x2B;HepW9u8mfW3jljIHA8wbFbGQq5xXHWPxH&#x2B;BP8AwW5&#x2B;HbeHrq31PTvFHhuZ5rSR7RvOsHBXdJDMyeXLBIFAMcgVmUAtGjBSPF/2t/gd8Wv2Vfgp4n1LQf2ktA8OeD9Lsw1loWkXNzZT3UifKsNsJbiZ4Gbd9yCUJkZCDrX0eCy2hKksuxS5KvNfWLT1sklJKV0&#x2B;1lrfXqfGZlnWKhWec4F&#x2B;0w/JZcslKOl224NwtJPRvmbtZWvofon8PP2kfAfxW1htN8P&#x2B;LND1DVo08yTTRciO/iX&#x2B;81u&#x2B;JVHuVFdtX5v/APBKr/gnn8F/jf8ACnQfjJeXHjDxd4surlpLl9X1F4f7N1CF/nZPJKNIc4YO7vkMpwpyB&#x2B;jzOsERZmCqgySx6Aeprwc4wmHw2IdChKT5dHzK1mu2uv3I&#x2B;q4dzDGY3BxxWKhGPMk48snK8Xqr6aPyTfyHUVl6X420nWtfvNKtdQtZtS09Y5Li2WQebGjruR9vUo3IDDKkqwzlSBqZryz3jg/jx&#x2B;zB8P8A9pzw5/Zfjzwlovia1VSsTXcH7&#x2B;2z1MUy4kiPujA1&#x2B;Y/7X/8Awbg6hpEV9rPwY8RnVI1DSp4d1t1juPXZDdDCN6ASqnA5cmv10or6jh/jLNsml/sVV8vWL1i/k9vVWfmfWcN8bZxkcr4Cs&#x2B;XrB6wfye3qrPzP5Zfi78EPGHwD8VyaH408N6x4Z1SMn9xqFq0JkAONyEjDr6MpKnsTXK1/Ux8ZPgX4P/aE8GzeH/G3hzSvEujzHd9nvoBII2/vo33o3HZkIYetfmf&#x2B;1/8A8G4EM5vta&#x2B;C/iTyW&#x2B;aVPDmuOWT18uC6HI9FEqntuk6mv3zhvxjy7GWo5nH2M&#x2B;&#x2B;8H894/PRfzH9EcL&#x2B;NmWY21HNY&#x2B;wn33g/nvH5qy/mPyXortvjh&#x2B;zf48/Zr8T/2P488Ka14XvmJ8sXtuVjuAOrRSDKSr/tIzD3ria/X6OIp1oKrRkpRezTun6NaM/ZsPiKVemqtGSlF7NNNP0a0YUUUVqbE2n6jcaRfQ3VrPNa3Vu4kimicpJEw5DKw5BHqK&#x2B;1f2Pv8AgvB8Zf2amh07xJdf8LO8Nx4X7NrVwwv4VH/PO8wz/wDf0SD0Ar4kory82yPAZnS9jj6UakfNar0e69U0eTnGQ5fmtH2GYUY1I&#x2B;a1Xo90/NNM/on/AGQf&#x2B;CyXwT/a2tba1j8QReDPE0uEbRvEEqWsjue0MpPlTZOcBW3nugr6tVg65HIPQ&#x2B;tfyV19Sfscf8FgPjP&#x2B;xw1np9jrreKvCdqBGNB1xmuLeKMfwwSZ8yHAzgK2wZ5Q1&#x2B;H8R&#x2B;Ce9bJan/bk/wAlL8k16yPwbibwJWtbI6v/AG5P8lL8lJesj&#x2B;jCivh39kD/AIL2fBv9o4W&#x2B;m&#x2B;Kbhvhj4kkwvkaxOG0&#x2B;Zj/zzvAAgH/XVY&#x2B;vGa&#x2B;29M1S21rT4bqzuILq1uEEkU0MgkjlU8hlYcEH1FfiGbZHj8sq&#x2B;xx9KVOXmtH6PZ&#x2B;qbPwbOMhzHKq3sMwoypy81o/R7P1TZPRRRXlHjhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFGcVG9yqd8/SgCSiq73pP3R&#x2B;dQvO0nVqALjzqnVqhe&#x2B;/ur&#x2B;dV6KAJHuHf8Ai/Ko6KKACiiigAozk1leM9CvvEmgS2mna1feH7pypS9tIYJpY8HJAWaN0II4OVzzwRXgnxS8d6jD8WtJ0zxx8LdWuIYDctoPiTw5qjXOoSeSEYt5UKxyIXBDeUCw4b5WVWauHGY1YdXkn0V9bau2rSdvVpLVK55&#x2B;OzBYZXlF6tJPW127auKk16tJXaV&#x2B;30B4n8SQeEtEm1C6ivpre3G6QWlpLdzAeoiiVnb6KpPtXGfAz9pnw38fpdXt9J&#x2B;32l/oty1vcWeoWr2s7Lk7ZkRwGMbgZBIDDoyqeK8a8W&#x2B;M/jF&#x2B;0B4V1Tw/4T8J&#x2B;JNF026aP7L4i8S3R8OahZSJIHJMds3myo2MfKkfBIO7NepfCL4A65omh28Xj7xRF46vLbbLZzzaesNxpMuPm8i5DecR1AdjvI7jpXDTzCvXxC&#x2B;rwfs7atxsm/Jtr1vFSTvZ26ebSzPE4nFRWGg/ZW1co2TeuzbT7NOMZp3s7dOu8T/FBfCnjLT9Jn8P&#x2B;KLmDUhhNSstON3ZwN02ymMtJH2&#x2B;ZkC/N97AYhviXS/GB8c6beaNq&#x2B;jroKjbqOnXtkzTSf7UM6ONh9nRxx2zx1EEQt4UjUsVQBQWYsxx6k8k&#x2B;5qrqniHT9EuLSG9vrOzl1CXyLVJ5lja5kxnYgJ&#x2B;ZsAnAya9Z0pSupSdr3VtLeV1uv6dz2nRlK6nJ2umraNeV1uvX0dzxf4rf8E7vhz8UpbqSJfE/hGS&#x2B;mNxdDwxrtzpUN1ITuLvBG/kFy2SX8vcSSSc1wfws/4Ip/s&#x2B;/DHVTfTeFbzxXebzIJNfv3u0BPJzEuyJ8/7aNX0N4q&#x2B;OHg7wL470fwvrXifQ9J8ReIIpZtM068vUguNQSIFpDErEF9igltucDk4rzpP249Hn&#x2B;Kr&#x2B;F18N&#x2B;JLH&#x2B;zGnOt3etRxaImkQxIWN0q3jxG8tsK2ZrIzooRixA27vYp5xjoQ9nCrJLybPPq8O5XVqqtUw8HJdXFP9LXPX/CvhHSfAuhW&#x2B;l6Jpmn6Pptqu2G0sbZLeCEeiogCj8BWDr3wB8B&#x2B;KrlptU8E&#x2B;EdSmY7mkutHt5mY&#x2B;pLITXJ/Cz9uX4U/H7wj4i1b4e&#x2B;OfDHjb/hGIHmvbfTdThEseFJUN5jKEVyNqyOVjJ/iwCR59&#x2B;xj/AMFYfhf&#x2B;2/rS6P4bTxHo&#x2B;vSW/npaapYBopMDLKtzbvLbF16GMyrJwfl4OOGNWafMm7&#x2B;p6ksPTlHklFNLpbQ&#x2B;jNM0nTfBXh9bWxtbDSdMsYyUhhjW3t7dBknCrhVUcnsOtfOXg7/goR8I/wBpbSPEvhfVNY0W40mSGWzvtS0PxBFq2jy27go0jXtk/mWa4YDzLpLblhsZuGqp&#x2B;118YLzSvh/NpHiqx&#x2B;N3hvWrzTrnT2uPh94Vl8S2OrCSMoSoS3uFiBJyon&#x2B;zyg8byvzH58/4JX/8Eu18TfBrwL4m&#x2B;Lkfxq0/WvhzfTweD9E1vWhotvptqpHlXkVlYMklvJKuBIk8juWVgxdSGbNtt3ZrGKSsjrv21v2SPHngP4X&#x2B;F1/Z3mez&#x2B;G/hfSknsvD&#x2B;mw2moWliYC0q3VpueC7jmkjeVfNtrppJDJ/Blmfpv&#x2B;CXP7TXxY/al8CWfi1dIvv&#x2B;Fb3zY0298RXtpJLqcAkKNLbvbzT3ELxEMrQXn2hnZT/pMeNtfSniSy8A&#x2B;HY4vA91Ivhq31IPcw2tpPcaRb3LTyOHSOaIxo0juzs0SuXJbeV&#x2B;YMed8JaV4P8A2JrPw34D8K&#x2B;E9G8GfDvyrq4N79r&#x2B;y2VlNuLmMZVgZJGbcTM8a4ztZ2Gygd9D2SivhH9ob9peD4yfGjwl4m8B6j4q1b/hBFnbUdL0y3TVtN06U/eupJ45E0dZo4i433Oo5jUuFiDbt3un7KfxA&#x2B;L3xbk0/wASa4fBUHw91K0aazXyJ/7euieEaQKRbQrwThTLuBBDAEZBWPeqKKKBHPfFD4TeGfjX4PufD/i7QdL8RaLdj97Z39us0RPZgGHysOzDBB5BFfnF&#x2B;2P/AMG5Xh/xV9o1j4L61/wjV5y50HWJpJ7GT2inw0sf0fzASeqiv0&#x2B;or6DIeKs0yepz4Cq4rrHeL9YvT579mfScP8W5tktTny6s4rrHeL9YvT579mfzv&#x2B;EP&#x2B;CMP7R/i74g3Hh7/AIV3eaW9nJsn1DULqGHT0H99ZtxWVf8ArlvPtmvtH9nX/g2n0rTZorz4qePLjUyAC2meHIvs8W7/AGrmYFmXtgRIf9qvvfXPjH4q1zxxd&#x2B;GdL03SPB92svlWt94mZ5Tfjr5lrbwkR3Ckc7RdJInG9Fzisv42/sx&#x2B;Lvib8M76xs/iVqkfiKZR5Nxe2q/2Yn95DaW7QiRG6YnabA6hq&#x2B;9zLxUz7FqNP2kMOna7gm3r1u&#x2B;ay9GmvM&#x2B;lzvx14kxtKUMDFQsrPkSTbW6vNtp9rJevU&#x2B;R/2iv&#x2B;CEvwF&#x2B;KqNovwv8VW/gfxxp0IX7CdW/tSO4IGSZ4JJDMjHH3kYAcnY3Svzb/a1/4Jn/GD9jS9upPFXhe6utAgb5df0tWu9MkXOAWkAzFn&#x2B;7KqH2PWv0&#x2B;i/aU&#x2B;Iv7C/hG38IftC/B/Sde&#x2B;HtrIptfFngbT4xY2pU/LJLbKsawyBsMHAhYY&#x2B;VWIzX0x8CvjhoPx78KLq/wr8caP460FkK3Wi6vO7XVsCMbTKym4iPJJFxHLv4AZBzXVlPiBn2TpOvL6xR7yd7&#x2B;lRXab7TTseVwT9ILNsLU&#x2B;q4yXtnu6dS8ase9m/ekl/MudPoj&#x2B;a2iv3G/af/4JA/Ar9p/VLmPTdNvfgr8QboloEhhSOyv5Dk/LAG&#x2B;zzjqSLaRWXI34PFfm3&#x2B;2D/wAEhPjN&#x2B;x5FPqWoaGPFXheIsf7a0FXuoYUHO6ePaJIeOrMuwHgOa/ZuH/EXJ81apKfs6j&#x2B;zOyb/AML&#x2B;GXlZ38j&#x2B;puFfFLIc8tTo1fZ1XpyT0d&#x2B;yez9L83dI&#x2B;Xa9v/ZT/wCCi/xg/Yzmjj8D&#x2B;Lry30dXLvot6PtemSknLfuXyELd2jKMf71eIUV9jjMDh8ZSdDFQU4PpJJr7mfd47AYbGUXh8XTU4PdSSa&#x2B;5n7dfsd/8HFPw8&#x2B;LL2mj/ABS02T4ea1IoU6lEWutInfpyQDLBk9mDKO8lfoL4L8daL8R/DlvrHh/V9M1zSbxd0F5YXSXNvMP9l0JU/ga/lAr0j9nT9r34lfsm6&#x2B;2ofD7xhrHhuSZw89vDIJLS7I6ebA4aKTA4BZSRnjFfjPEXgtg8RerlE/ZS/lldw&#x2B;T1lH/yb0R&#x2B;I8TeBuBxF62TVPZS/lldw&#x2B;T1lH/yb0R/UZRX5Ufsg/8ABybpepW9rpPxp8NyabdZCHXtAiMlsw/vS2zEunuY2fJPCKK/Sn4M/Hrwb&#x2B;0N4Ph1/wAE&#x2B;JdI8TaTMqt51jcCTyiRkLIv3o39UcBh3Ar8Kz7hPNcnny4&#x2B;i4rpJaxfpJafJ2fkfz9xDwfm&#x2B;ST5cwouMeklrF&#x2B;klp8nZ&#x2B;R11FFFfOHzIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUjOqD5jionvVXplqAJqC2KqPeM3T5aiZix55oAtvdqv&#x2B;19Kie8Zvu/LUNGaAHPIz/eJNNrlbf46&#x2B;CbvX/7Jh8Y&#x2B;FZdU3&#x2B;X9jTVrdrjd/d8vfuz7Yry3xP&#x2B;2ZrFl&#x2B;0hqXw30nwH9q1LT7cXUMupa5Hpp1VCFObVWjYS9T/EPuNnG044a&#x2B;ZYaik5y3fKrJy17aJnn4jNsLQipTnu&#x2B;VWTl7z6Wim76HvlFfCf7Uvxs174gfGPw6sd94&#x2B;8JSaOhj1bwG2otot5qwDNmexuoWMV03zABA&#x2B;5vLAQEs2O6&#x2B;FPxV8V3lm2o/C3xlJ8SNPsMjUvBXjCRbXxHp&#x2B;PvKlwQGLZ4HnBl4OHY15dPiOlKvKkoN2dtLXfdqO7t1SvJdYnjU&#x2B;KqM8RKhGDai7aWbemrUd3brFXmusUfT3i/wAbaP4A0K41PW9SstK0&#x2B;0jM009zMsaIoxk5P1A47kDqa8X1D/goj4J1bxfpeg&#x2B;C7XV/iFquqRSzrDoghBhSMZbd58kZ3Y5AA5APNUxbfCj/AIKSeDbyy1XSbu117QXNteWt1H9j1vQpOQVzydhOeDuRiORkYHO6/wDsz&#x2B;LLi50vwz420WP4l6FbOkOj&#x2B;MNJni0rxL4dC/cMrMyiRVAHzI5JxllYkCoxmPxtS08FZ03a0knJ3vqn/L2vyySfxWIx2ZZhVtPAcrpStaSTk276p6Pk7X5JpP4uWxl/HT9sHxd421LTG&#x2B;Gt3qOl/wBiy48VeGrjR418VQQ7gTLBbT5WZQm7/VE4OCTg5GVpP7TeofBnwze&#x2B;LPDvxX0f4neF7ctPqPhvxLOmn&#x2B;IbDn5lgY4ZnBP&#x2B;rdMYUhMkivW7P9kLUfG2l3Oh/EjWrHxrp&#x2B;nlW8P66tu1j4j04g5G64jOCV4&#x2B;YcuRlgc4HoVr8APDcnh2ys9Ws7fxLfWEAgj1bWbS2vNQbAwHaRo8M445K845zzXJDL8yq1JVpTcW1pdvRrTSKk4&#x2B;bXvRlv7uxwwyvNq9SVeVRxbWl2/da00ipONurT54y393Yx/2e/2uPB/7R9s0ej3NxYa1DCk9xo&#x2B;pRfZr6BGUMrhDw6EEEOhZcEcjNenV4Pp37D/9r/HfSPiB4u8ba14l1bw2QukQxWdvp0NtGpYqjiFQZANx7rnJBGPlr3ivoMtni5U2sZFJp6PTVd2k2k/JN99Nj6bKamNlSax0UpJ2T01XdpOST8lJ99NkVn&#x2B;JPC&#x2B;n&#x2B;L9N&#x2B;yalax3UIcSKGyGideVdGGGR1PIZSGB5BFaFFd8oqSs9j0pRUlyyV0eWeIv2RvD/AIvvo21XXPHeo6fG4k/sy48S3clnJg5AdC&#x2B;XHs7HNep0UVjRw1Kk26cUm9/MxoYSjRblSik3vbrbb7ugVyfjz4GeEPif4u8N694g8P6bq&#x2B;seD7h7rRrq5j3vp8zAAyJ23cDBIJB5GDzXWUVudB8uWnhP9pPwv&#x2B;0TrGjeX4D8b/B7Urqe7s59c1OS3vtNtzHGYLNRHA8rPHOsxeSVpg6PFtMZRgfnCf8A4JmftIR&#x2B;P7nQfAfijw78M/hRvcvpXiHxDL8QbVmYllktbW8sojCY2IZS0ocED5iOB&#x2B;mVFBXMfC/wU/4ICfBvwnqZ1r4lXGsfGTxNPZLZT3GueXa2IQOHHl2tuFAw3I8x5Dyea&#x2B;yPhh8KPDPwU8F2fhvwf4f0fwxoFgCLfT9LtEtbaLJySEQAZJ5J6kkk5NdBRQTcK878QfFg&#x2B;DpfFFrrHirwbo9/bsZtIXU4WsIkg8tSGlZ5z56hiwaWLYFOQVypz6JVfUtItNZiWO8tbe6jjcSKs0YkCsOhAI6j1oA&#x2B;H9Z&#x2B;InxZ/bd17xVpPgm6sJPAen6rbadPqdndteafqUcsAaaTT74R2StBEDJHJuGoBnIXy8cr7r4f/YS8Jav4TtdH8eWsvjy10dvI06PWb6W8s3hUDypZNPIXT1nU5wYrZVUBdoHNe5gbRiigdzB&#x2B;Gvw7s/hb4OtdEsbjVLy1tQQsmoXj3Uxz23MflUdAihUUcKoHFb1FFAgoopskywgbmVdxCjJxknoKAHUVT17Xbbw1pM19eNKtvAAXMcLzMASB91AWPXnA4GSeATXI&#x2B;N/2mvh/8O/EV5our&#x2B;MvDNnr9jai7k0mXVLeO&#x2B;2MCU/dM4OXwdoON3bvQB1viHw3p/i3R59P1Wxs9SsLkBZba6hWWKQA5GVYEHBAP1Fc0/gjXfB7RyeG9Wa7tYz8&#x2B;la3O88TL/0zusNPG2ecv5y4G0IvUY/7M37WHg79rbwYNe8G3GpXFh5cUu&#x2B;60&#x2B;W3RllTehSRl8qUbepidwpyrYYED0qtI1JRVunbp/XnuZ1KMZO70fdb/wBeWx8nftmfAPWP2n7y2j0X4ofET4K&#x2B;OIbb7Ja2R1WWPQ9aBLHbthkEUrtkjKP5oXG&#x2B;IjaK/PTxZ&#x2B;yZ4n/YQ1g3/wAQdG8b&#x2B;C9ahnaTTfih4CumvNPjLHG26tj5eFbJBAeBiP8AlnJzn9tNV0m117TprO&#x2B;tbe8s7hSksE8YkjlU9mU5BHsa424&#x2B;Ft/4Ut3XwvfK2nyFvO0PV2a4sJUYYaOJzuktweAFG&#x2B;JRkCHnI&#x2B;myriSphoewaTh22&#x2B;6VtvKSlHufE59wXQx1X60m1U77r1cW0r/3oOEux8E/Cv8A4KU&#x2B;PvBvw3kk&#x2B;J2h&#x2B;H/2gvhXMipceKfCUUc1zZJ1xqNi6p5bYAOJo4RkcM9fV37N37R3hP8AaI8PR6n8HfH1jrcMChrrw3rcztcWy91y2bm3OeA7CaLAIRcYI8L/AGlP&#x2B;CfHw3k8RXXjDw1ceLP2e/iPbqbiG88OwyT2OqvnlIIoCFldyMCGIxSt95ojmvlPRv2ZLnSfiBrnibxVZSXXj68ZNb0&#x2B;91u8Hg248tFKMyaZZSfaHeZiuA72bu4wGJZs&#x2B;xLB5bjqTqUW6cu1tG/8N&#x2B;R6fajKP&#x2B;E&#x2B;cjmGdZXXjRxCVWHdyd0v8SXtFr9mcJrX42fYX7VP/BMD4D/tR6tcjXvDd18JfHmpf6nVbALBaX0zHAI2/wCi3DM2SU/d3DDkhc5r83/2v/8AgiN8Zv2WLe61XT9Pj&#x2B;IPhe3JP2/QonkuYU/vTWvMi9ySnmIo6sK&#x2B;0NGtdc0nweJrPWPFGv2&#x2B;nXXm3NhotpLY6bZ3W2KV47/R7V11S8HlttmkmnlK8HZLgpX0B8Pv2hdQ8H&#x2B;faz2LeDdTjKSQaDbytr9nq0ZjjYSWtjD/AKfapIGwgRDHFtYyRBuD7uTcYZ1k1oUavtqa&#x2B;xO70/utvnj6apdVY/eeCvHTO8qapVW6lJW92o&#x2B;ay7KS0W2mqj/dbTR/PY6NG5VlKspwQRyDSV/Q18bP&#x2B;Cc3wx/4KD&#x2B;C/wC2fHXw4vvAPjCYuP7QspreHUj6SM8W5ZkbqBcIJByCqGvzH/bH/wCCD3xX/Zp03UNe8NTWfxD8K2KNNJNYr5GoW0Y6mS2Yndj/AKZM574Ar9g4d8UMnzKSoVpexq7csmrN/wB2a0fzs30R/WHCfi9kecxjCpL2FSVvdnonftJ2XykovyPh2uo&#x2B;EHxt8XfAHxlD4g8F&#x2B;ItW8M6zANq3VhcNEzL3RwOHQ91YFT3FcvRX6LVpQqwdOolKL0aaumvNH6hWowqwdOqlKL0aaumvNM/Uj9j3/g5H17wytvpPxo8PjxFaqVQa7ocSW96o7tLbkiKQ98xmPAH3WNfp5&#x2B;zR&#x2B;2f8M/2vfDn9pfD/AMWabrmxd09mH8m&#x2B;tP8ArrbviRBnjcV2nsTX8vdepfsz/s5/Fr4xeMLO6&#x2B;GPh/xRcajayhodV07faRWTj&#x2B;I3eVSIj1Lg1&#x2B;RcV&#x2B;FOR16csVRmsK929PZ/NNq3yaXkz8Z4v8Isgr05YuhNYV7t3Xs/nFtJf9utJdmf1BZor5N/4Jw6f&#x2B;0f4R0iDS/jd4n8J&#x2B;IrXyNtr5Eby6tCwHAmuF2ROMA5O12JwS55r6yr&#x2B;ZsywccLiJUI1I1EvtQbcX6NpH8s5ngY4TEyw8Ksaij9qDbi/RtIKKKK4TzwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKZPOtvHuY7V6VE18T90fnQBYprzKg5YVUe4Z/4vyplAFl70D7q5qJ7p374&#x2B;lc78R/ij4b&#x2B;D3hWbXPFWu6T4d0e3IWS81C6S3hDHou5iAWPYDk9hXgdx/wWP/ZrttVNm3xPsTMG27l0q/aLP/XQQFMe&#x2B;cV14fL8VXXNQpykvKLf5I8/GZtgcJJRxVaEG9lKSj&#x2B;bR9NZorgfhp&#x2B;1H8PfjR4Xv9Y8H&#x2B;LNI8VWumQme6j0iX7bdQqATg28YMu444XZuY8AE1yfwJ/bv&#x2B;Hv7V41zS/h74ktZPFmkrMh0vV7WazuInQlQ7wOFkaMNjcV5XODtbil9RxFpNwdo2vo9L9&#x2B;xX9qYS8IqrFud&#x2B;VXXvW35ddfke1VXm1a1huxbNc263LDKxNIA5/DrXw746/4KBeOfhN/wkXw8/aL8P8A/Crv&#x2B;EotbrTtA&#x2B;IPhVZ7rSEeWNlRwSWkSSPIcHIbK5KRj5q&#x2B;KG8Er&#x2B;yF8PZtN&#x2B;InwS8I/EKbxbqBn074pX2tXl3odxbSBRGwltgzLzlsq8cmG5XjNfQYLhepVT9pOzduXl5WpLq03KKduqTcvI&#x2B;RzLjmlh2vZU7pX53Lmi4NbKUVCUlzdJNKP95n0r4m/wCC1fxK/Z78VePNO8cfC5fE1joOpPa6frGl2t/o1nEWb93DP9qhLA7Tw2FJK8BgQ9fdXwP&#x2B;Itj&#x2B;1J&#x2B;zxpWtahY6V9l8UaeVvbG11KLUrVd6lXiE0XyuMEg9CM4IBFfn3&#x2B;zV8dvB/wCxd8KNWvvHv7R/h34naDqEEm34c6NGdctmLAhLeKW6ZpkTnG1xGmBltx5r2T4af8E/hHFY/Fj9m/xl4o&#x2B;DMniuAX0/hjXNLabS7gPn5ZbOQgxd8EFwAQY9qkGuzOMvwLhycns9bKdp8snbVNNLl73jGS8zy&#x2B;H80zOUrzn9YTV5Ur0&#x2B;eCbdmmm1NW0tOUZW6H0lZ/sYfC6w&#x2B;HD&#x2B;FY/BOg/2RJG8ZD2yyXHzZ&#x2B;bz2zLvGeH3bhgYPAr45&#x2B;HXizwP4Z1X4jfCf43a19q0XwDqBbwrq10z/wBq2ah2AWCSMGTdtELhVBA&#x2B;bIKgAfXf7MfgT4xeEptXuPip488M&#x2B;LPtzK1lZ6Tof2JNNxwdsu7c6t12uhIP8eOK9Dvfh9oOpeJodauND0i41m3Ty4r&#x2B;Szja5jXqFWQjcB7A1&#x2B;X5tw9TdSH1Vw93R&#x2B;63GUWvha926Ts15rTufRYrI1i4Uq&#x2B;Gpqi43TjKKacGrcsoxlZpO0oq&#x2B;jXRnyn4a8I&#x2B;Kv2hPgzc6Vpkun/FHwXloLZfH2mXWj6xb8YSSG8SNlnOORKFVh0JB4rtP2f/ANiGSX4N2OlfGCPR/E3iPTLhv7P1Oymmjv7G2wBHD9sXy5m2ndjnABC8hRX0hXmvx&#x2B;/as8J/swTaXceOG1TRfD&#x2B;puYn8RNYvLpGmyZAVbudM/ZgxPEkoWPPBcHAM0choRmqlb32lbXZr0d27dE27dLHZh&#x2B;G8PGcate9SSjy2esWvR8zduicnbpYk&#x2B;DP7Kfgj4C6/qer&#x2B;HdMuY9Y1hQl5f3d/PeXE65B2l5XYgZAJxjOBnOBXoN9fQ6ZZTXNzNFb29ujSSyyuESJAMlmJ4AABJJ4FfO37UviT9prxFFfN8C7H4L/2G2nR3em6vruq3d1d6o7AEpFDFEsEXHKSPLIjZUkAE7cXwR&#x2B;1L4g&#x2B;Oeh6P8NrLxhH8LPjhYCGbXtK8W&#x2B;GkGp3tooYTz2ES3H2aYMRkTwvPENrAqpPy&#x2B;tQw9KjD2dGKiuyVl&#x2B;B7mHwtHD0/Z0IqMeyVlrvoj6CsfinpvjX4ZzeJvBNzpnjm1kt3m086TqUElvqTrnCJcbvKGWGNxbAPWvIdP8A&#x2B;Ckngl/AXi681LR/GGj&#x2B;MvAenSalrXgS603b4kWOMEs1tBu2XkXBInt5HhI53ivzH8eaRqXxo&#x2B;Naad4n8B6loeuax4oZ10Ow8PytqeoSWavJHfeIvDW1dN1K1kVZMXFpOkux1AaU4WvoLwr/AME0Pit8Ufir4bTU/h78Pfh78OdP1Ddr2n2/i/ULy1vUKoyaj4ftTbrc6FdL8wxHcQ5IVXjdQc7HRyrqb3jz/gqJ8Q/j38WfCNp8BdS8N6de&#x2B;IvDzXf/AAjniq2t9ctbiRiksEhuNFnuH0&#x2B;VomdT9veKHKqAud7Bml/tK/EDwb&#x2B;0d4i1qf4katofinxAyWcPw18f&#x2B;F9Sl/smUJuMWl/YLkWV9FIyHy50LPyFaRmcg/Q3hv8A4JR/C&#x2B;Dw3f2HiM&#x2B;IvFE&#x2B;pzOb6/8A7Vn0W61iIjaseof2a1sl&#x2B;wUbWluUkkkH32avoTwN4H0f4Z&#x2B;DtL8PeH9NtNH0PRbaOzsbK1jEcNrCihURFHQAACgLo84/Yo&#x2B;NPj748fBRdc&#x2B;I/wAPbr4b&#x2B;Ilvp7VbGaQkX0CEeXdpG&#x2B;JYVkyf3UwEilTnIIJ9coooJCiiigAooooAKKKKACiiigAooooAKKKKADOKp6nqE9lNaxw2Nzd/aZDG8kbRqlqNrMHk3OrFSQF&#x2B;QM2WHGMkY/xF8I2/im2tGvLWTVLOxkMsmniKB1nbGFkHmIWV4ydymN0bOeTwK&#x2B;TPjx8Hr79pb4n&#x2B;HvA9nqHjm1k3zv8A8JvD4Ku7LUvCtrGC6W41G78tHMwygkHnyB8N5QDF1APYdF/ao1zSNVuJvFWm6JZ6WvmLJFZ3EiSad5bEb3muRDmNhtJe4itFQ5VWn&#x2B;Vjj6z8W9Y&#x2B;M/wcvr74frovxu0W81G8h1GC11G10y80wpIrQ20Cyo0EjR7eTO43Ha2WR/l7mP8AY28E6za6Qvi61vPiNcaGXNnP4smGpeWWYsGMTKIXdckLI0ZkC4G7AAr1G0tIdPtY4LeKOGGFQkccahVRRwAAOAB6UDPCdF&#x2B;CHxQ1a38SaNN4xbwf4WvUVNJeyuhqOtW245kk8xoIorZgMKkMYmjQg4LLhRZ8L/sCfDDwhruoeJvElneeOtdupEv73VvGV8dUAlihSIXCwSYtbd1jiQb4YYyAoGcCvYfFPizS/BGhzaprOoWelabblfOu7uZYYIdzBQWdiFUFiBknqRXzn8aP&#x2B;Clvw08I/HDV/hPqnh/xF4svoTBZahbaVZWurmb7TFHIU/s&#x2B;OZr2eJYpkaR0tmjAYjJIIAGp7x4j&#x2B;J&#x2B;g&#x2B;C/hx/wkxlnvfD8UCTRzaPYzan5kTY2vHHbJIzpgg7lUqBySAM1z/wCzN&#x2B;0jo/7U3w1XxRoun6vpdnJO0KW&#x2B;qJHDd7QAVd4ldmi3Ag7JdkgwQyDv85ftp&#x2B;HPFX7M903xS8C/EbXNKm1S8srWHwgVmurW4gl8i1Yw6XKz&#x2B;dJCuyQQWq2jEI5Z927f9a2fgqG6fTdQ1eHTrzxFZwJHJqVram1Z2H3gg3u6RM2T5ZkcYOCW6kEVfhr8VLT4nJqot9L8S6TNo149jcw6xo9xp7M6/wAULSoEniPaWFnQ9mrpqKKAIb&#x2B;wg1WyltrqGK4t7hDHLFKgdJFPBVgeCD6GvMPiN&#x2B;ytpPi7w/Np9i1pHZPvaHT9Tt3vrGydlK77YLJHPaMBwPs80aryQuTmvVaK2pV6lJ3g7GFfDUq0eWqrnhfw9/YR0Hwp4d0nTdQ1bU7qy0eA21tZabI&#x2B;mW0cRYsY/MV2vZIyzEmOa6lQ5ORjivXvB3gHQ/h3pX2HQNH0vRbPJbyLG1S3jLHqSEABJ9Tya1qjuLqO1TdJIsa&#x2B;rHFVWxVar/Ek2ZYbAYfDq1GCXTzt2vvbyPgX/gqD&#x2B;3d&#x2B;01&#x2B;yyt5J4T&#x2B;Fmi2vg9WZU8VxSya2UQc75IlWMWx6f61HTPAZq/H/AOPX7XXxM/ae1Z7zx54017xEWbetvPcFbSE/9M7dMRJ/wFRX9M194wtolKxq056dMLXzX47/AOCcPwM&#x2B;IvxYXxnqXwz8NtrAHzpFG0VncNnO&#x2B;W2VhDI/XLMhznnJxj9W4K8Qcoyiny4nApTS0nDWTfnzu6v1albtE/dOBfEjJsmpcmJwCVRLSpCzk3587ur9WpW7RPwV&#x2B;EnwF8afHnXF03wb4X1vxJdMwRhY2jSJET3d8bYx7sQPevtj9nv/AIN9fH3jGSG7&#x2B;IniHS/BtiQGazssajfn1UlSIU/3g7/Sv1x8P&#x2B;G9O8J6TDp&#x2B;lWFlptjbjbFbWsCwwxj0VVAA/AVdrozvxpzXE3hl8I0Y9/il97Siv/AX6m&#x2B;e&#x2B;OWbYm8MtpxoR7/HL72lFf8AgL9T5h/Z7/4JA/A79nyeG8j8MnxZq0OCL3xE4vSrDusO0Qg55B8vcPWvpqzsodOtY4LeGOCGFQiRxqFVAOgAHAFSUV&#x2B;U5lm2Nx9T2uNqyqS/vNu3p29EfkWZ5xjsxqe2x1aVSXeTbt6dvRGx4GTd4hj/ANlWP6YruK4v4fru1xv9mJj&#x2B;ortK8880KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCj4h/5BUn1H86xbPUntTg/Mvoe1bfiD/kFSfUfzFc5QBuW90l0uVP1HpUlYMcjRNuUlW9RWhZ6uJMLL8p/vdjQB8X/APBa39g7xl&#x2B;2L8M/DOreB5G1DVvBcly8miNMIxqMUwjy8W4hfOTyxgHG5XYA5AVrX7A/7ePwh&#x2B;IHw60v4ZeJdJ0P4aeOtDgj0nUfC&#x2B;r2MdhDPcIoRvJDgKxYjPltiQEkYb7x&#x2B;1AcivOfjl&#x2B;yJ8Mv2lIVXxz4J0DxFMqeWl1cW&#x2B;27jX&#x2B;6s6bZVHsGFe9RzanPCRwOLT5YtuMo7q&#x2B;909JL7mu58niuH6tLMJ5rl8o&#x2B;0qJKcZq8ZJaKzWsXbsmn1jfU8C/bK/4JZeB/Fmg3vjj4cTQ/B/4heH4Jb&#x2B;01jRJf7MtJWRS224VNqopxzKm1hklt4G0/MX7DunaP/wAFdPCGsR&#x2B;LEu/CPxs&#x2B;H4t7i0&#x2B;Inh2MWl5fxvvWNrkR7VeRSmCcqzLjay4bP1tL/wAEZ/gXcBbeTSfFMmjqwI0l/FF&#x2B;bLA7bfN3Y/4FW5ef8EmPgC8cbWPgRdDuYUCR3Wk6tfWNwuOhLxzAsfds161DPMNSw7oyqzlPTlnyq8V1Ws3zJ9Yt29TwcVwvja2NWIhQpQptP2lPnlab6SVqaUZReqklzPujxn4lfAH9rzxP8Fta&#x2B;Feuf8KZ&#x2B;J&#x2B;gatbvYxeI9ZE8N9HGwISaSMAL50fDK6q7KyglnPNek/sH/wDBMtv2MNPs8fETxXqkF1YKmseHvMifQLu7ZSJJVikjLqOmCrKx2/MSp2D3nwpY&#x2B;D/gHY6H4Th1iPTn1WR4NJs9W1yW6u9QdF3OkJuZXllKqNxVScDnAra8dfETw/8AC7w9Jq/ibXNH8O6TEyo97ql7HZ26MxwoMkhCgk8AZ5rxcRnledKWHpqMYSd3aKV33a1SfpY&#x2B;kwfC&#x2B;Fp144ys5TqRVk5TcuVdk7Jtf4rtmfo3wP8ABXhzWV1HT/B/hex1BW3C6t9KgimB9d6qGz&#x2B;NdRXhnhL/AIKU/BHxv8QY/DOn&#x2B;PbJtQudTm0W0uLiyurXTdRvom2yW1tfSxLa3EoYY2RSsSegNfO3gn4f&#x2B;Mv2Gv2xvHXjj4sab8Rfix4T8UatPqXh3xvo11f6sfBdnJuzpl1pELFo4UB4mt4ZEIxuCdF8eVSUneTufSU6MIK0El6Kx9&#x2B;V8w/tOf8ABS7wj8NvAPxGj8IalNf&#x2B;LvAnmWU0974Y1SXw7Y6igUi0vNRWOO0t925VLyXKLH5isxx8p&#x2B;Z/i9qvw9/aU/butfFfw31lfjRqHi6wj0vUPB2uafrkWn&#x2B;HRCny3drqMEDrpMjbQrCSIhncsWjyzDqvAf8AwTK&#x2B;JXx08X6pH8Uta1jw/wCC/CmrQa38N7S88RReLdW0O72bLiO5e6t3gvLQgJ5a3QlmjCDbIh3FpNLLqR/E3/got8afH/wxh8Pw6V4X&#x2B;BvxQ1PU7K70GKbWbbV7Xx1pHlh7pdH1OeEaWbxtymNHeXjhlTIevC/GesfED9sbxT4Z1T4hQa7JeeE9QePwdp2pfD&#x2B;/8QX2tpOywzrrdlbWsWjz2RQFvPtZVaIDKu7AKfvv9mj/AIJqeBf2fvAOt6BqU174&#x2B;s/Et3PfalY67HE&#x2B;iNLLM8rGDSkUWVsAX2/uolJAGSa9z8DeAdB&#x2B;F/ha10Pwzouk&#x2B;HdFsQVttP0yzjtLW3BJYhIowFXLEk4HUk0BzJHxH&#x2B;zl&#x2B;yD&#x2B;0N8F/wBoXS7jwja/Dv4PfDe3t5F1/wAOWOv3vibw/rMxkTEun6fLDavpj7PNJ8ubYWEeY3w277G&#x2B;K3wI8G/HK00&#x2B;Hxd4a0jxB/ZF0l7YSXduHmsJ1IIkhk&#x2B;/G3A5QgkcHIJFdZRQK4irtUKOg4paKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcn8ULTxZqsEdn4cnttLt5oJXuNWSZZL2zlXaYkitZIGinWT5lYvLEVGCNxOV6yuE8e/s4&#x2B;GfiNuW&#x2B;l8VWMMjFpINH8U6po8MhJy26O0uIlO45LcfMSc5ycgHyt45/4Ksr4D/tK0he31D4jSRWdrZeC9XSfSpt7SEPP9iitLjUTIVJzFbi8jUIuZIiWNdhb/En9pb9pAfDLVfC/hM/BW1m06a58Vp4q&#x2B;yajbmaREaGOK2Qi7k2PGwIkNm2yds/MoA&#x2B;gvhR&#x2B;zz4F&#x2B;BcMy&#x2B;D/CXh/wAOyXR3XM9lZJHcXjd2mlx5krHuzsxPc12VBWhy&#x2B;reF/EV1pNrNZ6/Y2evpbLFcu&#x2B;nPNpd0&#x2B;OWNqZg6gEkjbOGwQGZwBjjf2Zf2Zbr4DeIPG2tajr2naxqfjjUY9QuINL0GHRtNsCkQjxBCrSS5cAM7SzSFm5G3Jz61RQSFFZ03i/SbfxNDosmqafHrNzA1zDYNcoLqWJSA0ix53FQSAWAwMitBmCLljgDuaAForNvfFVpaD5X85vROf16Vk3vjK4nGIVWEev3moA6aWZYE3Oyqo6knArNvfF1rbA&#x2B;WWmb/AGen5/4Vy891JdNukkeQ/wC0c4qOgDVvfF11dcR7YV/2eT&#x2B;dZk0z3D7pGZ29WOabRQAUUdTXJ638c/Cfh7x54f8ADF1rlmNe8USXUWl2ce6WS6a1A&#x2B;0D5QQvl5AbcRgnHXigDrKKKKACiiigDoPh2udUmb0ix&#x2B;orsK5P4crm6um9FUfqa6ygAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKev8AOlS/h/MVzddJrozpU34fzFc3QAUUUUAWLTUJLU/3l/umtK1vY7tflPzdweorFoVijZHBHcUAdBXzj/wUW8HftBeJPh/ZXHwN8UWOlfYZPM1nSobWCLWtXt8/Olle3Ilt4Zdv3VkgwT/y1ToffrPWOiy/99D&#x2B;tX1YOuV5B7igD8yPAOuzft5f8Jh8PfDfw9TSdW8J3kWreItH&#x2B;MF7CdU8S3wiWMzCztJRNo0hyJI7&#x2B;ziWNnGRGRXE&#x2B;LP2bvHvx&#x2B;htbTXPCXxS8Qa18P8AUbZrZdYEDeMvBh8wmFkuJv8AiU&#x2B;J9MDb8GVkuArSAnJOP1C8VfAjwb43&#x2B;JHh/wAYat4Z0e&#x2B;8VeFd40nV5bZTeWCuCHVJfvBSCcrnbznGa6ygrmPin4Xf8Ew9YS2uI9aHw/8AC&#x2B;l6lqBXxN4S0bTW1LwX44tiFzdvpNwEGl35IHz2szqGjDN5o4r6e&#x2B;AnwJ0/9njwbJ4f0jWPE&#x2B;qaOty81jBrWpNqDaXEfu2sMsg83yEAwiyM5UcZxXWX/iLT9Kvre1ur6ztrm6OIYpZlSSb/AHVJy34Vm&#x2B;KPih4d8E6bdXura1pun2djcJa3dxNOqw2UjgFFmfpFncuC5A&#x2B;df7wyC3N6ivkfxf8At96x8XtU1PRfh74fvrO30dLqDXbrVZYrO6s3SWNUWGaOSaG0umTzGjg1IWwl3wncFLCpviFq3xa&#x2B;Od02n&#x2B;G11/S75dqWmrNbX3h6z0xWcvILm2mU&#x2B;ZdCNSkUqte2jOMyQRq67wLHvni79oTwr4I8SyabqGp2qfY7d7jUrhLqFo9HUNGFNyu/zYlbzNwcp5aqjl2QAE&#x2B;SeKP2/Jta0DxcngvwXrl3q2gwt9mm1OONbdm2Bop5baKRrxbOUkhLkQ&#x2B;SxUkyJGPMrzzTf&#x2B;Cb3jeb4RLo58QeGtAlk1Sa&#x2B;/s/TLZNmmO8h26jpt41uZdO1HYd7mKN7YuCI4IVdifqfwX8CfCHw&#x2B;uIZtI8P6baTWs09xassI/0F5wBObdfu24lK7nWEIrsWYgsxJB6Hn37Ln7SPir4rxQx&#x2B;KvC13p0mpYnsLi20q8hijg8svm5dhJaK2QFU2t5dLJvBUhQTXt1FFBIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVT8ReItP8I6Feapql5a6dpunxNPc3VzKI4YI1GWZmbgADua534O/HzwV&#x2B;0F4bbV/BPijRfFGnRuYpJtOulm8lx/C4Byh74YAkc9K2jh6rpuqovlWjdnZN7JvbU2jh6sqbrKL5U7N2dk3sm9rs66iqd54gtbIHdMrMP4U&#x2B;Y1k3njZmyIIdv&#x2B;05z&#x2B;lYmJ0RO0c18q/wDBRz4ufE79mbwRqnxc8F&#x2B;NtAl8NeCdPe81fwhqmkrJFqca43Ml1H&#x2B;9WXsq5C5PJxxXuV5qlxf/AOumZx6dB&#x2B;Vcv8VPhZ4f&#x2B;Nvw91Twr4p02PWPD&#x2B;tw&#x2B;RfWUjuiXMeQ20lCrYyB0Iz06V1YPEKjVU5JNdU0np1369no13OPH4V4ig6cZOL6NNpp9NV0vundPqmfC/7e/h/R/wDgoR/wS5j/AGhPCfwpuLH443GiWup&#x2B;F7vw6Z5fENrctcRwoiTWypLOFVmIV1YKMkAYzX2B&#x2B;xofGUP7IHwth&#x2B;IV1q1z43Twpph8QNqchku/7QNrGbgSnJzIJS4PuDXZeBPAei/DDwdpvh7w7plno2h6PAttZWNpEI4baNeiqo4ArWrGrKLm3BWV3ZdkdFJTVOMaju0ld931CiiuM&#x2B;NX7RPgT9nLwrca1478XeH/AAnplrF58k2pXiQ/JvSPKqTub55I1woJ3Oo6kCszQ7OivkP9rn/grj4b/Zu8T6Loel&#x2B;HNQ8TX&#x2B;sXDwGd5xZ2tr5eqzaZPnKs7MkttcMFCgMseQwzkfM/7en7f3xG8Vfs62OoWeuTeEk8XfAGz8eSWmkOYPs2o3DCSZUm/wBbtERCAF&#x2B;gJ6k0Dsfot8W/2pPh38CNU0/T/F3jDQ9E1PVjMLGwmuA15eGGLzZfLgXMj7Y/mO1TgEeoz8s/tF/8Flrf4d/tC6r8M/Cfg2TU9W0/wnqfiT&#x2B;1dRufLtlks727sjAIEBZw0lo7hvMX5CvGSdv5q6TBN4k&#x2B;Lv7FWnztLNNdaTMskkjF3la48K6LJlieTk3JOT1zXa&#x2B;LbtvEv/BTprpsFdR8FNZKOu4ahPrFyo/EuPrQPlP0b/ak&#x2B;JXiLVfEXxk0ddWvU0fRfC3iYQWsb&#x2B;Wq&#x2B;ToGlTgnbgsQ&#x2B;oswLZwTxivO/hHA2o/tr/CG9wGW38afEhs/3VudW8QbP/HbNfyrpv2gp9nxl&#x2B;NcIb5dQ0DxLY/Q3Gk&#x2B;Cbf/ANmb9axf2aoBfftW/DEZ/wCXe914L6/a7vxW278fNH5igD72ooooJCiiigDqPhun/H43&#x2B;4P/AEKuorm/hymLO5b1cD9P/r10lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAVNc/wCQVN9B/MVzVdNrnOlTfQfzFczQAUUUUAFFFFABU1reyWh&#x2B;U/L3U9KhooA2rS/juxxw3dTU1c&#x2B;DtORV601gp8svzf7QoA8Z&#x2B;Kf7HNvrXxn1vxzpel&#x2B;C/E0niyzgsfEGheLdNW6tr&#x2B;OBCkRt7nZI9rhWO&#x2B;MxTRPjIRHZ3bk/g/8AsWeKfCPxS8RatfSaXoOj6r5EGkw6H4guLi68PWscTK9qWuLTy7&#x2B;2dzujt7hPLtQziIAEY&#x2B;o0dZF3KQw9RS0DueY/Dj9jf4b/AAy0Hw/Y2vhXS9Tk8Kqq6Ve6tAuoXmngHIEEsoJgQHlY4dkafwqo4r06iigQUUUUAFFFFABRWJ4z&#x2B;JGg/DzRb3Utc1ax0yx00RNeTzyhUs1kcIjyn&#x2B;BCx&#x2B;&#x2B;2FABJIAJHz4/7ZXjzVdL8U694X8IWnizwvo/iKbSJpAGtdV8PxQO0VxLPYRPcT3ShkLrsEM7pIpW3K4kcA&#x2B;mby&#x2B;h063aa4mighUgF5HCqCSAOT6kgfU1yHjT9oTwf8O/DGv6xrmr/ANm2fhiNptSWa1mFxBEJDEJRDs8142cFVdFZXIO0mvnfxVd/EL9pjxJrGm6hFq998N/F3hoQQ23ha6sLqxmIeSO5eO6ubfbKZVlhVoLprV4zDJ5QnHmNHY&#x2B;EP7AesH4R&#x2B;F9N1qfw74dNjPdvdaTBppuv7OSa4cynT7lbhZrVrqMhp4ZZby33SNGFeNfmBn1bpmoR6tp1vdRLMsdxGsqLNC8MgBGQGRwGU&#x2B;qsAR0IFT1w/wAMv2ePDfwlTTf7IXVF/sm1&#x2B;x28b6lP9kiQgBvLtFZbWHO0cRQoq9FCjiu4zQIKK8m&#x2B;OH7YPhv9n/4jaVoGuW&#x2B;o3f8AaVkb6V9Jt31G60uASiL7Tc2sStMtrvIXzlVlDbtwVVLVzHh67&#x2B;Lln4ktfHUPjLw/8WPBN5auE0DwrYWulKVLkpcW808s/wBqcLtUo11bpw7AsSI6APdLfxBYXer3WnxX1nJf2KJJc2yTK01ur52M6ZyobacEjnBx0rzfxb&#x2B;2J4O8C&#x2B;DNb1bVm1bT7zw7Gkt9o9xZmLUY42mSETBGIVrfe6g3SubdQGZpQqsw&#x2B;Y/2lfgD4&#x2B;/anurXUtJs774geEr7T3gSHW7Sz0XU4pZLphc2M8my0ubGCJEj&#x2B;Vor5Zip823cKok9G&#x2B;HH/BOi6sPGWl3niDVPClpoGk&#x2B;e8Wj&#x2B;GNCbSWmmkjRY7ppopljgvIj5im4sre1aZWwwVD5QCtCpZfttfEL4p6Z4ik8J6HpMOhNdmDRfFNtpd9rot2BgkEdxp8AX7UDGZ4/P066uYw6qziIZWvRPgf8AtG&#x2B;JvEviLw74f1Tw/Hry3sMsV74j0Oe4ns7GeKLzD9qE1nbJDvOECRtJIHYAoAGdex8Cfsq/Dn4a65p&#x2B;raN4L8NWWsaZG6W1/FpsMdxAZF2yuhVQEaQZ3lAu/JzmvQKBBRRRQIKKgvNSgsFzNIqe2eT&#x2B;HWsq88bRpxbxtIf7z8D/AD&#x2B;VAG5Ve81e3sf9bMin0zlvyrlbzxFeXv3pmVf7qfKKo0AdBfeNsgrbw/8AApP8K&#x2B;C4f2KvFHg//gslo/xJ8HeGbPwz8LV8KyprsunzxWdtqGpTfa1INsjBnb5oGJ2bcqGzu6/alFehgczr4RVI0npUi4ta2aflfddL7HoYHM6&#x2B;EjUjRelSLjJa2afknq10vsFFFFeeeeFFFFABXjf7W/7Zuj/sm2ljHfaTqOsapq2larqtjbwOkUcq6fDHLKjyNkqW81AuFb&#x2B;I9sH2Svg3/gsKwu/jL8HbPdt&#x2B;1aT4rtue/m2MGB&#x2B;PlYoA&#x2B;Of2of8Agt58ZPjX/wAE&#x2B;Pih4y8PXdl8Ob7SvGF74d02XQg32pLS2l0gbjNIWbzW&#x2B;3OC8YThhgDGa4f/AILl2lxrv7VvjbQ7iSS4uG0mwtpC7FnJlm8Hqck88sjH3Oa&#x2B;Z/BKTeI/&#x2B;CUf2VvveKPHniCQ/wC0ftngpB&#x2B;rn9a&#x2B;tv8Agrnaf8JN/wAFU9et4/mjv9Z8I6WF/vGW805CP&#x2B;&#x2B;rBvyoLI/&#x2B;CsWutYfGywljYL9hfWb9gOy/2746uv8A21X8hU3/AAUQvBoPwO8F2fO2D4FQ6CR/d2eH1uVH/fXNcV/wVV1ZdU&#x2B;LepfN80fhC4n&#x2B;pmtvH9yT/wCRVP410v8AwVbmOn6DrVuv3fDmlW2lyL/zzEngWMgf99SLQBT&#x2B;HGjMf2/P2S9DkH/ID0LwrIyf3BcaN4UsmJ/Wofhhe/8ACRftzeE7pmLSTad8Ko2P93&#x2B;0LL5gfqbvP410Wh2n9kf8FafB8RbP/CMfD/wvdE/3Wt9Y0W2P5Lb4/Csv9lvQv7R/4KKzaase5NIf4LREf3Ta6dpe/wDJlagD7u&#x2B;K&#x2B;qLrPxi8bsvJuNdOnk/3/tWu&#x2B;GNP2/nabak/ZMf7T&#x2B;2n8G4du43HwMstYYjs32iXJ/8AJ/8AWuZi1H&#x2B;3fiL4xZ2CiP4g6KwP9wJ8ULxGz9U0s/8AfNdR&#x2B;w9ZteftofDeY/d0X4B2unMP7rH&#x2B;wZMf&#x2B;PMfxNAj7wooooJCiiigDsvh4uNHkP8AemP8hW9WL4CXboP&#x2B;9Ix/lW1QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFPXpPL0yTj72BXN10XiL/AJBb/UfzrnaACiiigAooooAKKKKACiiigCS2u5LVvlb6jsa1LTUo7rj7r&#x2B;hrHo6UAdBRWRBqssLLuYso7Vp290l0uVP1HcUARazrNn4d0i61DULq2sbCxhe4ubm4lEUNvEilnd3YgKqqCSSQAASa5bxR&#x2B;0P4G8HfCC8&#x2B;IF94q0MeC9Pt2uptZguluLMRr1ZXj3BvQBcknAGTXYSxLPE0bqro4KsrDIYHqCK8Q8N/sFeDfCvjtb7T0l0nw/YWsMemaVpM9xpk1nKstw8vmXkEyTXNq6zRRrZzFreFbdAiBcKoBynjr9t/UNX8f2&#x2B;k6DoPiLT9Ft4LfVLrUpLSS31SODMhkYaVcWpuLy0H7gSSWmWUTH5kKMRxt/8AHz4mfETx9rOo6XqWua54ZtdKUNp/w5k07U1gmjI86e1vZ4GhunZJYibS5a1uECkxJcBgw&#x2B;mvC37PPgrwZpqWNj4dsV0&#x2B;31FdVs7KfdcWumXKjCyWkMhaO1xyQsCooLMwGWJM3jX4&#x2B;&#x2B;Bfhr4jj0fxF4y8L6DqsluLxbTUNUgtpvIZyiy7XYEIXVlDHgspAyQRQUfJf7KH7FOoeO/hb8O9WurrS9L0rT5L&#x2B;3vbRLVftt5pzPMixCdVS&#x2B;tLibKvcJJdzFZFkSTzstj2b4W/sJeGtBi1bSfGGh&#x2B;E/HPh/T5IrXwq&#x2B;taXDfanp2mrEh&#x2B;xTzvGPNiSbzDEpB2RlVLNgEL&#x2B;0v8AtW6l8G/EE1lfac3hfwTeaS0sXxAYS6hBbXUiskUcdpBbzb5FkMRCzvCsm8LGZGyo8&#x2B;&#x2B;KPxz&#x2B;LGhS3UVrqGr6bFr&#x2B;j29hoVxPottC9xcuMi/tVuVjR7x9wDaZevasCreUZscgas&#x2B;vFUIoVRhVGAB2rgfg/wDtFaN8c4NevPD9jrdxoug393pZ1WS2EdvfXVpPJb3McClvOfy5onQsYwrFTtZq82&#x2B;Dut/GXxbqfh&#x2B;9vmkWz03SYNP1NdRtl0&#x2B;3195MbtWhzALiG4TY2&#x2B;xmggUNJhZGUBz3HwG/Zuj&#x2B;E1xPrWqatNrnjLVC7axqlor6XZ6u5clZ5dPhk&#x2B;y&#x2B;eI9iGbYZGEaguQAAEnm2vf8ABQAeLfgpofi7wvo&#x2B;oeGtL8SXaWlprPiawjurSKViyLbSwWt2JILp5gkCx3b2qrLIEd1kxG3ifwtv/iH&#x2B;1D/wk3hfVo/iFc2PijS2vNW0bU7qa003SlnuGkSG2vWtVns76MxnzNPu1vIPLZIvP8tjv&#x2B;zJ/wBmn4f33ia71q&#x2B;8IaDqusXl8moyX2pWi31wk6BRGySTbmjCbFKqhVVIyoBJJ7igZ8k/AD/gnhrngzUtD1DxBruio1jLcTs2mWFzpuq2iSJtW1tprS7jtLWIssUkyW9qkVw8Sl48jNe&#x2B;fBL9nfw38AE19vD8d8LjxTqT6xq09zdvKb27fAeYpkRozADcY0XdgE5PNd1RQK4U2adLeMtIyxqOpY4Aqtea5a2OfMmXcP4VO41518cvAHhf9oLwsNF8TaLHqmnpKJkEkjxvG47q8ZDr74YZHBrOq5qDdNJy6Juy&#x2B;bs7fczOs6ig3SScuibsvm0nb7meoVHc3kVmm6WRYx7mviX/AIJTaz8ZbP4W&#x2B;K7P4nf8JJa2drrLR&#x2B;GotYiEVxHYgHAGQJdgOAPM7dOK&#x2B;oHkaVtzMzN6k5rLB4h16Mari4t9H0MMDiniMPGs4uLa2fT&#x2B;unkdJeeNIIuIUeY&#x2B;p&#x2B;Vf8aybzxReXf8Ay08pfROP161n0V0nWDMXbJ5J6k0UUUAFFFFABRRRQAUUUUAFFFFABX51/wDBZ/WPI&#x2B;PHwpXdsaxkUKfT7W00BH4lQK/RSvy5/wCC3Wsf8ZGadbsx/wCJbpnhO/jP/PItr96jt&#x2B;KIRzxxQOJ&#x2B;bX7Pmgtqf7AfwRs/4da&#x2B;IN/bEev2jV/Da/8Atmfyr6k/bajXxr/wVm0dl/5evi74E0sjPUDW/ECt/wCkq/lXiX7H&#x2B;hRX/wCyx&#x2B;yBaOu7&#x2B;0fjJokbpk/NHNrl8HH4/YV/75Hvn2bxNdL4p/4Kw&#x2B;H1uP3j/wDC/wDTFAP92y1/xkB09Bs/TOaCzx//AIKJ6quofFfUmPzH/hAtPYH1D&#x2B;E9dmz&#x2B;Jv0P416p/wAFi7N7Sf8AaTjX5W0mbRHHsH0jTNO4/wCBbhXkP7VVrJ4p&#x2B;L95Aw8xD4S0CwOe3/FM&#x2B;F7XHHvqTj1/eHvjHun/AAV3t11T4l/Gi0YeYPE509Qv/PR4fFdnaAf9&#x2B;0K8enrzQIh8ayx6N/wV38dSR/6vSfAl3Zx/W016eYfktmfyrqP2QPC2f&#x2B;Cw3jC0VQq/8JJo9jt9f7L03Tj&#x2B;mSa4P4g3Euo/8FUfjj5bfPYW/iqwDY&#x2B;4BZeL7xR/33Ah&#x2B;oHbIPuX7GNlDqP/AAWE8WXwQMF&#x2B;NPjXSyw7Lb6Ja&#x2B;Wnp8pj478UCO80ST7HrHjm&#x2B;yWhvNbsr3/gcXi7xzqhI/4CYzXtX7EOgfZ/2yvGCMu2Twz4P0XSiP7ok03TJMf&#x2B;Qv0rh/h18APFXxO&#x2B;EfnaTpcsNxq8Ucourr9xCEm8Oa1JHKWbgqL3UowxUEhpDkYUgez/ALKdnHB&#x2B;3v8AtJLGF8m2j8KwwY/gC6fNE4/8gqP&#x2B;A/WgD6XooooJCiiigDuvBC48Ow&#x2B;7Mf1Na1ZvhBdnhy1&#x2B;hP8A48a0qACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooApeIf&#x2B;QVJ9R/OucrpPEH/IKk&#x2B;o/mK5ugAooooAKKKKACiiigAooooAKKKKACnRyNE4ZWKsO4ptFAGlZ6wHwsvyn&#x2B;92NXgciufqe01CS1PXcv900AM&#x2B;Ifw70v4peGn0jWBqDafJIksiWmoXFi0uxgwVngdGaM4wyElHGQwIJFfJvxP/Yj8dfD/wCMuneIPhxqWsXl3qWqpbtM7wx2XhvRHZFnsle4uZHkiwpmELW1xE0pfy1tWk81Psi1vEul&#x2B;U89weoqagLniv7M/wCy1rHwNn8UWOqa/wCHdU8H65DEln4Y0rQJNP0rS5P3v2h44prq42LOHjDQR7IVMRZUDSOT6l4D8BaT8MfClpoeg2a6bo&#x2B;ngpa2kbs0dqhJIjjDE7I1zhUXCooCqAoAGxRQAUVDd6hDYrumkVPYnk/hWTeeNYkBEEbSH1b5RQBuVWvdXt9PH72VVP8AdHJ/KuTvfFdxd3CwtcLHJIrOsSHazKCAxHcgFlB9Nw9a5q48d6dcavNpGn32m3uvrbS3EVibraTsERPmFQxjX9/BklScSqQDmgDu73xsAMW8JP8AtP8A4VkXmvXV&#x2B;SskzY7qvyj/AD9a&#x2B;G/ht8f/ABp&#x2B;2d420XQ77xLeeDrddXu9N1XSdChexuZUsrm8Zrsm4jW8gyba0gaM7QrTyBgxKhfcP2JPCy6J8Ppry/8AA&#x2B;peFvGWoJB/wlepajbxx3XiLVEQi4n3q7PNEshcRu2F8tlWMBFUAA9qoorl/ih8WNL&#x2B;E0OgPqk0cP8AwkWt2mg2Yct&#x2B;9ubhisartVuTgnnAwDlhQB1FFfHvxA/by8YwfHjxN4R&#x2B;H3g3xL8Wm0bXFi83Q7WGHTtPhWwBuLea/aQQmVbl1AjbawaOQb3IMcftX7Mnjb4qeNG1Rvib4R0vwjcWtrbLbw2Ooi8iuZDJcmR8BMRt5Yt9yLNOilsLISGJAPWKKK5H4vfG/wAOfA/w5/afiDULe0tzcQWwVpo423TMyp/rGVQMJIeTlvLYKGbCkA66ivD/AA/&#x2B;2VY6h8aNB&#x2B;H6202pa9qmqalb3ssdpPBDpMMP2qa3SVmjKC4e3jgYRF1dlZ5NoUYr3CgAoryL4qftxfDn4TxeddeIdP1W3t9RTStRfSbiO&#x2B;bSLhrq2titwsbExbHu42ffgogZiOK5DwJ&#x2B;3nD4/j1rXLfTfs/h2w8JXXiOwtHtbh77UzbJavNiYD7MgRrlIfJDNKz/ADjCY3AH0U8qxFdzKu47VycZPoKdXx74F1jx58Ttd&#x2B;Cs&#x2B;v6Hr03xD8Eza5FqcWuaZa2&#x2B;nXsMQNuL9mG7ybuRRamOa0EgiF7cRt8shFfYVABRRRQAUUUUAFfk7/wWpuhJ&#x2B;1Z4xWT5o7b4a6Leqf7jWmp6pcN&#x2B;hH51&#x2B;sVfkn/wWjvFg/aS&#x2B;IU0g3RzfC7W7NT/AHZINMa5X8vNz&#x2B;NBUT5a/YasI3&#x2B;FP7DdkwzJP8RtA1LHqE1/xbk/&#x2B;QlrqzrP2L/grV4RmYbvM&#x2B;Ker6yfcwpqV8fyN4T&#x2B;NUf2ItLZfGH/AAT70eGKSTzjBqbhVJx5Wp&#x2B;JZyx9gLkc175pn/BMv4iXX7Yeh/FTxXqHhf4ceCtN1LUpTeeINSSC4uJtR8O2VlD5UOfvi9NwCkrRk&#x2B;Wdudy5BnzD4g0Ma7&#x2B;1RqGnSN5mb7QNLC&#x2B;6XHw4tyP&#x2B;&#x2B;Sw/Cvcv22fhL4q/aC/aTj0XwfoOqeI9QuvG97a30dlA032W0tvF5nkmkI4SNFAJdiAOOeRX01afsufA/wCBPjn4g&#x2B;MP&#x2B;Ef8VeP/ABlot/bajA&#x2B;oi4h0m4vvt2l2yR2gtY5JZBBe6ZZbv3Uzb45FQSkNGOo1Xw/JoUN18cNX17TdJ8JfEhdItLufRTeaVNYWt02nNeMWcRT28ks1vLF/DLuuASUkJUAjyvwL/wAEv7rR/wBub4ueNviJ4&#x2B;8I6FD47S/1XT9Btb4Ta19hksNWs7q5aNgAqr/aTsGTzB8mG2k16j4W134X/s&#x2B;&#x2B;JfCXi7wb4Ll03X/jT451HxVPf&#x2B;JfPv57Vry&#x2B;srK&#x2B;nUWZuFsy/wBtgiQy&#x2B;WkWdkxR2KnR8BfssfE7x/4j8O3Hii5uEuLfwVaS6rPrdhDPDea2/h99MkV5o7n7TNGJLm4kaIxxBW85hI5nXy/ZPhv&#x2B;xH4d0DRvDL6paWNnfaBe3WoDT9AQ2Gjo013bXawLAOsUUtlZsv3SzwbmGJHQgHzP8SPiT48/aE8GfFjQ9autavdB1PWdKOmCx0BPEdlb6cdZ1hY2NlBGJpluILCzhkt58qrSpK7iOWRF&#x2B;1PgX8LLH4aeBdNA0TS9J16606zj1h7Qb2nmihVNrTHLyqh3BSxPBJ6k53PBvw90D4dW19D4f0PR9Ch1O9l1K8TT7OO1W7upTuluJAgAeVzyznLMepNbFBIUVNaWE1/JthjeRv8AZHT61t6f8Pp5drXEixL/AHV&#x2B;Zv8AD&#x2B;dAHPVe03w3earzHCyr/ff5V/8Ar/hXZad4WstNIZIVd1/if5j/AJ&#x2B;laFAFbR7JtO0yGBirNGuCR0NWaKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAq6zA1zpsiINzHGB&#x2B;NcyRtODwfeuwqpqOjx6gM/dk7MKAOaoqa8sZLGTbIv0I6GoaACiiigAooooAKKKKACiiigAooooAKKKKABWKtkcH1rQs9Y/hm/wC&#x2B;v8az6D0oAsXnjO3h4hV5m9fur/j&#x2B;lYup&#x2B;LriVPnmW3jYhRtO3JPAGevNUa8b/bo&#x2B;A2t/tKfAv/hEtBv20q7vtUs3lvQqOtrCkoaRmRmXzEKgqyKyuyswVlYhgAdR41/ag8A&#x2B;AtEt9S1PxXpX2W9e3WFreQ3bSeeoeJ9sQZhGyEN5jAIFO4sF5rw39oP9u/Um&#x2B;B/h/wAXeAVj8O3L&#x2B;JW06a38W2ixxXkLeH7vVIFZI5C489DZuiq6S7nWNgjb0rB8Lf8ABNpTqureOPiJ4i0DTPElw9zd3D2ES3ljp8VxcyXbQZvg8aRwSuI4pYIreUIkjFw0oEX0V8Hfgl4c/Zu&#x2B;Deh&#x2B;HYzNfW2gLCz39&#x2B;0t5dXFyFWL7QzyNJJuxhV&#x2B;YiNAqLhFAAB8l6n4E&#x2B;Nn7XvicalrmgyDR7SXxBpF1oerrJpMNgk4t0t4VmNvE93FHPDb3HmIs0bG1kKTyFkjX2z9mf8AYD0z4GeJ/E2rXXijVda1LXLK60WUwSNZ/ZrN7l5INrRt5iXCWv2SEyKyn/R0ZdvGPQPi18dvDdr8JfFd1p/ivTbWayhu9OW&#x2B;guo8Wd6tmZ1UMx271Vo2A55ZQR2ryv8AZ0&#x2B;H3xS8RfBbwxq3iSzg0nxIPGI8RalaXk0k08tktq0JVVl/5bykKQkpiEJk3AJ5SR0DPYfCHh74f/BDQr6TT4dL0WDw1GbC&#x2B;1C6ctcqG/0xhNdTEyzM7XLTMzuzPJM7sS7MT558fv2wJfAOkeHfFfg3TdT8feGdU0u8uYrnSV83RZpAoMBuL2GGdoEJSQGQL5cYDGQj5QdXSv2bLzx74QvLDxZ5C6P4q8Qy&#x2B;Jdc0S6Zr6VyJY3tbQTmQqiIILcyIodCVeNCIiK6DxZ8ZfAH7MujWehwxWOnW9qYre30bQraJpbZp5fLt40s4f3mZpm2IEjILEk4AZgCMS38U&#x2B;MPjX4p8Lw2li3hG30mO11LxXYalG081jcl45Us7e5t5RFJKFSVJSGkjCSoSpLgVNpnwN17xv8AtCXHibx1/Zd9onhnKeFLGK5kmh8xpzN9umhZVSO5iURRIQZMBGdShYg&#x2B;F&#x2B;Nv&#x2B;CmXiDU5JLnw3o9joumalDf/ANhX&#x2B;s273cd0IrWyubaSW1hZJt9w0zW8UIlVzJPCCpf93Xuf7Nd58SrrxLrFz40jvpNL1eOS8tlufs8Y0edb26jFpEkaLI0RtRasJJCxLBm3HzMKDOwm&#x2B;OPhzRrPWptUvItBt9C1BtOla&#x2B;kjjMrhIXLogYuEPnpjeqsQQ4BjeN38ah/awvPjB4E8aaV4X0&#x2B;/8YeNvhr4kih1my0J/wCz45LePVJwoikklHmk21m26NHO9zsIAZlW54&#x2B;/4JvfD74kfEzVNUur3XvJ1SWbVtQ0htWuLq1k1Cd1AvjbzSPBny4mhVXiZVVFEfl&#x2B;Xzk&#x2B;If28vhL&#x2B;zBDbeH9F0W30zS7GDVnk0rSLS3sXgksNSj00xRRZjty0s7MVBlRtioxHzrQIoeEvCv7S3xd&#x2B;Hel6Xqa&#x2B;GfhHbx61NqV/eQ376jrV3bi&#x2B;knitlhjYwwh4iiu5unOSVMe0Mr0vFPhCL4STeNtST4q&#x2B;F9L8dSX7&#x2B;M77SNd83xDb6RZ27ahdiIWUdzbtsjiuDOmzYfOt926RQuzqPiF8aLr46/s4&#x2B;INQuNB1IaO2uaZBFpOg3F1d6/eWEfiBbaeSWC3RJIo54reQhVYjy/OEjAK4HE/BT9g7xfrlpND44u7zTbey8QaDr9m82qrqcl6lvokWm31lMgQHEsJmheZ55WkO19oEa7wZ6tc/tNWMvhfxN4g0fwzfax4o8GeJNN8FXyNZQQX2piW&#x2B;s4ZTBulUCPddS7BJIqCWJ84AJPzr8HPjT8Rv2jrbw94rRfGmua&#x2B;tnoeo614ZswtpYQ2hl0G9iaFZXjtWnm3Xswl83Jj8&#x2B;ItiNVHtd4vw3/ZH&#x2B;B/i/wAdaP4ebXFsdW06z8SzMwE2qXUGqKsmoMMFZLiOW6kmyAGYxIi7Qke3lvCf7Ymr/tKfDO80PRLPT/DseseGbiOyudJvHk1Ca6OlPMYLaJVH2Vwzo0EjNIZFs7nEa/u3IBc8D/8ABPG48Za3/bHj6bTbdjZxaPJpWnubmK9s7fUGvonmkZUxI8ktwrqqsAjRgOSpJ9m&#x2B;BX7I3gP9nW0tV8NaOY7y30q00Z766ne4ubiC3hhhQsWO0OyW8HmMqqZGiQtuKrjuvCNrNYeFNLguDI08NpFHIXOWLBADk&#x2B;ua0KBBRRRQAUUUUAFFFFABX53/ALXPgfwD4/8A2wfH0vxKhvLzwrpumXuny2lvfJY/a5L3T9BsfKkmdkEUZjv5GaQugjCmQsFRq9s8beKdY17/AIKjeF9LtdcV9J0HS4GuNFTUJobiHzrPWmlvDbI3lz2rOthE0kqfJMkIRwd6v698ef2e7f4u6Bbrps2k6Frlnrlj4gi1CfSEvo5bm1eMoZot8Zl&#x2B;SNFB3gqY4yCQgWgZ8&#x2B;&#x2B;GPirp/wCz9408C/D34a6B4O8F&#x2B;H/&#x2B;EWWO00y8tHmmtI20rUtQinfUY5nhFrFNapExzL5rzTsr4jy3K&#x2B;AvD/jr4x/Czw7caLfeP5Lq38ZS32gasmtWevQWVwunWcMs15dySyqbb7TJqrGO1LoPngQquyNvrH4dfsy&#x2B;Fvhnq&#x2B;h6hYx6pPeeHtBt/D1j9p1GaW3t7eFBGHS33eQkzIqq0qxhyo2525B720tIrC1jhgjjhhhUJHGihVRRwAAOAB6CgR434Z&#x2B;B3jjX/FXxFvfE/iS30RfEmoW39iXnhqVv7S06zs7lpLaNpJ4zCFZeZIDDIrPcXQMjpIqJ6p4K8H2Pw/8AB&#x2B;l6Fpsbx6fo9pFZ2yu5kcRxqFXcx5ZsDljyTknk1qZq5p2g3eqn9zCxX&#x2B;8eF/OgCnSqrO21QWY9AB1rqdO&#x2B;HiqFa6mLHusfA/P/APVW9YaTb6Ym2CFI/fHzH8etAHG6d4Lvr8BmQQKe8nX8uv51vab4EtLPDTbrhv8Aa4X8v8a3KKAGxQpAm2NVRR0CjAFOoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBk9ulzGVkUMretYmp6A9sd8OXj9P4hW9RQBx9Fb&#x2B;p6Al1ukj&#x2B;ST9GrDnt3tpdkilW9&#x2B;9ADKKKKACiiigAooooAKKKKACiiigAoY4U0Uj/cP0oAwKq67rdp4Z0O81K/uI7Wx0&#x2B;B7m5nkbakMSKWd2PYBQST6CrVcL&#x2B;0Pq3hex8ArZ&#x2B;KtNn1q11u6XS7PTreHzbm&#x2B;uZldVjiGQA&#x2B;zzG3FlCqrMSAuaAPFov2HvBvx/1K3&#x2B;JV9pmr3d34o13S/FL6R4n06KBreOGKeE213BszNshu5wqzmQRlIQmAmW9h8W/CLxFc6C9r4f8AG95p93ca3Pqc1zq9n/aojt5opo2tIY/MiVFQyq0RfzFQxruSQZFeXfHP/goHpfg/UrzS/Caw61qUGm6hiO&#x2B;WfTEa7insooZVuJoijWpWa6YzIkiObYhSSCDzni/4lfF74mz&#x2B;AvCWh23iCOz1zS9D1DWtesrI2yvaT2WoC&#x2B;IvSBHHMs6WTKkRWVd2QNrUDPT9Wf4M/sieFtF8N32neG/Duk6RbSa7ahrCNlhe2a2tjdHapc3J&#x2B;0xjzAC7ASHOFNZnxc/bbj8KeA9F13wzokesQaxqlzYxf2reHSxcx2rlJTbgxu8skjqYoUKr5jFTkIQx8v8ACn/BLu/8V&#x2B;IrHVPHXiCxuJtHjaKznSzTVNSu43trG3aK&#x2B;nvllS5RI7NwivG2WuGdiWB3ey&#x2B;KI/hb8LvHPg/w/rDRw33hfTdQ8Q6TDcQG4jtI1lhSWYsVbbLum/dgEMQJioIRsAHhGP2jv2iLrS55NSuNF02ay0bUorew08WemztcC0upJZZvtEV0oti93CYUml8028JlhVCUuO40v9gO2/4Vho&#x2B;l6tq&#x2B;m&#x2B;FfEEmvafqaDw1I1rCktuLAvHDIwEskjpp0ku8hTvnkZlYAk4/xK/4KBeL4fi5YR&#x2B;D/AAlHqfhm3u5LGdb26SGbV1a58OwiaAKruskbawyhH2K&#x2B;ckjaKy7rwX8ZP2jNFvtYvry2bTksBBo8PiOzk0XSrg3Fnqcd1JdafIjyMY7iSzVBPGwMMSkA&#x2B;bKzgHpfi342fCX9kPT9R03wnY6HL4jtYha3VrpcRmktXi0p54P7RmiWSSFXtbBVVpQWcRqQGAJGd4T/AG3/ABB8Vvi/pWk&#x2B;HPC8FroK3sP264vC11cXtjcw2k1rcQ&#x2B;UwWAmK7WVxKGKhApUeYHXj/FH7L/gf9lH4dzav48vNe1&#x2B;yv5LKxg0fQonjigt7LTdUjW0jVpSzRJa3d4NqNGXWGHajTs7TbXiP9uf4e/BHS/G2g/DnwrZ/wBo&#x2B;E5r5bq0jtP7JspNRils1liBCfvGAvYZHKqSqsgOCwwAcT4m/Yb8b&#x2B;NmvLzxTqnhXUNF1KFI3sPGEUclpprpqOqTxNHHEv750juUVfOfOLyZgwMaxncn/Z2&#x2B;A/wH8OLr3jTx9qWsabqcV74itLafUWVnjvLi3u5r6GO0UXcmUtLVXfcyeXFJlVWWYN23ijwf40&#x2B;Jnjr4b63r/h&#x2B;bVrjw&#x2B;3inT7&#x2B;bSdM0&#x2B;K3icXsUFpP5WpSyPEs1vbuwaEyOS&#x2B;MiN2NeJ&#x2B;Hf2KrPwle&#x2B;HNB8W/FnT21TR9LfSPE2laJdMNRvrOWw1adPPWRpQrrDLd28UiQwMbdZijhlgSAA9c1j9vzTdG8T6Zovg/wPqi6FcXVrDLrUtmLeyhNxqaWoWKIFfOaQNLIiq4lbKsIpAxrB&#x2B;IHwV8ffEbxxOul6PrPhXWF8cLqWu&#x2B;MZNTFqLnSre8LWUNuY5i0tumnghoHj8sXEhJUNJLOnpXwj1nwHrfhPwj4o8C&#x2B;FdNtb3VtUm8I2V9f2CfbktbG9u/tMZlyZPLxZ3Ukal8bmQlQcrXh3xf8AAvxQ&#x2B;M3ww8feDbfUPF/jK&#x2B;8YRanZadf3UUNvptnJYX&#x2B;rwGN2iSKCDekOnoAwLyNKW&#x2B;ZUkZADq/CHiT4cfsu/s2f8I7rfiTQfGNlZNa69NaaBFbWGlxSDVYZY5hLLMIY4TcT2is00&#x2B;0rGzEAGQV6n&#x2B;yXruk3F/wCKPD2geBtN8D6X4Fe18OS29tCqlpoYswIsihRJCumvpssbAEKt15ecxMK8m&#x2B;F/7BFr4U8c&#x2B;INFvviOmn694gtre6lsdLS0e9urOw1YXdlqRhlhMUU3ntIZNkHkFruRAuI4in1Z4e8G6d4WvtXurK3EV1r92l/qMu4lrudbaC1EjdgfJtoUwoAxGDjJJII1KKKz/FHinT/Bnhy/1bU7qGz0/TIHuLmeVwiRIoySSSAOPU0AaFDMEUs3AHJJ7V87ftVft5J&#x2B;zr4h&#x2B;HdpFobXlj4/jEi30kh3WLG80&#x2B;JIjAvLNJDdXBVg4CyQRrhvM44bxP8AFTxZ&#x2B;1F8PfD&#x2B;saX4Z0/xFrGn6jcXNromlTXc&#x2B;javDCJ1kR9UZo7MLIQkBE0T5KXKKpWbzIwD660jWLTxBpdvfWF1b31ldxrLBcW8gkimRhkMrKSGUjkEHBqxXH/ADwfdeAfgv4b0e&#x2B;sbfT7&#x2B;ysUW7ggdXjWY/NIQVAUbnLNhRtG7AyADXYUAFFFAG44FACbRu3Y&#x2B;bGM0tamn&#x2B;Dr6/wAHy/JU/wAUnH6da3tO8A2tthpme4b0Pyr&#x2B;X/16AORtbKa&#x2B;k2QxvI3oozitzTvAFxOQ1w6wL6D5m/wrrLe2jtY9scaxr6KMCpKAM3TfCdlpvzLF5j/3pPm/&#x2B;tWkBiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqG8sY76LbIufQ9xU1FAHN6jo0mn/N9&#x2B;P8AvAdPrVOuwZd64PesnVPDoYGS3&#x2B;U907H6UAYtFK6NG5VlKsOoPakoAKKKKACiiigAooooAKR/uH6UtI5wjfSgDArzv9qf4Aw/tOfBnUvBd1Nptra6sypNc3Wm/bZrNRn99a5dBDdocNDOd3lOqtsfGK9Erwf9vvw9471zwV4HuPh7ZalqeuaD4si1x7G0uvsqaklnp9/cJaTyEhUhuLiO3gJc7AZlJ7UAWND/AGfvg/8ADPwPeaprE2keItHjnOni&#x2B;8R3MOoQ2qLeQxw6fGWHlhYbqCCOOPBcTIMlpWZm858Rf8FRNJ1n4W6DJ4F0Ca68Sa/4atfEA&#x2B;2gx6N4cglaVC17cKAyxq9rdxB1jKGWFFJQSoTzvwl/Ynu/g9408L3vj7xd4bsVs7caVptvbRb7zUZ5fFNvqiszEAndMtupOXAa5yBGUZ5uy&#x2B;F3g74E/s4eKPD3grwvp2j65No2np4bu7j7auoXWmq9xbQwwTRcqoll1OR8AKqedcbVAkdaBnlfxu&#x2B;LPxe1bwZrmpy3/iL/AIQz7bqOjx6fp9yuj3l3IqWTWL296uy5eaS6uZ0KQvh4rUxpG0gIk9t&#x2B;IP7JfhPx14&#x2B;j17x14p1qy1r&#x2B;wFgiht9Wezt7fT7aynt52kGTG7pNqc8vnthkLRbSAr7vGPir&#x2B;2B8XvGPxJ1TQ/B0N3JqvhHxNrFjc22l2jkvpMjT2tleFdkvmSRtZaowXY4aW0T9225UPYD9hnx18a4NG1Dxl40vY9Tn0fXdM1U3gMk8ov7O2tUuLaGOTy7R4/KZiiNtAnmTbmQSIDOi8ZfFbwb8FvgZ4u1X4I6JouteLPD&#x2B;h6S&#x2B;mXlxaXE1pq0V/KkFmRfNg3aP5Qy0cr4MahjuXA8bg&#x2B;Nnxa/a91i60nw/H4iuPBHjTxHeXSXMViILe38PyaZayac0V0YSqSFhHc4MsThrvAEykiL2mwuvhf8Asl&#x2B;K5vCuoahN4kvPENut3qNmGS6h0&#x2B;40y3sWjRLCMEQMyOt1kjICPKz7VDDiPE3/AAUy8ValqWj&#x2B;HfAPwtGnarqT3cOl2uvXkEYuRZ3F1ZvabIZQsU7S2dx5ao82Y4SzKieY8II9C&#x2B;Mn7NK/EP8AZbj0X4p6x9j8O&#x2B;BbuTVpr1JX1e9u9MhsJo3Msk6M63IWabEqeZKvlRyK/mnKedW3jHw38DPHnjfwx8O/CnhW28WaPHcapJqfibULq9mulFzZ2zmCJvnn2eTCJQk0Qi2WQO7zAy9V8NPAnju&#x2B;n&#x2B;IGv/EbxXrFv4FkTSZ7S68TyRafbz6ZB9mnvHuLUOEtHIjukk3RQYE2G8xVQxr4p&#x2B;IPwp8BaTrfxE0&#x2B;41P4jwX1pqOo29pBPHLp&#x2B;XvrATCJcAeZI1zZbXIfMUWVIBbzAZwfxI8VfGz9oL4q3Xh7wj4g8QaKNN8UrLpurJpU1jpkcVtZapp99C7AFbi3a4t4Z18xnUS3sQVmMQ25/wANv2OvGfhzw34k8Z&#x2B;OPEVn8MYzoWjzzSXxg1Z7AReHjp&#x2B;okCMoImjE8oWQyzK8sUbmMxoqSexfHr9oDxl4S/aC8H&#x2B;CPAei2snh7VIrG9bUYJLeO3xcW2vSGDaWLMH/ALPhkVkRQNj5c7wp8j8G/AP4kfFXVLHVtG0vxCum654Q1LRNSuPHF5eWdxZ6rcJos0119nuFafypZrOWLy40SIGB3TCOhcEdB4R/ac&#x2B;Fv7N&#x2B;r6X4Z8JvrvjG08R6rqGv6DNdXZ&#x2B;zaPez3l3Hd2pVo0a2CTTTRKrI8m&#x2B;R0cq2C2xrHxy8Y/tG/sw69Y&#x2B;H7jWh4u8b3WnW&#x2B;kDSUj01dGt76yi1H5LsSu2Es/M3XD7GaXISMbo0Jr/wV&#x2B;EXwXm8O&#x2B;MviNrP/CST&#x2B;Nri8uYbuGLbpMtw08niZrhAhLJGj6eDCWkbhI0YuXJOD8OP23rBNY8NaV8M/hvpfhCG6TSfEHinTFFnbQONWt0kbabZWZrqJ2CuJUiZjsbJQgsAeu/D238Zan8bLPx5rGlyeB7aTwTaw&#x2B;KrfU79Zra4nW4lkXy0jYxRNbKLkmTzPmS&#x2B;j3plBt6n4pftZeF/AuqXWh6fqWm6t4mhR1NoksklvZzLPZweVdywRym2ctfW5CyKCQ&#x2B;eBzXmX7VHwF8VftQ&#x2B;OrXU9GudFsvCNr4Uu9PZtYjmiXUotTs7tLiNl4KxpImlzsJEJJttny/MaxPgj&#x2B;zz8LfH/jjXoZPHVv8AES88R6hqOoXNroVyYNNt4i&#x2B;lXIiZopXbERj08qY5UVjI37sISiAGl8Ov2wPFHxz/AGh9e0PQNPm0fQ9U8EnUPDz36CT/AE2K91K0DSFBsheZ4CwRnf8AdWeQNzOI&#x2B;Ltf2IvG3xq1XRW/s9Phd4R0/wALx2Mulay0OsXGpak9zFLcXN7bQzNDPMTE0guDcF2kMTushBVfs3w74X03wjpsdnpdhZ6fawgqkVvEsaqCzOeAO7O7H1LMepNX6BHFWPwE8PS2ukf25aReKL3Q8Cyu9Ugile3C3cd3DtRVCAwyw25jfbvXyIzuLAsexs7KHTrSO3t4Y4IIVCRxxqFSNRwAAOAB6Cp7e2kupNkcbSMeyjJra07wFdXQDTMtuvp95qAMKrWn6Ldaof3MLsv97ov512WneD7HTwD5fnOP4pOf06VpqoQYUYHpQBzGm/DzIDXU3/AI/wDE1vWGi2umD9zCiH&#x2B;9jLfn1q1RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFXUNKj1BPmG1uzDrWDfabJp8mHXK9mHQ11FNliWZCrKGU9Qe9AHI0Vqap4eaDMkGWXuvcfSsvoaACiiigAooooAKbJ/q2&#x2B;lOpsn&#x2B;rb6UAYNeUftS&#x2B;PvGHge8&#x2B;G8HguHTbvUvEHip9NubW/uTa211bjSNTuCryrDM6bZLeOQbEyxjCZUMSPV68p/bM&#x2B;JviX4PfBC48ReF7jTra8028ge5e&#x2B;0ifUoVti22QssMsbRIMhnm&#x2B;fZGrkRu21aAPk3Qv2f/AIxftT&#x2B;CtQ/4TTVta8I6LZ6Hp0cF94n8vfYXEFzDJdzKuFd0khtIpCZdnzSbS5YSOPStD0b4VfB/xJ8RviJ4m8Yv4v1bRbC08R6l9mhe307TtPN2L60e2fJWaGJ402ssrhY4UVgOjeVajf8AxR/al8Xw30Og&#x2B;Nr6XSPGmsTtouqWN3oytoj6RFJFYvJK0dpsMsjWrRTp5kssiSh1hhct6/8ADT9mHTfgz4cubf4nanpOlWPjbQdI8IpptldXF3bk2MV5ey5aZfKhhVDcDYkaRLHBJI7FpSECjW1P9tP/AIQ/WNLtP7E8O&#x2B;Ch4hnaCUa0wto9IuZDp948t3KrKmTFq8eYwAWunaPzcMJG8zt9A&#x2B;Lvxw1A&#x2B;JNN0rxBa6T/AGHqVvdW&#x2B;ozXljM11caTp0rQxrcZme3F6L63CAYRmSSNj5Cq/cx618Cvghr&#x2B;h6d4Q8HTeIo7q3toDrWmebdWthaQi1urSMX8r7JIjixAhhlf92tsHTylTFSb40/E/wDaZ8Qxy&#x2B;FZLjw/4Z1CIWsE&#x2B;jo01xBG0WjXckslxITBuljvJ44yIleNYXdHy7BQRm&#x2B;Lv2LfAH7NXhbUPiP48a51Kax1S4k0&#x2B;w0WdtPaB9W1BFi01ZpbhY/KEly1mhza24t7iTzEXc8h6jRv24tB8HePf&#x2B;EU8P8Aw8ms5rzxG2lNeI6w2Um7ULpb65LpGzYgmcyyeYFRnupAkjMGLc58C/gV4n8R&#x2B;G/i9Z/Ei9XTJfGsljoN/rL2Utx/ash1LUMoIr6BYiRb3tpZo0SS248pTHJIFwsvgz4v/BrwN44/srw74DvL2&#x2B;8PeNV0Z7zUlW8&#x2B;ySLqF7bXOo2o3zNH5F1czwu7rBLsuYj80bw7wCH9qj4JeLv2mPiPqNjoem6hJdXnheH7Pr638tnoQimsdShlto5fnLNLPcW0hCxSbVhR3&#x2B;ZIg3Yv&#x2B;yP4Lsp/GHi7xneReItPtV0/VfEXhuS4XWrO3vLDSfKljmkuF8y4Ekf2K4/epG7yWltK33iD5t4A/bg&#x2B;KX7QlroNj4X/ALJRhc6INXvNJtJNQvtOEh1KO7ju4vKkih86SwSSMt5KpFOm6VC8bntPhjoeu&#x2B;HvhXq3g743eJbDSG8ePpBtt&#x2B;tP/aWpu9pbwXmnrH58kkcj/YpWYQSyhftUrJK3ls1AGT4m/wCCivgv9n34T22oeG/h3rkuk6H4e0IQLMfJnSymjdYrYtiWVjaF0jkZ8xrJcMnmeYSrR&#x2B;FPiX8Tvj34102y/wCJvBLHqrW2q6hoH2q106HTYddMdxbeeziEXIhheNnjCXIVG&#x2B;5uXPA/FD40/Bv4PWPhfXPB/wAOdD8TaLq12bHRtW8QWd7eWsSypf3r3FtEkVzP5Yc3VsQLeN9wwzeVAgOprP7Qvxm/aT8LeI9D8H6jb/274le4sLaDTbmKBfAt5bXsogMl4mTJHPDaXBfeDu8sBBiUKQDovD37PvheP9nmH4dfFHxTHrOqfBmKPxN4hi0pJPtF7bsrTQxuHyzL5cTW5WL5XjUIojDeWk5&#x2B;Jtj&#x2B;zVq3xN0jwT8MdI8O33hHSL61sNTvtQ&#x2B;3XeqXFlYW9xap5S5K27/boWVBPvZ5piY0dmLdn&#x2B;z98EfiRq83iabxo1roul69qsetx2Yulu5Ltn1d9QKzoI1KPHZG2045lkG20BUBFG/2iT9l3wn4v8Vy61eeF7DWtSbXIfEcVxfQC4&#x2B;x6hDaw2kc8JfIiZYoIwCuMEbuvNAj4Z0jRfjp&#x2B;0vY6pHq0fiXxRot8urxCzuriDT7W2&#x2B;36TZNplxG6wxQXdtBLLLIY2VpYmm&#x2B;/K9p&#x2B;9&#x2B;yPgd8Cm8Ba/8A8JHqEVuviC&#x2B;8OaboVyPPF7Mn2WW7kybryofN3/aVBxDGB5KgDG0L7lpnw7bCtdTbR/cj/wAa3tP0G00v/Uwqrf3jy35mgDjdO8JX2okHyvJj/vSfL&#x2B;nWt7TvAFvbkNcSNcN/d&#x2B;6v&#x2B;P610FFAEdrZQ2Ue2GNI19FGKkoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAIzVHU9Djvssv7uX19frV6igDk7q0kspdsi7T29DUddZdWkd5HtkXcP5Vg6nocliSy5kj9e6/WgCjRRRQAU2T/Vt9KdTZP8AVt9KAMGvH/2vfiN4P&#x2B;HSfDUeMvD669Z&#x2B;IPHNhpFgZGXyNLvHiuJoryVWO1ki8hjyDtYqwwVyPYK8d/bT8G&#x2B;CfH3gHQ9L8a&#x2B;HdZ8ZJeapNbaV4e0qRI7vW7qfTL&#x2B;2khRnkiRcWc95JuaWMJ5W/eCoyAeCaT/wUX8d/G7w9b6D4S0nR9P8Xalp91dSXUEUl7JpTxamlv8AZzasADL9mmhkDl2Xe2THtIU6viz9l34n/tJeL/7b8YXen&#x2B;Gf7DmmTQZdUYXscMk39vwrPDbQyrsYw6jpcWTJFP8A6K3zKyozaT/t&#x2B;/Dn4efD6TxX4H8FyQ6PqFub6/1Wa1h0pFjbfMrsG/ezgSy3GQowrLP8wxk43g3xF8cP2r/AGoas8enrazs1tZ6XJDHYaPcSW0&#x2B;jzRXSTKZrnbNnUhvinlRVQBCzqHYKOmj/AGdfhv8AsyfA7xBot1NefFDUfBvh19RuPC11d/aZbmM2LWkrNZRK8rw3QU71lScF1DIpdFFZl9&#x2B;3/faxrv8Awh/wy0Pw3cyaDp2k6p9tt0mvdKv7Ge3uJXhsVjWHcc2phRwxVN&#x2B;WTdG0Ndd&#x2B;yz&#x2B;wivwJh1hrzWDbtrmlQ2Mdnpd5ciTSGFtawXUkN1vQZma0hlLw21u28ndvAiEeD4&#x2B;&#x2B;I2jfsTR&#x2B;LLz4f/DzwhZ6Lod1p2g30cSm0vdc1a4igNvG9wqsIoIbeeJmmlEpYysMR7GdwRx/wk8J/Gj9pD4hWf8Awmt7rWjaLYz6R4rttN1ZUgurJrfWobmKOVYYo1YyW8d9FhlVgYIWdRwx6TUvhT8E/wBlT4x6hf8AiS5u9S8U6vPr3juO7d/KSxSC&#x2B;GoyWrx2oV5gsl956CeOYkW28keRCF5TXP8Ahof9oDxT4gvtIh/sPSvEGmJZq1jOLFLMWfiO9iNu0zMztLJpcc/76A4867hOEQRuO18A/wDBMTS9T8UT6x44uLS6uXbV7cQ6N5ltLqVtqFva2kxv7kbWubiSC1UySLHETNLLKMOVZQCn8OfjrbeM/D3j/Q/B3hHXPBnjN9OGkXs1zqElwdCvZJk0&#x2B;wjt1Ysq2kV1JqKoIxHGjafOyxkSbq2/iD&#x2B;xVqGp/tJR&#x2B;L/DOlaLpKt4msNY1G9OpT2N1qEUem3lrIzPbq0lwytcJ&#x2B;5mZY5FUqzFcq30N8J/2ZrL4earqF9pcd5E2pQW9qz3s3nOsULTSBd7DzZWaa5uZmkmaSR5LmQlyNqr6XpvgG1tRuuGa4b/AL5X8v8A69Aj5j/Zr/YG8L/ATwz4V023m1jxG/guJF0f7Y&#x2B;6HS/9GlhdYY1GfKY3F0ypK0nl&#x2B;eVUhEjVPbfhv8AdN&#x2B;Hugx6boWj6R4b0xW3/AGaytkhUtgDcVQAFiAMseTgZr0m3tY7SLZFGka&#x2B;ijAqTpQBk6f4KsbHDNH57jvJz&#x2B;nStVEEahVG0DgAdqWigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoIzRRQBl6p4eWcmSHCt1K9jWLLE0EhVlKsvUGuuZto5r5J/aN/ba8X/ABA12&#x2B;8F/s8&#x2B;C5PiF4jsZDBqPiKbbHoOkOBzGtwzpHNMM8oHwpH8ZBUehl2WV8bU5KNklq5NqMYrvKT0S/PZXZwZhmVHB0&#x2B;erdt7JJuUn2jFat/l1sj6A1DUrfSLR7i6uIbW3j5eWVwiL9SeBVXRvE2m&#x2B;KLKSbTNQsdRhU7We2nWZQfQlSRX47/tsfsWftRW&#x2B;l3fjb4nW&#x2B;qeKLG3JmuJrXUo72LTl7kW8Z/dRgZJKIEUZJI614X&#x2B;yl8ate&#x2B;Anx88M&#x2B;INAvJre4i1CGKeFXKx3sLuFeGQD7yspI56HBGCAa/UMJ4V0sVgZYnC42FSaT0irxule3NzX&#x2B;bS9D82xXidUw2Njh8Tg5U4trWTtKze/Ly2&#x2B;V/mfvZXkv7W3hzS7zw/4d1&#x2B;&#x2B;8fTfDm78H6lPqtnqcMUFxJL/wAS&#x2B;7iuIUhmVxK/2WS4kUKrMrQhtrqrI3rVeM/tkfs4a3&#x2B;0bb/D1dB1u18P3vgrxWnidLyeD7SiSwWF7HbhoOBMn2iaDeheMmPzNro4Uj8fP1g8t8Zt8C/gzdeFDpTSa9dfCGPVZ7TSdMW0upbKWIwGaK5uplEkEiy3dsFt/PjMkk0Y8uQoAvEfEv8Ab51v46&#x2B;P9Js/CFjrun6NoviLSLiz1DS1nuk1mSe7ithpl&#x2B;EXy7QFjdMWnyga3j2Ft0Zk978A/wDBP3wraap4ouvE015451DxlfTXt&#x2B;l6gWB91xazqgjX5iEeytiN7t9zaAse2NfdNM/Zy0Od9Jebw/oFuNDlM&#x2B;m/6BEz6dIV2F4fl/dMV&#x2B;UlSDjjpxQB8o/sWfs9fETR9Z1if4tWMesDxF4eNrLJqV695faaJL&#x2B;7lfTxIZpw0TJMGfZMwHlwpyixhPerf9lDwz4h&#x2B;Ltx4xbw9Y3Wo3Olw6W6yWqGApFIXV2BG1nXCKrYyqpgcYA9w07wdY6cQ3l&#x2B;c4/ik&#x2B;b9OlairtHFAHL6d8PDnddTf8Aj/wAT/hW9p&#x2B;iWulr&#x2B;5hVT/exlj&#x2B;PWrVFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUd3dx2NtJNNJHDDCpd3dgqooGSSTwABzmpKzfF3hHT/AB1oE&#x2B;l6rbreafdbRPbuSEnVWDbHAPzIduGU5VlJVgQSDUeXmXNt1Jlzcr5dzyW5gvv2xo5YxPdaX8JZgoWS3dobzxivVvmwGhsDwMqQ9wCSCsRHm&#x2B;veG/DOneDdCtdL0mws9L02xjEVvaWkKwwwIOioigBR7AVcjjWJFVVCqowABwKdmunEYp1EqcFywW0f1feT6v5KySS58PhVTbqSfNN7v9F2S6L5u7u3k&#x2B;PvEWl&#x2B;EPA&#x2B;satrkkMejaXYzXd&#x2B;8qhkWCNC0hYHgjaDxX4X/wDBMn9m9vjl&#x2B;0gviq9tDa&#x2B;BPhy//CQ6xcycwwiLdJBBk/eLOgJXuiP&#x2B;P2l/wUL/AGjPEH7d/wASv&#x2B;GcvgqV1SMSiXxfraSbbO1jjcZhMg48tGwXIyWYKi5O4Hg/FHxA0j4YfDe3/Zu&#x2B;ANk3iNNYc2&#x2B;ua55Ya41&#x2B;7biXy&#x2B;iiPCYLn5Qi4BwpdvuaOcPhXIq3tHbE4tJRh1jBJpSa6OXM&#x2B;Vej8j8d43zjB18bSxNT3qeHbUUtXVqu1qcEt0mo87Wiu1u0fTXxV/b1&#x2B;GnwreS3fXBrmpRnaLPSF&#x2B;1OW6YLgiMHPGC&#x2B;faug&#x2B;EWmfFT4&#x2B;hdS1exj&#x2B;F3heYB7eEot3rl4p6E&#x2B;YPKtxj&#x2B;/GzZ4x/FWD&#x2B;xb/wAE&#x2B;/CP7L8tjrPjC90rVPiA1u12iTTL5Gloo&#x2B;doUb7xX&#x2B;KYjjttGSfqDTfGej6tcwQWeqabdTXUH2qGOG5R2miyR5igHJXII3DjINfllD21T3q75fJfq9/usfZZLHOMfbEZ1UVFPajTdn5e0nfmvr8MXFd73sR&#x2B;DPAmm&#x2B;BNMFvYxyFj/rZ55WmuLg&#x2B;ryMSzH6nAHAAAArYqO3uo7uPdFIsi5K5U5GQSCPwII&#x2B;oqSu5WSsj7enCMIqMFZeQUUUUywooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5v4mfFjQ/hLoy3ms3bRvcMY7Szgjae81GXGfKt4EBkmkP8AdQE9zgAmrp051JKEFdvoiKlSNOLnN2S6s6G5uY7O3kmldI441Lu7naqgckk9gK&#x2B;Pvi78cPG37fGs3XgH4HX02ieBY5ja&#x2B;JfiOARCwHElppuMGaTBw0ikAdAwBDN3GrfBnxt&#x2B;2XcW9x8Q3vfA/wAOd29fBVpc41DWkzx/alxG2FjIGfs0JIw2HkJGB754V8J6X4G8O2ekaLp9lpOl6fGIba0tIVhgt0HRVRQAo9gK92hUw&#x2B;Wv2mlSt0W8IPu&#x2B;k5LoleC6uWy8StTr5ivZ606PXpOa7LrCL6vST6KO7/O/9tHUfCP/AAT/APgzZfBj4U2/9k6pr1utx4h1RTm/uoOVHmzDBLyndkDARAQFCuBXpn/BHH9nvS9B&#x2B;EVx8Qrq3huNb165mtbSZly1paxNsZV/ul5Ffce4VR65&#x2B;X/&#x2B;CqvhfVtB/bO8RXmpRzfZdYitbjT5mUiOWFbeOMhT0&#x2B;V0ZTjuM960v2Gv&#x2B;CkV9&#x2B;yh4em8N6tpEniDwzLO1zAsUwjuLF2&#x2B;/syCrKxGdpxgknPJB/PcRms6&#x2B;aTxOPk5O71euvdn8&#x2B;4XiXBYXjepUzePs6NDmp01b3adnaLsr7q7uk9ZJ7LT9KviH8CtP&#x2B;JHiKbULrUNUtftGlzaTLDatFGssUkcyEsShdioncqpYoGCnbnOc3xZ8CNBttTh16bWtQ0ODRNPSGNllt0htPJW5CXBkkjZlZBdSnl9hwNysAQfJfhz/wAFCvEf7RcqW/w1&#x2B;FOvagsrbG1XWblbLTbQ92eRA&#x2B;/H9xTuPYV7F4R&#x2B;Dd/qN2mqeOtYTxRqiussNnHB5Gk6Yw5HkwEkuwPSWYu4xldmSK9aE6dXWmr&#x2B;eqX9eh&#x2B;4YTGZdmd6uXU3UTd3NqUY38pOzl6QTV92tyt&#x2B;z7oMPha2nsfDtrqsfgv5rizn1O4Z5JJX2Z&#x2B;zq48zyGIkkLSnLPKSg2EGvS6MYorqpx5VY&#x2B;mweFWHpKlHZdlZLyS6JdFrZdWFFFFUdQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFV20q1bUlvTbwG8WMwifyx5gQkEpu67SQDjpkVYoou1sG&#x2B;4UUUUAc78SvhH4Y&#x2B;MehrpvijQtN12zRt6R3kAk8psY3IeqtjjKkGvP/AAl/wT&#x2B;&#x2B;Dfgm/wDtNj4A0SSUNuH2wSXqqfZZmcD8BXsVFZyo05PmlFN&#x2B;h5uIyfAYiqq&#x2B;IoQlNbScYtr5tXI7Szh0&#x2B;2jht4o4YYVCRxooVUUcAADgAegqSiitD0lpogooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//2Q==" />
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="data:image/jpg; base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4QBaRXhpZgAATU0AKgAAAAgABQMBAAUAAAABAAAASgMDAAEAAAABAAAAAFEQAAEAAAABAQAAAFERAAQAAAABAAAOxFESAAQAAAABAAAOxAAAAAAAAYagAACxj//bAEMAAgEBAgEBAgICAgICAgIDBQMDAwMDBgQEAwUHBgcHBwYHBwgJCwkICAoIBwcKDQoKCwwMDAwHCQ4PDQwOCwwMDP/bAEMBAgICAwMDBgMDBgwIBwgMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDP/AABEIBAAEAAMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5&#x2B;jp6vHy8/T19vf4&#x2B;fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4&#x2B;Tl5ufo6ery8/T19vf4&#x2B;fr/2gAMAwEAAhEDEQA/AP38ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqvquqW&#x2B;h6XcXt5NHb2tnE000sh2rEiglmJ7AAEmgCxRXHw/G3SZ4VkXT/F&#x2B;1wGGfC&#x2B;oqcH2MGR&#x2B;NO/4XRpX/QP8Xf&#x2B;EzqP/wAZoA66iuR/4XRpX/QP8Xf&#x2B;EzqP/wAZo/4XRpX/AED/ABd/4TOo/wDxmgDrqK5H/hdGlf8AQP8AF3/hM6j/APGaP&#x2B;F0aV/0D/F3/hM6j/8AGaAOuorkf&#x2B;F0aV/0D/F3/hM6j/8AGaP&#x2B;F0aV/wBA/wAXf&#x2B;EzqP8A8ZoA66iuR/4XRpX/AED/ABd/4TOo/wDxmj/hdGlf9A/xd/4TOo//ABmgDrqK5H/hdGlf9A/xd/4TOo//ABmj/hdGlf8AQP8AF3/hM6j/APGaAOuorkf&#x2B;F0aV/wBA/wAXf&#x2B;EzqP8A8Zo/4XRpX/QP8Xf&#x2B;EzqP/wAZoA66iuR/4XRpX/QP8Xf&#x2B;EzqP/wAZo/4XRpX/AED/ABd/4TOo/wDxmgDrqK5H/hdGlf8AQP8AF3/hM6j/APGaP&#x2B;F0aV/0D/F3/hM6j/8AGaAOuorkf&#x2B;F0aV/0D/F3/hM6j/8AGaP&#x2B;F0aV/wBA/wAXf&#x2B;EzqP8A8ZoA66iuR/4XRpX/AED/ABd/4TOo/wDxmj/hdGlf9A/xd/4TOo//ABmgDrqK5H/hdGlf9A/xd/4TOo//ABmj/hdGlf8AQP8AF3/hM6j/APGaAOuorkf&#x2B;F0aV/wBA/wAXf&#x2B;EzqP8A8Zo/4XRpX/QP8Xf&#x2B;EzqP/wAZoA66iuR/4XRpX/QP8Xf&#x2B;EzqP/wAZo/4XRpX/AED/ABd/4TOo/wDxmgDrqK5H/hdGlf8AQP8AF3/hM6j/APGaP&#x2B;F0aV/0D/F3/hM6j/8AGaAOuorkf&#x2B;F0aV/0D/F3/hM6j/8AGaP&#x2B;F0aV/wBA/wAXf&#x2B;EzqP8A8ZoA66iuR/4XRpX/AED/ABd/4TOo/wDxmj/hdGlf9A/xd/4TOo//ABmgDrqK5H/hdGlf9A/xd/4TOo//ABmj/hdGlf8AQP8AF3/hM6j/APGaAOuorkf&#x2B;F0aV/wBA/wAXf&#x2B;EzqP8A8Zo/4XRpX/QP8Xf&#x2B;EzqP/wAZoA66iuR/4XRpX/QP8Xf&#x2B;EzqP/wAZo/4XRpX/AED/ABd/4TOo/wDxmgDrqK5H/hdGlf8AQP8AF3/hM6j/APGaP&#x2B;F0aV/0D/F3/hM6j/8AGaAOuorH8IeObDxvDdtYi&#x2B;jaxmEE8V3ZTWcsblFcfJKqtgq6kMBg8jOQcbFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcv8AFiFdY0Oz0RlDr4hvorGRG&#x2B;5LAMzXEbez28Uy&#x2B;5YDjOR1Fcr5B1/4w&#x2B;YzMbfw7p21FHzRtcXL5Yn0kjjgXHfbdN2IyAdUOlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcre2q6D8XrO&#x2B;5WPxBYHT5WJyGmt2aaBQOxKS3hJ6EIvTAz1Vcr8Yo5LTwf/AGxCwS48NzpqwPUmKL/j4QDpue3MyDPQuDxjI6oHNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcr8IjJqfh&#x2B;71qYKH8R3suoR7fum3OIrZsdi1tFCxB5DM3ToM39pr4lad8JPgbr&#x2B;uatrdv4Z0&#x2B;OOO0l1eeTy49L&#x2B;0SpbrcE/wDTNpQ3bO3GR1rzCL/gqh&#x2B;zR4a0aKGH4weA4rSzjWKOKC&#x2B;D7EGFVVVQTgDA4HArsw&#x2B;X4rER5qFKUltdRb/JHbhstxeIjz4elKa2vGLevyR9F0V86/8AD239mzzLdf8AhcngvNwAU/0s4H&#x2B;8duE&#x2B;jYNIP&#x2B;Ct/wCzWRcf8Xk8F/6KcP8A6U3PX7vy/P0/hzXR/YeY/wDQPP8A8Al/kdH9hZl/0D1P/AJf5H0XRXzmf&#x2B;CuH7Narbt/wuTwZ/pJwn&#x2B;ktx0HzfL8nX&#x2B;LFOH/AAVs/ZsMs6f8Lk8F5t1LOftZ2kf7Jxhj7Lk0f2HmP/QPP/wCX&#x2B;Qf2FmX/QPU/wDAJf5H0VRXzmf&#x2B;CuX7NYtopv8Ahcfg3bM21QLhtwPT5l25Ue5AFer/AAk/aJ8G/HnQDq3g3Wo/Emj4fbqFhbyy2chQgOqTBfLdgTgqrFsg8cGsMRluLoR569KUV3cWl&#x2B;KMMRluMw8eevSlFbXcWl97R2tFYzeOrFdGW/8AI1jyGk8oKNJujNnBPMXl&#x2B;YF4&#x2B;8Vx71b/AOEht/7bGn&#x2B;XffaGTzN32Obycf8AXXb5efbdn2riOEvUVjp45sn0eS&#x2B;EOseRHJ5RU6TdCYnjkRGPeV5&#x2B;8FI688GrH/CTW/8AalrZ&#x2B;XqHnXcfmo32GfylGCfnk2bEbg/KxB6ccjIBoUVkp40s3sbu48nVvLsnCSA6Xc&#x2B;YxJx8ieXukHugIxz0px8W2oubKLydS3aggeI/2dcbVB6eY2zEZ9nKkdxQBqUVlf8ACY2m2&#x2B;Pk6p/xLTtl/wCJZc/PyR&#x2B;7&#x2B;T9706x7hjB6EUN4xtFisW8nVMai22LGm3BKcgfvBs/dDkcybRjJ6A0AatFZqeK7WSe&#x2B;j8rUt2nqXlJ0&#x2B;cKwH/PM7MSnjpHuJqI&#x2B;NrNbG1uPJ1by7xzHGP7Lud6kHHzp5e6Me7gDHOcc0Aa9FZo8UWx1S5s/K1HzrWMyu39nz&#x2B;UwGD8kmzY55HyqSevHBxBJ47sYtIjvjDrHkySGMKNIu2mBGesQj3qOPvFQPegDZoqh/wAJJbjWWsPLvvPVPMLfYpvJx14l2&#x2B;WT/shs&#x2B;1Vh45sjozX/AJOseQsnlFf7JuvOz/1y8vzNv&#x2B;1tx70AbFFZ48SW51aGy8u/86ePzVb7DN5IHJw0uzYrcfdZgenHIquvjezfTri68nV/LtXEbr/ZV15hJOPlTy97j3UEe9AGxRWa3iq1W9s7fy9R8y&#x2B;QSRkafOUUH&#x2B;&#x2B;&#x2B;zbGfZypHpTF8ZWbQXsnk6rtsG2yg6ZchmOcfu18vMo46xhhjnpQBq0Vlnxfag2P7nVP&#x2B;Jh/qv&#x2B;JbcfJ0/wBZ8n7rr/y02/oaVfFtq8l8vk6lnTwTLnTrjD4z/qzsxL06R7v1FAGnRWS/jOzS1s5vJ1XZfNsjA0y5LKc4/eL5e6Me7hRjnpUv/CT239oXVr5eoeZZxmSQ/YJ/LYYB&#x2B;R9m2Q8/dQk9eODQBo0Vjt43s00qG88nWPJnkMaqNKujKDz96Py96jj7zKB78irI8R251mSx8u&#x2B;86NPMLfYpvJxx0l2&#x2B;WTz90MT7UAX6Kx/&#x2B;E6sf7G&#x2B;3eTrHkiTytv8AZN152cZz5Xl&#x2B;Zt/2tuPerP8Awkdv/a8Vj5d/500fmK32KbyQOTzLs8tTx90sD045FAF&#x2B;isdPG9nJplxeCHV/Jt3EbqdKuhKScfdj8vew56qCPepj4ptRfWdv5eo&#x2B;ZfIJIz9gn2KDz877NsZ4&#x2B;65U&#x2B;1AGlRWUvjKza3vZPJ1XbYNtlB0y5DMc4/dr5eZB7oGGOelK3i61U2P7nU/&#x2B;Jj/qsadcHZ0/1nyfuuv/AC029/Q0AalFZY8XWrSXy&#x2B;TqedPGZf8AiXXGG/65nZ&#x2B;96f8ALPdRP4wtLfRI9QaHVDbynaqLptw046jmIJ5i9OpUDp6igDUorP8A&#x2B;Ekt/wC2I7Hy7/zpk8xW&#x2B;wzeSBgnmXZ5anjoWB6cciq6eOLN9Mnu/J1jyreQRup0q6EpPqsfl72HP3lBHvQBsUVnN4otlvrS38vUPMvUEkZ&#x2B;wT&#x2B;WoPPzvs2xnjo5B9qjTxlaPbXk3k6rtsW2yA6ZchmOcfu18vMg90DDHPSgDTmhW4iaORVeNwVZWGQwPUEVzPweu5D4Hh0&#x2B;4DreaDI&#x2B;kz7z87&#x2B;Q2xJT6ebGI5QPSUcnrW5Za9DfvbrHHeKbqIzJ5lpLGFUY4bco2NyPlbDHnjg45ebUn8A/EbU5J7fUptJ16CK6je00&#x2B;e8Md3GPKl3&#x2B;UjFQ0QttoPBMcp&#x2B;oB2lFc5/wtLTP&#x2B;fXxH/4T9/8A/GaP&#x2B;FpaZ/z6&#x2B;I//AAn7/wD&#x2B;M0AdHRXOf8LS0z/n18R/&#x2B;E/f/wDxmj/haWmf8&#x2B;viP/wn7/8A&#x2B;M0AdHRXOf8AC0tM/wCfXxH/AOE/f/8Axmj/AIWlpn/Pr4j/APCfv/8A4zQB0dFc5/wtLTP&#x2B;fXxH/wCE/f8A/wAZo/4Wlpn/AD6&#x2B;I/8Awn7/AP8AjNAHR0Vzn/C0tM/59fEf/hP3/wD8Zp&#x2B;n/E/SdR1u105TqVveXpYQJdaXdWolKqXIDSRqMhVJxnsaAOgooozQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHyb/wXM/5RWfFj/r30/8A9OdpX83Nf0jf8FzP&#x2B;UVnxY/699P/APTnaV/NzX9H&#x2B;Df/ACKa3/Xx/wDpMT&#x2B;lvBb/AJFFb/r4/wD0mIUUUV&#x2B;un7EFFegfsn&#x2B;GNP8AG/7U3w00XVrWO&#x2B;0vV/FWl2V5bSD5LiGS7iSRG9mViD9a/omk/wCCRH7M0Kbn&#x2B;D/hBV9Skg/9nr4virjjCZFUp0sTTlJzTa5bdNOrR8PxZx1hMgqU6WJpyk5ptctummt2j&#x2B;Zmv6Fv&#x2B;Dd//lGP4b/7DGp/&#x2B;lDV6Z/w6T/Zg/6JJ4L/ACf/AOLr2T4MfB7wV&#x2B;zv4Fh8M&#x2B;CdJ0vw5oFtJJNFY2jYiR3bc5GSTyeetfkfHHiBg87y9YPD05xakpXla1kmujfc/HuO/EbA55lyweHpyjJTUrytayTXRvudlRUSX0MjBVmiZj0Acc1LX5GfkAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFGaM0AFFG6jNABRRmjdQAUUZo3UAFFGaM0AFFG6jNABRRmjOaACiisvxGu7UdF/082e2&#x2B;z5Yz/pv7mX911H&#x2B;/wA5/wBX07gA1KKKKACub8bfGPwj8NbyG38R&#x2B;KvDnh&#x2B;4uV3wxalqUNq8q5xlRIwJGeMjvXSV8p/teeKNa0b9qPwVbmTS9O0a8uNNjlU2v2ybWoxfxgqS9q625h8yY581MrIWDlhsUA&#x2B;nbzxVpeneGJdbuNSsYNFgtTfS38lwq2sduE3mYyE7RGF&#x2B;YsTjHOcVm&#x2B;Bfi34U&#x2B;KEl4nhnxN4f8RPp&#x2B;37UumajDdm23M6rv8tjty0cgGcZMbD&#x2B;E4574&#x2B;aZZWX7KnjOy042tnpsfhW9gtjHHC8EMQtHVcLIREUC44chMdTtzXnH/BOXShD8NdavLrR/susNfLZXepsbN5NW8uMSF3e2uJlZzPPcyPnZ&#x2B;9uJm2ZZmYA&#x2B;iaK&#x2B;Ofjf4fk8af8ABQvRbVZtF1RYZbPydJvNX1HR5BNDH9plmjltbVlmaOHa/kzSmF8qp2Ekr9jUAFcT4o8Oaf4o&#x2B;L&#x2B;m2&#x2B;p2FnqNuujXMgiuoFmQMJ4ADhgRnBPPua7auVupVb432Khl3LodySM8gG4gx&#x2B;eD&#x2B;RoAn/4U94R/6Fbw5/4LYf8A4mkPwe8KDmPw7o1rJ/DLbWiQTRn1V0AZT7qQRXSUUAcmfBuseF5mm0HV5rqHHOm6vM9xEx/2Lg7po2PcsZVHZBzWl4Q8b2/ixZoTDNp&#x2B;qWYX7Xp9ztFxa7s7SQpIZG2ttdSVbacHIIG1XP8AjrwnNrK2&#x2B;paayW&#x2B;vaVueylZiqSAlS9vJjOYpNoDZB2kK4G5FIAOgorN8I&#x2B;JofGPhy11KGOaBbhTvhmULLbyKSrxOASA6OGVgCQCp5NaVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHyb/wAFzP8AlFZ8WP8Ar30//wBOdpX83Nf0jf8ABcz/AJRWfFj/AK99P/8ATnaV/NzX9H&#x2B;Df/Iprf8AXx/&#x2B;kxP6W8Fv&#x2B;RRW/wCvj/8ASYhRRRX66fsR6d&#x2B;xL/yeb8I/&#x2B;x00b/0uhr&#x2B;kD9u3wrpfjn4U&#x2B;G9H1rTbHWNJ1Lxt4dt7uyvYFuLe6ibVLcMkkbAqykcEEEGv5v8A9iX/AJPN&#x2B;Ef/AGOmjf8ApdDX9KH7Yn/Il&#x2B;D/APsfPDf/AKdbevwfxabWZYNrs/zR/NPj8k3RT/kn&#x2B;aPiL48fs&#x2B;2/gb4//FrQtH&#x2B;CfwvuPD&#x2B;j6N5/heWL4X6fKTe6gNLtLIGXyCsyQXMmoSsoAIWP94zKQEyvEXwlsbi18F32jfAnwA2pX/wk1XV9U0Zvhpp0kY8RWtrceXx9iEis91FtWMS4cBQIxnLcf/wWE/Y88N/sFeBo/iN4e8K/D3V9D17xFBo9vo9/a6z9qtDLazzNI90uqBZPnt34EKYEg5&#x2B;Xn5H&#x2B;NXiyb4W6X8HfFmqfBn4e6L4d8daauox6fDq2qXE2rxJIscssjG6Jt1kzmNEYsqkbiTXy&#x2B;X4b6zRhUpTbvdapK7UdVbn363/HqfxvmmMeDxFWlWppNWbSbaSc9GmoaK1lZ9Ol9D9Iv2Svgx4f07wP8LfFV14D8J6P4sh&#x2B;LV7pVrrNt4MsvD9/eabHHqCQMywW8JCyRKjHCgNwcV&#x2B;iVfLuu/sk/D39k/UfhrafD/w6vh&#x2B;31n4g2U14gvbi585ksL8KczSORgMemOtfUVfE5tiFXmqkW7O9r6dXpa7/ADP0rI8LLDU3RmkpK17O6bstbtJu/mgoooryT3AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACgjIoooA/N/xz&#x2B;zF8QPgpbSaho/wjvvEl9b/GPRda0XW7WSyPii5s21VZL6W&#x2B;njlKvC8MskCzMUcW7MLhVWPex8e/2b/ib4Fg&#x2B;PnjrVNF8L&#x2B;E9J/wCEN8VpfahoMCWp8WtcSLLYTSBLiSSSaKFGLyTxxtG7skReNyR&#x2B;kFBGaB3Pz&#x2B;8Y/s&#x2B;&#x2B;JPAn7ZXg/UNe8KpNq/ir4r6nPH4/TVI2e/0m40XVWs9KaEN5&#x2B;22VY08t1EINsJEYvIQOIP7Pmufsd/8ABND47L4x0&#x2B;Twx408VfDh/B1na6WqNB4g1O30y&#x2B;VLyIQTTyzXdxJKQbido5ZBHEPKi2AH9OMZooC58rftk&#x2B;NbD40f8E&#x2B;YJ/C0y&#x2B;II9Q8ReFNOSOO8l0/7XIfEOmRPAZwPMi3bihdQSoYkZxXiXjL9h/4mXfw91Sz0z4U&#x2B;DZPBuseJdR1DRPA2ovbXl14JilsLCCCS1lFzFb2oa6gvrhxbSO8P2yNossJFP6LEZozzQFz879c/Zb&#x2B;KN5J8Q/BNt4KuLrV77wH4Jm1PxPLcRR6Z411vS9QmmvJWKzRu891HGIiXaNwqReY8aNG1aH/DBHiXw98NPDsMnw3/AOEy0m4tNekXwbPqdlpdr4N1a9uIXtLu1ijle3hhhjicKYJZZrYys0XmNI5H6AbuaM0Bc&#x2B;DvGvw00nwH4p&#x2B;FVj4PuP7e/ag0vXPDVj408Q6RazRzavZxC2TWLjVHwENpJZrOyiY/61ofL/eBa9v/AGzvhb488V&#x2B;NvBmveCdJh11tP03XNDu7R9SSxEDahbRRw3bs/DRRSQ/OEDSBZMojkFa&#x2B;gd1c1rHxh8OaH8RdJ8IzakJPEetJPLbWFvBJcSLHCqNJLL5asIY182Ib5SilpY1BLOoIB8Y6D8PPiV4LuPCOpeN9BbwxEtx8N/CltEusR3z3c&#x2B;nX2oC7mbyiQqyG5iK5JLJtLbW3RpD4k8Z&#x2B;IvC3gX4B&#x2B;AVvNFnml8ZaNqN7bo92&#x2B;qtGNdlZnUCPyvICINxdgQFfjAGfuH4h&#x2B;P8AR/hV4B1zxR4gvo9N0Dw3YT6rqV5IrMtpbQRtLLKQoLEKis2ACeOAa1bW7jvLaOaNt0cqh0b1BGQaAufD/wDwUJ0eS/8A2jNWmurLUbnxFb&#x2B;FvD5&#x2B;FMsUE0ht9e/tm8/tA27IMLJ5X9l&#x2B;aTj/AEcPu/diSt3/AIJfeGNC07xZ44vL7S9Dh&#x2B;IX9qarFdahcwzL4surQ6pOV/tVpF25IW3MQR2Qx7SmFwK&#x2B;xt1LmgL6BWT4kdV1HRd1g14WvsLIM/6GfIm/enA6YynOB&#x2B;8HsDrVm6&#x2B;JTf6T5d7FaL9s/eI5wbtfJl/dr6nOHx6IaBGlRRRQAV4D&#x2B;0c1xD8WNCbUvHngfQdMtby21H7Nea3d6PqEdpHLE0g2pc&#x2B;Tcq7RygmWIIVfyyDgsffq&#x2B;UP279cl0X46&#x2B;A4Vmlkt9ZEWl3en2d5d2V7qdtNcbJY4/IeL7SwyjBPNxEomJRvNRkBo&#x2B;ifHt1pevfB/WpmubWXRbzSJpDcRo9zC9u0LHeFhZXkXacgRurMPusCQa85/Yy1bw9r&#x2B;meJL7Q9c8SeIpLq&#x2B;Wa6vr2x1a1sZCY1RVtWvnkEwUR4d45ZCDhSVCoi9p8cvC8eofs4eMNFsRY6bDN4cvLK3EtmZ7a2U2zooaBQS8ajGY1UkgYArzf8A4J1&#x2B;GtB0H4PakdJ0Dwxot7HqstnfyaLp1zZx3bRhWQkXTNcHCy8eYRwxKgKwJA6Gbfadp&#x2B;qf8FErW6trex0/U9Ng8u7uXnCXWpxtYSYiSJrzLxKXjYutrkNCRuwGavpKvkn4g&#x2B;Arf4gf8FE9JXVbfSrvSbG6RkuNnl3VveJprzQW6OlusquAs05kNwUZAqAKylX&#x2B;tqAYVk6cdNt/GOqQ29nDDqUkFvd3k6QqrXIbzI49zDliohYc9BjHtrVn25vT4nu/MjjGn/ZofIcY3NLul8wHvgL5WPqffAI0KKKKACiiigCO2tY7OMpDHHErOzlUXaCzMWY/UsSSe5JNSUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfJv/Bcz/lFZ8WP&#x2B;vfT/AP052lfzc1/SN/wXM/5RWfFj/r30/wD9OdpX83Nf0f4N/wDIprf9fH/6TE/pbwW/5FFb/r4//SYhRRRX66fsR6d&#x2B;xL/yeb8I/wDsdNG/9Loa/pQ/bE/5Ezwd/wBj54b/APTrb1/Nf&#x2B;xL/wAnm/CP/sdNG/8AS6Gv6UP2xP8AkTPB3/Y&#x2B;eG//AE629fg3i5/yMcH6P80fzX4&#x2B;/FQ/wS/NHyD/AMHOP/JhXhP/ALH6z/8ATfqNfn9/wUh/5Na/Y7/7ER//AEoSv0B/4Ocf&#x2B;TCvCf8A2P1n/wCm/Ua/Pf4q/st/tG/Hz4Sfs72beC5vFnhOPRIrbwtq2hWEkwht7iVXMN8y5ETRHje6opQbtzYYj5zhlwjgqFSclFKc93b7LWh/GPGSnPMcVSpwcnKFPZXt76ev3fefuL&#x2B;1N/yMfwh/7H21/wDSG&#x2B;r1uvI/2pm/4qL4Q&#x2B;/j21/9Ib6vXK/OK38KHo/zZ&#x2B;vYf&#x2B;NV9V&#x2B;SCiiiuY7AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvnj/god8G9c&#x2B;Nfw9s9L8H&#x2B;D59R8eSR3EXhzxgl9b2a&#x2B;ALt/K26gztKtwQCobZbxymTySjgK&#x2B;T9D0UAfAXiTwV460n43fC/UPD/hXxFrWq/wDC2/F1vf8AiTTJIZItJ0u6tdYCR3QeVSIFme1n2sDHvtkQEymJHi&#x2B;H37HfxX0X4czW9n4PuPDXiHSfCEVn4kuH8SxXP/C0PEEF/p90moJKJWZcpaXyCa7EMhOpBWUJHkfoF0ooHc&#x2B;A/EPhDxn&#x2B;01a/G6G1&#x2B;GWrWPxDk&#x2B;IHkeHNSudcso5PhnO3hjw6Yb6SaO4JJHEzRWnnh2Vo2yrlj0HxA/YV8ZeIfij4u&#x2B;KG/wAUR&#x2B;IfiKmueFtf0zQ9chtLq00CS2uYLGaykkcQR3pNppL7iRsZ5ck4bP20saoWKqAWOSQOpp1AXPzH&#x2B;Lv7BPxV8dfsxX/hm&#x2B;&#x2B;E9jrl/qnw61Xwx4asbDWLPSbfwXqUt5qLLfXEK3JhE13aT2ImNq8yiWCWIYglLDtvEvgTxh4Z&#x2B;K9rq&#x2B;n&#x2B;B/EHjHVtN&#x2B;OUU8F/pF1A0mhaa&#x2B;h6XBcwyGSVCkMpRywAMeIsuQSmf0CoAxQPmPhzw1&#x2B;yl8VPHtrpfgXxBpOpeGtH8L&#x2B;GvFmir4rGtW8wvr691CzuNLvbaKORpgIlgLnz0Rkddu1lO5uh/wCCckHxA&#x2B;M/jvVPiF8Rda8YXlx4Y0qLwja6Zr1pZ2xsdWIim1uSIWttbpLAJ0treKRlZv8ARbghtsmK&#x2B;wqMYoFcKx/FDWw1PQvtFrLcSHUMQOhIFvJ5E3ztjqNu5ee7Ctis/W/thvdL&#x2B;y3EMMf2v/SlkxmaLypPlXg/Nv2NxjhTz2II0KKKKACuX8bfBbwv8Rdd03U9a0mG&#x2B;vtJure9tZi7oySwed5JO0gMF&#x2B;0TYVsr&#x2B;8biuoqnfWFzc3G6K&#x2B;lt4/k&#x2B;RY0YfK4ZuSCfmUFT6A5GDzQBzX7Q9q198AfG8KSTRNNoN9GHhultZEzbuMrM3EZHXefu9e1eYf8ABOaNr74H3GpXFw0l7PqU8E8Nvr0&#x2B;p6bbFCMpbCWR2jUMWyG&#x2B;YvuIJjMde9ajbyXenzxQztazSRsqTKoZomIwGAYEEg84II4qPTtM/s6S7fcrtdTGZj5aqR8qqASAN2AoGTk4AGcAUAfPfiLwrJfft2WFxrNx42js5Jo5NGFnqOo2&#x2B;jySR2MjFJlEPkO&#x2B;VnbYJ1RgfmjZt2/6Or4/OreDfix/wUTsLldC0WPV9Kv7jR7ua8jtZdRungs7kqvkmcypb/IsqTiLBKovBZtv2BQNhWRZpaDx3qLJNI181jaiaIj5EjElx5bDjqWMgPP8K9O&#x2B;vWbbCceLLzdawpa/ZYPLuQB5kr75t6E5ztUbCOOsjdecAjSorB&#x2B;Kct/B8MfEb6VrGn&#x2B;HdUXS7k2erX8QltNMm8ptlxMhZQ0cbYdlLKCqkZHWvhseKv2gv&#x2B;j2P2bP/CUtf/k&#x2B;gD9AqK/P3/hKf2gv&#x2B;j2P2bP/AAlLX/5Pr0D9lvX/AIxXvx30GPxV&#x2B;1F8EfiNoLfaPtXh7w/4ft7XUdQ/0eUp5Ui3cjLsfbI2EOVjYcZyAdj7CooooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfJv/Bcz/lFZ8WP&#x2B;vfT/wD052lfzc1/SN/wXM/5RWfFj/r30/8A9OdpX83Nf0f4N/8AIprf9fH/AOkxP6W8Fv8AkUVv&#x2B;vj/APSYhRRRX66fsR6d&#x2B;xL/AMnm/CP/ALHTRv8A0uhr&#x2B;lD9sT/kTPB3/Y&#x2B;eG/8A0629fzX/ALEv/J5vwj/7HTRv/S6Gv6gfjD8H9H&#x2B;OXg3&#x2B;w9cbUo7Nbu3vo5dPv5rG5gnglWWKSOaJldGV1U5UjpX4H4v1Iwx&#x2B;EnLZJ/mj&#x2B;bvHinKpUoQhu4St96PhD/g5xP8AxgV4T/7H6z/9N&#x2B;o19Mf8Eqf&#x2B;Ucvwb/7Fi1/9BrZuf2G/Dd4m2bxd8X5VByA/xC1hgD&#x2B;NxTov2IvDsEYSPxj8YUVRgKvxD1gAf&#x2B;TFfltTHUJ4CGCu/dk5Xt36Wv8AqfzjRyzFQzSpmVl70VHlvtZ3ve36Fn9qj/kZPg//ANj9bf8ApBf165XkehfsX&#x2B;F9G8XaLrU2t/ETWrrw/d/b7GLWPGWpajaxTiN4xIYZpmRmCyOASDjdXrleVXlBxjGDbtfpbr6s9vC06qlOdVJczWzvskuyCiiiuY7AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxfFb2S6p4f&#x2B;1rM0raiRaGPGFl&#x2B;zz8t/s7N/TuRW1VHWPt32vTfsaxGH7V/pe/qIvLk&#x2B;777/L/DNAF6iiigAooooAKKKKAPnfxN8cvF1h&#x2B;2pY&#x2B;ErHUNMk0q4u1gWwurhrdLiEaeZ5wm2wkYzxsySbjcpEyMqbQ&#x2B;419EV84eLP2dPEHiL9vHRfGbabOvh&#x2B;1LvNqNtqtxauqxWkYhjZY7tBKrztKGie2dSqAtIQQi/R9ABWTZpGPHOoMt48kxsbUPalTthXzLjbID0y5LDjn90M9RWtWXaux8ZXymxWNBZ25F5t5nO&#x2B;fMee&#x2B;zAbHbzfegDlf2q/hqPjP&#x2B;y98SPB7ana6KvizwtqejHUbofuLD7RaSw&#x2B;c/I&#x2B;RN&#x2B;48jgHkV&#x2B;En/ABC7W3/R03wk/wC/Q/8Akiv3b/aq8aaR8N/2X/iR4i8QaHb&#x2B;JtB0Hwvqeo6lo86o0WrW0NpLJLbMHDKVkRWQhgRhuQRxX4V/8PyP2OP&#x2B;jDvh9/4AaR/8h0Fxv0IP&#x2B;IXa2/6Om&#x2B;En/fof/JFfQ3/BKf8A4IMQfsX/ALfHgP4lp8ffh342bw3/AGhjRdMQC6vfP066tvk/fN9zzt54PCH614B/w/I/Y4/6MN&#x2B;H3/gBpH/yHX0J/wAErP8Agqt&#x2B;zV&#x2B;0l&#x2B;3r4D8F/D/9kvwd8MfF2tf2h9g8S2Nnp0dxpvladdTSbWhtkkHmRRyRHaw4kOcjIIN3sfsdRRRQZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHyb/wAFzP8AlFZ8WP8Ar30//wBOdpX83Nf0jf8ABcz/AJRWfFj/AK99P/8ATnaV/NzX9H&#x2B;Df/Iprf8AXx/&#x2B;kxP6W8Fv&#x2B;RRW/wCvj/8ASYhRRRX66fsRNp2pXGj6hb3lncTWt1ayLNDNC5jkhdTlWVhyrAgEEcgiu2/4ao&#x2B;J/wD0Ufx5/wCFBd//AByuDorKpQp1NakU/VJmNTD0qmtSKfqkzvP&#x2B;GqPif/0Ufx5/4UF3/wDHK/ez/ggX4y1jx5/wTg8P6lrmq6lrWoSatqKNdX1y9xMyrcMAC7kkgDgc8V/OvX9C3/Bu/wD8ox/Df/YY1P8A9KGr8r8WsPSp5JGUIpP2kdkl0kfk/i/hqVPI4yhFJ&#x2B;0jskukj7iooor&#x2B;bD&#x2B;ZQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAp6/rMfh3QrzUJlZobGB7hwrKpKopY4LEKOB1JA9SBXifgv/goV4L8W&#x2B;NLHwzNp&#x2B;v6P4kvdas9EGnXH2S5aN7u1vbq3mM1rcTQNC6addrlJGZXiKsq17F498D6X8TfA2teG9btVvtF8QWM&#x2B;m39sxKrcW80bRyISMEbkZhxzzXhnhz/gmb4B8K6S/wBj1LxTH4gXUtP1S18Qrc26alZS2EU8NqE2wiAqkd1dKQ8TGT7TKXLs26gDS8T/APBRL4f&#x2B;FLG8muU1&#x2B;R7Z7yCKCKyDzX1xb67/AGCLeIb/AJpJb8pHGCQpVwzMgzjyz4d/8FStQuv2i/jt4a8W&#x2B;DNT0fSfhrqfhXR9F02O3hXWp7rWLeVily5umtCvnIuyRJFjEbBmYj5h23/Ds/wabSHQ2k1Sbw3BpVzBFcS6lNJrEF9Lra60t2twTy8d4olVmBbcq53DILov&#x2B;CXHw9mufiHf6hqfi7Wde&#x2B;J19o&#x2B;qa3q&#x2B;o3kFxcPd6UzNZypGYfIULuKmMxGIrhNm35aB6Fw/8FKfBM3w11HxNa6L4t1C30fw/qHia/tbaC1ae2srC&#x2B;lsrxg32gRSmKSCZv3UjiRE3RGTcoboPGH7cnhHwJ8StG8PanaatDb6/cQWdjq6vaSWktzPB50ULRLObqMuuFDvAse8hd&#x2B;SM838ZP2B1&#x2B;KfhrXtDtfFF/otvrXw8uPAo1WOKOS/iWWUuWMYVYDGQSGREjOCVQxjBBoP/BMj4e6b8QdN8UX1xrur6xZzWd/dNcTQrFqWo2tktlDfShIwwkWBIxsRliLRRuY2dQ1AaGfH/wAFNvDviL4EX3jPSfDniLTvtHhGDxj4bh1&#x2B;BbaPxNbXDpFbrD9ma4lR5JpYIgrxBy08ZVHUg16P8FP2p7T4r&#x2B;NJvCereFfFfgDxpb6VFrTaJ4git/NltHfyzNFNbTTQSKkmEcLJvQsm5V3rnkfHH/BPbw1qXwR8O&#x2B;E/DupX&#x2B;iXngfw1pnhzw1f3H&#x2B;mLZJpt3ZXlk80eU87bPp9sXG5N6hxld2Rr/CL4G&#x2B;Orv4&#x2B;n4lfEjV/C82safoEvhrSNL8O20yWdrBPcQ3FzPJLMxeSSV7a3AUKqxrERly5YAHtVY3iqOzfVNAN1JNHKuok2ojHEkv2efhuPu7N57cgVs1na4boX2lfZ7WG4j&#x2B;1/6S8gGbePypPnXkfNu2Lxnhzx3AI0aKKKACiiigAooooAqHQbE3v2j7Jb/aPO&#x2B;0eZ5Y3eZ5flb89d3lkpnrt46VboooAKy7Uf8VlfH7d5n&#x2B;h23&#x2B;h8/uPnn/e9f4/u9P8Alj37alZNp5f/AAm&#x2B;oYs5I5fsVtuuyTtnG&#x2B;4xGB0ynLHHP70Z7UAUPjPYR6t8HvFlrN4ZXxpDc6PeRP4eLRKNdVoXBsyZSIx52fLy5C/PyQM1&#x2B;cf/AAzr4b/6Rc2X/gz8L/8AyRX6K/HrVNN0T4G&#x2B;M73WfEGo&#x2B;E9Hs9CvZ77XNPbbd6NAtu7SXcJ2PiSJQZFOxvmQfK3Q/lkP2rv2Yv8ApI1&#x2B;0n/4HL/8p6Ckdx/wzr4b/wCkXNl/4M/C/wD8kV6f&#x2B;xl8GNE8JftKeG9Qs/2C7X4L3Fv9p2eMkvtBkbR82syn5bWZpj5oJh&#x2B;QH/Xc/Lk188f8NXfsxf8ASRr9pP8A8Dl/&#x2B;U9eu/sH/tBfAnxx&#x2B;1d4U0vwb&#x2B;2n8bvi14kuvtf2Pwpr90H07VdtnOz&#x2B;aP7Nhz5cavKv71fmiXr90gan6OUUUUEhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHyb/wXM/5RWfFj/r30/8A9OdpX83Nf0jf8FzP&#x2B;UVnxY/699P/APTnaV/NzX9H&#x2B;Df/ACKa3/Xx/wDpMT&#x2B;lvBb/AJFFb/r4/wD0mIUUUV&#x2B;un7EFFFFABX9C3/Bu/wD8ox/Df/YY1P8A9KGr&#x2B;emv6Fv&#x2B;Dd//AJRj&#x2B;G/&#x2B;wxqf/pQ1flni9/yI4/8AXyP/AKTI/KPGP/kRR/6&#x2B;R/8ASZH3FRRRX8zH8vBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFGaK/NP/guf4j1n4N/FTwh8RvEGpa3r3wa8O6BPBrfhHw78RZPCOtW95LdIserRJHIjXoRWEYiDcMc9C2QFqfpZmjNflnH&#x2B;0Hof7P8A&#x2B;238d9P8H&#x2B;PPF/ijQNd&#x2B;BkvjZfDk/jZ5dS/t5J7wy29k0rSm0vBbID5aITGcHYQqgeD/AAn/AGlvGWla/wCJv&#x2B;EBbxToHg/xp8BPFHii/tJfi5N45lspYLHzLPVd7AS6ddec4iIyNzMRtVo6CuU/cTNGa/EXwh8Zp/i74m8I2Hxc&#x2B;OPjn4e6T4T/AGZdF8XeGJ7fxdPpDaprEtupm1F38xTeXCuCvluX34I2n5s858P/AIv&#x2B;O/G/gb9lOLXvEHxA8Vab40&#x2B;FGtvqFgfig/hKPXbyDVmKyXF/LMpdolaNiFJlKqow0YZSByn7u5ozX5i/tOar8TPgD/wSk/ZZt9Y&#x2B;KN94n8YXXxC8K22p&#x2B;KNF1iVk1y0uZ5pFj&#x2B;0qQ1zCYGiQu2RMEDHO6vsr/gph4j1Dwf8A8E7fjlq2k395peqab4E1m6s7yznaC4tZUspWSSN1IZGUgEMCCCMigk9wzRmvxI/Z6&#x2B;P158KviT&#x2B;zTrnw1&#x2B;LnxF&#x2B;NGv8AxI&#x2B;E3iTVviR4dl8ZTahIbyz0U3Nsqo5lWxnF4r20Z8slfJAwxZy939jj4yzfET9p34daHDeeLPC/wg&#x2B;L3w&#x2B;1bVPGi33xun8UzW9rFDFLDqc0xMcuk3PnssDsGTcZGUKhQ5CuU/arNGa/Di//AGo/FGvfsA/syw2nxI8Wa/LY/FrVvCetvYeOxpWo6lp5m1FLS0u9QaVRF5sESrHJKwO1QyEMFYdTeX3jz4c&#x2B;Dfgt4K8dfF7UvDvwY&#x2B;K/xe1qLUrjSfiFLqk3hbTorWM2Xh&#x2B;bXgwc750nD7ZMDpuyGwByn7PZozX5p/sKfAiy/bW0/wCM3gDU/iT8UPE/wl&#x2B;FfxBms/A3iHTfGt5FcXsclpG01o99E&#x2B;&#x2B;7itZGxGWdseZ1IAAq/wDBMb9oH4lfBr/grj8aP2T/ABP488QfE7wX4H8Pxaz4d1bX5xdarYRk2cywzXGA0xKakI2Z882ybQoJWgVj9Ns0V&#x2B;VP/BQz9q6&#x2B;&#x2B;CH7VH7Yek6h8Q9S8LpJ8D7O58I2UmtyWgGoP50Pm2Me8YnMrIu6Ib8454rlJ/2yL74hQ30Phn4m6lrE2h/sP6lrepf2dr8k32LXFS2IuZSjnZfJkne2Jl3ckZ5B8p&#x2B;wOaK/Mf8AZE/ap1r4f/HT4W654p1rxx4i0G0/ZB8M&#x2B;JtS0&#x2B;1a61Se&#x2B;v5L5EkuxbKWM104OGkwZGGckivSP&#x2B;CR37Tt5&#x2B;1J&#x2B;1t&#x2B;1lrSX3jJvDcPiHRBoml&#x2B;IY7m1m0iNtPcSItrNzb7nUsVCjdkNznNArH3hWR4mW3bUtD868ktXF&#x2B;TCigkXL&#x2B;RN&#x2B;7OOg27m54yg74rXrM8QGQX&#x2B;j7LGO8H2355GXJsx5Mv70ehzhM&#x2B;khoEadFFFABRRRQAUUUUAFFFFABWbbCb/hL70tdwvb/ZLfZahv3kL7590hHYONgB7mNvStKsezltT491JFgkW8WwtTLMT8skZkudigeqkSE/749KAHePv7c/4QXWv&#x2B;EX/sn/AISb7BP/AGT/AGp5n2H7X5beT5/l/P5Pmbd&#x2B;z5tucc4r5VDft94&#x2B;5&#x2B;x//wB9&#x2B;I/8K&#x2B;hP2qPhZffHT9mH4j&#x2B;CdLurax1Pxj4X1PQ7S5uCwht5rm0lhR3KgttVnBOATgHANfhgP&#x2B;DSP4/kf8lV&#x2B;GX/AIFaj/8AI9BUbdT9S937ff8Ac/Y//wC&#x2B;/Ef&#x2B;Fdh8BT&#x2B;14fizpP8AwtBf2bx4F/ff2n/wiza0dW/1L&#x2B;V5P2geV/rvL3bv4N&#x2B;OcV&#x2B;Qn/EJF8f/APoq3wy/8CtR/wDkevoP/glj/wAG7Xxf/YU/by8CfFTxT8QPAuuaD4W/tD7TZafcXrXM32jTrq1TaJIVTh51Y5YcKcZOBQGh&#x2B;xFFFFBIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8m/8FzP&#x2B;UVnxY/699P8A/TnaV/NzX9I3/Bcz/lFZ8WP&#x2B;vfT/AP052lfzc1/R/g3/AMimt/18f/pMT&#x2B;lvBb/kUVv&#x2B;vj/9JiFFFFfrp&#x2B;xBRRRQAV/Qt/wbv/8AKMfw3/2GNT/9KGr&#x2B;emv6Fv8Ag3f/AOUY/hv/ALDGp/8ApQ1flni9/wAiOP8A18j/AOkyPyjxj/5EUf8Ar5H/ANJkfcVFFFfzMfy8FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxHxR/Zn&#x2B;HPxv8QaTq3jTwD4L8XapoJJ0281nRLa/n0/JDHynlRmj&#x2B;YA/KRyAeorgv2&#x2B;P2tr79k74YaTcaBo8PiDxf4q1WLRtE0&#x2B;ZmEck75O5wpBZRgLtBBLOvIGTVH9mLxZ8dtS&#x2B;IUtr8Rbj4VapoP2N5J5PDNxM15pV2GTbbyq7YwQX5AbmM/N0z58sypLEfVkm5aXstFfa7/rTc82WbUlivqkVJy0vZXSvtd/j1stWaWj/APBO34UaH&#x2B;2Pf/HK38K6TH42v9IXSiyafarBHJ500st8oEQf7ZKJjG85cs0aqvTOZPiF&#x2B;wr4B/4UH8VPCnw98G&#x2B;Bvh/q3xO8O6ho13qOk6Fb2XnS3NtLCks5hRWkCtKWwST1xya9atvGej3ljeXUOqabLbaezLdSpcoyWxX7wdgcKR3zjFNufG2jWek2t/Nq2mxWN6wS3uHukWKdjnARs4YnB4B7Gu72ke56HtI73PDPhv8A8E9PB&#x2B;nfsk/DTwH408N&#x2B;CfGnif4a&#x2B;ErXw/puu6hokN09lcQ2qQme3aVWeLLoHG0g8DuKzP2Uv&#x2B;Cafg/4ZfsO/DX4Q/FLw74F&#x2B;KbfD62ljin1XQob21ErzSSGSKO4V9h2uFJHJx6V9NA5rFk&#x2B;I3h&#x2B;HxWugvrujrrjDcunG9jF0RjORFnf056dKJSS3YSmo/E7HyX&#x2B;3h/wSt8Yftl6zoVlpPxz1D4deAPCt1pupaH4T07wfp9xa6Xe2IIgnjlJR8LniI/uwABtI4r1Lxr&#x2B;yj40&#x2B;IX/AAT58a/CHxR8SZPG3jDxb4c1bQ38WX&#x2B;kQ6f5jXaTJEz21thAsSyIvy8sEyeSa9q8UeMdJ8EaWb7WtU07SLIMENxe3KW8QY9BucgZOOlEnjLSIfDy6s2qacukyKrLem5QW7BjgESZ24JOBzzRzxTtcPaRTs2tNTyv9kL9ibwT&#x2B;yn8O/C0Wn&#x2B;E/Bdv440vw1p&#x2B;g6x4l03RYLW91lre3iid5JlQSurNGGw7HtnkV0Gg/sf/AAm8KR&#x2B;JE0v4YfD3TV8ZI0evrbeHbOJdbRiSy3QWMecpJJIk3Akk9Sa6a0&#x2B;LXhXULuK3t/E3h&#x2B;eedxHHHHqMLPIxOAoAbJJPAArZ1PU7fRdNuLy8uIbWztImmnnmcRxwooJZ2Y8KoAJJPAAojKMvhdwjUjJXizwb9n//AIJifBX9nv4A3nw2s/AvhzxB4Z1W&#x2B;l1HUotc0izvDqczzSSqZh5QRxEZWSIFf3aAKOlejP8Asu/DR/hIPAB&#x2B;Hvgf/hBByPDn9hWv9kj5t2fsuzyvvHOdvXnrWv4B&#x2B;MPhL4rC4PhfxR4d8SCzIFwdL1KG88gnoH8tm25wevpT/HnxX8LfCy1in8T&#x2B;JNA8OQzEiOTVNQis1kI64MjAH8K19nPm5LO/bqT7aHL7TmVu99PvPKfjf&#x2B;yZ4on&#x2B;F/h/wx8B/iBp/wCzxa6FcSOY9E8HafqFlPC6nMQtZAsUeHO8MgBznrk1z37Cn/BMTwn&#x2B;xN4v8UeNpNd1/wAffFTx2gXxL4u1x1a61EiV5SI41G2CMkxjYpIxBF/dFfQPg3x7ofxF0ddR8P6zpWuaezFVutPu47qFiOoDoSM/jUMPxM8N3PiCbSY/EGiyapb7vNs1vojcR7Rlt0e7cMAEnI4Apckr2tsV7WNk7qz28zK8a/s7&#x2B;APiT4503xR4i8D&#x2B;Ede8SaLC1vp&#x2B;q6jo9vdXtjE27ckUzoXRTubIUgHcfU15x8Vf&#x2B;Cf3w81H9m/4i&#x2B;C/h94I8A/D/VfGvhDWPC9vqOl&#x2B;H7az&#x2B;yLf27Rvu8lFYxmTy3ZQfmManqAR6l4K&#x2B;NHg/wCJWpXVn4d8WeG9fvLHm4g07U4LqS35x86xsSvPHNfP3/BRT/goh4m/4J9SaLrVx8Jbzxl8Pb&#x2B;RIdQ8QadrXly6O5cAiW3Nuw5B&#x2B;RjKquw2kocZ6MPg61eqqFNe89k2l&#x2B;dv&#x2B;CcuKzLD4ag8TVl7i3aTdvuT07vZdSt8Pf2CPiD8OPAPhPRdA&#x2B;I/h3wrqHhj4Q6P8O7fX7HwjaXmr21/ZSRl7tJ5wWe1eNCotXOxWYyferc/YF/YG1r9jrxp8UPFHif4nah8UvFHxVv7LUNU1K70WDSmV7aFoVxHAxj5RlHCr93uSTXo3wY/bO&#x2B;Ff7QOiaReeE/H3hXVW1uFZrazTUolvvm/ha3ZhKjg8FWUEEEV6dnNY1KU6cuWomn56HRRxFOrHnpSUl3Tv&#x2B;QVl&#x2B;I13ahov/Eway232fLGf9N/cy/uuo/3&#x2B;c/6vp3GpWT4kdV1HRd1g14WvsLIuf8AQz5Ev704HTqnOB&#x2B;8HsDmaGtRRRQAUUUUAFFFFABRRRQAVn2/2v8A4Se73zQtY/ZoPJiGPMSTdL5jHjOCvlgc9Vbp30KxrL7H/wALA1Ly/P8At/8AZ9p52ceX5XmXPl7e&#x2B;7d5ue2NvvQBzn7VHwx1P42/sw/EfwZot1bWOs&#x2B;LvC&#x2B;p6LYXNw7xw29xc2ksMbuyBmVVd1JKqSADgE8V&#x2B;F4/4NU/2pv&#x2B;itfDH/wfav8A/Idf0GUUFKTR/Pn/AMQqf7U3/RWvhj/4PtX/APkOvoL/AIJX/wDBv/8AH39iT9vPwH8T/G3xD8C674Z8M/2h9ssdO1fUZ7mfz9OubaPak1skZxJMjHcwwFJGSAD&#x2B;xVFAczCiiigkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA&#x2B;Tf&#x2B;C5n/ACis&#x2B;LH/AF76f/6c7Sv5ua/pG/4Lmf8AKKz4sf8AXvp//pztK/m5r&#x2B;j/AAb/AORTW/6&#x2B;P/0mJ/S3gt/yKK3/AF8f/pMQooor9dP2IKKKKACv6Fv&#x2B;Dd//AJRj&#x2B;G/&#x2B;wxqf/pQ1fz01/Qt/wbv/APKMfw3/ANhjU/8A0oavyzxe/wCRHH/r5H/0mR&#x2B;UeMf/ACIo/wDXyP8A6TI&#x2B;4qKKK/mY/l4KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD4g/wCCx&#x2B;ix&#x2B;JPEvwD0&#x2B;TUp9Hjv/GSW738Enly2Id4FMyt/CyZ3A9iM1yviD4GeH/2Hv&#x2B;CnPwcsPhit5o&#x2B;n&#x2B;OLOe01rSxeS3CTxruHmN5jM3JAfk4DQ5GOa&#x2B;r/2qf2MfB/7Ylv4ct/GDas1p4bvGvIoLK4WFLosFDJKdhbaQuPkKsM8EVzPwG/4J2&#x2B;E/gj8Y5PHlz4g8ZeNvFEVubPT73xLqX26TTICCuyI7Qc7WZcknCsQAMnPyWMyevUx0q0YLWUGpX1io25klbra2m/U&#x2B;Jx2RYirmMsRGEfenTkp396KglzJK32rW0evXSx8rfs/XkVp&#x2B;xB&#x2B;2CZJFT/ieaynJ7tEVUfiTisr9oq8i/4dXfszw&#x2B;YvmSeJdOZVzyQsV2GP4FgPxr6h1b/glH8PNa&#x2B;I/ijWJtY8bLofjK7bUNW8MwauYNIvbksz73jRQzBXYuqliFbpx8tYWlf8Ebfh9a6Hp2m33i74larY6DfLeaNb3WsRtDpA3l3jhj8ry1EjYLkKGOwYI5z58slzD2bpKC&#x2B;Fwvzf3&#x2B;a&#x2B;3VaW77nlzyDM/ZOioR&#x2B;Bwvzf3&#x2B;e9rbNaJb33sj6e&#x2B;J3ipvAvw28Q62iiR9H0y5vlU9GMUTOB/wCO1&#x2B;Vv/DPWk&#x2B;KP&#x2B;CV&#x2B;rfHu8a8uPitLrp1sa&#x2B;buQXIcamtsQMNtH8TggZ3Y54AH6teNvDMXjXwXq&#x2B;i3DFYdWsprKRgOiyIyE/k1fmD/AGZ8TtC/Y51D9lP/AIVr4suPF1xrogh1mK0J0VrE3i3Xn/aegUuMZI2hWOSGBWu3iampTXtI8ydOoo6N/vHy8vo97P1PQ4upqU06sXKLp1FHRv8AePl5dtnvZ&#x2B;p6NdzWv7fv7eHw38NeOIW1Twnpfw6tvE8mlGRoYLi9uoI3aRthB/5bR8Zx&#x2B;7A6FgbX7EPw38I6vpX7SXwW8bL9u&#x2B;GPgLxKLyC3ur6aFLO1824kGZUdXVU&#x2B;yRucMATuJ&#x2B;8c6nxg&#x2B;G2ufsKftaeAfifpvhfxB4z8GW3g&#x2B;Hwfq0ehWv2m&#x2B;tXgiCRyeXkDYwSLBJAyrAkEqGx/hP8Asw/EL4n/ALKH7R3iiTQ77w/4q&#x2B;Nl/JfaXo95&#x2B;4uhaxyySJE4bGxpFlljAbGRgnAYGvOp0qixL9pT5qidRyTV&#x2B;aHs7RTezTdkl3voeVTo1I4t&#x2B;0pc9VOq5pq/ND2dopu1mm7JLXW&#x2B;m5wv7E37GfhP9qX9qlPid4K8MyeBvhD4E1OM6TC13cz3mv3luwkWUmZ3KIH2MwBAACoAW3sv6UfEPwHpvxT&#x2B;H&#x2B;ueGNaha60fxHp8&#x2B;l38Ku0ZlgnjaKRQykFcqxGQcjNfHP7An7WWseFfAHw9&#x2B;Etv8EfiHpOp6V5em6tez6c1tptmNxM128jDduZizlWVcsxAY8Z&#x2B;yPHj6wngXWW8PLav4gWwnOmLdf6g3Xlt5Qkx/Bv259s19DwtSoU8PzYd&#x2B;9JpyaTilJ9ErKyjtpt6n0fCuHwkMDKVFXctZ2jZczWsUrJWWyS&#x2B;erZ&#x2B;Rvw1&#x2B;B&#x2B;h/sJ/8HC/hHwP8MxfaD4T17SytzpxvJbhHil0&#x2B;eRomaRmd082FJBuYkMBg4AFehf8FF/jV&#x2B;x34l/bi1i3&#x2B;NHhf4leLPGfhLTbbRHsbKKRdOhiG66SRPImjkZiLrksdvCjaOSfmX4n6h&#x2B;0s3/BZzwfNq1n8PF&#x2B;OYsU/s2GAv8A2K0X2K4xv&#x2B;bdnyvN7/e219tftHfsH/HbQ/2kfB/7Rvwim8F/8LYm8O22m&#x2B;N9C1CR00/VrlbdI5DE2RmM7VXaZIyBBEwYnNfs2K5IV6NXEVfedJK6nZuSe7lZuzWnN3PjsF7SphsTQwlD3Y123GVPmSi0lZQulzRdny9j43/ZK/aN&#x2B;H/wD/4K2eA4/wBnuPxlovw1&#x2B;I0ttomt&#x2B;HtbSRQss0jxApvkdnSNjFKrsxZT5i52kg8/c/AWH9qD/gvx4y8A32oajpujeJPFOrxas1lcGCa4s44Jp5rfevIWVYvLPs5r7q/Zs/YI&#x2B;Nnx2/br0j4/ftIv4R0688H2P2Tw74b0GVpIbaQb9jsdzgKhlkkH7x2ZyudqqFOD8FP&#x2B;CX/xS8Cf8FotU&#x2B;Ol/FoI8C3esavextHqG678u5s54Ysxbeu6RcjPAzVPNsNCdScJrnVFq/Ne8tbLmsuZrTW35ERyHGVKdGE6b9m8QpcvLy2hZKTcbvli9dL6fM8M/aO/Zb8L/wDBNr/gsj&#x2B;znH8JYb/w7pPjC&#x2B;0&#x2B;2vLJr6W6UCe&#x2B;NncKHlZnKSQyDKsxAIJGOAOt/wCCn/xU8Wf8FAP&#x2B;Cmvhn9lHw7r2oeH/AAbZyRDxG1s&#x2B;0X0n2f7bM744dYrcKERvl83JOflI&#x2B;hv&#x2B;Cgn7A3xA/aP/AOChPwB&#x2B;JPhuPR28NfDnULC51hrm88qdUh1FLh/LTad58tTjkZPFfK/7T2s/8O9/&#x2B;DgjR/id4uVrXwL44xOmoFC0cUM9j9hmZj2MM4DsBkiMqcfMKywOJjiXTq8ynWjSna&#x2B;r509PV21R0Zng54ONWhyunhp16albRcjS5rW2TaSdvQ93&#x2B;Pv/AAbq/Bu&#x2B;&#x2B;B2qQ/D2HxDofjrT7N5tL1GbVpLgXdyi5RJ0b5ArsMExqhUnI6YOj/wb7/ty&#x2B;Iv2qP2fPEHhLxlqF5rHib4cXMES6jduXnvLK4WTyRIx&#x2B;Z5I2hlUseSvl5yck/T/AO0N&#x2B;3V8Nf2e/gNqvjzUPF3hy80&#x2B;1snuNPitdShmk1eXbmOGAKx8xnbA&#x2B;XIAJYkKCR8Lf8Gx3wV1rSPh58TfiVqcLQ6f4yvrXT9NLLt&#x2B;0m2M7zygd03zqgI43RyDtXlKtXxOU1545uXLKPI5b3b95Jvy3R7Tw&#x2B;GwefYanlqUeeM/aKO3Kl7raWl77Pdn6mVm6&#x2B;JTf6T5d7FaL9s/eRu2Ddr5Mv7tfU5w/wBENaVY/ihrYanoX2i1luJDqGIHQkC3k8ib52x1G3cvPdhXyJ98bFFFFABRRRQAUUUUAFFFFABVG3&#x2B;2f8JLdeYsf9n/AGaHyWH3zLul8wH2C&#x2B;Vj6mr1UoNEjt/EV1qQeTzbq3htmQn5VEbSsCPc&#x2B;ac/QUAXaKKKACiiigAoqHT9Sg1WBpbeaOaNZJISyHIDo5R1&#x2B;qsrA&#x2B;4NTUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfJv8AwXM/5RWfFj/r30//ANOdpX83Nf0jf8FzP&#x2B;UVnxY/699P/wDTnaV/NzX9H&#x2B;Df/Iprf9fH/wCkxP6W8Fv&#x2B;RRW/6&#x2B;P/ANJiFFFFfrp&#x2B;xBRRRQAV/Qt/wbv/APKMfw3/ANhjU/8A0oav56a/oW/4N4D/AMax/Df/AGGNT/8AShq/LPF7/kRx/wCvkf8A0mR&#x2B;UeMf/Iij/wBfI/8ApMj7ioozRmv5mP5eCijNeO/t1/tM3v7I/wCzrqXjbT9LtdYurG5t4Ba3ErRxsJZAhJK88ZzWOIxEKFKVappGKu/RHPisVTw9GVeq7Rim36I9iorlvgf8QJfiv8FfB/iq4t47OfxNollqskEbFkhaeBJSgJ5IBfGT6V1Oa0p1FOKnHZ6mtOpGpBTjs1dfMKKN1BOKosKKM0A5oAKKN1GcUAFFGaM5FABRXyf/AMEnf&#x2B;Ciesf8FFfhr4u17WPDmm&#x2B;G5fDesjS44rO4eZZ1MSvuJYDB5xgV9YZ4ruzLL6&#x2B;BxMsJiVacd1dPpfdadTuzLLa&#x2B;AxM8Jilacd1dPpfdadQoozRmuE4QooJxXyt8Ev8AgoRq/wAVf&#x2B;CnfxK&#x2B;Adx4d0200nwJoh1WHVo7h2uLps2A2MhG0D/TG5B/gHqa6KGFqVlOVNfCrv0ul&#x2B;py4rG0sPKEars5y5V5uzf5Jn1TRXxt&#x2B;0r/AMFO9b&#x2B;BX/BWD4P/ALOtr4X0vUNH&#x2B;JmkDUrjWJbmRLmxYvfLtSMDaw/0ReSf4z6V9k5rnOoKNvNGcUZoACM0UZozQAY5oozxRmgDn4vhP4Xh8fz&#x2B;K18O6GPFFzEsEur/AGKP7c8aghUM2N&#x2B;0AnC5xyfU10FGaM4qpSb3ZMYxj8KsFFGaM1JQV59&#x2B;0j&#x2B;yx4B/a3&#x2B;H0nhn4g&#x2B;G7HxFpRbzIhLlJrSTp5kMqkPG/bKkZHByCQfQc0Z4q6dSdOSnBtNbNaMzrUYVYOnVSlF7pq6fqj4b8Nf8G8P7Nfh/xJHqE2j&#x2B;KNWhjkEgsb3W5DbHBzg&#x2B;WEcj2L819p&#x2B;EfCGleAPDNjouh6bY6PpGmQrb2llZwLDb20a8BURQAoHoBWjmjNdOKzDE4m31io5W2u7nHgcqweDv9VpRhfeySuFZ&#x2B;ti8N7pf2W4hhjF3m6V&#x2B;s0XlSfKvB&#x2B;bfsbjHCnnsdCjPNcZ6AUUUUAFFFFABRRRQAUUUUAFc340ZofFnhF45JozJqcsDhJCqyIbK5cqwBww3Ro2DnlQe1dJXIfFLxBYeGta8HXOpX1np9v8A2y6&#x2B;bczLEmTYXmBliBk0AdfRXOf8Lh8I/wDQ0&#x2B;HP/BlD/wDFVFd/Gjw1Co&#x2B;z6l/a7Z5TSLeXU5E92W3WRlHuQBQB1Fcz458WTxXK6DozK/iDUIiyNgMumwk7TdSg/wAKnO1OsjDaMKHdIn1bxH4tkWOxsD4dsWXL3l&#x2B;EkumB6eVArFVJBzulbKkAGJsnGv4U8I2nhCxkit/NmmuJDPc3M7b57uU9XkbucAAAYVVVVUKqqoAJfC/hy18IeHrPTbNZBb2cYjUyOZJH9XdjyzscszHJZiSSSTV&#x2B;iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5nxZ8R7fStQbR9La31TxPKm6HTll&#x2B;aEHpLORkxQjqXI5&#x2B;6odyqkAseM/GEmg&#x2B;TY6fbf2hrmoKxs7TftXC4DSyt/BChZdzYJ&#x2B;YBQzMqmvb&#x2B;CNY8lfP8Za4ZiMv5NrZJHu77VaBmC&#x2B;gLMQMZYnk2/B/g5fDf2m6uJhfaxqRV769MewzFQQqKuTsiQEhEycZJJZ2d226AOL8V/BO1&#x2B;IWitpPiXVdQ8SaLNLFLcabqNpYyWt35Uiyosii3G5d6KcZ5xWV/wxr8H/APolPw2/8Jmy/wDjddz4lN4NPj&#x2B;wywwzfarfc0v3TF5yeavQ/MY94HuR061oVvSxVakrU5tLybR0UsVWpLlpzcV5Nr8jywfsM/BMSzSf8Kf&#x2B;FvmXKlJm/wCEUsN0oPUMfK5H1pp/YU&#x2B;CJt4oT8HfhX5MDbok/wCETsNsZ65UeVgH6Uv7XOueMdA&#x2B;HulzeC7jUrO8fWII76exsDezRWhSTefLW1umxuEYysDEZ/hGWHlviT48fGrxW3jvSbHwrJoNvHb61F4e1E&#x2B;Hr2S4mmjhQWUTASbFdnMr/aATCwjRRtZxWv8AaGK/5&#x2B;S/8Cf&#x2B;Zp/aGL/5&#x2B;y/8Cf8AmeqH9h74K/bJLj/hUPwv&#x2B;0TLskk/4RWw3uvHBPlZI4HHsKjP7CXwPexW2Pwb&#x2B;FRt1beIv&#x2B;ETsNgb1x5WM&#x2B;9cj8YdU&#x2B;L2p&#x2B;DfDN5pObXVdLv9ebUoNP0&#x2B;RV1EW1vfpp7BWlbZHK6W8mxzIGaRByBg0vh78Q/jjba5Z2t9o2nyaNHqv2eZ7zSp2vpbY3WmoZPNWdUX93eXjA&#x2B;UQBp5yGySp/aGK/5&#x2B;S/8AAn/mH9oYv/n7L/wJ/wCZ6CP2IPguL77V/wAKi&#x2B;GH2nbt83/hFrHzMem7ys4rpvCnwM8E&#x2B;A/B/wDwj2h&#x2B;D/C&#x2B;i&#x2B;HzMbg6ZY6VBb2fmnGX8pECbjgc4zxXl/jL42/FLSPFrW2n&#x2B;GIrqBdWmtjbjQbyQmBbqCOBRdCUQ5ntnnuPtGPLgMQikUuRnz24/aV/aDn0aHV7fwXaRLMkkKWU/hnUMx/6RYYuJUWQzApDcToYkB3PBI6M6jAzqYqtUXLUm2vNtmdTFV6q5ak215ts&#x2B;rD4S0ttWtr7&#x2B;zbD7dZxeTb3H2dPOgTBG1WxlVwzDAOOT61AvgDQk0&#x2B;7tF0XSRa37iS5hFpH5dwwOQzrjDHIzk55rwDwl8TPjV4q0X4sXt9pEeha5pWgEeHLFNHuJrUXsdxqYQxvI6i8aaFLGX5AgTzkjZd6OKwfGH7RPxuu/HNxLovg2&#x2B;/szRb&#x2B;WCyjm8OXkI14eXdIscoMpEKySQwOlzuMcaXSGVQyui85hY&#x2B;ov&#x2B;EM0drixm/svTjLpiCOzf7Mm60UcBYzj5APRcV4b/wUK/ZX1D9oL9mLxB4Z8Fabo1v4g1y&#x2B;tbqV5Ntqtz5c3mM0jhcs3LHnPJPrXL&#x2B;B/jD8en1uHSdS8P2mm6RpTaOst/Po95e6hqMcj6cLp/kxB/y3vlYAiSL7MGKMrb17Dxp8bvino/i&#x2B;&#x2B;tdN8Mw3EEOozQQW50C9l85FkhW2j&#x2B;1rKIR9piaaU3G3y7XyhHKrMwJ58Vh4YijKhU2kmn6M5sZhIYqhPD1Phkmnbez0O6&#x2B;Avwch8EfAb4d6DrmmaXPrHhHQ7GzZ/KSYW1zFBEsjRMRxmRM7hgnANdgvgzSFuL6b&#x2B;y9O87U0Md4/2ZN10p4KyHGXB9GzXzjH8dPjnpjw3ereG7NY30qSVbWx8MXlwrXctvpkkSSFbhnUQSTX6uw&#x2B;&#x2B;tuQqeYUUw6L8d/2gdQ8Hyas3gvSrC7Oj6dfvp1/pd1JsvLm0t/Pt0aFvMEdtO8rOPLlkZUZRzjGtOmoQUI7JW&#x2B;40o0lTgqcdkkvuPo9vh/oT6fa2baLpLWti5ktoTaR&#x2B;XbsTksi4wpyScjHJqf/AIRLSxq9xqH9m2P268j8me5&#x2B;zp50yYA2s2MsuFUYJxwPSvnz4s/FT4ma34f8IzeGbPxloeuah4VuNW1O2Ph5WtI5jaPtt8GObyr5ZmWRI3nKf6P5bbzKA1D4L&#x2B;PfjKnirxTLrMfiPVLGx07WJtEt9S0eO1jvoY/sZ0mWRkhjb7XNm8EsOVK7RmKL5N1mh9Ev8OvD8mippraHo7afHJ5yWps4/JV&#x2B;RuCbdobBPOM8mrY8MaaNc/tP&#x2B;z7P&#x2B;0tnl/a/IXz9v93fjdj2zXyv8U/2tPjB8Evh9r&#x2B;r&#x2B;JNI8K2a2E0y2N5/Yl2IbnYmqskflfai7NKbOyw6sBGt0WYEDI6L9pH4qfE7wH8QtS/4RaPXL/VmYJ4X0P8AsuOTQdajXTpppPtN35e&#x2B;O48&#x2B;ORVT7RGSI4AqkPISDse9J8OfD8ejPpq6Ho66fJJ5z2os4/Jd&#x2B;BuKbcFuBzjPAq03hLS21a3v/wCzbD7dZx&#x2B;Tb3H2dPNgTBG1WxlVwzDAOOT6181fEP8AaH&#x2B;N2sT3i&#x2B;FfCMOl6Y1hd3dteX/h7UJryTyr6&#x2B;jQLB8oEjW0Fm/lS7Hf7WSoJURlPFP7UvxW8G&#x2B;JL&#x2B;zn8LywaLbzeUms33h27nDPP4jtbK3MccEi&#x2B;cpsLl3EQ2zb4MncGBYEfR6&#x2B;ANCTTrqzXRdJFrfOJLmEWkfl3DA5DOuMMc85OeaefBWj/arK4/srTfO01BHaSfZU3WqDosZxlQPQYr5ttPjn&#x2B;0FF4a1jVE8EWV1cWttbXNvpVxp8scl7LNZQFoYZBKvlJHcNIW8wStgMu4YDD3b4C&#x2B;J/EXjL4U6XqXiu0s7HXblp/PhtbW5tY1QTyLEfKuVWZGMQRirjhicErgkA&#x2B;Tf&#x2B;CMH/AATy8WfsS/B34gaD8RtN8OyXHirXEvo0tZVvI54FiCgSZUdG3EA565719mv4G0V009W0jTGXSjusgbVMWZyDmPj5OQD8uOg9K1aK9DNMyq5hip4yvbmm7uystrbfI9DNszrZhi542vbmm7uystrbfIzY/BmkRTX0i6XpyyaopS8YWyBrtTnIkOPnByeGz1qE&#x2B;ANB&#x2B;x2dt/Y2k/Z9PcyWsX2SPZbMTuLIMYUk85GOa5j46fFab4bWltHDY&#x2B;JppbuCee3m0jQrrVl8&#x2B;ExFIJlghlKJLvYFjs4RtrKcEeKXHxv&#x2B;M2sWepeMl&#x2B;HGoW0mk6Xd6dpulN9oWSaW7uMxXEsGczCH7LAhChXxPJICiPgeeeefTDeEdJbVLq&#x2B;Om6f9tvYvIuLj7Onmzx4A2O2MsuFAwTjgelfFvwD/AOCcGu&#x2B;Av&#x2B;Cs3xV&#x2B;LGsaH4Uk&#x2B;HHirQTYaRbr5ckkdxnTuTBswn/HtPyPUf3q7rwjD8X/ABL8WfCdtqHhbW7HQ/BV&#x2B;wuorjXHa31CK4ncrcTTGXddS29t5JVVMkXmmcGNSYTBa8QfFrxx8Q/jJ4w03w7pPhnxZpvh/WdObTbSy8SpaarpMtnMBerfQu52LKCfKKLho5FZwdy11YfFzoxnGFvfXK/S6en3HHjMvp4mVOVS96cuZW72a18rM8l/a0/4JyePvjD/AMFrfgf8eNEtdB/4QPwLoi2GtvNdiO8eYNqH3Ytv7wbbiEZJ9R2r7gX4b&#x2B;Hk0dtOXQtHXT3l89rUWUfktJjG8ptxuwAM4zxXn&#x2B;q/Dnxj8afhj4PuPFFxN4N8X6LrcGpX1p4e1qYWVxCk7xy27yKFM8Mlq7HayjD7DhStdhcQeNj/AG75N14XXdqls2jb7ac&#x2B;XYBbf7Qtxh/mnLC72Mm1AGh3KxD7uU7Ta/4RTS/7Yi1D&#x2B;zrH&#x2B;0IY/JjufITzo0wRtD4yF5PAOOarr8PtBXTLixXRdJFndSCWeAWcflzOOjMuMMeByRmub&#x2B;O3x/0v9n/w7/aGqWOsXwkgnkt4bC0aZ7uaNQy2yn7gmlzhA7KGKtzxXmnwZ174zar8a7zUJvAum&#x2B;Hfh34heHUmi1LVl/tK3kkt0WbciB9pBjQrFhPmkl3MDjAI91Pg/SWvrO6bTNPa509BHaym3TfbKBgKhxlR7DFRr4D0NLa9hXR9LWHUm33cYtI9t02c5kGMOc85Oea818d/tCeKWnuNL8FeBdW13xJY3txBc2epWl1pdl9nTeqXEd/LELaXcwiYRxuzFZDjGxiOB&#x2B;K/ir4t/ED9nH/hD7rSrfTfip4gmuYmGk2Eslla2avKYbgyNN9nRtqwb4pLh1cl48MGwAD6KPgnRS1i39k6Zu0sYsj9lTNoOP8AV8fJ0H3cdKF8FaMr37DSdN3aoCL0/ZUzdjnPmcfP1P3s9a8V/aVl8XeOvh1/wiFjoHiy38UXENnNaapoEkdvDZyEbbmRLqRwkTIplCq/zE7Cuc/LB4w&#x2B;Pmr/ALLv7O/hi11jQZrTxRfWT6dYwRQXmqW8uoiSOK3heWPzmEk4cuBLKcsGUzHBkoA9vbwJob21lC2j6W0OmtvtIzaR7bVs5zGMYU55yMc1IPB&#x2B;ki/u7r&#x2B;zNP8AtWoRmK6m&#x2B;zp5lyhwCrtjLDAAwcjivDPiR8QPilrniHQ9O8PeEL3ULrS9Ls9Q1C5aeTTre31EyASwSAzRx3Ufl72EcUzqGA3nay7uj&#x2B;AHxR&#x2B;KXiTxPb6J8Q/BNn4euLXTri5udQsJDNZX7ieNLcxkM6ws0fms8DSSsp24dlG5gD0p/h7oMmlQWLaJpLWNrIZYbc2cflROc/Mq4wDyeQM81NL4P0mfW11OTTNPfUozlbtrdDOpxt4fG77vHXpxWlRQBkr4D0NLa9hXR9LWHUm33cYtI9t02c5kGMMc85Oeac3gnR2exY6TppbSwBZH7KmbQDGPL4&#x2B;ToPu46CtSigDLXwTo6PfMNJ00NqgxekWqZuwc58zj5&#x2B;p&#x2B;9nqaa3gPQ3trKFtH0todNbfaRm0j22rZzmMYwpzzkY5rWooAK5H4o/D&#x2B;x8ffYVb&#x2B;zm1bT/MubKO9hWeGUfKrq8TfejOUBIwykqQQeD11Y949r/wn2mq8MzX39n3ZhlB/dpH5lt5in/aJ8sj2VqAOb8HeDvBviq2mSTwfoNhqViRHe2UunQGS2cjI5C4ZG6q44YA9CCBs/wDCnvCP/QreHP8AwWw//E1P4k8Cwa/qltqEN1eaXqlqpjS8s9glaM9Y2DqyumecMpwRkYPNQf8ACEan/wBDh4j/AO/Nh/8AI1AB/wAKe8I/9Ct4c/8ABbD/APE0f8Ke8I/9Ct4c/wDBbD/8TR/whGp/9Dh4j/782H/yNR/whGp/9Dh4j/782H/yNQAf8Ke8I/8AQreHP/BbD/8AE0f8Ke8I/wDQreHP/BbD/wDE0f8ACEan/wBDh4j/AO/Nh/8AI1H/AAhGp/8AQ4eI/wDvzYf/ACNQAf8ACnvCP/QreHP/AAWw/wDxNH/CnvCP/QreHP8AwWw//E0f8IRqf/Q4eI/&#x2B;/Nh/8jVTurXU/Cvibw&#x2B;reINU1ODU717SaG7itQu0Ws8oIMUKMGDRL3xgnj0ALn/CnvCP/QreHP8AwWw//E06z&#x2B;EvhfTdYstQtfD&#x2B;j2d9p0jS289vaJDJGzRvGeVA6pI4weOfXFdDRQAUYoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACob/UINLsprm6mht7e3QySyyuESNQMksTwAB3Nc/8AEdry4uPD9haaleaWuqakbeea1EfmmNbW4l2gyIwXLRqCQNwGcEHmpLP4U6DbXUdxNp66ldQsGin1KV7&#x2B;aEjkbHmZ2TnnCkDPNAENv8XdL1mINokWoeIvM/1UmnWxktpsddty223OOf8Alp1BHXimxXfjDXpnaO10Xw7a9YjdM&#x2B;oXUg9HjjMccRHXKyyg&#x2B;1dViigDlbX4UxXKt/bWsa54hZjyt1ciGAr/AHGgt1jidevEisSDgkit7Q/Dun&#x2B;GbH7LptjZ6fahiwhtoVijBPU7VAGTVyigAooooAx/HLWQ0WH&#x2B;0PO8j&#x2B;0LLb5X3vN&#x2B;1ReV/wAB8zZn2zWxVDxGLw6fH9hSKSb7Vb7hJ90Recnmn6iPeR7gVfoA4X4&#x2B;/GSH4JeHNN1K6a1t7O4vyl5d3P8AqbK1ht57u4kbkcmG2kRSTgSOmcjIPD&#x2B;Av24fD/xO8M67eQx3XhGPSNFu9Ve/163C2sItrm4tbhmRXDMsMsGXUlGCyR52lxXbftF&#x2B;O7X4eeArS&#x2B;vPB&#x2B;qeNoZtY0&#x2B;ySwsPsfmRzzXMcdvKftU0Me1Z2iGQxYFgcYDEcX4E/aU&#x2B;E&#x2B;p2aafJZ2Ph6&#x2B;1CdtFk0m40gpIyJdy2qhtkZRrbzg6CUEwB3K79xIoH0PPfGP7dvi7wXpGiteWHhe2ute0FdTR7tXht9Mk&#x2B;3WdsWuMTs6q0d2jmJgjRO8Ue&#x2B;Us5j3PiX&#x2B;3FqGhLoc3h610XVLjVtAttSvtEkcLfeHpLmVYIZLiQyrGV89mjMLCNj9nuH8xRE2Ox8Y/G34UfDq/vNJbTbS4vJLqDRp7Wx8PyTLMxkjRULLF5bxxPNEHIYrC0qBtrOoONof7XfwS8WeDtN8UalNo&#x2B;nSaxpLXtwl/pDi4s7eS2Fy63BMXyK8c25S&#x2B;Fm3/Jv3DIMi1j9vrS/DngzwbqEXh/XvFX/CVeHk15bnTYra0iEZglmJMc9xlcrBKQoeQAADe2QTFF/wAFC9F8U&#x2B;GfiVceH9Humu/h9ZJdM9/cQLbSK9/fWAll8qR5IIo5tPuHk8xFZYlDYzuVe18WftGeAfA&#x2B;sRWOuRyabGmmWd5A8&#x2B;lvlYbiO&#x2B;dUMIUzQ&#x2B;XDYXTv5saIiK2Tw4XmvCvxn&#x2B;CPgfxj4s1Cw1IR6trUZudauJ7e&#x2B;uPtFtCLmQOGkVl&#x2B;yri5KGPEPLBfvAEEYtn/AMFDdD8F6X4qh8WfZtRvfB929vJfeH9r2etRiG8nL2qPIW3xrZzRyx7n2Soy72wSHH/goVa29z9o1DwprWh6ZiHYL1U&#x2B;2XTyR6rhFhVt67pNN2xsQS4lX5VJ4mj/AGnvgz4F1vw3pPh/SdMuIb25aGGWx0yO1t9Jluby0ilRmlWNIpDLfxSTQgiUbsshZlDXtc/a2&#x2B;B&#x2B;g&#x2B;CNSvENleWOk6PLczWlr4dmd0tEt7m4ERj8kBPMhiuXjR9okXey5U5IM53RP&#x2B;CofhXxdK0en6HrsOx7EF5/srkmdNImdDEs/mrti1eAeYyhN6uMn5A/T/Cv9vTRPit8SdG8K2/hTxdZarqSb7nzoIZIdLVoZJ4jNJHIy4dI/wCAttZ0B4LFd3RPF/wp8HeD/Fnjyzsbex0tLsrruof2HcqwltUhtmBQxb9sIt40bYuyNoGzhkfFzQfjx8L/ABJ8Q9N0uxvNNm8QNeXdhYN/ZsiN58XmxzrHM0YXn7JcIGVsSG1lVSxicKCPPbL9viHwJ8M9Q8QeOtNuLWXzJrjTrWzt4oXvbVbuO2URb7lzM4L7y37v5Qf3a4G6TV/&#x2B;CkXhzwrfXVnrnhbxRo97bXkVosEn2adpwbnULeSRPJlcbYn0253bscGMgnccdxrPx4&#x2B;HFt4W0HWfEUdrpdnqC3v2CTUNO3pCIFd5x5iqyRkpCzBSwLhOASMCnd/tIfC3U9UvLXVoZLObTdQS3f8Atbw5c2&#x2B;yXy7ebzj5sIMcaf2hCGlfaqPcAEguNwBwOvf8FNNIg07S/wCzPCGu3WpaxYWmpw21xPbwpFBcXcEK&#x2B;ZKHZFfyZ1nC5&#x2B;6QG2k12Hwr/bM0/wCLvjuxt7PTb7R9CuJtS0/z9Wg&#x2B;zy3FzbzWkcTxfNjynaeSMhgHEvlLgFsHY8M/Gz4T/EW4m&#x2B;wy6TeSHQTfStNpEkedMCRyEEyRDKCO4hk8rrsnjbbtdSce0/ac&#x2B;Ck11caxHd2EdzbszySvoNzHNl8zySANCGYAWHmyOAQotldyAqmgD2i80&#x2B;31FUW4ghnWNxKgkQNtcdGGehHY9qmxXmf/AA2H8OMz/wDFSR5tppYZB9iuPkETypLP/q/&#x2B;PeN4Jle4/wBShicM4INZnhn9uj4a6z4Fg1y/8QQ6CjaYNVuYNShlt5LWEJbtI53KA6R/aod0iZTD53YBIBHr9NkjWUYZVYZBwRnkHI/I815Po37a/gO&#x2B;8KaprF5eanpdrokd3c6h9p0m8BsLaDULmw8&#x2B;fEX7kNLaTkLJtYLG5IARiNbwf&#x2B;1T4J8a&#x2B;KbTQ7bUri31nULy8sbazvLGe2knktpbqOTG9AMN9iumTJG9beUrny3CgHomKK811D9r/wCHOk6rc2N54jWzubG8msbtZ7K4iWyli&#x2B;zb/OZowsS/6Za4dyqN9oj2k7hW98JPi/pvxm0zVL7SY76O002/aw3XdrJaySsIopC3lyKrqP3oGGUHgnoQaAOsooooA4D4lfHW0&#x2B;HvxW8K&#x2B;GJljQ61p2q67e3MxKx2enaekAnkz/eE15aDB42tIeoFO1H482OleLtD0i6t/wCz5Nbu7xIXuriLY9pbQGR7xXjLoEZjEqpIyORIW2jaRUHxLfwivxu8B/2pNcR&#x2B;LRDqI0qGCzluGubJkgjvEl2Iyx24keyZncqodIRu5weH16b9nPwF4Q8Qa1Nofwvh0TT9Kj1S/u7bR7OS3u7cyXDRhGRCs7mSxmxGm5t0QwM4oA9X8J/GDwz478M6PrWi61Y6lpPiCaSDT7u3ffDdPGsrOFYcfKIJck4HyHvXKfAj48&#x2B;FvjjrXirVNFt7QDS7u3sodSELRtq1tLbwywyq7ou5GkkkRQCwJj65OBJ4l&#x2B;HPgbwtN9tn1hfC9jo8cqwW1tqi6bYaXLIC0s6xKVjWVllJLMDgSMQAZHLYFnpXwV&#x2B;HXhKXwHpN94b8J2MmmxaxO2kaiunyxQQvbCK7muonVwzNJAVkkfMuTy43UDOr8R/tF6DokGnxrKp1LUNStNNNpKSpt5JriSGRXkQPGGi8i5yN20tEF3DzEJwviN&#x2B;1ja&#x2B;DNI1ySx0m41bULGdbTTbRDKTqUu64WRj5UUrxxR/ZLlmKo8hWBikblolkxtL/AGdfgP4M1bUvEF3B4Zv9Q&#x2B;0vp&#x2B;panrmr/wBoTNcSQuskE0lxI3zvFK2Ubkqw4wFxUtP2aP2b/DN5Z27aD8NVuPDf2yMx3UtvI6mNFkuftAkYmVokdXPnbvKVwRtBBoDQ9D1v4&#x2B;aTpEnhHT1vdKuNc8dWFxdaGIbgyWd&#x2B;8Nus7bJguDGVYENxlTkCqPg39pHT/id8LtU1Lwn/AGb4l8VaTocGqT6Da34VlnuLU3FvbNIy/J5mNoZl46kDBFcj8S/A3w98S&#x2B;NNFmbxB4Kn0awt7XR5vC11pdnq1rLHH&#x2B;9gW3hHz28qxzg5QMvlMhKYVWHU&#x2B;EPHPwf&#x2B;GF7Bp/hm68C6Xc6wpSK10KO3El4sMqRkBLcZYRvdLkY&#x2B;TzSTgbjQIqeCP2gPFXjT4k&#x2B;FNLXwGtl4f8ReHIfEM2rzawmbXeH32ywrGTJJGxtQx3KuLnIJ2EHU&#x2B;IXx9k074L6X4y8GaP8A8Jrb6y9gbSBLr7C00F5IkUU&#x2B;ZV&#x2B;VA0qM24KRGHbkqFbpdO&#x2B;JnhK9n0&#x2B;O11/w7NJezzafYrFfQs08sX&#x2B;tgjAb5mTb8yLyu3kDFaN3otjZX19qy2CTX09rHBKyIDLcRwmR44&#x2B;eDhpZCAccuaAOd8MfFK61D4neJvDerabZ6W2jraXFhLHqAuJNTtrgyokpj2KYsSQyJtJb7pOcYrznQ/2uL&#x2B;/h8ZR6x4c0fSNU8Jxsmm219q/2Ua7dp5iuYpJYViWAOnl&#x2B;YskjBt4dEGwyejWVrov7Qvw5huNQ0u&#x2B;s4bx2VoTeLDe2kkEzLjz7SUlHV0b/AFcuRkqcHctcX4K&#x2B;B/wr1j4Wx&#x2B;JofhF4f&#x2B;0G0luXsrnQ7K61aSVN2&#x2B;N3JfzJ2dSCWkJZzlmzk0DPWfDviGDxJ4bsNUhZVt9QtY7uM71YbHUMDuUkHgjkEivGdX/bg0HR/BPjW4knsX8QfD/7dc6tYRiYxtbWUrPN5UrIqyTfY187y1JKmRc5HNTeL/gr4V/aj8PaDps114i8O6K2i2NzcaBp89mtje2LSCWG1l2LKgVGhxm1kTK8CRl246nVv2UvAFx4R1TRdM8KeHfD1rrka22onStLt7R7223q0tu5RATHKgaNh/dc4wcGgR6NRWX4p8caL4Ghs5Nb1jS9Hj1G7jsLRr66S3W6uZM&#x2B;XChcjdI2DtQZY4OBVHw58TNO8UePPEnh23W7XUPC/wBm&#x2B;2GSErE32iMyR7G6N8oOcdDxQB0VFGc0UAFFFFABWfcC9/4Sm0Mcka6d9ln8&#x2B;M43tLvh8sjjOAvmg4OPmHXjGhWLe/Y/&#x2B;FhaZ5nn/wBof2dd&#x2B;TjHleV5lr5m7vu3eVjHGN3tQBtUUUUAFFFFABRRRQAVznjf/kZvB/8A2F5P/SC8ro65zxv/AMjN4P8A&#x2B;wvJ/wCkF5QB0dFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc543/5Gbwf/ANheT/0gvK6Ouc8b/wDIzeD/APsLyf8ApBeV0dABRRRQAUUUUAFFFFAGP45S1fRYPtk00EP9oWRVohljJ9qi8tf91n2qfYmtis3xU10umRfZLWG8l&#x2B;1225JVyqx&#x2B;fH5j9R8yJucehUcHpWlQByXxn8TeFfCvhK3uPGNxHa6T/adkYXdZGBu0uElth&#x2B;7BO7zo49o6MwC85wePt/gr8I/G/jLT9Yht9LuNe8PyxyQPHqM0dxalrq4mRXQSA7Hnedtjgq5XoQi7fQfiH4Hh&#x2B;IWgW9hPNJbpb6lYamGQAktaXkN0q89maEKfYmvCfGn/AATn0Pxn4km1K28QTaeLzVIdWuxDYxGS5uIbm&#x2B;mRjKuH3J9s2LkkARDIOeAZ6PqXwH&#x2B;HfiLxTdXE1os2oarKb0iPU7kKjxz20rtEqybIS00dq0gjC&#x2B;aQu8Pk1nT/ALIvwl1XVIW/sGwa7Wx/s1RHqE6vLbG0jtREwWQb1FvAiruzt2swwzMx4/wh/wAE5tB&#x2B;HGi2Nv4d1y60i40&#x2B;ysoI5orKHbJcW0umS/apEAAeSRtLi3k9Q7c8DDfg/wD8E0/Bfwc13wvq1jM1xrHheG0hi1CSygW6uBbo0YLSBd3zRtsOD90Y6UAeheMPCvw1&#x2B;IfxN1Wx1hbC98TLpMKX8bXEqMlk0epQR7trBQNlxqS5&#x2B;8N7E9EI5Pwn&#x2B;xt4B8J6z4jk1qZda/4TS2k0SK0mnmW2tdP8uaQ2kKmVyi7JJWO0qigLsWMDB5q9/wCCZnh268U&#x2B;ItSbxBcLceILuG&#x2B;EQsLfY7wX898n2kYzdK0tyUl8zmWIBCRndSP/AME1vC&#x2B;lQXQk8U6pFHqGmLpLrLFbiNVTSZtNQxrtAXMU0jOvKuI4UIEcKKADtPCP7M3wc8dm31DStNh1SPT7pokU6pdyQi4sbyGNnMTS7HkS406FGkKkv9mVSzLwcv4e/Cn4D694N1TRdDttPutDs9Lh/tBZry7aCKye1naPfLK&#x2B;AhttQlYZb7k4PTaRD8AP&#x2B;Ce3h74C/EU&#x2B;JLfUpNQvJLW/gZfs/wBlWD7ZeTXUiQLE4jigBmIEWxsFFYMDnPSfsxfs2f8ACjdR1TUBrtvq8mrWen2d2sVuEVJrKxt7EsrBjgMLYNs25VmYZIAoA4zxfon7Od58Ptb0vXtS09vD/ii2XxpqFzfa1ehdRgW3t4Rei7eXcyeTLbIdkmP3qAjLc&#x2B;l&#x2B;B/gh8O7nxRZ&#x2B;KNC02H&#x2B;0/D9xfWEVzFcTr5Uhubg3EciFsPiea4I3hgpkYpgEGsHVP2QND1r4aal4RuNYu5Ptfw9HgC3mKoZtPs2ikhmuIx2ebMJfPyk2sXHBz2fwv&#x2B;G8/wAOtU8RXVzqUdw/ibV59TkhWMIkbsdkYXvkW8UCsOhdHb&#x2B;LABHLav8AsMfDHxBewXGoaBeX0lqbnyBc61fypbi4DiVURpyqIfMchVAVCxKhTzWxe/sq&#x2B;CdS1T7dcafqdxeNKk0ksut3ztOypbJ&#x2B;8zN&#x2B;8VltLXcr5VzAhYMRmvRKZPcR2sDySSJHHGpZ3Y4VQOSSewFAHm3gD9j34dfC6bVJNB8OrYNrVnLY32L65kF1FKQZNweQgu2ADJ9/AA3YAFSa/wDsj/D7xMpF3oLbiHBeG/uYHKusquu6ORTtZZ5lZc4ZZGBBHFekBtwyOQehooA831P9kf4e6u6tN4fVWWB7UtDe3EJkt3lnmkt3KSDfC73MxeJso&#x2B;4BlIVQuZ4r/Ys8C&#x2B;L9U0P7VpFqdJ0XT7jTTYlXb7VBLY/2f5LyFyfJFszKUH3mEbE5jGfW85ooA8p8R/sT/DXxf4FuvDeqeH7jUNJvtxuUuNWvZJrgtLeTMXmM3msTJf3ZJL8&#x2B;eQeAoGzoP7Mvgnwx8QovFVjo7w69C1wyXRvrh8efJNLINjSFNpkuJ3C7cK0zlQpY13tFAHlOg/sSfC/w1pOpWNp4UtxZ6xMZ7yGa7uJ1uGJtDyHkb5f9BtflHy4hAxgsD23w6&#x2B;GWj/CrRprDRo7xIbic3Mz3d/cX080hVVLPLO7yMdqKOWOAoroKKACiiigDxv8Aau&#x2B;E/gX40DSLHxn4wj8PWuiSNdyW8d5Z2c06yRykZnkQzwo0dvcg&#x2B;TJH5kaTq&#x2B;9AwHjfjz9m34G&#x2B;K/Bev2&#x2B;r/Gy1ik1y2WfVtTGs6LC0tvJHe2W/y/IFvEjpqLxB0jU7kjIbeXL&#x2B;gftRfCDwZ4n&#x2B;K93rWreMl8O&#x2B;IbzwlPoroYftEcGlMl59qlkTOIw3nArMdpVrbaGZXljfkrr4PeE5/EGtR&#x2B;Kvi3bXlta6fFe65aW97qNpNGNNuGMtwZWv5GRVW3kjdjulG1v3oX93QM7P4xfCv4Za98abPW/EvxIg0u4R7bxOmgz6pp8NrcNa&#x2B;XKL0rJGZjH5VgASHEYSKRsAgsOF1D9iX4PT&#x2B;NI/CyfFC6tde8qOLTtGj1XTFvbaSKPTRI6ReT50m6PT7Xckm9VEjFFTKbLPxm8P/CX4krq2l3XxI0nRfBWraQE1jR4YAtxCtla3KpsnJzbbIUkZoWjLMLUkbV80P3H7PWneFbf4mSXEfj6w8TeNoftyavbx2ws3aa9h0y4U/ZizPDttbS1IVidwkLZHQA9TkPiH8GPhV4w&#x2B;G/hn4e6N8TvDmh2Oj&#x2B;MLyS48i/02S9mur231WNrJEdGiE5a5m2q0TMEt3AG5dwi8dfs0fA3VNf8Asc3xG0zSbzTbm&#x2B;0y4sW1fTpGF5fy31wiSJMjMtwjT3hjxtkZUbcX2Eh3hX4S/D/TfHfgjVr74qWN/F4TkVfDVtZTfYWksbBrrTBFLJFLuuWS51NIpH4RyI0MY3uXyPEvww&#x2B;G&#x2B;pah/wALW0r4u2el2en&#x2B;I28Q3l3dXEzW1uyWupTmHC3EL26m01CeVlUqsipHIyOpYOAdrbfs7/DLwRpFvHqnxGmuLfT7260e2n1TVLDzob24u7TULmFpvLV3uHms1kZXJYLI4AAC7ed&#x2B;B37FPgLwJ8H9BNz8SDqx8N6PZXupanbXVhHZtZpBpzRyZWLEdsf7IhdJS29lEm6Vxyq6V8KfD/7P16vjC1&#x2B;MCtdtNPe3txqWmR39nc3J&#x2B;XVLgRQGNkMu62&#x2B;YNiEwpyyM6seBfgd8PvA3wC1DT9P&#x2B;JGtLoN9Ho/hq9vWaWe4uX04kSWsCz&#x2B;ZjzhvjeCNGSMCVAgIbaAWP&#x2B;Ga/hN8NtCVpPiFYSah4TlsriCbVNX0&#x2B;1W1aH&#x2B;yryzhmZIh5aNDoNrltu94hO2T8pT3fxP8AFfwLd&#x2B;EIW1TxZ4bh0bxHZ3Bt7htYihjvrdYyZnilDjKohJZ0PyjnI618qS/s6/C25SO3s/jJpsOsaSRfRXs6QtHcWUGjRrZecQyLcJbWaed5iuoxcSsdnm5rc&#x2B;JPw0&#x2B;G&#x2B;vfC7TfDd38UNP8AD93Nb&#x2B;ItXvdRubM2mp3UWoteXeoGJGeMRWpeO5d4njlDR2wOd8azAAgu/wBjTwzqvxMt9F8E/G7U/Deg&#x2B;Hme1tvDem6npl5c6VczXUd9PFG09tLOmTZmcLI8jF03AokW07/wA&#x2B;Anwf8ABC/EbU4fjJffEK01TTWsvFcmq&#x2B;J9Pljs4ZS8zPPJaRwtGzCR8PK2QjEKVBq34Q/Zi8NyfESSwX4nahfaRpPiS6FroVjfTWc9jqM8N/e3MLzW86nzdupPJlEjkMSKkjS8tTLPQ/hx8Kvhf4m8NSfEe1tZP7T025/tGaANHp95pFpYW6sw&#x2B;5JHFJpSPP8AMBHl0do8A0AZfhL9jH4e658UIdQ8FfHfx1Y6i2hrDpmmaF4h0qZbLR0vXeJIVNrJK1tHco6Kzu&#x2B;djRszAFa6Cy/YDuPh/wCG/Hg0Px3448Ta/wDELR20S81HxLq8KvZowkAuUa2tEaWaPzDtEh&#x2B;6AgZFqx8Hb34d/BrxbqPia4&#x2B;IUGu6xrG/RL5rNpRZC9/tnUJJwLaN3SNvtt1LAofdIvlhPMZnct61eftC&#x2B;B9PacTeKtDj&#x2B;y350qbddoPJuxcW9qYG5&#x2B;VxPd2se087p4x/EKBanjPjn9mrWfh38MPDsMkPxE&#x2B;L9xpniOXVdROna9a6Prt/G1rJaxZmWSxhkjEflebE0kfmEZJfBRug&#x2B;Kv7KV18XdHXVtB8ReNPhrq2qJZ3F7p1tNp7KzW/lGBJt8N0iSQGP5WgfbuJJLjbjtrr9q74d2UckkvivTUghmjt5JyW8hHeA3CqZMbB&#x2B;4BlPPyoNxwOa9CoEcv8FvANz8MPhdo&#x2B;g3mpS6ve6fDtub2RERrmVmLu&#x2B;1FVVBZjgKqqBgAAcV1FFFABRRRQAVnz/bP&#x2B;EptfLihbT/ss/nSH/WJLuh8tRz0K&#x2B;aTx1VenfQrHvI7M&#x2B;PdNZ5pV1BbC7EMQH7t4jJbeYx46hhEBz0ZuD2ANiiiigAooooAKKKKACuc8b/8AIzeD/wDsLyf&#x2B;kF5XR1znjf8A5Gbwf/2F5P8A0gvKAOjooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDnPG//ACM3g/8A7C8n/pBeV0dc543/AORm8H/9heT/ANILyujoAKKKKACiiigAooooAyPG3k/2ND9ovJLGP7fZ4kQEln&#x2B;0xbI&#x2B;OzthD2Ac54zWvWX4tLf2VFtsV1Bvtlr&#x2B;6YZ2D7RHmX/tmMyf8ArUoA8r/a1/Zuj/AGpvAuk&#x2B;Gbu8ax0pdUF1qEsaxNcCIWtxGDCJYpY/NWSSNlZl&#x2B;QrvUh1U15Hcfsy/HbwzF4xtfDvjXQ103UI500G2nv7qH7D5&#x2B;opO7yPHHu85YzOwlBJLT7HDoi17B&#x2B;1fYfEDWfBGlaf8N9QbSNe1DUjDJffuxHZxfZLlhJIXgnUIsywnHlnccJlQxYeK3/x8&#x2B;P8A4ETxlZjwpa6kuj2076LczaDqN9canM&#x2B;prHHMwtyI/s6wySKYFf7QiwpKA8bHAM6j4e/Bb48WHxY0q/8AEHjbR7jw5a6nPd3MVve3DXFxE8dudjo0YhK7luI1RVQJGY2&#x2B;aUvLWP4o/Z//AGi9R8b6xcab8RtJsdFaK/8A7Lge7naYPKbxo/P/AHW3B861UGMKYRaKyDLyLJe&#x2B;Hf7R3xq8V/F3RdN1LwXp&#x2B;k&#x2B;H7jWLq3vbifQdUj/0YR27xRxTfMqyIJZN080aQSvG0cR&#x2B;XzGh8bftBfHjwr8Q7y2j8IaHceHVh1i4tp4fD&#x2B;p3VzMIZtRjtEAhd03rHb2MzCQxfaVvGSAB48MAaHxW/Z4&#x2B;LniPwb4GbQfF2n2viXQtLvdP1a8nvJo5bpbiezkVY5ljL/ILbO9vmfy1Viwkdq53xZ&#x2B;yD8Wvi7P4iXxl4i8O31r9rvp/D9vBqN55NsZ9P1ayWSRGjIVit1YFkXKKUuCiru2vqfBH4x/GX4lfEaOPxZocmgWdv4VvZHt7Xw9e2sM96U04wzi4ncrlpGvlS22iWNYiXJ3qTzuk/tM/tCaNpU8N34FsZLiz1SwsoIW0DVLm4ltdtwZpJp0xAzzxxQuksRZLd5TFOgbaSDO6&#x2B;CX7P3xU8N/GHR/EnjXxbHr1vZprFtcW9vq1ykJW5&#x2B;xNbzLBsCMQbeYGI4WIz5QkDFYXgz9kj4nfD7R/D&#x2B;gaL4sj0zRbW4tW1GaHWrgyy2pm8y&#x2B;gSNoTmaV2eUXRcSDPl4VfnrA8IeOv2ifh9qvhnTp7Kx1r/hIbyL&#x2B;1tW1PRtRktrFnumzDHBBJK8O6KRm82Rvs8X2ZFbyxIpG1efFz426VJ8Fb630u51y81bw/PD4qs38N3VnbzagbvTEKsfMxYukJv5Fml3xOIWCr&#x2B;9joA6j49fs8/EK88aeKvE/w31iw0/XvEGiW2jxTalqtxGtv5Vpq0aOB5UoUR3N5ZzgKvztDITgn5sfxH&#x2B;x9448U&#x2B;NNN1C&#x2B;8WX0wSWG6ubgeIbtJLaWJ9U/494gmxNyXtsm5dhCwOOc5PN6D8WP2gNSstO8W6vZ6Xp0Y0dILiztPCOs3UdlPJfSh5zYmeK4ndIooYvLAbHmGZJPLLK3YeBvjP8dNR8deB4fEHhbw3pOk&#x2B;Iru&#x2B;/tW2XStQln0yKKXyo4ftUTyQrIVUzCWZY4pVdY02sN7Aix8D/gh8ZtI&#x2B;IUOo&#x2B;PPHdvqmmx3jXM1rp93KkdwAs/lKUMS4UeZArIpVG&#x2B;zhipLSb8vxb&#x2B;yR8QvGmk&#x2B;LtLvvFFq2h&#x2B;JNV1XGnRX80Fsum3MhmiQqkQxN5p/eMCcqzLuYMwNf4m/tR/GTSfEerWfhn4fyXy6W99bxJceHtQP9ozJJqf2YRzbkhERig093lLEH7Syxh5Dsj9q/Z78c6948&#x2B;GljdeKLWO118Bvtf2fTL3T7aTLt5bRxXiLMuY9hZWBKMWXJwCQDye3&#x2B;AXxpudQ8S/aPH0dtZ3GlX8OkJb6jKWXUpBOtvdtmAeVEEkgH2ceYsbW24GQu1U9X/Z&#x2B;&#x2B;Olj4nsbfR/HFjJ4bXxHb39w19rF41/Hp6akxkt0YRkNv0wrDhyf3yhwyuWmP05RQI&#x2B;VPCf7Mvxs8H6Jodrp/izTLRrZrI3cn9sXEzs8MGlQzyys9sWuzLHaXyBZWXYLiNgdyqYva/gJ4L8XfD/SLvTfE2qLrkO6CW1vZb6S5ud32WBZ0ffGvym6W4kU7iAsqqFRVCr6BRQAUUUUAFFFFABRRRQB5R&#x2B;0N8IPD&#x2B;u6b4m1rxB4qvvDOg674ebw74iG62W0ubI/aFRneWNjEyNeTfOrKpD/ADAgKV8s139h/wCFrTzWWleM9U0OPxrp97oUdnpstpLHNa6n9vumjjDQvsDLLcsj56QjBJBz678dovG2spqmhaH4dsdY0nxFpRsBeS6qtoNLmfzUkkkQxszKEeNl2biSjDC8MfGLz9k/9oC0v7iPSvih4Ns9NWHS7fTozpNzI&#x2B;kCxSaMSWyySvFHJOsiebuRwdhA4K7QZJ4v/ZG&#x2B;Ffxcu/GOoa/431eTxBr1xdeHNQ1W9uLG3nNwum3VnNHFGIViBFpcH5dmcW6Oc/Oz9hpn7Hvg34EeML3x8fFWraHqM8H2K4v3e1gtlaSzsdNt2KeUEBiFspjBG0PczZBVlVcPTf2OfHGs29xY&#x2B;Jdb8MXkmseFLm31zXrG1&#x2B;y3ur&#x2B;IWQ2tvqUlskSx5gsyY94kDSZVWTbFFt9M&#x2B;Pll448Qpe6HoGg2Wo6brVhHDDqMuprbf2LdCRyZ3jKFnCjyXQJkloyp2A7iAeb3P/BN74Z2d5ptjDr3iazbRLuz1jTbeTWBcS6eYHtVbYZg7mGYWoR1YlczSFdrlWXesP2GfC&#x2B;vfCw6DceKPEWuQyBLdtReW084xwWE2mpCPKhWPakcsp&#x2B;6WMhO5iBtGD45&#x2B;FPxi&#x2B;MXjHxtdQX3hvTfD95HLpGjWHifRYrhra3khtTJKn2eZg&#x2B;LmBnQz5JLNhFVUL9H8F/g/wDGPwP430L&#x2B;2PGXgGLwLpa3kc3h3RPDclsZVlZ3g2TtMfLWEsiKixgbEOSxbIBmnoP7E/hXwz4BfwzY3utQ6Sttq9lbxebGfsdvqEiO0MeU4SFY0jiByQigMXPNV/FfwJ8N/DxNT1ebxlqnhu8vvEr&#x2B;KLOeIWoSxu5IHtZEgtzCUcSxzyB8o0jvMXLbyGrjfiL4Z&#x2B;MHxy1Cz03w/p&#x2B;o/DEwzyXPiK&#x2B;1WdJdP1x18qOKO1bTr&#x2B;O9VVVCwbfbhlAEilmZB654k&#x2B;HHijVvCXhmVda0Wfxh4cEkzXz6bLFYX0z2k0DAwCdpI4i8ivt852GwDcx5oEebW/8AwTM8AWWoNdQXviKGaayFjcSCeEvcIuljTYmJMRw0cRdwVADSSEuGVUVcD4p/8E9vAOt2L2fjDxx4um1DxZbXehQXstxAk26Vr2&#x2B;fyiIdsZWJ7kYPyeUhUggkGn4d&#x2B;Cn7Tc3i/TJIviN4f8O6L4PeGCLTpdIN5beKIUjmQCWZ7mS4RcSRlnJWV2t1PBZmrqfir8D/AIw/Fz4MeFdHh8SeD9N1FYpJ9cl1XR/tkxeWOaM26Lvkt9oinMT71mDgNyd26gDb8Efsc&#x2B;G/BvjyHVvD/ivxJDqmm6quqapG19FeLeXbi9eZpY5UYQmcajMzLEIwB5ewKBzc1j9j2LUDeLa&#x2B;NvFmlw3A1OCBLeKxY2dtqM3n3luhkt2yrSrGys2508pQGKl1byXTP2Yf2qNKNxdL8dPCs&#x2B;pzNYyiSfQ5ZLUyW8PlSBrfeEEVwAGkSLyzvLMjIdu33z9nWHx4NF8QT/EI2q6pdazI1nDaxrHbQ2qwQRr5QEsrbHdJJPnbfmU5VeBQByvgb9g3wd8NtX1m70W61qzGuXlnqFxAJo2i&#x2B;0WupG/jlAKZ3EiKFiScxW8Q4YF2x7H/AIJs&#x2B;BLO2vLeTUvFd7a6taRQapFd6kbj&#x2B;05xc2dxNdyMwLLNObG3R/LKJtX5VQ/NX0JRQI&#x2B;aNJ/4JdeC7LQZtPvNd8Task0ltdGe6Wz&#x2B;0G5g0ttOjnZ0gXcwRvN2sCnmD7uwlD9H6baSWVmsc11LeSKTmWRVVmySRwoA4HHToO55qxRQAUVg/ET4g2Pw60Bry7mtY5XISCOecQrI7MqgljkqilgXYA7Vy2DjFefeHvj/AH1proh1jUPDd1BNqK2kAtV&#x2B;ytNbyFtl2jvO6silHBUhSwUOpIaNXAPX6K8L/aZ/av8AFHw7&#x2B;Imn&#x2B;Afhj8Obz4m/EC&#x2B;sBq11A2pxaVpWg2LSNFHcXl1IG2mSRJRHFGjvJ5Ep&#x2B;UIWrmv2Zf8AgoJdfEv9q3xz8C/HnhW18J/EbwPDb3vm6bqg1LSdatZ0MkUkMhSOWOTywWaKSMFcHDMMEgWPpms24W4/4S2zK2sL2n2S48y5IHmQvvg2Ipzna43k8dY16cZ0qybsR/8ACdafuvJI5vsN1stADtnXzLfdIT0yh2gZ5/enHegDWooooAKKKM4oAKK5/XvipoHh26ktptRjuL6EgPY2Ub3l4M8/6iEPLjHJO3AHJqAeLNf1dAdO8MyW69fM1a9S2V1PQqsQmfPqrqhH1yAAdPXOeNz/AMVN4P8A&#x2B;wvJ/wCkF5UFt4M17VYz/bXiab5jhrfSbVbGFk9CzGWYN/tJKnbAFXtB&#x2B;Guh&#x2B;G9WOoW2nxtqjRmI39w7XN4Y&#x2B;DsM8haTZwPl3YHpQBuUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBznjc/8VN4P/7C8n/pBeV0dU9c8O6f4ms/s&#x2B;pWNnqFuGDiK5hWZNw6HDAjPJ596yP&#x2B;FPeEf&#x2B;hW8Of&#x2B;C2H/AOJoA6Oiuc/4U94R/wChW8Of&#x2B;C2H/wCJpR8H/CQP/IreHf8AwWw//E0AdFRXOn4Q&#x2B;E2HPhfw6f8AuGw//E0n/CnvCP8A0K3hz/wWw/8AxNAHR0ZrnP8AhT3hH/oVvDn/AILYf/iaraj8GtDCJPo9hY&#x2B;H9Ut28y2vrC0jikjbGMMAAHQjhkbgj0IVgAbHjBN&#x2B;kwj7d/Z3&#x2B;nWh83JG/FzGfK4I/wBZ/q/&#x2B;B9&#x2B;lalcx4c11fGMcuk63aR2utaa8M9xah9yOUcPHcRHq0RdMqTyCpVgCCK6egDg/2gfifffDLw9o/wDZ8mj2d5r&#x2B;qxaTHqGrsw07TC8csgln2spYHyvKRAyb5Zol3LuzXmUX/BQjSotdudLPh3VNRuNOjmnu7qymtTALeCe5t5pwpm3L&#x2B;8s5isZy5Vos4JYJ9B6hp1vq1lJbXUEN1bzDbJFKgdHHoQeCPrUNv4d0&#x2B;0MhhsbOPzjmTZCq7ztC88c/KAPoAKAPm&#x2B;1/4KTaP4r0nwzHo2i31t4g8R6vYacmm6iY1ltxLfG2uFdQ4IePypoyy7kEoHLrydC0/wCChmm2Xww&#x2B;HOvat4W1W2vPiRoEGuWVrZ3MNzDCGgaWZHnLIFSHMCvK4VQbmPOPm2&#x2B;&#x2B;WvhXS7IwmHTbCE26hItlui&#x2B;UoJYBcDgAknA7nNU/&#x2B;FcaKfEsWrfYI/tkFjLpsXzN5McEsiySoIs&#x2B;WN7IhZgu5tigkgAUAeK23/BRLw3qDQ2lpoerXWtT65/wj66fHcWu5pxc2Fs0obzdrW4k1CP94M7ljYgElVMPxK/b3Twj8W18K6X4ZvNUubPUr&#x2B;2uwl1bb5orLTvtcxQGUGJgZbfaZR86iYAAhC3v0PhjTbadJY9PsY5I40hR1gUMqIcooOOFU8gdB2qrovw/0Xw9qOo3lnptpDdatcG6vJtmXuJCu3cScn7vGOgyfU0DPnvWP&#x2B;CmHh9bm3gs/D&#x2B;vxefqkmjtc3VsDCt5DdQxS2oCMWMhhl85M4Dxgsu/ayiPxP8A8FQPC/gSysbrWNK1DGsWqX1laWTR3U32do4W3u8bNEMNc26nLqoMhAZyAG&#x2B;gfC/wu0Hwekn2HTYRJNczXjzTs1xO0szh5CZJCz8kKAM4VURVAVFAur4P0lAgXS9OAjZnQC2T5WbJYjjqcnJ75oEeE/Ff9szWNO&#x2B;Dmm6x4Z8PeT4g1fVZ9EistVCSraXCPsDv5cyq6jIfCuNw&#x2B;Xcp5B8SP&#x2B;Ch/h/4efFrUPA8Wg634g8QaYzRyrZKkULSR6fLqEyiSZlTKQxdFZjuYA47/QTabbuqqbeEqrbwCg4b1&#x2B;tQnw/YNfSXX2G0&#x2B;0y/flMK&#x2B;Y/y7eWxk/Lx9OKAPFU/b88Jt4F1HxG1jq1vpOk6rLol5NOIolguorae5dSWfG0RxR4bOCbiMDndjn7v/gph4esfGNrocnhHxg17qF4lvaeTBHOs8bXWoWxlPluxXD6ZcnawHyFGJHzBPe9A&#x2B;HOi&#x2B;GtEuNOtdPh&#x2B;x3V3LfTRzEz&#x2B;bNJKZWdjIWJO85GThQFC4CqBeufDen3qBZrCzmUMrgPArAMrFlPI6hmYg9iSe9AHy9F/wVt8FyWS3X/CO&#x2B;Ivs7aWmpHypbS4lG9tVVVEcUzs650e6PmIGTbJAwLK5K7Grf8ABSLT9L8Jt4gbwfrkOj2E89vqQuZoodQtmh0ibVG2WpJkbMcQVd2wtuLYAA3e8QfDHw/beMbzxAmk2I1jULGHTLi58sFpLaFpmjix0Cgzy9BzuwcgDF2PwfpMRXbpenL5aoi4tkG1UBCAccBQzADtuOOpoHofPfhr/gojZ&#x2B;K/Hf2WPw7q2m6Tpvh/V9Z1SO9iRdS32MNhOUht/MEm0x3owzoN5wPkI&#x2B;bl/EX/AAUe8QR3S6/ZeD7qy8D2Vguo6h9ssmbVDDCNZmuWhjM0e7dDpDiIFQSZgzdPLP1jY&#x2B;HNP0yVZLaxs7eSOJYFaKFUKxr91AQPujJwOgzS2Og2OlwRxWtla28cPCJFCqKn3ugA4&#x2B;83/fR9TQI8I8Dft623xJ1bRrfS/CeqW632sW&#x2B;kXh1W4jsJbQyrKwmSF/3skZCLtYqgYyBR8ysoh8R/8FF/DfhnXvEFjNoWsu3hy1v9SndJ7X97a2U13DOUUy7jOXs5dlvjzHUq3GJBH7xD4R0m38ny9M09Ps6qkW23QeUquHULxwA4DADoQD1p7eHNPeVpGsbMyPOtyzGFctKoAEhOPvAAAN1AFAHh1/8At/6JZeJP7Bi0HUdR8Qi7Nm9jZXtpLhhDp0xcSGUKU2alFhs4Jjkx/Dn1H4HfGHTfjt8M9N8Taarwx3yHzrWXInsJQcPBMpAZJUPDIwBB6it218J6XYnMOm6fCdgjylui/KOi8DoPSrGm6Va6PbLDZ21vawqABHDGI1AACjAHHAAH0AoAsUUUUAeG/tWfBHxV8VfH/hi&#x2B;8O&#x2B;TGum6Nqtml2&#x2B;rzWDaRfzz6c9rfKsakzeUttc5jOA4k8tvkkcjkdD/AGU/Gl38MPF3h&#x2B;/u302bxBpmmadd3dn4guWm1W8iuppL7U1kwHt5JopEA2ncCgThYoyeu/as/Zz8QfGv4heFdS0eLw39n0zSdU0uS81C6liu9Dnup9Okh1GyVInElxCLOXaDJDzIPnxuB8x8J/8ABPrxTb&#x2B;GVXUrjwvDqWl6Y9lbQwvDNbayxljeT7TKthDNClxGjQymMvLskbfLOOKCi38Nv2UPiV9ttR45m0zXr&#x2B;bUpJZ9Xj1iby7SzOr6hcXMK22wKy3dncRRFRwu7aTi2hLdLefsZ6zrPgv4T6LHrjeHofBWiSLqktjNI01zqJewkDI&#x2B;QdrvBciR2yWjmkTA8wsvnvij/gmx4m8cz6peXE/hPQ4NYtZrEeHtPnd9O0m2mj1NJYIJ/syTbS13BIVURxszzExZjhZbOl/sA/EHTviLD4i1DWfDviS&#x2B;vra4h1S5u7to385o4IIbqNJLOcb0t7aFSI2gcncRKMsGAINX/Y1&#x2B;MnirVoNbXxRb&#x2B;H9St2l8mGDVppmty2laZp6us2wFQJ7Se6ICner7GAaRinZar&#x2B;zz8RrOeHUvBv2PwbHp1pp4g8PSaobyzuru3fUGkklnKeays09uS3DSYJcZGKb4X/Y98W6H8Ek0q4tPBd1OniO21tvB5vpz4buIItPis2s3mNsWCPNGb84tdvnkAo2Xlaf9lf8AYa1j4K&#x2B;PfEGpeKNV0nxRp/iPSodMubZ4zIuyLTtKtQhDpumjZrS64nkk2IY9m1prjIBw3iL9i74rQeC7XRbfWYtauNPtv7NbULvVnb7TY/bFvP3ayqzx3RZ3gdmZo5YY0DjKoB33xC/Zg8ceIPGVvr2ga0NDm0vwVZ6Dpdp9qKJDest/BPLL5YCmKGO6hmCIo82W1hwUEYzw&#x2B;kf8E6vFWh/DLS/C1q3gu3kt/CyaZLr0M0qX1vP/AGFLp01nFF9nKtZy3Uj3jSM4JeWUmFnKyDqfgt&#x2B;wx4m&#x2B;EPxu0LxJH4gsJtL0/Urj7baB3T7bZCHU0tGEaRpDHNG96MxxokQWWUKAscSUAY91&#x2B;yr8W77wpeabdappv9vx6TZ6N4f8R2&#x2B;qTyf8I&#x2B;lreTETfZpgQ8k1sYDI&#x2B;4tK6sjnYkbG54i/Zo&#x2B;LesalZ3VjfaXpOlw6Fb&#x2B;GrrQk8Q32Ly2j8q4nl&#x2B;1gGQTTzJJb&#x2B;fs84RTmQnfla2/2o/2Bn/aP&#x2B;MF54ofWl0/dZ&#x2B;HbK1jWCCTaljqtxd3ZkEkEnmK8EwVInLQtIqmWNtiEcf4g/wCCdXiDxX4B1nw7fr4Jke&#x2B;8OTWCa25mmvp520WPT4rOVXiP&#x2B;hw3EaXaP5jPvihPlh1aRwDG8ffscfGrxh4Vmk0fVNH8L6hBoWr6bp9hZ6nNbWcRubi8igEiRgruWyuVYsvC3Cqy8KK9P8J/An4haF4U&#x2B;IVvt0lNauRaalouofb5C&#x2B;s6nb3dzdB7mTG5IJMWiGPaRErSxqGjVM0dU/Y11nT/ABr4mvtP8O/D7VNFufEllrFhoeoTLb2WoW0WlyWP2a4EdgxiEDussQY3SErhUgOGCeIf2ENS0mGO&#x2B;8EXXhvwn4j02&#x2B;1XUdKvLe08uK2nvL&#x2B;ZhJJGigSbLC4lhAPAbZj5VBABz3hH9iz4iXPhvWNP8WavZ6tjw1faFp5OqTyLNM88F5bXUgZQUlWaW8i3DJCQwkH5iq&#x2B;u/Bj4JeJvh18Q4Ly81x7rw7bx67Da6XuXy9PS41KKe0VCFDOBbowO9j5Z&#x2B;VflJrhNK/Yq1fwx8BviL4K0/T/DbR61qK3WgyyX6KHRLxriAXf/ABL2Y&#x2B;SPLHlzG7WUIUJjjYqMxv2KviFcJeRxa14R0uW28VXnjC0vIomkOp3pnlms1nijhgaOKMzvlZZrvBSPHygIAD6vzmivPv2e/CXir4f&#x2B;FG0TxBa6EtvZ3V01pc2Ooy3MlzHJcPKjSI8EYjba5BUM4BUYY549BoJOB&#x2B;PfhPUdd0SG603y3kjSSxuY5bZrpY7W42JPMkK4MkyIp2gHJV5AAxYA&#x2B;T6d4J16PVYl0u6MOsXMU6RPqvhe7uYdRje4niZp90iGFAjKzCRi74Vsvna30N4q8NWnjPwxqOj6hG0ljqtrLZ3KK5QvHIhRwGGCMqTyDkVh6B8E/DvhrxLHq1pYst5DLLPEWld1hklRI3ZFJIU&#x2B;XGkYwAAq4GMnIB8b/wDBZH9kP4vfFP8AZe8TaX8FNc1Kx1jxEumx6uYtz3uu21os0bWjzKPMj8zzInBUbWMcqyFFkJOX/wAEhv8Agk9qH7GfifXPHHi7xfrfj74jeLL4Xeu&#x2B;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&#x2B;pXnxI1O60/S7maw0Szd7a/1GHKT3EqtteC3f&#x2B;HaQVklAJU5VCHDNH0mgeHrLwvpUNjp9tFa2sOdsaDuTkknqWJJJY5JJJJJNAGDb3PjPWZWP2Xw/oMA&#x2B;aMyySajNIOwdF8lY2HfbJIM8A9zP/Zni7/oOeHP/BHN/wDJddHRQB5/4v07xRLrvhm1ufElvb2d9qTxTjS9ONrNKos7mQKXkllAXcikgKCSo5xkHZ/4VvN/0M3if/wIi/8AjdSeN/8AkZvB/wD2F5P/AEgvK6OgDmP&#x2B;Fbzf9DN4n/8AAiL/AON0f8K3m/6GbxP/AOBEX/xuunooA5j/AIVvN/0M3if/AMCIv/jdH/Ct5v8AoZvE/wD4ERf/ABuunooA5j/hW83/AEM3if8A8CIv/jdH/Ct5v&#x2B;hm8T/&#x2B;BEX/AMbrp6KAOY/4VvN/0M3if/wIi/8AjdH/AAreb/oZvE//AIERf/G66eigDkl&#x2B;EVvJ4i0zVLnWNevbrSZGktvOuEwu5SrKdqAlSDypOCQpIyBjraxb5VPxE0tv7SkicadeAaeM7boeZa5mPOMx4CjIJ/fnBHOdqgDLHhlhfX039qapi9jMYi8xfLts/wAUY25DDtkmoW8Hu2mWtt/bGsBrWQuZhKnmz852udmCO3AHFbVGaAM3/hH2/tq4vP7Q1DbcReWLfzF8mLgDco25DcZySepqs/gyRtCWx/trWlZZfN&#x2B;0iZPPbgjaTsxt56Y7da280UAZ40Jhry3326/2rHs&#x2B;y71&#x2B;zn/axtzn8app4MkTRZLP&#x2B;2taZpJfM&#x2B;0mZPOTp8oOzG3jpjua3KKAM1vDrNq1rdf2jqW21i8oweYvkz8EbnG3JbnqCOgqFfCLrp95b/2xrBN44cSmVPMt8HOIzswB25B4rYozQBlnwyxuNPk/tPVP9BUKV8xdt1jvJ8vJPtimr4VZRqH/ABNdWP8AaByMyp/onJP7r5eOuOc9BWtRQBkP4Ud4tPX&#x2B;1tWX&#x2B;z23EiVM3fIOJfl5HGOMcE09fDTLd30v9pani&#x2B;jKBPMXZbZGN0Y28Ee&#x2B;a1KKAMVvB7tplrbf2xrAa1kLmYSp5s&#x2B;Tna52YI7cAcCrP/CPt/bVxef2hqG24i8sW&#x2B;9fJi4A3KNuQ3GeSep4rRooAw38GSNoS2P9ta0rLL5v2kTJ57cEbSdmNvPTGeBzVwaEw15b77df7Vj2fZd6/Zz/ALWNuc/jWhRQBiJ4MkTRJLP&#x2B;2taZpJfM&#x2B;0mZPPTp8oOzG3jpjuast4eZtWtbr&#x2B;0dS22sXlmDzF8mfgjc425Lc9iOg4rSooAx18IuunXlv/bGsE3jhxKZU8y3wc4jOzAHbkHinnwuxurCT&#x2B;1NU/0FAhTzF23WO8ny8k98YrVooAyP&#x2B;EUbbqA/tbVv&#x2B;Jg25T5qf6JyTiL5eBzjnPAFK3hV2i09f7W1Yf2e25iJUzd8g4l&#x2B;XkcY4xwTWtRQBlx&#x2B;GmjuNQk/tPVG&#x2B;3IVCGRdtrnPMfy8EZ75qE&#x2B;EHNhZw/2xrG60cuZfNTzLjJztc7MEduAOK2qKAM1vDrNq91d/2jqW25i8oQeYvkw8AbkG3IbjOST1PFVZfBckuixWf9t64rRyGT7Qsyec&#x2B;c/KTsxt59O1blFAGf8A2A39uNef2hqG1o/L&#x2B;zb18gf7QG3O78app4KkTRHs/wC29cZnl837SZk89eANoOzG3vjHfrW5RQBnf8I&#x2B;39tQ3n9oahthi8s2/mL5MnBG5htzu57EdBxVZfB0i6XdWv8AbOtZuZBIJjKnmw4OdqHZgL9Qa2qKAMxvDbNfWM39pakBZoEMYkXZc4H3pBtyT9CKiXwky21/H/a2rsb5twcyputeScR/LwOcc54FbFFAGSfCrE6f/wATXVv9A6jzU/0rkf635eenbHU0q&#x2B;F2WTUG/tTVP9PBABkXFr1/1Xy8de&#x2B;egrVooAx28JO1nYw/2tq4Nm&#x2B;8yCVN9zznEny4I7cAcVKPDjf2neXH9pali7jMYh8xfLt&#x2B;ANyDbkNx3J6mtOigDyP9ru81f4WfsdfEfXdD8QaxZ654V8L6rrNhfExSSC4gs5pYt4ZCjKHVTtK4OMHIr8GX/wCC6v7Vj363H/C15gynOweH9KEZ4xyv2XFfvP8At&#x2B;f8mI/Gv/sQtd/9N89fyxV&#x2B;5&#x2B;E2T4DG4SvLGUYVGpK3NFStp0umfvHhDk2AxuExEsZQhUakrOUVK2nS6Z9aD/guh&#x2B;1WI7hf&#x2B;Fs3P&#x2B;kHJP8AYGlZT/dP2X5fwpT/AMF0v2rCbf8A4uxcf6N0/wCJBpXz/wC9/ovzfjXyVRX6z/qnkv8A0CUv/AI/5H6//qjkf/QHS/8ABcf8j62H/BdP9qxWuG/4Wxcf6SMEf2BpXyf7v&#x2B;i/L&#x2B;FNP/Bc/wDarMMCf8LZuv8ARzkH&#x2B;wdK3Pzn5j9l&#x2B;b8a&#x2B;S6KP9VMl/6BKX/gEf8AIP8AVHI/&#x2B;gOl/wCC4/5H2B/w/r/au/6Kkv8A4TOkf/Itfcn/AAQy/bT&#x2B;I3/BQb4zeNrX4xazp/ja38L6LHLpcdzoljAtq806iRgIYU3FhEg&#x2B;bOMcYyc/i3X6of8ABrP/AMl0&#x2B;K3/AGAbT/0oavj/ABAyDLMNkGIrYfDU4TXLZxhFNe/FaNK&#x2B;2h8Z4icP5XhuHsRXw2GpwmuWzjCKavOKdmldaaH7C/8ACnvCP/QreHP/AAWw/wDxNbek6PaaBp8dpY2tvZ2sOfLhgjEcaZJJwqgAZJJ&#x2B;pqxRX8xn8thRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc18SdSuJbS00TT7qS11LXpDbpNER5lpABunnXrgqnyqxBUSyRAjBrpa5iztlvPjJqE0i&#x2B;Y&#x2B;n6NbJbMf&#x2B;WImmuDMB/v/Z4M/wDXNaAN7R9ItvD&#x2B;lW9jZwrb2tpGsMMa9EVRgD8qs0UUAFFFFAGL408LXHiRdNms746ffaTd/bLd2hE0TsYpIisiZBZSsrfdZTkKd2AQdpelZXjUTN4dk&#x2B;z38Omy&#x2B;bDi4lYKqjzUyuT/AHhlR7sK1aACiiigAooooAKKKKACiiigDFvnA&#x2B;IWlr/ZbTE6deH&#x2B;0ecWv7y1/c9MfvM7uSD&#x2B;4PB5xtVj3qyHx5prDUo4oRYXYawLfPct5ltiYDuIxuUnt549a2KAOD/af&#x2B;O9h&#x2B;zF&#x2B;z34w&#x2B;IGpQtdWvhXTJr/AOzq21rl1X93ED2LyFUz23Zr8qf2I/2KviB/wWmtPEPxa&#x2B;NnxK8aab4UuNSltNF0rSLoRxkqcyeSkgeKGCMlYxhGZ2VyxyuW/Q7/AIKtfDDVPjF/wTv&#x2B;K2g6LbzXmpzaMbqC3hQvJObeWO4KKo5ZmWIgAckkCvBf&#x2B;DdP9oLw/wCP/wBhCy8DW91bR&#x2B;I/AV/eRXtkXAneG4uJLmO429ShMzR5/vREemfqctqSw2V1cXh/4nOot2u4xte67Xelz4nOKUMZndHA4t/uuSUlG7SlO9rO29lrY&#x2B;ZvjpoPxG/4IEftLeBdW8P&#x2B;PvE3jT4L&#x2B;Lp2ivdK1WXzNqxsgniKD5FlEciyRyxqhJBUqVUhv0d&#x2B;NP8AwUe&#x2B;G3wI&#x2B;PHw9&#x2B;HeszaxPr3xONn/AGHJZWYmtZRdXH2eFnk3DaC5BJwcDmvhb/g5U&#x2B;Jmn/Eq&#x2B;&#x2B;E/wj8OvFrXjS61eS8k0&#x2B;1YST25lVILeNlHKtM0jbQeSI89CM4P/BTrw2PhF/wU/wD2MdOvrlTb&#x2B;G4PDVlNdsdsbfZ9WVXfJ7YG456A16v1OGYUsPVxS/eSjUbtZOXL8Len/Dnif2hVyqti6GBd6UJ0kk7tRc9JJa/hfRn6K/trft9eAv2BvC2iax4&#x2B;OtCz1&#x2B;6eztf7OtBct5iJvO4FlwMd6k/bH/b6&#x2B;G37CngfT9b8f6tcWx1h2j03T7O3Nxe6gygF/LjyBhQy5ZiqgsozlgD8H/8AB0d4t09Phd8KdD&#x2B;1QnVZdVvL8WwceYIVhRC5XqFLOACepB9DXI/8FMtQ8bSf8FwfhTDoNt4OvtWt/D9mfC9t4xaQaG85W7IL7GU&#x2B;Z54OwggmVYhzgCvPy/IqFejQqzuuZVJPW11C1knbTfV6nq5rxNicPiMTQpJPllSjHS9nUvdtJq9raLTU&#x2B;3f2UP8AgsT8Hf2ufifH4J0mbxJ4Y8WXSs9npfiPThZzXwVS58tld0LbQW2lgxAJAODj4u/bN/4LtNa/tx&#x2B;BbHwb4m8R6T8LfCupxReNLIaXClxfywXjidUY5kaMxKoCq6hsnIrp/wBpb9iP9rr9qX4&#x2B;fC/x94zsvgZ4c1b4eanDJZ3ug6hdWs90PtEMqxu0xkLlWjOxQRzK/Xdwv/BU7yrf/guF&#x2B;y0z&#x2B;XHGzaUCTwpJ1aYfrkfnXZgcFl0cSnFKfNCTa5lJRaT68ut1az3T7nm5nmObzwbU5Ony1IJS5HFzUmunNpZ3UldqStsfot&#x2B;zL&#x2B;0X4d/ay&#x2B;B&#x2B;h/EHwn9uPh/xAJjafbIfJm/dTyQPuTJx88TY56YNec/tMfH341&#x2B;C/H82j/DP4QxeL9OsbJLu41a81SO1hkZi2YYkYoXdQvO1mPzDgcZ&#x2B;gI1VF2qAqjsBXz1/wUB/bTi/Zh8Dw6L4dhbWviZ4uBs/D2k2yedMJH&#x2B;QXDoMkqrfdGMu&#x2B;FHAYr&#x2B;b5xWpwozq87pxTvpZu3Rap3b0W12fbZpN0cDz16zhypXlFJNvsk1K13stX0uZHw1/4KbeH/Fn7E/iD4uappNxpd14UmfTtS0fzcsb8eWI4Y3IBKuZYvmK/LubIOw5xfgX/wAFDPGl58bPCfg/4sfDmPwKvxFszd&#x2B;Gry3vhcpMcbhFMvVXIIHOGVmQFAGyPn39rX9lDUv2Vv8Agklp&#x2B;j3jyXGu6h4otdd8Turbws0yOhQnuEIhTOcFgSOtew/8FH7qDXP2sP2TF0uSKaaTxUbqLyTn/RvPsGZhj&#x2B;EoDz0IB9K&#x2B;VeYZhCKlWlyypxpNxsvec5NO&#x2B;nRdrWdz5OWaZnCKnXnyypxotxsvedSbjK&#x2B;nRfy2tK5f&#x2B;Mn/AAUs8baV4/8AiAvw8&#x2B;GcXjDwZ8J5fI8TatLqIt3DpnzhCmMkR7XyQHwELEAYz9RfBP4uaT8evhPoPjDQ2lOl&#x2B;ILRbqFZRtkjzwyMASNysGU4JGVOCa&#x2B;H/wBhS6h0f9jL9qS11dlTUrHWdfOorKcOoNjt&#x2B;bPqySjnuDXun/BIW1uLP/gnr4AW4VlLC/eMN1CG/uSv4EHI9iK7snx2Iq14&#x2B;1ldVISlay91qaSSsr2s9b31Vz0shzLFVsTH20&#x2B;ZVISnay91xmopKyTtZ2d7u6ufQ2peJtN0e2uJrzULK1htcefJNOsaw56biThc&#x2B;9F14o02xks1m1CxhbUiFtA86qbonkCPJ&#x2B;bqOmetfn/4G/Zf8MftPf8ABR79oyw8YQ3Wo6LpqWcqaet1LDC9y8AWO4YIy7njXzAucgeaxxXgHgT4AaF4y/4JGeLPiVrH9oah4u8M6pFZaHeS3sxGkWq3dqvkRJu2BSZ5mPHV89hU1eIq8eZxoqyVRr3ulN2l9nr089zOtxTiYc0o0FZKq1771VJ2lpy6X6ee&#x2B;mp&#x2B;wes65ZeHdPe71C8tbG1jxvmuJVjjTJwMsxAHNOtdVtb1wsNxBMzIJAEkDEqcYbjscjn3r86/ifbr&#x2B;1b&#x2B;2F&#x2B;zf8P/AB9d3V54R1DwFa&#x2B;Ibqye5eJNWvntp3YsVIJJMKDOc43gEbjXSfsUfDDRfgx/wVt&#x2B;LHhfw7LK2h6R4UjSyt3uHn&#x2B;wI72Ept1ZiTtRnYAZ4GB1FdMM9nOsoxprkc1C99b8vNe1tum52U&#x2B;I51K8Ywpr2bmqd&#x2B;bXm5eZvlttbTc&#x2B;&#x2B;KKKK&#x2B;jPqgoorxDxf&#x2B;0fpvh/9tfw74Hk&#x2B;IWg2P23SZBL4Xk02V7y6unO6GQXQHlx/IpxGxBPo29SuGIxEKKTn1aW6Wr9Wvw17I58TiqdBRdR7tJapavRbtfcteyZ7fRXl&#x2B;neMvFK/tiap4fuLrSz4Pbwnbala25iYXgu/tUscjK2dpTbt3A9zFjHzZj/AGif2hJvh98C/GfibwPb6X421rwUy/bdMt7xWMWx42uI5NhJSRIGd9pGeBwehiWMpxhKpK6Ub&#x2B;um9ktzOWOpxpzqyulHmv393eyWr026nqlFeVfsefHjXv2lPhEPGOt&#x2B;FZvB9vq1z5mkWc03nSTWJhiKTs21c73MpX5R8m3r1Pp9jqVvqcTPbTw3CRyPEzRuGCujFXU4/iVgQR1BBFaUK8K1NVIbS1XTT0eprh8RCvTjVp7SV1dNad7PUmoqGPUbea/ltVnha6gRZJIQ4MkasWCsV6gEq2Ceu0&#x2B;hrg9S&#x2B;N5T9qHTPhvZ2tvNJJ4buPEmpXEk217WIXEdvbqiYO8yOZySSAoh7lgK6KdNzvy9Lv7i6laEEnJ7tL5s6nxX8RdA8C3Wkwa1rWl6RNr14NP05Ly6SBr65Ks4hi3Eb5CqMQoyTg1sg5r5Ci/4I3&#x2B;A/Enx917x9428SeMPHV1qHiqHxXplhqN6VtNJmTJaHylxFLG58tcFARHBEmcBi3rXw7/a8sfHX7ZnxC&#x2B;Dh0u7stR8DaVp&#x2B;rR3kuRHqUdyuZCgIHyxlol3AkFmYcFTntq4Wm43w0nPlV5aWS1S01u7N2f37Hn0MbWUrYyKp80uWCvdvRvWysrpXWr7bnsdcv8AGH41&#x2B;E/2f/A1z4l8aeIdL8M6HaELJeX84ijLH7qL3Zzg4VQWPYGvC/8Agpt/wULuP2CPh/oM&#x2B;ieEbnxz4q8SXE5tNKhd1EdpbRiS6unKI7bI1aMHjA8wEkBTn47/AOCo/hbxd&#x2B;2XpfwD/aI8H&#x2B;AJ/in8MbPRP7Q1bwe08rNAzHzZhIkRDt8oMZeMNhrcblZSFPXluTyrypzrvlpzbSd1q0tld6N2sm9LnBm/EEMNGrTwy56sEm42eibSu7JtpJ3aWtrbXP0W/ZY/a18E/tl/D&#x2B;&#x2B;8VeAdQudU0Gy1OXSvtc1pJbCeWNI3YokgD7cSLgsoPXivSq8T/wCCfXxX&#x2B;Fvxo/Zj0XXvhHo&#x2B;j&#x2B;HPDFwSs&#x2B;kWFnFZnS7wBfOgmjjAAlX5ct/GCrAkMCfbK83GU1TryhGLik7We69fM9fL60quGhUlJSbSd4/C79r30Ciiiuc7DyT9vz/kxH41/wDYha7/AOm&#x2B;ev5Yq/qd/b8/5MR&#x2B;Nf8A2IWu/wDpvnr&#x2B;WKv6E8GP9yxP&#x2B;Jfkf0X4J/7lif8AGvyCiiiv2g/bQooooAK/VD/g1n/5Lp8Vv&#x2B;wDaf8ApQ1flfX6of8ABrP/AMl0&#x2B;K3/AGAbT/0oavhfEr/km8T/ANuf&#x2B;lxPg/E7/kmcT/25/wCnIn7UUUUV/Jp/IYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXO6X/yVXXP&#x2B;wXYf&#x2B;jbyuirndK/5Kprn/YLsP/Rt5QB0VFfnD&#x2B;1j/wAHMvwd/ZB/aN8XfDPXvA/xL1LWPB18bC6udPt7JraZwqtlC9yrYww6qDXnf/EXr8Bv&#x2B;idfFz/wG07/AOS6CuVn6xUV&#x2B;Tp/4O9vgMB/yTr4uf8AgNp3/wAl1&#x2B;qvhrXI/E/hzT9ShWSOHULaO5RXxuVXUMAccZwaBWaKHxFa1TwnMb61mvbfzoN0MRIYnzk2nj0bDH2BrcHArH8ex&#x2B;b4YlX&#x2B;0m0n97D/AKUCQV/fJ8vBB&#x2B;b7nX&#x2B;L8K2B0oEFFFFABRRRQAUUUUAFFFFAGFqElsPiZpKtYzSXjaZemK8BPlwRiW03xEdMuTGwzziFsdTW7WJfqp&#x2B;I2lN/akkLDTrwDThnbdjzbXM55xmLAUZBP&#x2B;kHBHOdugAPIr4N/aM/4IAfC74u/Fa68aeD/EXij4X61qErz3MeiOhtDK5Jd40OGiLEnKo4TnhR3&#x2B;uP2kP2lPBP7I3wf1Tx98Q9bXw74S0ZoUvL82s90ITNKkMf7uFHkO6SRF4U4zk4GTXl/wAKv&#x2B;Cp/wAG/j1F4fm8C6t4h8XWfiDxCvhiO5svDd/FFZ3hh84ef58MZji2Y/eEFckDOeK7MHmGIwsnPDycW9/P1WzODMMqwuOgoYumpJaq/R&#x2B;TWq&#x2B;TPgf9j/8AYK8Yf8E1/wDgpE1x4u&#x2B;FeufGHwvqDr/Y3jvTbKa8fQjIxH2uSFS4EgztkDAuoG&#x2B;NiOH&#x2B;9P8Agof/AMEzvBP/AAUZ8JaLa&#x2B;JLzU9D1rw3JI&#x2B;matp2wzQrJt8yJ1cEPG21TjggqCGGWDeifsuftVeFv2vPAWpeJPCX9pLp2la3e6BP9utxDJ9ptJTFLgBmyu4cHPI7CvSs13YrPMTWrwxSfLUirXXX5bLzS0fY8zA8M4TDYWpgWualN35WlpfW11q7dG9V3Pzx1z/g3Q&#x2B;GvjTwTFa&#x2B;IvH3xF1zxR9pSWbxFd3cc100CIyJaokisqRDdu7tkD5sACvo39uz/gm58Pf&#x2B;CgHgvS9P8WrqOm6v4fYtpWt6Y6x3tnnG5MsrK8bFVJVh1GVKnmvVfjf8dvB/7Nnwz1Lxl488Rab4X8M6Qoa61C&#x2B;l2Rx7iFVR3Z2YgKqgsxIABNcH&#x2B;yV/wUG&#x2B;E37cc&#x2B;uRfDPxJea5L4djt5r9LnRL/TWiiuPM8iRRdQxb0fyZMFMj5DnFYVM5xs5xqSqO8b28r72&#x2B;7bY6aXDuXU6U6MKK5ZpKS3vba9&#x2B;qvvvc8K&#x2B;Bn/BFex&#x2B;G/wAa/CvjbxZ8Zfip8RrzwTdpe6NZ6vf7rW3kThchzIdo9EKflkV6B/wUR/4Ja&#x2B;C/&#x2B;Ch6eH77WNW1jwv4m8MblsNX03aziJmDGORG4ZQw3KQVZTnBwSD9O5rF&#x2B;IvxI8P/AAh8E6j4k8Va1pfh3w/pEXnXuo6jcpbWtqmQNzyOQq5JAGTySAOSKUs4xjrRxHO&#x2B;aOieisvRK34Djw/l6w8sL7Nckndptu7Wzu3fSytqcf8Asj/s8P8Asr/AbSPBMnifXPGMmlyXEr6tq777u6aaZ5TuOT0L7RkngCvJP2hv&#x2B;CWHh79oL9oK9&#x2B;JEnjbxp4b166SGNDpM8cP2YRwrD&#x2B;7bYXXKg55/iPrX1DZXsWo2cNxBIssM6CSN1PDqRkEfUVDrWrw6Bo93fXG7ybKF55Noy21VLHA9cCvGzDDUsd/va5tebtr30t3NsRlOEr0IYarC8IWsrvSystb30XmeGfD/APYA0Xw38FPGPgPxH4s8ZePNH8Zqi3D65fefPZ7B8phbHylWCuOD8yA4PSsT9m7/AIJk&#x2B;HfgN8UtN8Xal4s8V&#x2B;OtV8O2X9m6ANbuBJFotvgqFiUeisygcKoY4UHBHdeCv24fh/4y/Y6s/js19qGl/Du60o6y11d2Mj3FvbBipZoIRI5OR91Axrz74B/8Fl/2bf2nvizpfgbwN8RJNc8Ua1LJBaWX/CO6rbCR0jaVlMk1skaEIjH5mHTHUgHk/sjB80JcivDbfTW/zs9VfZ7ELI8CpQn7NXp/DvprfvrZ6q97PYqfHD/glJ4X&#x2B;MHxQ8ReILPxh4y8J2PjZ45fEmkaTcrHZ6w6HduZSOpbLHcGG5iQBk19KeA/A2l/DLwXpfh7Q7OOw0fRbZLOzt0JIijQAKMnknA5JJJOScms/wCNHxX0r4D/AAe8WeONc&#x2B;1HRPBujXmu6h9mj8yb7PawPPLsXI3NsRsDIycciqPgn49aF4&#x2B;/Z30j4nWH23/hGda8OQ&#x2B;KLcSxBbn7JLbLcruTJAfy2GVz14z3rbD5fh6FSVWlBKUt387/AC1106m&#x2B;FyvC4epKtQgoylu/nf5au9lbXUwfhl&#x2B;yrpPwv&#x2B;PPxA8f2mpalcaj8QxALy2m2eRbeSpVfLwobnPO4muF8Nf8E3PDHhj9jTXPgrDr2vSaFrt2LyW&#x2B;fyvtcbCaGXC/JsxmFRyvQmvWP2dvjxoX7T3wP8L/ABB8M/bRoHi6wj1KwF5EIp/KcZXeoJCn2ya1ta&#x2B;Kfhvw5480Xwvf69pFn4l8Rxzy6XpUt0i3moJCu&#x2B;Z4oidzqi4LMBhcjJ5FS8twrVnBfaX/AIHrL7yJZThGuVwW0112m7z/APAnufH/APwUK&#x2B;FXwb&#x2B;Hvhv4T2Pj7VvHPhm78OWJ0/RvF2gwlprJLRIFCXBRWILlgyFUyGVyCoyDy/8AwSf&#x2B;HVtrP7WHxK&#x2B;IXhex8TL4Ak0uLR9M1TXd7XmuzM8LzXLO2N7O8LyNj7vnIMDoP0FIDDsaXpXnyyGDxscVdJRaaSjrdRsryvquuye13oeXLhum8wjjbpKLTSUbO6jyq8ubVdfhT2Tbsgooor3j6UCcCvi/xt&#x2B;zleftSfG/U/iX4H8eaT4c&#x2B;KHgjxBeaPFbXVjBeW9ja2&#x2B;62CyRFS3mSAGYSsCdsyquAqkfaFcL4j/Zd&#x2B;GfjHxFcaxq3w78Dapq14&#x2B;&#x2B;e9u9BtZ7idsAZaRoyzHAAyT0FedmGD&#x2B;sxjFq6Tvu1r0aa1TR5eaZf9bjGDSaTva7i7rZprVNPY&#x2B;c7r9lD9qDVPH1n4jm&#x2B;M3guDVrTT59JW6g8PKWS3mkhkkGwoFZg0KEE9MEZAY13H7D37Dus/sj&#x2B;I/Gr6n4utfFum&#x2B;KI7RYwNKSxlDw&#x2B;cGeZVLLJI4lG6Qks5XLZNfQujaNZ&#x2B;HdJtrDT7W2sbGzjWG3treJYoYEUYVUVQAqgcAAYFTzTLbwtJIypHGCzMxwFA6kmsqOTYenVjX95yV2ryk91Z7u2q8jDD5DhqVaOI95zjdpucpWbVno3bVeXRHL/A/4ZR/Bn4T6H4WhkE0Gh2/2aIjOAgYlVGeyqQPwrF&#x2B;AP7Nmjfs73vjKbR7rUrhfGmvT&#x2B;ILlLubzPs80wXeiH&#x2B;7uDNk5b5sEnANdB8O/jD4T&#x2B;Lqao3hXxJofiNdFuvsN&#x2B;2m3sd0tpP5aS&#x2B;W5QkK3lyI2D2YGukzXfHDUlyWXwaLy0t&#x2B;R6ccJRXJaPwK0fJWt&#x2B;R5/pP7Omi6J&#x2B;0nqnxQt7jUv7c1nRU0S6gafdamNJFdXVD91vlxwcdTgEsW&#x2B;Yv8AgqB/wTx&#x2B;K37Qnxh8LfFL4H&#x2B;Po/BPjrQNJfQrsSX09it7ZmVplVZYlbo7vlHXa2VOQV5&#x2B;3c5orty6u8DV9rh0ru901dO&#x2B;915nJjMow2JoSw800pPm0dnzXvdNbO5&#x2B;TY/Yn/4KOKP&#x2B;S06b/wCFA3/yNXsX/BOz9l346fs7ftV6l49/aK8deGNauPEXh9fCei3D6wsl1cTfaVuUtkDRx7vlSdgoJb7xAxmv0CrF8f8Aw48PfFbw1JovijQdG8SaPM6ySWOqWUV5bSMpDKTHIrKSGAIJHBGa9mrn9WrB0pwhFS0bjFJ28meTR4Vo0Kka9OrUlKLulKbcb&#x2B;aPhD/gvH8NtY0Lwr4T&#x2B;L3hv4raX8M9c8EWt/poivLiWJ9chuljLW9uI0dpJW8vHllChDbmZAhNfMn7LH7EX7eR/Z28Hy&#x2B;CfiRa&#x2B;FfCV5psd3pWlT6y1vJaQTfvVDR&#x2B;Q20nfuxkkbvwr9NNT/4J0fB3xF8ULjxTrHgXwzrtxLbLax2OpaLZXVjaKMYMUbQkoeOx7mvYde8RaX4K0SS&#x2B;1S&#x2B;sdJ061Cq9xdTJBDECwRcsxCjLFQPcgVvSz/6vhIYalFTt1lFab2S9G3q310Oatwr9bx08ZXnKnfRKE2m3om29ldJaJdLu58af8Edf2IPi1&#x2B;x1P8VLr4ralouo3vjrUbPU4X028MyvOouPtErr5aKruXiJIHzbeelfbVZ&#x2B;l&#x2B;K9O1rWtS061u4bi80do0vYkOTbNIgdFY9AxQhsdcMp6EZ0K8PHYyeKrOvUtd220WiS/Q&#x2B;ky3L6eBw8cLRu4xvu7vVt6v1YUUUVynceSft&#x2B;f8mI/Gv/ALELXf8A03z1/LFX9Tv7fn/JiPxr/wCxC13/ANN89fyxV/Qngx/uWJ/xL8j&#x2B;i/BP/csT/jX5BRRRX7QftoUUUUAFfqh/waz/APJdPit/2AbT/wBKGr8r6/VD/g1n/wCS6fFb/sA2n/pQ1fC&#x2B;JX/JN4n/ALc/9LifB&#x2B;J3/JM4n/tz/wBORP2oooor&#x2B;TT&#x2B;QwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACud0r/kqmuf9guw/9G3ldFXO6V/yVTXP&#x2B;wXYf&#x2B;jbygD8b/8Agob&#x2B;3n&#x2B;wn8M/21viNoPxK/Zn1/xh460zVTDrOswrD5eoT7EJkGbpD0IHKjp0rxj/AIeWf8E2/wDo0PxN/wB8wf8AybX3D&#x2B;2D8C/gL4k/aa8ZX3ib9hH44fErXrm/L3vifSNNEljrMm1f30Tf2hHlcYH3F6HivNf&#x2B;GcP2af8ApGz&#x2B;0V/4KR/8tKDS6Pmc/wDBSz/gm3j/AJND8Tf98wf/ACbX9A3ge7tb/wAF6PPYwNa2M1lDJbwnrFGUUqvfouB&#x2B;Ffkj/wAM3/s0/wDSNn9or/wUj/5aV&#x2B;unheKGDwzp0dvaS2ECWsSx20ow9uoUYjbk8qODyeRQTIq&#x2B;PGRfDMnmae2qL50A&#x2B;zLnLfvkw3AJ&#x2B;X73/Aa2Ky/GYmPh&#x2B;T7PfQ6bJ5sOJ5WCqo81Mrk/3hlR7sK1KCQooooAKKKKACiiigAooooAxb9wPiLpa/2W0xbTrw/2jzi0xLa/uOmP3ud3JB/0c8HnG1WPerJ/wn&#x2B;mMNSiih/s&#x2B;7DaeW&#x2B;e6bzLbbMB3EY3KT2M6&#x2B;tbFAHwz/wcfKzf8EhfiQEbaxvtECsRnB/tiz5xXK/tLS/HD4C/Fr9lfSPHfxfPi&#x2B;&#x2B;8TfF1La6uNB0lvDdvc6ebF/8AQ7iCKeRZ18xWf5zg7gNvy5r70&#x2B;I3wy8N/GDwlceH/F3h/Q/FGg3jI8&#x2B;m6vYxX1pOyOHQtFKrIxV1VhkcFQRyBR4r&#x2B;Gfhzx5qejXuueH9F1m88OXYv9JuL6xiuJdLuQCvnQM6kxSbSRvTDYJGaB3Pxb&#x2B;Ap8QeKfDfwH8EaX408Z&#x2B;DtH8dftAeOdO1xvDmsT6bNf2o3O0TPEwPIDAN95C25SrAEXvhmPHXwo8O/CbxtH8YPi5rWoaL&#x2B;1Snwmt7XVPFFzcWMvh37bcRPbTwlts0j7TmWQM2CqjCogX9fNJ/Zq&#x2B;HOgXGlzWPgHwVZy6HqM&#x2B;r6c8Gh20bafez8T3UJCDy5pMnfIuGbPJNSH9nP4etp9vZnwJ4NNrZ67/wlMEJ0W28uHV9xf8AtFV2YW73MzeeP3mWJ3ZNA&#x2B;Y&#x2B;M/8AgvLe6b4Zsv2b/EnjS1a7&#x2B;E/hv4sabd&#x2B;MA8ZltbeIxyrBPcpyGgRy24EEHcFwSwBP&#x2B;CvP7auj337PHgWx&#x2B;Gvxb0nTdF8VfETw74f8beJfCevwPeeG/D968/mXXnwuTbKxiCrKSB94AnJr7v8AFHhXS/HHh680nWtNsNY0nUIzDdWV7bpcW9yh6q8bgqyn0IIrzzwX&#x2B;w58F/hx4W17Q9A&#x2B;Evw10bRfFSJFrVhZ&#x2B;GrOG21ZEJKJcRrGFlVSzFVcELk4AyaAufmn4n/ansf2V7X9p74f6R47&#x2B;JnxM&#x2B;EujXnhOx8O6jZ&#x2B;O2XUNI1XUpD9o06PXHLtDbt5QMjZYwqzrwzlq8j&#x2B;O7a14&#x2B;/4J9ftueCdV8Ua3daR8JNV8N6xo2n6f8Rr3xZa6fLcxbLmzfUJY4pLu3DFnaCRCkcyd2j3V&#x2B;y2ifshfCnw18I77wDp3w18B2PgfVHMl74fg0G1j0y8clSWktwnlu2VU7mUnKjngVN4W/ZV&#x2B;GHgfwnq2g6L8OfAuk6Hr1nHp&#x2B;p6fZ6DawWupW0auqQzxqgWWNVkcBXBADtgcnIHMflD&#x2B;034o8Wap&#x2B;0X4J&#x2B;E3gvxl4q1bwNpvwgTXPC94fjPJ4Za81GW7nWXUn1BhIb&#x2B;S1KhFgdsIqE425q94u&#x2B;I/iP4ufFt9F&#x2B;PPx01r4eSeB/2f9N8S6Fd&#x2B;G/F32LTfEepyLILjVw0bCLUNxRQIxuR1YgLgnP6c&#x2B;IP2Ffgr4s8AaH4U1T4R/DbUvDPhjf/AGPpV14bs5rPS97l5PIiaMrHvYlm2gbiSTnNafjf9kf4V/EuTw23iL4a&#x2B;A9dbwfEsGhG/wBAtbj&#x2B;xolACx2&#x2B;9D5SDauFTAG1cDgUBzHi3/BD7n/gk38DP&#x2B;xcX/0dLXjH7J/xV0/4GfDv/goJ4y1Q6wun&#x2B;GPiV4i1K4OkuI74JFpVsx8hjwsvHyseFbBPANffvgjwLonwz8J2Og&#x2B;G9H0vw/oelx&#x2B;TZ6dptpHa2lomSdscUYCIuSThQBzVLSfhF4T0G28QQ2Phnw/Zw&#x2B;LriW71xINOhjXWZpUEcktyAoEzugCs0m4soAJIoEfiv4K&#x2B;NPiAz/H3wvHresR&#x2B;EvGX7KviHxfJ4fvvilc&#x2B;PntrsxbYbqaeaJFtrp4Jm3wxF1wVbOCoGv8Asi&#x2B;LbX4cH9mrT/Afxi8V&#x2B;Ol&#x2B;J3wU18fEDw5d&#x2B;Im1Kw0IWWiq1oUtdxSz8m4VrRQAuVhI6ly36y&#x2B;Dv2KPg38PdKurHQfhP8N9Gs76xutLuYLLw1ZwR3FpdbftNs4WMBoZtib4zlXCLkHAqx4A/Y&#x2B;&#x2B;E3wo13UtU8L/AAx&#x2B;H/hvUdZsxp1/c6Z4ftLSW8tcBfIkaOMFosKo2H5SFHHAoHzH40&#x2B;CviP498WeGP2YfhhZ3etx&#x2B;Ev&#x2B;FDQ6/ptjZfE1/AEd1qrXksL3Ju1RvtMlvFHGy256b2c5XcD6rB8OtS8R/t&#x2B;fsN&#x2B;IfjD8QNSj8VeIfBWqPqOr6R40ddL1K5sooTbvbTROIit2nlvMsfyz&#x2B;ZhgRgV&#x2B;nvjf9jX4RfEvwLovhfxD8L/h7rXhvw2uzSNLvfD1pNZ6UvA228TRlIhgAYQAYGK0PF37MPw38faN4Z03XPAHgvV9P8FyRy&#x2B;H7W80W3mh0NowojNqjIRDtCIBsAwFUdhQHMfn7/wS/wDiDrXwq/4KJa58M/iR4g1/x94/8SaNqniLT/GGl/EafXPDmtac18pjD6WW8uwlhVVjQquMB1HDAn9PK4H4Tfsq/DH4C&#x2B;IdU1bwP8PPBPg/Vdaz/aF5ouiW1jPeZbcRI8SKzDd82CcZ56131BLCiiigAooooAK4z9ov4l&#x2B;E/g78BvGHijx19m/4Q3Q9IubrWUuIRPHNarG3mRmNuJN65QIfvFgveuzqj4l8Mab400K60vWNPsdV0y9Ty7i0vIFngnX&#x2B;66MCrD2IoA/Pv9kb9uvwL4s/4Js/tFeOdB8I6P4e8E&#x2B;BzdrYeHvCN7HaSR2C6DYmKP7XbIgjuSxkjaVC3kvGwV3WJWPnvwX/AGmGf9lz9k34lW2sfETQ9D&#x2B;HmpeJPBnirRNH10eI7jWprfR724ijadcpfeZJpkLQFMoTdIq8bSPpj9p//gir8Jf2mvGUGsR6t8QfhsI9Kj0abT/AmspomnXlvGZPLEtusTRkqJXUEAfKcEHFeR&#x2B;Hv&#x2B;DZb4I&#x2B;E9Lt7DTPiL8f9P0&#x2B;0uvt0NpbeLooYY5&#x2B;nmqqWwCvgkbhhuetBWh6F/wRZ/be8D/tGfsVapeaHqHxObSfhtqN3Yapq3xFvY7rUnHN2XkuUYoyRRSqmMJsWMAqBgn6A/ZH/bO8DftteCdY17wLdalNa6DrE&#x2B;iX0GoWEljdW88W1gWhkAdVkjeORCwBKyDIDBlHy/Y/8G53wC0jWD/Z&#x2B;r/FvTvDNxIkl/4VtvGM6aLqpCKkv2hMGV/O25kxKCcnG0YA&#x2B;g/2Kf8Agnn8O/8Agn9pXivT/hvFrlnp/i2&#x2B;j1C4ttR1KS/W1eOIRIkTSZk2BFUYd2PA5oB2PTfFvxh8NeCPhr4i8Yajq9pH4c8J297dareo3mR2aWYc3O7bk5j8twyjkFSMZ4rxX9rL/gpv4K/ZmW303RtF8XfFzxteWSapH4U8Cac2sapFYMARezqnywW5BG13ILlgFDckfNfhHxl&#x2B;2J4B/Z/k&#x2B;Al5&#x2B;zD4f8ZXn2C48PT&#x2B;Pp/HVpHoOsxzh0l1O5tWT7QTJ5jySxffdmc4BbbU3gr/AINmfhD4U0eRV&#x2B;KHx&#x2B;t9Q1KCJNWlsPFkdtHqEiRhMsotySo5CqxbapxmgNOp7/8AsdftX3f7Qv7VfxCihvrm48G6x4I8H&#x2B;N/CEUyeW8FlqUF6JAy5IDmSAMeTy2P4RXhX/Bdn43&#x2B;ELL4X6fDZeCdC&#x2B;JvxA8FeJLWwh0nWNKvdVsbB7&#x2B;xuLiFZbS3IWZrv7KttEXBEckwcFSgNfRXhr9mOD9iLw7B4g&#x2B;HPhfW/iFqWh&#x2B;DND8CRaVJqttbX0mlaSLwwGF5FSGS5Zrs7xI8SsFBDKVCP882v/BN7xh/wUv8faz8WvjpcfEP4E6heQwaN4e8J&#x2B;DPFEdtd2&#x2B;mW7zuk2pzxo6TXEklxIyouBEmF5LNgDQ9w/YP&#x2B;OUvxs&#x2B;NfxI1NtPt9Os/EXh3wf4x06AW6xzwW2o6W4EUrAAyMklrKMtyBxwBivqCvMv2ff2VPDv7N5h/sO41K6a38L6J4RSW9lWSV7LSY50ti7Kq7pD9plLNgZLcADivTaCQooooA8k/b8/5MR&#x2B;Nf/Yha7/6b56/lir&#x2B;p39vz/kxH41/9iFrv/pvnr&#x2B;WKv6E8GP9yxP&#x2B;Jfkf0X4J/wC5Yn/GvyCiiiv2g/bQooooAK/VD/g1n/5Lp8Vv&#x2B;wDaf&#x2B;lDV&#x2B;V9fqh/waz/APJdPit/2AbT/wBKGr4XxK/5JvE/9uf&#x2B;lxPg/E7/AJJnE/8Abn/pyJ&#x2B;1FFFFfyafyGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzulf8AJVNc/wCwXYf&#x2B;jbyuirndK/5Kprn/AGC7D/0beUAfCP7VHxd0fQv2hvFlncf8FDrX4VzW96Vbwm1joTnQjtX9zmdDKfX5zn5q4D/heeg/9JTbL/wXeG//AI3X038b9M/aQl&#x2B;LOut4S&#x2B;DP7O3iDw21yfsGo67rtzDqN3HgfNMi2bhWzkYDHgDmuV/sn9rL/ogP7Kv/AIUd3/8AIFBR4cfjnoP/AElNsv8AwXeG/wD43X6heHJBN4esHW8/tFWt4yLvA/0rKj95xx83Xjjmvi46T&#x2B;1lj/kgP7Kv/hR3f/yBX2tpAmGk2v2mOGG48lPNjhO6ON8DIU4GVB4HA4oEzN&#x2B;IT2qeFpDeWs15b&#x2B;fb5iiJDFvOTaeOythj7A1tDpWb4u&#x2B;3HQn/ALOuILW682HEk2NgXzU3jkHkpuA46kdOtaVAgooooAKKKKACiiigAooooAwdQe1HxN0lWsZpLw6XfGK9DHy7eMS2m&#x2B;IjplyY2GeQIWx1Nb1ZN4L7/hONP8u8t49N&#x2B;w3Xn2hI86aXzLfypF4ztRfNBwQMypweMa1AHJ/Gv4z6L8BPh/ceItc&#x2B;3SW8c0Fnb2tjbNdXmoXU8qwwW0ES/NJLJI6IqjjJySFBI5f4Q/tceH/ifqmq6Tqmma/8P/EuivZi60TxVDDZ3my8d47SSNo5ZIZkmkjkjUxSud8bIQGGKuftSfBXUvjh8N7S00HVbXRPE2gaxY&#x2B;INFvLu2N1ax3dpOsqpPErKzxSKHjbaysFkJUhgK8Duf2XPi98ZfiP438VeNI/Cmj&#x2B;LNNv/C58JNYSPNoV3ZaXfnUnSRy32oTSzSTxSM8KLGogMYlxJkGfS/in4&#x2B;eBfA0MMmteNPCejx3F8&#x2B;mRPfavb26yXafft1LuMyr3QfMPSucT9sn4dah4j8RaLpXibTdc1zwjr1h4c1nTrK6ia50&#x2B;6vJ7WCPerMuUV7uIMyk4YPGMyIY6&#x2B;cfE/wDwTM8aeLLiTVtX1rwxrmpazP4pi1nSlv8AVNJ06az1ue1maJJbWQSt5X2VY3RwVnVsnyioI9R1r9jzxBc&#x2B;IPGVlZalo0fhfxJ4x8J&#x2B;MbVpmnkvrWTR5tF822fdkSLJDpAKyFt2&#x2B;b5gQNxA0PWx&#x2B;0V8Pzca9CPHXg8zeFZFi1pP7Ztt2kO0nlKtwN/7kmQFAHwSwx14qrY/tL&#x2B;Cdeg0O60bxFoviDSdeu7myi1TTNRtrqxgkt7eW4l8yVZMDakTZC7iDjIAyR8V/tH/APBPb4tah4A8Ya1qmv6f468QalpcWgwqI729bUTL4j069FzJaPIIIIY4YHD29sqrhXYu2/5PZJP2FPFvjHxXrfijXtY8N2OueJNfvtYurLTI5nsbZJPDT6HCqM4VpJeUlkkZVyAEA&#x2B;QEgHvGlftI/DvXfDOsa1Y&#x2B;PPBl5o/h5gmq38Gt20lrpjHoJ5A5WIn0ciuk8KeLdK8d&#x2B;HbTWND1PT9Z0nUE821vbG4S4t7lP7ySISrD3BIr5T&#x2B;LX/BNTUfGnhyzg0fXdL0q40XQfBVhp8KLcW9vLP4evb652yNA6SxxyLeBUaNt8TIHAbaFPu37LHwSj&#x2B;AHwgh0EWNlp9xNqF/qt5Daajd6hD9ou7uW5lcTXTGZ2ZpSzFsAuzkKoIABHo1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc9q3iXVL6/sV8N2&#x2B;i6pb2&#x2B;pfZNae61CS3eyiEZLGEJDIJZlYxjy2Ma4LZcEYPQ14Dqf7KvxO0fXdXXwf8d9Y8OeHdW1K71RdPufC&#x2B;nalPp0l1O9xMkFxIqny/MlkKCVJSoIXJUAUAdVcftleA47Tw9cR6lNNa&#x2B;IfElz4VWXyDH/Z95BJdQv8AaUk2vEnn2jwhivLyR/wtuHK6P&#x2B;0tb&#x2B;Kf2v7bT7XxBc2Xhew07WtD1CxvkghtZdWtm0a6gmgl&#x2B;9JvtL6Uj5yu1DhVKvnjtJ/4I8/Ce5&#x2B;IK&#x2B;IPFml6D8Qbl5TeX03iTwfoN9fa5dyeebia9u2svNkDvMjqkZjWLyUVAI/3Y77wb/wTq&#x2B;EPhj4BxfDm98A&#x2B;BPEPh&#x2B;O/l1Yw3/hDR0hlvXBRbprWC1itfPWLbEJFhViiKDnnIPQxPjr&#x2B;1r/Z&#x2B;seNYfD/AIqtdFh&#x2B;F&#x2B;nQa1rlt/wj41S/1m3kxPGdPb7VHG6Olve27AoXEiZBXaC8P7Wv7XuvaRo114Z&#x2B;D9tpev8AxAuNLttcsvtd3b29rdae10ILo2ss0iwvdwq0b&#x2B;VMyJ&#x2B;/iOW5Sqnwt/4JCfAPwNpk6638L/hf4yvboRNJPqHgDQbeOF0iSN/Jjt7OPYjspcqxfDMcEDiovh1/wR&#x2B;&#x2B;BPhLW9Svta&#x2B;Gvww8Ufbiyw2lz8PdAt7Wxj86V08tYbNXLhJFjZndgwiU7Qckg9DrP2CfiNbePvhxqouPG3jrxZ4otr4Sa5Z&#x2B;MLWystV0GZ4122/kWcMUKwEIWjePzEky5WWQZI92rh/gx&#x2B;zH8N/2cE1Ffh78P/BfgVdYMbX6&#x2B;H9EttNF6Y93lmXyUXft3vjdnG9sdTXcUEhRRRQB5J&#x2B;35/yYj8a/&#x2B;xC13/03z1/LFX9Tv7fn/JiPxr/7ELXf/TfPX8sVf0J4Mf7lif8AEvyP6L8E/wDcsT/jX5BRRRX7QftoUUUUAFfqh/waz/8AJdPit/2AbT/0oavyvr9UP&#x2B;DWf/kunxW/7ANp/wClDV8L4lf8k3if&#x2B;3P/AEuJ8H4nf8kzif8Atz/05E/aiiiiv5NP5DCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK53Sv8Akqmuf9guw/8ARt5XRVzulf8AJVNc/wCwXYf&#x2B;jbygD8bv&#x2B;Chv/BEb9r39or9tb4jeNvAnjrS9N8I&#x2B;I9VN3pdrJ4vvLRoYtiDBiSMqnIPANeMf8Q7v7dX/AEUbR/8Awur/AP8AjdfUP7dP7aP7Evw&#x2B;/a58eaL8RNa/aDt/G2n6kYtXj0TxJrFvp6TbFOIY4bxI1XBHCqBnPFeTf8PAv&#x2B;CeP/QwftRf&#x2B;FZr3/ydQaJs83P/AAbvft1Y/wCSj6P/AOF1f/8Axuv6BvA&#x2B;l3Gh&#x2B;C9HsrxhJd2dlDBOwbdudUVWOe/IPNfiCf8AgoF/wTxH/MwftRf&#x2B;FZr3/wAnV&#x2B;4Hg&#x2B;5tb3wjpc1iZmsprSJ7cysWkMZQFdxJJLYxkkk5oJlfqU/iU9gnhGQ6mtw9n9otsiDG/f8AaI9nXtv259s1vCs7xX/aH9it/ZawteebFgS/d2eYu/8AHZux74rRFBIUUUUAFFFFABRRRQAUUUUAc/qUunj4qaMkkVw2qtpV&#x2B;1tIp/cpCJrPzVbn7xYwleOiv079BWbdDUv&#x2B;EwsfKMP9j/Y7j7SD/rDPvg8nH&#x2B;zt8/PvtrSoAKKKKACiiigA60UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVj&#x2B;IfiH4f8ACN2lvq2uaPpc8ieYkd3exwuy5IyAxBIyCM&#x2B;1bFeI3Xw28O/EL9trxd/b&#x2B;g6LrgtPA&#x2B;g&#x2B;QNQsYrnyd1/rW7bvU7c7RnHXA9K2o04yu57JX09Uv1OfEVZw5VBK8nbX0b/Q7rxL8Svh34y8Oaho&#x2B;reIvB2paXqttJZ3lpc6hbyQ3UMilJI3UthlZSQQeCCRXjv/AAyF&#x2B;yP/ANCF8B//AAA03/CvWNb/AGc/h7baNdyR&#x2B;AvBayRwuykaHa8EKcfwV&#x2B;PP/BD/APaB8SftOftwx&#x2B;GPHn/CPeI9BbQb26NnP4c05EMqGPa2UgU8ZPfvX0GV4erPD1q&#x2B;GqyhGmk2k2r79vTqeXiuKsbleJoYOEnF120uVtK6tvqu/mfp94d/YW/Zc8X3TwaT8L/gvqk8aeY8dppFhMyLkDJCqSBkgZ96/JX/AIOK/gL4J/Z//ag8Eab4H8J&#x2B;H/COn3vhYXNxbaRYR2cU0v2u4XeyoAC21QMnnAFfrhpPw78P/D7/AIKE6HHoOhaPocdz8O9UaZdPso7ZZSNS07BYIBnGTjPrX5d/8HRP/J3fw/8A&#x2B;xPH/pbc19p4cYzETz6lCdWUoyhJ2k2&#x2B;j6Xt0P2nwjzjHYnP1TxNSTspq3M2vhvfX1PzLooor&#x2B;kj&#x2B;qwr9UP&#x2B;DWf/AJLp8Vv&#x2B;wDaf&#x2B;lDV&#x2B;V9fqh/waz/8l0&#x2B;K3/YBtP8A0oavhfEr/km8T/25/wClxPg/E7/kmcT/ANuf&#x2B;nIn7UUUUV/Jp/IYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXO6V/yVTXP&#x2B;wXYf8Ao28roq53Sv8Akqmuf9guw/8ARt5QB&#x2B;Vv7c37Lv7FnjP9rfx3qnxC&#x2B;FP7RGteNL3UjJq19oegazcadczbFG6F4V8tlwByvGQa8o/4Y2/4J9f9EV/ap/8ACY1//wCJr9y6KCuY/DM/sbf8E&#x2B;sf8kV/ap/8JjX/AP4mv268HwWtr4S0uKyjmhs47SJIEmBWRIwgChgeQwGM55zWlRQJu5g/EmOxl8JSLqU08Np9otiXhGXDefHsHQ8F9oPsTW9WX4xN4ugP9hs7e&#x2B;ufNhxDMAUK&#x2B;am9uSOVXcw56qOvStSgQUUUUAFFFFABRRRQAUUUUAc9qUenn4raK0j3A1ZdJvxbIuPJaAzWXnFuM7gwg289C/XjHQ1lXbX/APwm2niO1t30v7Dc/aLlsedFN5lv5SLznay&#x2B;cWwDzGnI4zq0AFFeZ/ti/tAx/su/s1&#x2B;K/G3l2s99pVqItMt7qXyobu/ndYLSJ2/hR7iSJWb&#x2B;FSx7V86/CP8A4KO&#x2B;Ibv4XeHdB06Pw78VviNJ8RZfhzd341EaNp13nT7zU7XVCYoJsRvaW8QdI4&#x2B;JPOVcmPaQD7Wor47i/br&#x2B;J3jHxDoUll4O8J6R4fuvBPivVdaB8Ryyajp&#x2B;o6Lfw2M4ts2JiljSZiIy&#x2B;3zVlLsIjEI5rHhj/goh4tktRdt4F02&#x2B;8K&#x2B;Gm8L2niDWbjxKI9SkfWbaxdZYLOOz8uQxPervDSQhlXMYLHy1AsfXlFfInhf/AIKjXEHg&#x2B;81rxh4Jt/DK2c2uWlxpi6tNLq2l3ljZC&#x2B;trG7t5bSLZcXVtHeSL5TSxkQxGN5xNlM74&#x2B;/tp/EzXfgD8RvEHhfwrpeg2fgnV7Lw/9rXxAZNTudWj1Cwiu7aOA2vlC2JmmhE7yh227xEqsDQFj7Mor5dtv25/HV74v/4V9D8PfC5&#x2B;Ky&#x2B;I7zRJLJ/FU66AkNtpdhqb3IvvsPnHMOpWiCL7LuMhk52IXPmni/8A4KVfELxH4O&#x2B;IHinRfC&#x2B;h6V4N8O/CC/8AG6P/AG2f7cs7&#x2B;2&#x2B;3xSRqj2Uts4FzZtGpYshQCbD7vJAOx920V458Af2h/Evx1&#x2B;IHiSOz8M6Ta&#x2B;B/C&#x2B;oT6C&#x2B;r3Ost/at9f26x&#x2B;cVslt/LWAO7KHacO2zcIwrKT7HQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiuA/aL&#x2B;LN58FfB2n69DoviLWtLg1OFNYXQtLl1TULW0KvmWO1iVpZh5giRxGrOscjuB8mQAbVj8VtI1fxboelWE39or4i0q61myv7RkmspYLeS1jbEisQSxu4yuMggOc8cy6x8QbW08N6drGniHWNL1CeBPtdtewLBHDKwX7R5juqsgyDhCWbPyhjgV8229n46/au8Sa54v&#x2B;F&#x2B;oeIPhhYR6QvhnTpPHPhC7gUxy&#x2B;Y11c2Vg81rcQspWxKSTAK5icbCMMM/4F/wDBPX4jfs7fs2&#x2B;KPhnovjj4fa5oGu6xdXENjrvhO5m0210&#x2B;5jJntYraK9j8gGZiwRXaMfOQql8IDPePCv7R8Xij4uN4Q/4RrXrO4jn1WCS8la3&#x2B;zJ9h&#x2B;wkP8spfbMt/GyfLkeW&#x2B;4KNpbotA&#x2B;M/hnxR4l8RaTY6pHPdeE1RtWbynW3sixlG1pioiLr5L7kViyAKWChlJ8X&#x2B;A37Mfxc8GfFu01/xt468B6/ZR3b39yuleHLuxvbmU6Zb6fgyy3sy7CLaKVhsyXHBA4rS1H9nj4rad8bPiP4t0L4haCln4rhtLfS9D1rTb3UtLtRGkSSNJbi7jVHKJKuYPLDmXdIH2KAAeweCviFZ&#x2B;OtQ163s47lG8PagunTvKoCTO1tBcq8ZBO5DHcR4PHORjitDR/FGm&#x2B;IbzUrew1CzvbjR7n7FfxwTLI1nP5ccvlSAH5H8uWJ9pwdsinoRXzd4d/ZX&#x2B;N3w08Iw6L4L&#x2B;JXw28P2sr2d5cmXwXd3RimtkgiFrbgaiipZPBaww7GDSJG0mJC20ryXjj9jP9pzx/wDEzRfFl18ePB9jqGgajDe2lnpmg6xY6UYUcM9rLZx6qIriOVQUZrgSyAMdjRnbtBH2ZRXjn7LfwO&#x2B;JHwk8TeMtQ&#x2B;IHxMh&#x2B;IQ8TTW93aRQ6TLpsWkyKJRMkcb3M6rEVaFESPYAsAZ/MleWaT2OgAryvwz/ye142/wCxH8P/APpfrdeqV5X4Z/5Pa8bf9iP4f/8AS/W66KPwT9P/AG5HJifjpf4v/bZHwX8cv&#x2B;C1vxM&#x2B;G/8AwUg8afDKx8BweLvAnh0zWc9hpVpJJrQhithJcXaOGKts&#x2B;d9hQAouMqfnr5P/AODcb/lI5D/2LOofzir2D4FDd/wch/ED/rtrf/ptevH/APg3H/5SOQ/9izqH84q/TPq9CjlteFGCjejBt921L/L53Pxr61icRm&#x2B;GqYio5JYipFJ9EnDZ9tdultNz9kNZ/wCUh3hz/snWq/8Apz02vyj/AODon/k7v4f/APYnj/0tua/VzWf&#x2B;Uh3hz/snWq/&#x2B;nPTa/KP/AIOif&#x2B;Tu/h//ANieP/S25rPwz/5H9D/r3L9T&#x2B;rfBv/kpH/2//wCkI/Muiiiv6cP67Cv1Q/4NZ/8AkunxW/7ANp/6UNX5X1&#x2B;qH/BrP/yXT4rf9gG0/wDShq&#x2B;F8Sv&#x2B;SbxP/bn/AKXE&#x2B;D8Tv&#x2B;SZxP8A25/6ciftRRRRX8mn8hhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc7pZ/4uvri9/7KsD&#x2B;Hm3n&#x2B;FdFXLTXJ0P4xJ5qN5PiDTFgil6LHNaySP5ZPdnS4dlA7W8h7UAdTRRRQAUUUUAYvxCW3fwtILq&#x2B;l06Hz7fM8YJYHz49q8c/M2FPsxraFZPjYyDw7J5Wnx6o/nQf6PIMqw85Mt/wAZce61rDpQAUUUUAFFFFABRRRQAUUUUAYOopZn4n6Oz3s0d&#x2B;ul3whtAp8ueIy2fmSE9NyMIwAecStjocb1Y96Z/8AhPtN26bDLb/YLvfflR5ls/mW22EHqFkG9iO5gX0FbFAGZ4k8GaV4wl019Usbe&#x2B;bR71NRsvOXd9nuEVlSVR/eUO2D2znqAax9Y&#x2B;BvhHX/AIg23iy88PaXceJLOW3mh1F4R58ckEd1FC27&#x2B;8kd9eKpPIFxIO9Vv2hNN1rVPhNqkfh/VPF2k6ogSSKbwvDpsurOFcFo4BqKPabmGQTKvAJwQ2DXw/8AD79s/wCLXjDwl/wkVx40uLZvhnZ&#x2B;HW1LSTpFkreLJNQ8Q3&#x2B;m3MV9mHdDcRQ2YhAs2ijW8Wc/vYgiUDPtbVf2Xfh/rT6W1x4V0tm0Z9RezKoUMP8AaEhlvV&#x2B;Ujcs8h3urZVmCsRlQRyfhv9gX4b6H8XtU8ZT&#x2B;H9N1DUrm806705ZrYbNJFjZwW1siAHDiLyBJHvB8t2LJtPNcf&#x2B;054/8AiB/w2Z4A8IeF9c8faboF1oN1q&#x2B;pW/hfT9EuDM0d9Zwhrp9SQstuElkDfZyJOcgZArhrv9t7xN4K8Q3XiCSPUfEllpGkeM/8AiSyXMFt9vnsPF8OlW37xIVVNsRKqSpO1vnZ23SEA9j8Y/sC&#x2B;BPEcHh/TbHTLDR/D&#x2B;l&#x2B;KLXxhqNnDaiWbWL&#x2B;02m0LzyMWVI2RAVAO5EEYKpuU9jr/AOyz8PfFHi/VNevvCmlXGqa4sQ1GUoVW&#x2B;aJ4njeVAQjyKYIcSMC4ESDOABXlXwr/AG2fG3iP4zab4V8WfDfQ/D9vc&#x2B;KrvwTcX&#x2B;neK31PZqkWkzawhijaygL2rWcWDKzRyLMSnksg80u1PxH46/aD/a78eeDdH&#x2B;I2ofDfQvhfb6TKLXRtOsLrUNflvInnM1w97BOq2gCeUqwojs8c5MowqgDU9Y8c/sz&#x2B;A/iVb6hHrnhfS75tU1NNZuZShjma9W1jtBcCRSHST7NFHDuUgmNdpyCQafiT9kj4aeLbWzt77wXoMltYaFP4XhgjthDCulTxGKSyKJhTAUJAjIKrk4AJzXj/AIc/4KSzXDWeu694R03w78O/Ekeut4d16fxEHnlOlR3EszX9t5AFnFJFazurpLOVCASLG7Ba5ux/4KD/ABS8e6j4ZsNC&#x2B;G/hXTtU/wCE&#x2B;Twl4gt9V13U7NBFJpI1GCS2&#x2B;0aVDOd8bNuaW3j2tAFUSLKJYwNT6a0b4BeDfDfxMu/GWneH7HT/ABJqEQiu722Bia7wqoGlVSEkkCIieYwLhUVc4AFdhXxzF/wVY1ZrTxJq3/Co/Ek3he3S6j8PashvYoNRuo9Sh06GC7lnso7a1&#x2B;0TTB0aGe6CxxyF9jKEPYfsrfEb4ifGnx3&#x2B;0N4f8WXQ8G65oOtWWk6emjahFq8Ph/ztDsphLayz2yLLmSYzAT24G5iGQqOQD6Wor4v&#x2B;EXx48ffBn4WeMfE3ij4j6l8TtY/4TjUvA/hzQ9ftbPTIbuW1vpokMZ0jSpLuS4a3gkdlSGUERsQiKGZeU03/AIKY&#x2B;ONU&#x2B;IGvePdJ8IR33gXSfhDpvjbXtC1DXzYS6D5Opa5FqDWoNqzXNwUswqpILdGFuu5omYKQLH33RXxv4m/b48UfCXxH4i0XS/CupfEfxDqXirXH0yx/02NbTTNPt9OMiA2dldy&#x2B;YZL6FUV4lQmRt8qYGW3/APwUH&#x2B;K2i618TtU/4VTY33hnwxb6DcabZtqV7Bq2nx6hHHI8upW8dhNLCkMTySTiJZnhMGwRyAtIgFj7KorJ8B&#x2B;KYvHPgfRtagmsLiDWLGC9jlsbn7VayLJGrhopdq&#x2B;ZGQ2Vfau4YOBnFa1AgooooAKKKKACiiigAooooAht76K9sY7i3kS4hmQSRvGwZZVIyCp6EEdD0rxjwt&#x2B;1LqnjPxX4b/svSdD1jSdU8Jazq1/a6RrMF/fWuradc2MEmmxyq62rsHupYmZpECyQ4JUEkczpH7H/AMYvAlgmk&#x2B;GP2kNctvDtiPJ0601fwfpmpXNlbrxHCbgCJpQi4UNIC5AG5mOSfDvC3/BD7X/DXwwuvA//AAvjUpfCOoNepc2LeD7GVmgu4oIpoFeZpBs2W0G0Or4MascnOQZ9&#x2B;aPqDatpFrdNbzWjXMKSmCbb5kJYA7G2ll3DODtYjI4JHNWK&#x2B;GY/&#x2B;COPiOy/Z30n4Taf&#x2B;0L410n4e&#x2B;FYmj0HTLLQNOjZPmYob2UoWu9u92AHlYl2Sgq8abfoz42fE3xB8E9c8IXi&#x2B;FfGvjrQ1tLu31N/DtvHcXUN3/o/2eWW38xGeNlF0CU3hXKZXkMoI9azRXxz4u/ZL&#x2B;J37Wc/iDXrb4heMPg34V8XakL&#x2B;bwbqGj2l5c3ey0t7XzLp47gskciwA/ZRKUKkGRdzMi9V&#x2B;zl8KLX/AIJj/A7UfDcsnjD4hvq2tXGr2Vt4c8HuscDTLEv2SGG2DW9rHujL7pXij3SuxYcmgD0Lwz&#x2B;0m/iH9r3XPhmw8P2y6Pox1WJRezy6jfIfsf70J5AgSNGuHR1855V3WzlQsy1maj&#x2B;2Lef8NL6j8MtK&#x2B;GPjrWLzRb3Tk1LWI/scOl2djeQmSO&#x2B;3yTiR4w8dxEVSMtvtpB/d3eXfsTf8E69a&#x2B;DPxc0v4oeJta0611htGudOj8N2elRf8SG2nkjeKw&#x2B;3K5a4S1jjigDFQGEEeDtRAPqGy&#x2B;H9jYfEvU/FSbv7S1XTLPSpvTyraW6lj&#x2B;vzXcvXp26mgZtrIrswVgSpw2D0PX&#x2B;op1cv4W&#x2B;DugeDPiX4q8XadazQa540FmNXlNzI8dwbWNooWEbMVQiNtp2AbtoJyRmuooEFeV&#x2B;Gf&#x2B;T2vG3/Yj&#x2B;H/AP0v1uvVK&#x2B;R/24vBWn&#x2B;OH/aEj1DQ7HxFJpnwj07VbCyu7X7VG97bTa/NbnyjkORKiEKQckYwa7cFTU5Sg3a6S&#x2B;&#x2B;UfQ83MqrpRjUSu027bXtGXk/yPiXxH8K/jD8DP&#x2B;C5Hjjxxofwf8YeMrfVWv30t7aA2&#x2B;n3S3ViYo5GvGHkxxq7AOS2RgjG7APE/wDBGn9mz4qfsc/tmReMvHnwn&#x2B;J2m6Aui3lkZ4fDV1csJZPL2jZGhbB2nnFerfAj9k3wR8QPip8I9F1P4deE10XxQfFcNxqjeGI7U6sLSaOPT5irR4XKu7bY/LD&#x2B;Xu5AIPmtj&#x2B;z7ff8ADOHjvxFd/BLwnH4khbSNE8N2cfhFZHbULaC6OsSsgXLJJJp820/dRbgFcYWv0P6wp0ZYdtaxjBu1m0nKK&#x2B;16t6aLfsfkv1VwrxxcYv3ZzqJXuk3GE3f3Lu/upa6vRdWfqdLfrqv7fnhO6WOeFbn4a6nKEmjMciBtR004ZW5VhnkHkHivyp/4Oif&#x2B;Tu/h/wD9ieP/AEtua/Sf4F&#x2B;DPCvgL9p/4b6f4J0O18N&#x2B;F3&#x2B;F2p3thptvGY47VbjU9OuGG08gl5WYg9ya/Nj/AIOif&#x2B;Tu/h//ANieP/S25rTw3ilxDRS25Jb/AD9T&#x2B;pfBWTlxDzStdqW2q&#x2B;BbOy/Jeh&#x2B;ZdFFFf0wf1&#x2B;Ffqh/waz/8l0&#x2B;K3/YBtP8A0oavyvr9UP8Ag1n/AOS6fFb/ALANp/6UNXwviV/yTeJ/7c/9LifB&#x2B;J3/ACTOJ/7c/wDTkT9qKKKK/k0/kMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArG8c&#x2B;G5vEuiqtnNHa6lZTLd2M7qWWKZOm4AglGUtG4BBKSOARnNbNFAGP4J8YQ&#x2B;MdKaQR/Zb6zk&#x2B;zX9mzhpLC4CgtE34MrK3R0ZHXKspOxXP&#x2B;KPBEmpanHqmlXn9k61EojNwIvNiu4xkiKePI8xAWJXDK6EnawDOGp2/wAT10V3h8T2cnh6WM4&#x2B;1SP5mnTD&#x2B;8txgKvptmEbE8BSMMQDrKKjtLyG/tY54JI5oZlDpIjBldT0II4IPrUlAHN/EF7iXUfDVnDeXVnDqGq&#x2B;VcmAhXmjW1uJfL3EEqC0aZK4bAIBGa6QcVznjf8A5Gbwf/2F5P8A0gvK6OgAooooAKKKKACiiigAooooAw79FPxI0pv7UeGQabeAacM7boeba5mPOMxYCjIJ/wBIOCOc7lV5dItptXgv2hja8toZIIpSPmSOQozqPYmOMn/dFWKAMP4h/DbRfit4cbSdes/t1g0iy&#x2B;WJpIWDr0IdGVgevQ9zXJW/7Hvwvs7zw3PD4F8NwSeEEjTSPKs1RbMRzGeL5Rw2yYtKpcErIzOMOSx9JooAzZPB2ly&#x2B;MIfEDWNu2tQWb6fHebf3yW7ukjxA/wB0vGjEeqiucn/Zy8C3UciSeFtHdZlu1cGAfMLu8F9cg/8AXW6UTN6uM12tFAHOR/CLwzFrkeprounjUIdXfXkuPKHmLftaNZNcg/8APQ2ztFu/uMRWR8Sf2Z/Afxe8U2WueIvC&#x2B;l6jrenxfZ4NRKGK7WHdv8kyoVdot3zeWxKZ5xmu6ooA83X9j34XDVtavj4D8MvP4it7y01APZI0dxFeHN4mwjYouDzNtA808vuPNNsf2P8A4a6Z4buNJg8I6ZHZ3WpQ6xMQX8&#x2B;W9iRY47lpt3mGVY1VN5bOwbc7eK9KooA85P7Inwzd/EW7wXokkPiyG5g1e2eHfa3qXEgluN0JPlgyyKHcqoLuNxJPNbHwn&#x2B;BHhD4GW&#x2B;pR&#x2B;E9BsdD/ALauFu9QeBT5l9OEWMSyuxLSPsRV3MSSFHNddXLfGT41eGP2f/Alx4m8X6ouj6HayRxS3TQSTBGdgqjbGrNySBwKmpUjCLnN2S3b0SIqVYU4OdRpJatvRJebM/xP&#x2B;zT4D8ZeGm0jUvC&#x2B;l3OntrEniAR&#x2B;XsaPUZGdpLtHUhkmYyyZdSCRI46MQeeuP2D/AIO3JsN3w58LqumWMel2yR2gjjSzSeW4W1KrhWt/Omkk8pgULNkqcDHpPg/xbp/j3wlpeu6TcC80rWrSK/spwjIJ4ZUDxvtYBhlWBwQCM8gVo04yTV1sVGSkuaL0OD8YfsxeAfHq/wDE08L6bcSf2hLqgnQNDOtzKgjllWVCHUyIqq&#x2B;CAygAgiofE37Knw&#x2B;8XaxfahfeGbM3upWEOmXc0Eklu9zbQnMUbmNl3bOQCeQpK52kg&#x2B;hUUxlPQNAsfCuhWel6ZaW&#x2B;n6bpsCWtpa28YjhtokUKkaKMBVVQAAOAABVyiigAooooAKKKCcUAFFea/s0/tf8Aw5/bB0DVNU&#x2B;HHiSPxLYaLd/YryVLO4tvJm2htuJo0J&#x2B;Ug5AI969KrbEYerQqOlXi4yW6aaa9U9TbEYerQqOjXi4yW6aaa9U9QooorExCiivN/CP7XPw78d/tDeIPhTpPiOO8&#x2B;IHha0&#x2B;36ppItLhGtYf3I3mVoxE3/HxDwrk/P04ONIU5zTcE3ZXdlsu78jOpWp02lUklzOyu7XfZd35HpFFeU&#x2B;P/ANtz4X/C39pXwt8H9e8VRaf8RvGtqL3RdHNjcyNew5mG4SpGYl5gl4d1Pye4z6tWZoFGKKKACiiigAooooAK4f4gfs5eEfid4qGuavYXzat9kSxNzaard2LyQI8jojeRKgYK0shG7ON7etdxRVQqSg7wdn5GdSlCouWok15q55f/AMMc&#x2B;A/&#x2B;fXxH/wCFTqv/AMk0f8MdeA/&#x2B;fXxH/wCFTqv/AMk1X/b0uZLP9hr40TQyPFNF4E1x0dGKsjDT5yCCOhB71/Lz/wALK8Rf9B/Wv/A6X/4qv0bg3g7E5/RqVo4l0&#x2B;RpWs5Xur/zI&#x2B;84L8M6HEFGpWjONPkaVuRSvdX7o/qk&#x2B;Hv7Nvg74XeL31/R9NvE1h7NtP8Atd3ql3fSLbs6SNGpnlfapeNCcYyVFfjr/wAHRJ/4y7&#x2B;H/wD2J4/9Lbmvzl/4WV4i/wCg/rX/AIHS/wDxVUNX16&#x2B;1&#x2B;dZL&#x2B;8u76RF2q9xM0jKOuAWJ4r9R4X8OauU5lHMKmJ9pZNW5Wt1bfme3ofsXBvhYsgzCONjXUkk1yqHLurXvzP8AIqUUUV&#x2B;pn68Ffqh/waz/APJdPit/2AbT/wBKGr8r6/VD/g1n/wCS6fFb/sA2n/pQ1fC&#x2B;JX/JN4n/ALc/9LifB&#x2B;J3/JM4n/tz/wBORP2oooor&#x2B;TT&#x2B;QwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5l/g94bS9murXS49Kurpi9xNpcr6fJcsTkmRoGQyc8/MTyaf/AMKs0z/n68R/&#x2B;FBf/wDx6ujooA4zWPhCDqek3&#x2B;k6pqNre6Rdtcp9vvLvUbeUNBLCVaKScDpLuDAggqOxIOj/AGb4s/6DXh3/AMEs3/yVXRUUAc7/AGb4s/6DXh3/AMEs3/yVR/Zviz/oNeHf/BLN/wDJVWfGHiS60BtNhsbO3vLvVLs2sST3Bt41IhlmJZgjn7sRHCnkjp1qr/ani7/oB&#x2B;HP/B3N/wDIlAC/2b4s/wCg14d/8Es3/wAlUf2b4s/6DXh3/wAEs3/yVSf2p4u/6Afhz/wdzf8AyJR/ani7/oB&#x2B;HP8Awdzf/IlAC/2b4s/6DXh3/wAEs3/yVR/Zviz/AKDXh3/wSzf/ACVSf2p4u/6Afhz/AMHc3/yJR/ani7/oB&#x2B;HP/B3N/wDIlAC/2b4s/wCg14d/8Es3/wAlUf2b4s/6DXh3/wAEs3/yVSf2p4u/6Afhz/wdzf8AyJVbUrXxd4lSOzkTSdCtJW/0m6stQkuboR90jDQIqs3A3kkqM4GcEAGfoviLxTrXjtLO11Dw/faRp0jLqtzHpkseHAIFvE32hgZQ2C5IIQcYLHC95WPNpjeEfDNnZ6DZQpHbTW8CQAYWOAzIsp6jkRl2yTkkd&#x2B;h2KAKMtvqR1yOSO7sV00Jh7drRjOzc8iXzAoHTjyz0PPPFVbLXhplwp1LSTeNIDBKNNk8qNO4ZPPyx68hl&#x2B;lc7&#x2B;0j4e8WeK/hLdWPgfVP7F8TTX&#x2B;nNa3&#x2B;3zFs0W&#x2B;t3mkePenmxrCshaLevmKGTPzV8z3Vl&#x2B;1dYPe2&#x2B;nHUtP0&#x2B;18qKONY9I1aZoxDCry29xc3cbyzG5ErlblI08hztMcipDQB9gG21b7bZt9u04W8aAXSfYn3zN3KN5uIxnsVf61Gtprggvg2o6UZJGzZsNPcLAuTxIPO/eHGOQU9cdq&#x2B;dvCMvxo8f/AAp&#x2B;LEerx&#x2B;KkvWjvLLw8HTS7CeW4iv7&#x2B;MNY&#x2B;W/yRm3Wz2teOdzfNuKEs3J6zpH7U3iG21iFJtQiUTRXehx3kOjxqI0v7aWFbye3uFcXSxJKJUiie3dCVVixxQOx9btaa1mxxqGmYj/4/c2D/AOkdP9X&#x2B;&#x2B;/d9/vb&#x2B;o/EjtNaD327UNLZZAfsQFg4NueceYfO/eY4&#x2B;7szjt2&#x2B;adOP7TU/jaxa38yHwld3FsrprX9k/21YwtdSRTtL9lzbs6Quk6iIkERBSS7MptftHeAviP4g&#x2B;P02peHdG&#x2B;IV14RtbOOPVbPTvFEenjXm8y2K/Yf8AT0MLIA/mb1tsiGUBpfPIIB9ENaa8bayC6lpImjY/a2OnSFZxngRr5&#x2B;YzjIyS/PPHSpmtdXN9eML7TvsrxkWsf2J/MhfAwzt5uHXOflCofcdT88&#x2B;FPgN4l&#x2B;EmteEYrjSvGniqxutPjn1VtC8UfYI7TXJJUe8vblHurczwy/KQF80r5Uv7omZi30xmgRkSWWvHSLdF1LSVv1cmaY6bIYZE5wFj88FT05Lt0PHPHzB/wWS0jWtR/Yr8SLDJb3Vk17YeVaQ2Tm5DCdMkyCQhh97gRjqOeOfrag1yY7C/WcNPD3tzJq/a6OLMsH9bwtTCt254tX3tdWvY8j/ZJ03Xov2OvhjDHfabb3i&#x2B;GNK2mbTpGWKIWUQEbJ5ykyA9W3AcH5BXpjW2qHW0kF5Y/wBmhMPAbNvPZsHkS&#x2B;ZtAzjjYfr3rQorejT9nTjT7JL7jfD0vZUo09&#x2B;VJfcrGPHZeIBpEqNqejm/aTMcw0yQQqnHymPz8luvzBwOnHrMtrqw1G0Y32nfZEjAuY/sT&#x2B;ZNJg5ZH83CLnHylXPB55yNKitDYyVs9d&#x2B;xXinUtJNw7g2rjTpAkK55Dr5&#x2B;XOOMhk55x2qQ2usebYkX2m&#x2B;XGoF4v2F8zt3MZ8792PZg/wBa0qKAMtLTWh9v3ahpZ8z/AI8sWD/6Pyf9Z&#x2B;&#x2B;/ecY&#x2B;7s6H1wEaz1wxWO3UNLDxt/phOnyETjI4jHnfuzjIyxfqDjjB1aKAM37Lq/2u8b7dpv2eRCLRPsL74H7GRvNxIPYBPqKiez146ZbKupaSLxXJuJTpshilTJwETz8ocY5LMPbtWvRQB&#x2B;Yv/Bs/4d1vQ/gb8UhdR/YYJPEo8uG5spFlZ/s8eH3FgCg5BULk/wB4dK/SBrHxAdGWNdU0cah5mWnOmSeSUx90R&#x2B;fuDZx82/HtW1iivXz7NnmWPqY5x5ed3te9tEt7Lt2PY4gzZ5nmFXHuPLzu9r3tolvZduxRNvqX9trJ9rsf7N2YMH2RvPL&#x2B;vmeZtx7bPxqqlj4gGjyRtqejtqBkzHMNMkEKpx8pj8/Jbr8wcDkccc7FFeQeOZ/2bVv7UtX&#x2B;26f9iWPFxF9jfzZXweUfzcIuccFWPB55yPzb/ZJ8OeIYP&#x2B;Dg79oe6/dQtceEitveyadIbU/vNFONvmDcdoI4ccgnpxX6aUYruweM9hGpG1&#x2B;ePLvtqnfz2PNzDL/rU6M&#x2B;a3s5qW172TVvLfc/J39vrw3rF1/wcq/so3v2aa6itfCsaXV5DaOLdXEur7u7bM54BY4yOT3/AFOS01oC/wB2oaWfMP8AoWLBx9n5P&#x2B;s/ffvOMfd8vofXjU60Vwnp3MprPWzHY7dQ0sPG3&#x2B;mk6e&#x2B;LgZHEY8792cZGWL8kHHGC/wCy6v8Aa71vt2m&#x2B;RIhFon2F90DdjI3m4kGewCfUVpUUCMhrLXjptqq6lpIvFcm4lOmyGOVc8BE8/KHGOSzfTtU/2bVf7WuH&#x2B;2af9haLEEP2N/NjkwPmaTzcMuc/KEU8jnjJ0KKAMZrHxB/Yyxrqmj/2h5mWnOmSeSU/uiPz8hunzbyParYt9S/tvzDeWP8AZuzHkC0bz9/r5vmbce2z8avUUAYy2PiD&#x2B;x5EbVNH/tAy5SYaZJ5Kx/3TH5&#x2B;S3X5t4HtVlrbVP7Wt3W8sBYrHieE2bmaV8HlZPNwgzjgox4PPPGhRQBwvxe&#x2B;E2ofGn4KeMvBeq6xZwW/jDTLrR5Lm009ke2triJoZMK0rBpAjttY4AOCVI4PwDcf8Guvwla3txF8QviKkq489n&#x2B;xssnrtHkjb36lse9fpxRXtZXxFmWXRlDA1nBS1dras9vKuI8zy2EoYGs6alq7W1Z&#x2B;ZC/8ABrr8JRfzMfiF8RvsrIRFHmy8xG45ZvIww68BR1HPHMR/4NcvhX9gjUfEb4gfag&#x2B;Xk2WflsvoF8rIPvuP0r9PKK9T/XzP/wDoKl&#x2B;H&#x2B;R6v&#x2B;v3EP/QXL8P8j8yz/wAGu3wh/tJmHxA&#x2B;JH2PbgRb7LzA3rv8jGPbb&#x2B;NQD/g1z&#x2B;FY00qfiN8Qftm/Il2Wfl7fTZ5Wc&#x2B;&#x2B;78K/Tuij/AF8z/wD6Cpfh/kH&#x2B;v3EP/QXL8P8AI/Mkf8Gu3wj/ALQjY/EH4j/ZQmJI91l5jN6h/IwB04Kn617x&#x2B;w5/wSg0H/gm7471nWvh1qmseJP&#x2B;EmsBZahF4j1GOHydkivE0Rgtec5kDBv9nHevr6qFx9s/4Sez8uWFdP8Ass/nRnHmNLvh8thxnAXzQeerL14xyY7i7OMZQlhsViJShK107WdmmundI48fxhnONoSwuKxEpQla6drOzTXTukzL/tTxd/0A/Dn/AIO5v/kSpfC3jRtV1O40vUrZNM1q1Bka2E3mpPDkYmicqpdOQpO0FW4IGVLb1ZHi/wAIQ&#x2B;LLSH99LZ31m/nWV7CB5tpJgruXIIIIJBUghgSCK&#x2B;cPmzXornfBvjKTU7mTSdWjjs9fs03TQrkR3SAgefDkktGSRxklCdrc4J6KgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOc8b/wDIzeD/APsLyf8ApBeV0dc543/5Gbwf/wBheT/0gvK6OgAooooAKKKKACiiigDJ8aCFtIh&#x2B;0XUlnH9us8SICSz/AGmLYnHZ22oewDHPFa1ZvisuNLi8uyW/b7Za5iYZCjz48yfWMZce6CtKgCvqepJpVqJpEuJFaSOLEMLStl3CA7VBO0FgS3RQCSQASPDL/wCGXjD4x6VqnjzSfEnjbwHrmtaR9k0/RV1C2ubWBUukmjnVGWSFZJ4YghLIWjFzKDkgY9F/aJ1/WPC/wa1rUNC1Cy0vUrVYnS5ujtjjTzU8zDeXKFcx7wjNFIquVZkZQQfn3Vf24/HV1Z6Hdab4F12OC1ee61Czu7eRdR8iPS7&#x2B;WOK&#x2B;QW&#x2B;23knlht5V&#x2B;z&#x2B;YduVxlgjgz6Gh1HVPhfoOpf2n9s1rQ9B0mCaLU2ka61bUpwZvtPm28MCqMKsLL5QJcySARoEUNzvgD45&#x2B;IvFNjfXjeDNUuNB0/TLieDWMfZZNbuYW27ILCQfaI1lAYoXGCVIXehjlk5Lw9&#x2B;1drnh/4WaLq2uaLJqd1r2o61b28lpFN5MjQ6q0FlEn7kMUltiZFkZRuSEtlgS1chqn7bvxEvvBnhO4/wCFfPoupa9qOmvJbpLcXMrW8r6JLJbRhrYDzzDqVyrb9oQWM7BvlZowLHZfBLUPiV4x/aA8Ua1fWurWvw1k0uVfDr6nELO/a5knDuDayESIihdqefGjYX&#x2B;JWXb1WhfFDX57/wAE6XqlmdN1S3sX1LxbG063I06NbYqqPNHEsLM80iN8hQkROVUor7eF&#x2B;FX7aPizxz4A8UeJNW&#x2B;H8Wg2Hhnwf/wkpEmpNI91OzXmLQfuQFZFtCJNxDo0igxjNYN/&#x2B;3x46gsNVu7X4Yw32n6YttGmoJqNxDaXck9zfRB0aa2j2woLIK7tgiS5jABTDsAer/Dr4z&#x2B;MviR4kvoh8PbzTfC80FydK16bU4olvHSZ0iLW7KLiJJYwjq5jbBYjay7XbO&#x2B;HPxj8ceF9Th0Xx14Jn0rSdE0WJ9R8UpqkVxZzXalkYxpnznjk2FlJHmruUSRrvDHjbb9trxnqmqapp1v4As4NSstWtdLtornUJjDqJuNTSzMkMscDo6W0MizzkZKb9hClWIw5P26/G82pNpFj4TsftWn31nDqNzfS3O6xt3l05pp50jthHHH5N7IA2/cDCWKFQxUA9u8KfGXUrbwNqXijxdo154b0eMWtxCs8IEttDJHEJWkCyM&#x2B;yORnYvIkLKmQ0S&#x2B;WWbnvhj8bPEfxm/wCEo8RWHhnWpPAN1pVunhwxTWkGoavOs12lxNCTcbBE6fZ2ikdo9yjcMhga4rQf2zfHmqa2mhw/DuSW&#x2B;b7DCs19PcQlfPfTFa6lC2uwQD7fOo2sWL6fMMAeYYfZfCvxGvPiF8DI9dsdL1C11q40hbhtLgCLdW109ssv2dDcCOMurOFDSbUz97AzgA8i8F/GD9oDRZLWPVPgzd31pBFDBKW8VaW08pDkyzhgyDOxgFjYcmIbpMsWHuXwq8b3HxG8C2etXWj6loMl68xWx1CPy7qGNZXSMyLyAzIqtgEj5uCRgn5/1/8A4KAw6Zptv4c/4Rn4rSeNtLt7OTWLXT/BWoahNDMjg3UHmJaeRIpCeX58X7pvtEbxnBBXe&#x2B;JH7VXiiw&#x2B;GOi&#x2B;NtG&#x2B;HPxOaxv8ATdRMmlnRib&#x2B;3u1V1tEms1ilu1MkkfDhBGiTK0g7KAfQlFeI6D&#x2B;3Dp3ibxf4d0az&#x2B;Hfxm83Xbhbea6u/Auo2FnpW7IDzzXEUaKvAJIJwDzhvlqLTf22F8c6beTeEfA3i/XLiw12PQZrW5tv7NeSbzLhZjC82IpljjtxLuRyhSZMup3AAj3OivE/En7X9j8M/jDb&#x2B;Cdc0nxXcalrGpwW1hcw&#x2B;Hrz7CqXElokStdLE1udpuJtzeZgfZWBwzKD7ZQAUUUUAFFFFABRRRQAUUUUAFFFFABXzp8av&#x2B;CoPwy&#x2B;AniHxhpevL4i&#x2B;1eB5bmHUvs1isi7rfSYdWk2HeN3&#x2B;jTpjpl8r2zX0XX4v/APBUH/ksn7SX/YQ1z/1Xum0FRVz7Uv8A/gux8DdO/ZW0n4xSL4y/4Q/Wlvmt8aUv2rFpe2dlLuj8zA/e30GPm5XceMYPoHxx/wCCofwx/Z98VQ6P4gHiL7ZPoz66v2axWRfs6abfaked4&#x2B;b7Pp9xx/e2DPOR&#x2B;E/i3/lAD8Pf&#x2B;uPin/1JvDlfYH/BVT/k4DTf&#x2B;yaXf/qEeKaA5T9BIv8Agrn8Jpvgxo/jxV8Uf2Hrmn6Pqdt/xL187ydU1GfTrXcu/hvPt5Nwz8q4POcVD8Kf&#x2B;CwPwj&#x2B;Mfg7xZrmjr4p&#x2B;w&#x2B;DPCl14y1Dz9OWN/sFve3llJsHmHdJ5tjPheMrtOecD8w7D/lGV8N/&#x2B;xN&#x2B;HH/qZapWd/wAE/P8Ak2v9oX/s33Xv/Un8S0Byn6qP/wAFcPhOnxp8C&#x2B;Aivif&#x2B;3viJrl54f0n/AIl6&#x2B;T9ptfJ83zG3/Kn79MHBzzwMVF8If&#x2B;CvXwl&#x2B;Nvx1b4d6Kvij/hIVbTl/0jTljgzfadLqMHz7z/ywhfdxw2Bz1r8xbn/lJ9&#x2B;yf/2VPxL/AO46qf8AwTj/AOUsMn/XbwX/AOoXfUByn6dah/wWW&#x2B;Dum&#x2B;NdS0CRfFf2/S/Cum&#x2B;MJsaapT7DfrbvBg&#x2B;ZzJi5j3L255OK9v8AGv7S3hvwFrmm6ffjUPtGrR6fLB5cIZcXuo22nQ5OeP391Fu9F3HnGD&#x2B;GXjD/AJOi8af9kB8E/wDpPpFfqZ&#x2B;0/wD8lV8Df9eXg/8A9TLRaAse4an&#x2B;154T0i71iGYapv0Ow13UbnbbgjytHktY7zb83J3XcWwfxfN0xz1nwi&#x2B;LGlfGvwSuv6L9q/s9r6908faI/LfzbS7mtJeMnjzYHwe4weM4r4y8df8AIwfEr/sUvix/6V6FX0D/AME6f&#x2B;TXIf8AsafFH/qQ6lQI9yooooEFFFFABWNemz/4WDpvmed/aH9n3fkEY8vyvMtvMz33bvKx7bq2aoTm8/4Se08uOE6f9ln85z/rFl3Q&#x2B;WB7FfNz7haAL9FFFAGX4m8I2fiuO3&#x2B;0rMk1nJ5ttcQStFNbvgruVlIPIJBByGBwQRxWTJoXirQ7hXsdctdat8Zkt9WtlimkP&#x2B;zPAFWNR1wYJCT3GeOqooA5a5&#x2B;Il74fj3az4c1iCNDh7jTk/tKHJ6bViH2hvqYAB345rU8OeOdG8XNIul6pY30kIBljhmVpIc9nXO5T2wwByMVq1k&#x2B;KPAmjeNPI/tbS7K/e0YvbyTRBpLVj/HG/3o24HzKQRgc0Aa1FcvN8P77TI2/sXxFq1iyjKQ3rf2lbs/q/m5nK/wCysye2Oclh4j1zRdY02w1y30qZdQla2ivbGWRPNkWJ5ctA6ny1Kxt0lcg46gkgA6iiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOc8b/8jN4P/wCwvJ/6QXldHXOeN/8AkZvB/wD2F5P/AEgvK6OgAooooAKKKKACiiigDL8YJ5mkwj7b/Z/&#x2B;m2h83JG/FxGfL4I/1n&#x2B;r/wCB9xxWpWX4vx/ZUObFtQ/020/dDPy/6RH&#x2B;94B/1f8ArPT5OcDmtSgDz39qXx74o&#x2B;GvwT1DVvBdhp&#x2B;qeKFvLC10&#x2B;0vg32e5ee9ggKMVZSuVlYBs4U4YggEH5z8M/wDBUrUIl8QXmo&#x2B;FY9RsZtcvv&#x2B;EdggZ9PvJtIj0iwvrSZkmDCaSZro7thQxI6ZQ7WJ&#x2B;nPjz4i8SeFvh0154S0&#x2B;HVdd/tPTYIbSVmSOaOW/t4p97qjmNRC8hMgRtgBbB2186&#x2B;L/2rPjBN4X8RaPZ&#x2B;Cde0/wAT6bZS3YvbfRJbm2jlTWbeBYIJHj23KtaTOQ/lIcW7uM/MIwaNpf2&#x2B;dc8L&#x2B;ILrQdX8F/aNcj8T/wBiKo1OOztXRvtLq8M0yKJUH2dokZhG0sqyArGFBZ/w2/br8R69HaHU/COn3E0irLfR6ZeyMmnqt1a2sqIzR5nmWS6XMZWLaYpVLEgEy3H7WHxC1fxN4R0WLwD4i0u51g2c&#x2B;rSnSJpI9HzrCQTW7zkGN2Fsk29kXZ8wljkZCrHm/jh&#x2B;078bdK0e21Dw34N1SP8A4SH4eWF1b2kehzXcmi&#x2B;ILv7RK5kyoJS3ht3DRuAfMeBSAZACDN7W/wBuK&#x2B;&#x2B;Iv7LWqeIPDfhWz1DxBfanbaDYaUqz65bXD3Flb30gmS3jEjeVbTSiWMKcSQOm4j5qm8Wf8FC4LyXRbfwzpentNqVzGbs6tfG1bTrSWOyaGV0VGKyS/boxGj7QxRhuJrDh&#x2B;MfxC8Had4&#x2B;0bwR8JG8P2mgvrNzZPb2RWbVpLaVYLdYlYeW8twphkR5CF8o7QuIg51NX/bJ&#x2B;IkGpXVtb/D&#x2B;9jCx6alrcS6NftBcTXEFrJIThRLHCjTXSszxq0f2FhtkklWJACOD/AIKHal4X8P8Ak694LV9d0zS7e7vba01TMmoSS2H2wfYkaFTMsa7ftBO0W4dT&#x2B;9GCbOvftzzfDTxhr&#x2B;k6joHhddSsw11eAaz9hKymeGzt0YvCTKsjkqLn5VVLdjIkSqpaD41fHv4veEfjlqGh6H4f1O80GTxZoEdpeQaFJcImj5sV1bMgG3duvIwhPzbRdMuRbuUs/A79qj4jeP8Ax1Ffa74L1TRfB8kcVvOtzol1DdRN5eqzm5SMB2wVtrOJkLPlpkKlSwVwDH8Pf8FGNV1XV7KS70Dw/pun6nFdywrd6q0EdhGsejzW7390UK2u5NRkGBHIHfygrAZLdZH&#x2B;2hrfif4H&#x2B;M/FGm&#x2B;DbjS7vQ9I/tXS7S9l8y4u/wDSru2Mc0WIxFIHtGO3zGGJFyy8gcx8RP2mvip8PP2k/iJYw&#x2B;GfEGseEdHtVGii18OzXcU0rR6NsIdUj3AyXeobiJ3JEDfJH5DGWax/bJ&#x2B;KniTTFGnfCy9tdRlv72Blv7C8jt7WKGxku4v3gXMhk2pFuAQCaQx7SUy4A7WP26ta0m1fT5PCLab4g1KXVREsskZntvs91q0ULPDG0iyKsWlIJZElwr3VuACJPlyNI/4Kb3z21xqEng1b61vLieW1tYtYhhuNOghsNNuHgm8xV3Xoe9cPbrlk8iZQZCgDdH8ePjx8TvCfxB1abwz4f1zULGz8LaJq1jpUNmzi8vJtWMd5bs/2R/mW1A3FZw0YJYQsSGXP8ZftxeOdA1mex0/wNPq15DLfNb2q6TqEcmqwQyWKxvAQjbVMV28zNIFw1vJCAxUy0Adx&#x2B;0D8cdc8JeAdDeTVPh/4QutU1s6Vqc&#x2B;sM&#x2B;sadZJ/ZdzdmKUK9qRI0kUcYGeVkBAJcAeIv&#x2B;1LrHxH&#x2B;Hupt4s8G&#x2B;GU0uyubGzg8J3FgovdEvbnTXksoneO5aVZDfeRaBmtrfBnGwsAxHqUH7UfxK034t2/h7VPh/OunrrmnaTd6jZWVxPGqXEO57iLn95CJGCmQ7REkcjMGIKrH4z/AGkvGHw6uNVuP7I8WeINbbxLJpqeH7fw3K1jZaess/k3MdwsYLGa3jjdpPNlVXk2&#x2B;WpVlAIr&#x2B;F/2utUvfDnxbjg0JYZPAGi3eo&#x2B;E2n0e5tItXSzimt5jGZCEnj&#x2B;0wB1eGTb5N7bqSG3E591&#x2B;2b42m&#x2B;L91pM1novhaCx1mxsbbRNXtPO1bxGlzeR28sdvLDdGFZLaM&#x2B;c7IJhtni3iJVYt0/wn&#x2B;P3jrxz8HviLqmpaNfaf4ltILi70DT/7Du4hDs0qylNvmWJfOkjvJ5YiQT5jRvtACsic54O/ak&#x2B;LFpr99pOveB7lJ9OvxYNcvpN55OobLa0WW4t2hjdBAJHnusu254yIkBlRwoMwfEv7d/ibUvDGm3&#x2B;g614Jvp7zwTpuqTaNa27z6jc390t8t01vItwRGlm1ukkkbxOQqupdWKkUYf29PiPbXEekanpvh/RGnvb0f8JFcWcr6fY6el/JbW1zMGnjQSM1vLbFWlRBLLbylkjcx19KfBTxD4m1zxL8QoPES5tdL8Rpb6HILFrVJbF9L0&#x2B;f5d3Mm24muUMndkYYUrtHe7RQI&#x2B;eNb/bI1DTJ/g7PaWUuoaR4w06y1PxHeLotx/oMF6IobVy0Tyw2e6eVpGM0roIrWZQzMVeur&#x2B;BX7QbfET4teOPDt9q/h&#x2B;8Ok3FvPpH9llJIJrOZZTH&#x2B;/Wd/On2xbpI/LiaLchw8ckcjeu7ar2Wl2unNM1vbwwNcSGaUxoF81yACzY6sQAMnngUCLFFFFABRRRQAUUUUAFfi/wD8FQf&#x2B;SyftJf8AYQ1z/wBV7ptftBX4v/8ABUH/AJLJ&#x2B;0l/2ENc/wDVe6bQVDc&#x2B;O/Fv/KAH4e/9cfFP/qTeHK&#x2B;wP&#x2B;Cqn/JwGm/9k0u//UI8U18f&#x2B;Lf&#x2B;UAPw9/64&#x2B;Kf/AFJvDlfYH/BVT/k4DTf&#x2B;yaXf/qEeKaCjgbD/AJRlfDf/ALE34cf&#x2B;plqlZ3/BPz/k2v8AaF/7N917/wBSfxLWjYf8oyvhv/2Jvw4/9TLVKzv&#x2B;Cfn/ACbX&#x2B;0L/ANm&#x2B;69/6k/iWgOhq3P8Ayk&#x2B;/ZP8A&#x2B;yp&#x2B;Jf8A3HVT/wCCcf8Aylhk/wCu3gv/ANQu&#x2B;q5c/wDKT79k/wD7Kn4l/wDcdVP/AIJx/wDKWGT/AK7eC/8A1C76gDm/GH/J0XjT/sgPgn/0n0iv1M/af/5Kr4G/68vB/wD6mWi1&#x2B;WfjD/k6Lxp/2QHwT/6T6RX6mftP/wDJVfA3/Xl4P/8AUy0WgRx3jr/kYPiV/wBil8WP/SvQq&#x2B;gf&#x2B;CdP/JrkP/Y0&#x2B;KP/AFIdSr5&#x2B;8df8jB8Sv&#x2B;xS&#x2B;LH/AKV6FX0D/wAE6f8Ak1yH/safFH/qQ6lQLoe5UUUUEhRRRQAVj3qWp8faazzTLfLp92IogP3bx&#x2B;Zbb2J9QRGB7M1bFZ1z9oHiyz22sL2n2S48y5IHmRPvh2IDnOGG8njrGvTuAaNFFfPHxk/4KAW3wU0nx1rGpeDdYl8N&#x2B;EdVs9Ds9TjvIAmuX08iQvbxqxBiZJ5YogZMK5YncqrmgD6Horw&#x2B;3/bP8j4i&#x2B;LvDd/4O1i3uvBeo6Fpl7LDMssUr6vNBFbyREhd8SeaxkbqvlMACSBWdbft6wt8WZvCdx4J163uLTxTe&#x2B;HLmc3EDrHHDFZNDdqqtllmbUbNVj4dRKWYADkA&#x2B;gaK&#x2B;ffhX&#x2B;37pvxI&#x2B;I&#x2B;keGLrw7ceHdQuPDlx4o1U6jqMCx6NZW15d2Nw7OuVcLcW8QDKwVkn35AQgzz/t2WreMbzS7PwhrV9DY&#x2B;L7DwxLex3MAhWC7uJLNL85bPli9hmh8sZchQ4G1uAD3uub8bf8jT4P/wCwrL/6Q3VdJXN&#x2B;Nv8AkafB/wD2FZf/AEhuqAOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDnPG//IzeD/8AsLyf&#x2B;kF5XR1jeMfCkniePT5Le/m0280u6&#x2B;2W0qRpIpfy5Iyrqw&#x2B;ZCsjAhSrejA81nNqfi7QbhftGm6Xr9njLS6fKbO6B7KsExaNgOpY3C8H7vHIB1VFcrcfGLRdGi3a0114c2nbI&#x2B;q27W1vE3ZTcH9wSe22Q57ZrqLe4juoElidZI5FDI6nKsDyCD3BoAdRRRQAUUUUAZvirzP7Mi8q8jsW&#x2B;2W2ZHOAy&#x2B;fHuj&#x2B;sgyg9S4rSrJ8ZyW8ekQm6tpLqP7daAIhIKubmII/HZH2sfZT2rWoA4/wCPt7qmnfB/XptFub6z1ZLcfZJrS1lupUkLKFxHFBO5BJwdsLkKScDGR84af44/aCnl3ata&#x2B;KNLupZvDhsrePSrOa3mXzriPUVd7dJtrSRrFK/nNAkRkCK6hQ8nvn7VHhHxV48&#x2B;CGpaP4K1a80HxJfXVjHa6jayCOSxT7bAZpeSNyrCJCyfxqCuDuwfnDQdV/an8PPrl1b&#x2B;HLuS68Sa7qOsRW&#x2B;oapZ3lvo1tLpFj9kslTfnEF556ny5EVnjkbDrJvoGbH7O/jL47al4s&#x2B;H8fiybxR5U2sMuvRXehxW6NanQIHm3OlusaJHrJuY0YSq7RpHsE0beYb2hfFL42aBYag&#x2B;uaZ4kutTXXL0WcFrosc1nLZr5509d0cZYLLtInZijIUjwUR1eW58XE&#x2B;PWu&#x2B;FL/wAJ6bDqH/EwstStj4htTZW86KseuJbsD5gMc0pXRCGRAF82U/IQdtPW9U/aF1uDxpo8OnaroGnw/wBrQeHNQtH025vbhkhWOw3lyFSGQiWQsUMisY1L4zkGZuvftB/Gzxp4SL6L4bupdXutCybSw06S2tLTVEXVRd2b3b&#x2B;YC9vc2un24lUhJftMrrGwH7vpNQ/aT&#x2B;LF14gt9P0jw7o9xcx6hpsGoRXegajGbS3nsY5pJHaF5RGz3BmiAIYQCINIXWRGLvEOt/HjxDFLpen6Xeafa2sVyZNQlSyjm1IbNTe3jTZNmJm26WkjBV2tLLsKkF05X4sfGX47fCGDWLnVGsobO/1CePw/5NvYtcXE/wBq1dLSxWN5w0qyW0GlyMV3Tlp5Nin5kiANLwH8YP2ipPhVpf2jwppVprum6Wq30OpaRcXctzcLa38i4ljuY1cyG1swWCjD6htKq0bKbV9&#x2B;0Z8fLY683/Cv9HVbT&#x2B;2f7Ojj0rUJ3llt3jFlbyEFVIljaWb7RGWifyfKASR0zo/G3wx8XJfiJ48XwcdeWz1O1Fxpmpfb0RdPnXR7yJLe2gknaFkN0LZy7woRJO2fMCI8XW/s7638WdV8YeIP&#x2B;FgWS2Okx6pcx6OsKW7GazWSYQSSspBRnhFs5VQxErzAlV2xxgGX4y134oeOPhBdNHZLZap/wgmq3VzHYWcsa3erSoEsI4UuEEq4Czu8bAMrPCCSOvJ&#x2B;F9e&#x2B;Lll4q&#x2B;2ahfeOr7RfD/ibUpLqO00m2iXWtOSwkuYLZIZrRZl2TrHah45GEx&#x2B;dZf3m2Pmfhf8ACn4yajrngm01xviRpXhdrE2&#x2B;ri68RfadQgvms7NJbjzYb8P5JmFw0fmNOEYSnyQrx7d7QvD37QY1bwbrd5bzTS2epLqHiLT5NeS3iEY&#x2B;y6eYbaJFdLhWt4b698uSSFRNeQncWj2qCKGm&#x2B;P8A9pK3ufCy3uh6osmn34sPEkbWlkwvoLi8sHS8t2i3J/o6SzwFA/MMdxIwMix1U/Z68ffHab4d&#x2B;EbnxpZ&#x2B;IbjxRqkAsZ7qTw/EkkE7PozSCXbbRmGIZ1TLOiR5iYK0mIHk67x34L&#x2B;NE/xF8T3Ed5qd14PnvpmtbDT7n7Lfm0N5oTSLHObkAM9rFqqxhVieMs&#x2B;JFZ1NY&#x2B;k6J8Vrfwn4k0rUtD&#x2B;JF1Z3mo6Zc6WIPEEK30OmprkjS2puReLKtx/ZxiDsZMuFYGRmzkGeo/A3xj408dfC34TjV49bsvEH9nRyeMpb3SjYsbmOw8uePa8aqGa8mjdTGuxlhk2kqMHiH1H4w&#x2B;DLjS9PXUvFniCTWNfkgS5udKs2&#x2B;y2sXiKBD5rQ28ccUbaOszh3ALEvtPmGNa4V/hn&#x2B;0Ro/9i6havrc1y14U1e2/tW1WS7tpYfD0KSyMriNrmD7PeM7qcFY7pUz50YbsPhjY/GrRfgZ4v0u80LVLjx1eaXptpFqeoeICIrjVp98OoXUJ86ZILSBitzH5MMRMbiMQGSPBAOR&#x2B;C/ir9piyufC8Pjhtamsfs6nW7i10u0luI7l4YXt1Qrbxh4WkcrOyxB4SWUZWNrgeifs6ah8Xtb1D4cf8JDq&#x2B;pzaZqGi3V94mkvtHFtNb3ttIkcdqN9rbsouPtZcnyhgabhGYSM9UoNU&#x2B;KNnd/B3&#x2B;1tF8SXHiLQVvNP8Q6ZaaoradrEcbQxNqZuFmhLsFj82JJoir/a3R445Nrx/TSNuQHBXIzg9qBC0UUUCCiiigAooooAKKKKACiiigAr8X/8AgqD/AMlk/aS/7CGuf&#x2B;q902v2XtdZs77ULq0hurea6stv2iFJQ0kG4ZXeoOVyORnqK/Kr9qz9mbxJ&#x2B;1b&#x2B;1P8AtJeGfC7aXHqH27VWZ7&#x2B;5&#x2B;zwIs3gnRbNSXwcAS3UWT2Xce1BUT8&#x2B;fFv8AygB&#x2B;Hv8A1x8U/wDqTeHK&#x2B;wP&#x2B;Cqn/ACcBpv8A2TS7/wDUI8U1X17/AIIr/GPUf&#x2B;CTngX4Sx3XgT/hKoV1mJHOur9jumvdZ0i&#x2B;txFLtxIWgsZzwOoXrnI&#x2B;hv24/wDgm38Rf2hPjba3Ph2bwu7WngibSZLe41QR3CyyeG9c0xW2bSfLNzfwDd027z/DghVz5DsP&#x2B;UZXw3/7E34cf&#x2B;plqlZ3/BPz/k2v9oX/ALN917/1J/EtfTdh/wAExviIf2HvDPhBdQ8EvqXhXw74Q0zUpV1tDa20ul&#x2B;Ib7UbvMmMAC3njKk4y2RxjNV/2W/&#x2B;CVnxO&#x2B;B3wd&#x2B;J2g&#x2B;ILvwbb6h8QvhRqngzRAmsqy3WoXOtaxeRDJUfIYtQt8sM/MxGOOQLngNz/wApPv2T/wDsqfiX/wBx1U/&#x2B;Ccf/AClhk/67eC//AFC76vYPhB&#x2B;x94s&#x2B;On7YHwj&#x2B;JWkTaFa&#x2B;F/g78SNZvPEMuoX4tpFS6NmsIiBGHYtC4xkcleua7b9kT/glH8U/gb/wUBXxtr0nhOPSbg&#x2B;Hp4oYdWD3ciaf4cudNuWEW0EgXE8YBHBU546UAfIvjD/k6Lxp/wBkB8E/&#x2B;k&#x2B;kV&#x2B;pn7T//ACVXwN/15eD/AP1MtFr5P1f/AIJL/FTXvjr4u1m1uvBc1rL8KvDfg90XWlMtvf2EVglwJFC/JHm1lwx64HA7fb3xr&#x2B;DOo&#x2B;PvEvg7XtP1DQW0q3h8OW63El&#x2B;ix3D2viPTb&#x2B;QRt0ctDay7cH5m2gdc0EnkHjr/AJGD4lf9il8WP/SvQq&#x2B;gf&#x2B;CdP/JrkP8A2NPij/1IdSry34zfBTVvBll8StYvbjSVh/4Qz4hz/Z0uw1yY9Rl02a3fy&#x2B;u3bZTBj0Vto5zXqX/BOn/k1yH/ALGnxR/6kOpUB0PcqKKKCQooooAKybtYv&#x2B;E508teSRzixugloAdsy&#x2B;Zb7pD2yh2gZ5/enHetasy6Zv8AhMbFfsKyL9juSbzHMB3wYiz/ALfLf9sRQBp15D4v/Ya&#x2B;Hnj/AFnxpda1p&#x2B;oanD4&#x2B;a3bVbG41CV7H90m0&#x2B;VDnZF5mAZNgHmMoLZIzXr1FAHF/8KE8Pv8AaWmW&#x2B;uJrw6W1xNNdM8kzadKstszHuwdQWP8AFzmuNsP2FvBen&#x2B;KYNYW88WyXVt4h1LxLEsuuTvFHc37LJOioThYRMkcyRjCpJGrDuD7NRQB474F/YU&#x2B;H/gGPw2tva6pqDeFtITw/atqWoSXjXGnKl5GLSfzCfOh23smUfKny4eP3S4befsK&#x2B;Bbrx3B4jjPiKz1K28Uw&#x2B;LovsurzQxR3cUUsQiCKcfZ2Fxcs0P3Wa6mJ&#x2B;9ivZKKACub8bf8jT4P8A&#x2B;wrL/wCkN1XSVzfjb/kafB//AGFZf/SG6oA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArm5/hJoHmPJaWJ0iaQlnk0uaTT2lPXL&#x2B;Sy&#x2B;ZjqN&#x2B;RyfU10lFAHK23hvxR4ejItfEUWtRqd/l6vZosz/wCwJrcRqi&#x2B;5hcjnr0p1v8QbrS9Xt7HxBo8mlfanWKG&#x2B;huFubCWViAkXmYWRHY8DfGqliFVmZlB6iq&#x2B;raTba7ps1neQR3NrcoY5YpF3K6nqCKALGc0V5H8Tv2ifD37H2g&#x2B;d8Qtfjs/DrB/7M1K4dprmUr832V0AMkkgU/LINxdVO8hxuk&#x2B;C/jp/wcR6pLqE1t8N/AtjBaoxEd94hleWSYevkQsoT8ZWr6TI&#x2B;Es1zf3sFSbit5PSP3vf0V2fPZ1xVlmVaYyqlLpFay&#x2B;5bersj9PvFclxDpCyW91DZtHcQPJLKRt8oTIZV5B5aMOo92HI6j88/Ev8AwXI1yD4lSHSfB2jzeEYZyiJcTSrf3MQON/mA7ELDnaY2xnGT1rif2Wf&#x2B;C5PiD4rfFPQfCPxU8P8Ahz&#x2B;w9c1O1gGp6WstrJYy&#x2B;cjRPIjvIrx&#x2B;YqBsbSFJPOMH2LxR/wAEO9H1b4mTX2n&#x2B;NrnTfC9xcGY6f9gElzboTnykl37cDoGZCQMZDdT8n4h8L8SZRUo0aKUXK7unFprS2r6LW6320sfqngxxRwLmccVWzy8kklG6no9eZWjrd6cr20dmmfUvxIvLz47/ALNtnqXhMXE39vRaZq0Vut4bGa&#x2B;svPguJrYSqR5bTW4kizkDMmCyjJHgXxc8O/Hn4WfCNrzw1qviO1GJVstD0&#x2B;OHV7yz82XWpoIvMe2uCTF5mixOWYxCK2mWNiSDJ67&#x2B;0l4T0q4&#x2B;Acfwz8OeLF8G6tGumRaW1ixuNSsILW5t33wQIryO6xxEL8uC2ASASRzGk/AL4xL440tl1rwr4d8I6XBaRLpej6xqR&#x2B;0&#x2B;RBD8riRcIpnWcHyyrSRyKJC7DdWlNvlSk9etu58dUrYedaccO/dTel02lfS/nYbpHg/9oDVvitqV1feIZNM8Lw6011Z2Uf8AZ7&#x2B;fbfb7Rfs7P5TSGD7Gt0yn93LvkAJBArm/h/4A/aS06bwzBe&#x2B;ItWsrPT7nRrfUojFpF9DNDDaqty0bfu5fLkn83zdzeYqiAwhiJd1PVfgp8fH8N2tnqvi/wldWOmx3ba9Y6dq&#x2B;rXt1fWk8dxmyUNHJIVZmh2TFWuIwr7C4ARrHwx&#x2B;EHx0ttF0K&#x2B;uLy3sfDsUNvb/2Amt30WozW5urYxxzSFNtuYYvOy8Ko7xhUdcklNBJp7G/448AfG7RfjH4gufBbG30DVvE2lX5vLy7t57qW2TeL22KSMyrZGMRiMoFuFkaRcFNkiZ2seHv2jvCHh/R93iW41CPT7O8utW1FrayuZpXOjQbU8iGBWbZqPnvGsKMzKArAjaG9d/aV&#x2B;HXiDx58PbqK2j0rxDDZ6na6imgXCSW0GsW8WC9lcSAyBg7fOCY9hKorqV3NXll9&#x2B;yb8WvFem&#x2B;MdO1bxjpVro&#x2B;sRXsGlaZYahcpZ2sMltfxW0DxiJQscP2i0jKx4SVbNXZA7OHBh8VvhD8YfiJ&#x2B;zdfW6Xd3/AMJZq2tW2phIbyO2ezifSoo5IlZGiAWG8Mm3Lbtsav8AO3DZXif4b/HLRF17W59WvJmsteXUIRYTRXUn2NYtThZbGMQMxk&#x2B;yT2EYFxG&#x2B;bqOWQr5Y3Nr6t&#x2B;zr8eLy3vIj410y5FxpEOnJIviLULKRJt9sJrsGOEqsuI7maPC7Ve68p1lhiQVV0P8AZB&#x2B;KWjXenx3nirSbjRdO8UahrscUN5cJJZQ3F9bTx&#x2B;UogJeSK3XUItpYB2vzJuVoo8AGX8LNL/aa1rV9N1nVPEGpHQ7k6bNDpdxpmnW0z25a084XcrCOaGcbb1nVLfBSWIKA6tGvfePPAHxS&#x2B;LH7Lfhnwlpd4/hHxJtjs9a1ia7KXFubWJgtxAYeWMl3HC4B&#x2B;Vod4YDftre&#x2B;DHw88aa/4L&#x2B;HNx42vY7240&#x2B;K91TVxchluZbqZGhtoTHt2iNLe4nEikgh0jwGyxHk/if/AIJ2a4p1aDwzN4X8OQ6lo&#x2B;rWNvPYJb28mn3F1dX0kU6K1hK&#x2B;5YZ7ePMcsQxDtdZ0VFABV8U&#x2B;Df2i/Ekt9ouleJL/AEm8vpNTv9R26tp04sY72zYWkEDGPz4YoLjcIn2lmaCUk7VXfpeMvhR8ePHEl5Y2eoaloum38U8eoXVxe2DXeqxm01JreEqiMkO2SXTYZXhCFjFMyHGJGkvv2DPF&#x2B;s/EPwXrVxrmiW8fg2wsYzFBK8v9rXdtqq3Mk8jTQySRNcQiR3kjk85ZpSpkljMhlw/An7AvxS8M/CPw3oNp4k8H&#x2B;FpfD1pply1rYyXd9Y3&#x2B;radZmKK7f5bcj7RcOJ5cq2GsrclZi8mADrvG/hz4seMdA8Mw6D4o0a4&#x2B;JfgG4vG1u3TUVis5WusxQmWCPlYvs0kk0McoZ1McIZ5GDStyvhz9nP49WN/ofhpPFWtab4U8NxbbXUGv7S9vXdE/cy&#x2B;bOkkkkjb50kEyMMeWyszHEXeeEv2YPHWhXnxGhkuPCaW3jWCa1XUIpSdRm&#x2B;0Xtw8lxLILVJd8VrOEjjaaWPdCgXyEJA0viP8AspalP&#x2B;0HqfxE8M2PhNdSa10CO1iuXazkuXs7jUDdrLPHDIyLJBc2gDBXLG0RWUKiEAFr48eD/ij8Wvhb4e03Q/snh3XrWWS/v7qTUnhia4tkb7Ko8j5mSS5MU5U/IUgaOQEOVPlPiz4V/tIajoWr6LpfiPxFYw3beIblb1tT055j9pe/msIIptnmQ&#x2B;UX0&#x2B;JTtIGLgBo0jiMlHUP&#x2B;CbPxAkvr6ax8dWWn3GqWGjWkl5BNJFJZtp9ppsL7fLiSSZZ2trjJklDxLt8l4mnlZe4j/Yj1zXLvxtLeTaX4fPibWNDvbM6JqAjfTrOC2gtNQs0lSyhmCva/bIULyyYEytGLVwSARl/ET4P/ABw&#x2B;Ingrx1o9nfX2hw6rZ6lb2zy3tm8mptNDrItwxVWMKDz9IVjGY2328mMLlpPQNU8EePL5vhrqGu6bceKLnRre6t9ctLbWFsYzqLy2xg1DavlpJBGIbjCEGRUuF/du4YD26zs4tOtIre3jjhghQRxxou1UUDAAA6ADjFSUCPknwJ4D/aHvvHPw71TxhPdahZeHb&#x2B;51G&#x2B;s4bvTrdZgbXVo1jn8tMvJuudPSPy2EYWGVpMNt3anxt&#x2B;Bfxkm&#x2B;O154l8GeILyPRb7WzeTWTakP9Gt4dBa0j&#x2B;yxSBoVkluZ5iVlBj8yC1kZSFcn6iooHc&#x2B;aNf8Ah78VtX0vwXPeWer65q2i6ne3t35&#x2B;r2liLiyNnshs5ZLYJiSRigcrE6GZJWDRwmMD1n9mPwxrPhD4J6PY&#x2B;ILe6s9YDXM9zazzrN9kaW5llEMbLJIPJjDhIhvYrGqA8ggd9RQIKKKKACg9KKKAPnL9m/8AZq8TfDL9qbxl4q1KGNNM1h9VZZPtMMkUv2nUUubb7OiRrMuIQ4n&#x2B;0vJ&#x2B;9K&#x2B;Rsi3A7/7Sn7JWl&#x2B;O/Avi648L6TaWHi7xReWN7qV3Eyxz6tHBcWDTQF5FeMNNbafFAC6FPlTcCua9uooA&#x2B;Nfih&#x2B;xb468ZfAjwnoOn2un2etRWviDSWnd7Nv7DttSvY54JmAhCtdQxwxb7iD955qybQ5mM8foEH7N/imH9t658ZW0drY&#x2B;G/tz6zLdF4Xn1CR9Hi04W24IJljDxpL5bFowYg4Zy6xwfRVFA7nx18N/2XvHfwf/Z58RaDpPgXw/q6tJoy6JoGv6jb6gttdW20XGoSzrHELhAyxywwvsYvCSTB5m2PQ8R/sc67t&#x2B;DMug6HcWuo&#x2B;AdNi062u77WLaZNFze2U1y81uICk3mxWpA8hkCtsVUjG2WL61ooC54D8cf2T9N0/wAO6P8A8IX4F8P6vb2uuz6tq2hXEqwW&#x2B;sGbTb6z3OZAyfLJdI7ZH3FcgMwVTxt3&#x2B;xr4yh&#x2B;N3wv1CK7t7i38NaboMeta7LNFJPPLpkd2kiRB4zOgn&#x2B;04YK&#x2B;1xI5Yx7GS5&#x2B;sKKBHyKf2NfF8vhr4w6Xptr/YNv40Wef8A0jU4L1tZvJNTuLySRJPIHkwywy&#x2B;U0cqOoLkeWwRnmwfjB&#x2B;xB46&#x2B;In7O3hvw7b6fbwzafqHiC4hs1u7SG4sxqH2hbUXUvktDKipO/2hoVE5LK0crurvL9sUUDufMXij9kXWvGf7ak3izVrG1vvC&#x2B;oDy71TcRC0nsjo9xYvE0Wz7R9qaedukv2Y255QTAMfofwX4H0n4d6CNL0Owt9N08XE90IIRhfNnmeeZ/q8sjufdjWtRQIKKKKACiiigArLulz4zsW&#x2B;3eWPsVyPsWf&#x2B;Pj54P3vX&#x2B;D7vT/lt276lZetSWekX66te/Zbe30&#x2B;0nEt7NN5f2ZCY2YHPG0&#x2B;WCWJGNg65OADUori7HQ7j4p3a6lrVvdWehx7hZaRONjXPOBc3K9ckcpCfuBtzjzNqw6P/CofC/8A0ANK/wDAdaAOjornP&#x2B;FQ&#x2B;F/&#x2B;gBpX/gOtH/CofC//AEANK/8AAdaAOjornP8AhUPhf/oAaV/4DrR/wqHwv/0ANK/8B1oA6Oub8bf8jT4P/wCwrL/6Q3VL/wAKh8L/APQA0r/wHWrOk/DfQNC1GO8s9H062uoc&#x2B;XLHAqumQQcHGRkEjjsTQBtUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXA/FP4w3GgatH4a8K6fH4i8aXiK6WZl8u20uJsgXV7IMmKHIOAAXlKlUU4Zl6vxjHq03hq8j0OSzh1aRNltLdqzQwMSB5jKvL7QS2zK7iAu5c7hn/DX4Z2Pwz0ieG2kub2&#x2B;1CY3eo6jdsHutTuCApllYADO1VUKoCoqqqqqqqjqw/soL2lT3n0j3835emr8jlr&#x2B;1m/Z09F1l28l5&#x2B;ui8zyDRv&#x2B;CeHhHxf4pm8VfFYr8VvGV2pRrnV4cabp8fUQWlluMcUQ7bt7k5JckmsP4yf8En/hj8ZPBc2j3STaftjK2lzY6Vpdvc2hH3P30doszqvGQ8hLAfMSSTX09XzL/wAFSv217f8AZE/Z6vIdNuI5PHHixH03Q7VGzLGXG17rb12xg8erlB0Jx7WWYzN8djqVHC1Ze0bSjZtKPolZRilq7K1jx8yweVYLBVauJpx5Em5XV3L1b1cnsm3e5&#x2B;NP7KHwIv8A45/tWeEvBNjJI0l7rKR3FxbgN5FvE&#x2B;&#x2B;aYZBHyxo7DPBwK/VrUv2jvEnx4/aWn&#x2B;GXgH4ia7H4f0qCWbxH4lnisB5MMRAk&#x2B;zGO3j24YrGJSxGWJAwoZvn/APZt&#x2B;B2l/wDBNr9k7xB4w8Zzrpvxo&#x2B;IWky2ehacDuvdGtZRtUlc/u3J&#x2B;d2P3dioPmDKa/wCwz/wT18VftGRtq2rXWo&#x2B;GfAV5tS4kRjHPrSBg2yJTwUDAHewKggYDEHHb4tcWrNM2hgsC&#x2B;eFJNNrq2/es&#x2B;i0Sv5XWjR&#x2B;D5bUzLL5UcnwFNzrV2p1YxlyyjBfDCUv&#x2B;Xd7tzeklFpLVn0to/wAU/Cnwp1KXwf8ACHXvHXxE8UXDmS7TRodLlWWToZr3UJLMhiTkGRmfHTjivW/CvwN&#x2B;JHjXRQ3jn4ma5p/mOJU07w&#x2B;lpCYB/wA85br7OGmx32JEOv3hXoXwe&#x2B;CPhf4C&#x2B;EY9E8KaPa6TYpgv5a5kuHxjfI5&#x2B;Z292JPbpxXV18JSoyt&#x2B;8fyWiX6v56eR&#x2B;7ZZlGJVNfX5rTanTXLTj5fzT8&#x2B;Z8r/kRwuifBe88N6dHZ6f418TWNrHnbFBZ6VGi55JwLLqTyT3q5/wrbWf&#x2B;igeLv/AbS/8A5DrrqK6vI&#x2B;jjFRXLFWRyP/CttZ/6KB4u/wDAbS//AJDo/wCFbaz/ANFA8Xf&#x2B;A2l//IdddRQM5H/hW2s/9FA8Xf8AgNpf/wAh0f8ACttZ/wCigeLv/AbS/wD5DrrqKAOR/wCFbaz/ANFA8Xf&#x2B;A2l//IdH/CttZ/6KB4u/8BtL/wDkOuuooA5H/hW2s/8ARQPF3/gNpf8A8h0f8K21n/ooHi7/AMBtL/8AkOuuooA5H/hW2s/9FA8Xf&#x2B;A2l/8AyHR/wrbWf&#x2B;igeLv/AAG0v/5DrrqKAOR/4VtrP/RQPF3/AIDaX/8AIdH/AArbWf8AooHi7/wG0v8A&#x2B;Q666igDkf8AhW2s/wDRQPF3/gNpf/yHR/wrbWf&#x2B;igeLv/AbS/8A5DrrqKAOR/4VtrP/AEUDxd/4DaX/APIdH/CttZ/6KB4u/wDAbS//AJDrrqKAOR/4VtrP/RQPF3/gNpf/AMh0f8K21n/ooHi7/wABtL/&#x2B;Q666igDkf&#x2B;Fbaz/0UDxd/wCA2l//ACHR/wAK21n/AKKB4u/8BtL/APkOuuooA5H/AIVtrP8A0UDxd/4DaX/8h0f8K21n/ooHi7/wG0v/AOQ666igDkf&#x2B;Fbaz/wBFA8Xf&#x2B;A2l/wDyHR/wrbWf&#x2B;igeLv8AwG0v/wCQ666igDkf&#x2B;Fbaz/0UDxd/4DaX/wDIdH/CttZ/6KB4u/8AAbS//kOuuooA5H/hW2s/9FA8Xf8AgNpf/wAh0f8ACttZ/wCigeLv/AbS/wD5DrrqKAOR/wCFbaz/ANFA8Xf&#x2B;A2l//IdH/CttZ/6KB4u/8BtL/wDkOuuooA5H/hW2s/8ARQPF3/gNpf8A8h0f8K21n/ooHi7/AMBtL/8AkOuuooA5H/hW2s/9FA8Xf&#x2B;A2l/8AyHR/wrbWf&#x2B;igeLv/AAG0v/5DrrqKAOR/4VtrP/RQPF3/AIDaX/8AIdH/AArbWf8AooHi7/wG0v8A&#x2B;Q666igDkf8AhW2s/wDRQPF3/gNpf/yHR/wrbWf&#x2B;igeLv/AbS/8A5DrrqKAOR/4VtrP/AEUDxd/4DaX/APIdLa/CpptStptZ8Ra54kgs5FuIbTUI7NbdJlIZJSsEEZZkIyoYlVbDAblRl62igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooJxXifxf/AGodQu/Ft94C&#x2B;Fekx&#x2B;LvHsKbLy5lYpovhgt0e&#x2B;nH8YzuFvHmVgOig7q6sLg6uInyU1tq29El3beiXr6bnNisXTw8Oeo/JJatvsktW/T12LX7Xn7ZWg/sneF7TzrW88ReLtek&#x2B;zaB4b04eZfatOeBhRkrGD958HHQAsQp&#x2B;QdW&#x2B;Et9&#x2B;zjd3H7RP7Rc9j4v&#x2B;LGqOsPhXwzGQ1jocgBeMYzg&#x2B;TnOVyqHJDPI4cfXP7On7HGnfCPxPdeNvE2pTeOPinrEXl6l4mvYwrKn/PC1hHyW8CjgKgyR1J4A&#x2B;Av&#x2B;CtPxN1Dxr&#x2B;1zqWjTyS/2f4TtoLO0hPCqZIUmkcD1ZnAz3CL6CuvNM/hlOCnh8rfvz92VS1m77xhfWMO&#x2B;0p9bL3T8q8RM0xGAy3&#x2B;08Svf5lGlDdQk03zz6Smkm0tYxdrX3O4/YY/Zr1X9u74sap8UviZcyazo1ldeV5ExIXUbhVDCIKOFgjVlyowCSF6bq&#x2B;7/AB1P4s0PVZLXwxpscmnxaPKLVR5EUMN0scvlKQxDEFhCoA2KoJJLAny/nL/gkV&#x2B;0T4VvvgNbeBJb6z0/xJo91O/2aeRY3v45ZGkEkefvkbtpA5G0HoRX1h41&#x2B;JPh74b6Y954g1zSdFtYxuMt7dJAv4biM/QV8tl1OmsOpp6vVvrfzPQ8P8vwEMghi6Vb36tp1anMuZz3alJ3&#x2B;HVWfru7nMz3/jjS/E9gv2OS/wBPjsonugj25WaX/SDKocmNg/FuFOwIdzA45ZdT4YeKdZv7L7D4qt7HT/ESmSbyLe4WRJoNwIkQAltq71jJYAlkJxgisnQvidqnxksVl8J2VzpuizHjXdTtzF56d2tbZgHfI6PKETkMBKPlPV&#x2B;FfBVj4RW4e3Ek15esHu7ydvMuLtgMAu3tzhRhVBwoUcV3Q1d4t2PtMGnOoqtCpKUNdW/dd7fDpd7KzTUdW03qjXooorY9oKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDmfiX8Pbj4laaumtrmp6PpMwZb1NNf7PdXinA8sXA&#x2B;eJCMgmLbJyMOuDm94E&#x2B;H&#x2B;ifDHwta6L4e0ux0fSbMYhtbWIRxpnknA6sTyWOSSSSSTWxRWzxFR0/ZX93e3S/d935syVGCqe1t721/Lsuy8kFfLP7b3/BM/T/ANqbxUfFOj61/wAI/wCJmgSC486HzbW&#x2B;CDCFsYZHAwNw3AhQNvevqaiuOvh4VoclRXR52dZHgs2wrweYQ54N3tqrNbNNWaf/AA2x&#x2B;bfhL/giL4uu9SVdd8Z&#x2B;HbGzzy9hDNdSEf7rrEB&#x2B;f519Qfs7/wDBNH4a/s/6hDqn2O48T69Byl9qxWVYG9Y4gAin0JDMOzV9CUVzUctw1J80Y6&#x2B;ep85k/hvw9llRVqGHTmtnJuVvRPRNd0r&#x2B;YAYooorvPuQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/Z" />
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>